id	title	pub_title	doi	url	total_versions	first_reg_date	first_status	final_status	original_start_date	original_completion_date	publication_date	has_pre_recruitment_phase	has_recruitment_phase	has_post_completion_phase	has_post_publication_phase	has_unknown_phase	outcome_changed_recruitment	outcome_changed_postcompletion	outcome_changed_postpublication	outcome_changed_unknown	trial_phase_start	outcome_start	outcome_last_recruitment	outcome_last_postcompletion	outcome_last_postpublication	outcome_last_unknown
DRKS00000058	Pro-Active Rehabilitation and Telephone Intervention in Type 2 Diabetics: a randomized controlled trial of patients enrolled in a DMP.	[Feasibility and benefit of an active screening for rehab need and subsequent written advice to file an application for rehab treatment in AOK-insurants enrolled in the disease management program diabetes type 2 (PARTID-trial)]	10.1055/s-0034-1370984	NA	9	2008-12-19	Recruiting planned	Recruiting complete, follow-up complete	2009-02-12	2012-09-30	2014-10-15	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[""Change in HbA1c (<\/= 7%),\nblood pressure (< 140/90 mm/Hg),\nsevere hypoglycemia,\nglobal coronary risk (Framingham-Score),\ncomplications.""]	[""Change in HbA1c (≤ 7%),\nblood pressure (< 140/90 mm/Hg),\nsevere hypoglycemia,\nglobal coronary risk (Framingham-Score),\ncomplications.\n""]	NA	[""Change in HbA1c (≤ 7%),\nblood pressure (< 140/90 mm/Hg),\nsevere hypoglycemia,\nglobal coronary risk (Cederholm, 2008),\ncomplications. Assessments by questionnaire at screening for rehabilitation need and 12 months after screening.\n\nStudy arm 2 - telephone follow-up: Behavior change in physical activity (Stender et al., 1991), diet (food list based on Keller, 1998), medication adherence (MARS-D), smoking, improvements in depression (PHQ-9), well-being (WHO-5) and diabetes-related burden (PAID). Assessments by questionnaire at begin of inpatient rehabilitation and 12 months after discharge.\n""]	NA
DRKS00000101	Treatment of Childhood and Adolescent Anorexia Nervosa - A Comparison of a Day treatment and an Inpatient Treatment Setting	Day-patient treatment after short inpatient care versus continued inpatient treatment in adolescents with anorexia nervosa (ANDI): a multicentre, randomised, open-label, non-inferiority trial	10.1016/s0140-6736(13)62411-3	NA	8	2009-03-17	Recruiting ongoing	Recruiting complete, follow-up complete	2007-03-08	2012-10-18	2014-01-17	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[""difference of the BMI at admission compared to 52nd-week-follow-up""]	[""difference of the BMI at admission compared to 52nd-weeks after admission; additional follow up: difference of the BMI at admission compared to 130th-weeks after admission""]	[""difference of the BMI at admission compared to 52nd-weeks after admission; additional follow up: difference of the BMI at admission compared to 130th-weeks after admission""]	NA	NA
DRKS00000104	Hypocaloric nutrition in intensive care medicine and its clinical relevance	Hypocaloric vs Normocaloric Nutrition in Critically Ill Patients: A Prospective Randomized Pilot Trial	10.1177/0148607114528980	http://journals.sagepub.com/doi/10.1177/0148607114528980	8	2009-03-26	Recruiting ongoing	Recruiting complete, follow-up complete	2008-10-01	2011-02-28	2014-04-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""- glycemic control (every 3 hours) and daily insulin requirement\n- rate of nosocomial infection (microbiolgical diagnostic of tracheal secretion, urin and blood, C-reactive protein, leukocyte count and procalcitonin on study admission and on day 5)""]	[""- glycemic control (every 3 hours) and daily insulin requirement\n- rate of nosocomial infection (microbiolgical diagnostic of tracheal secretion, urin and blood, C-reactive protein, leukocyte count and procalcitonin on study admission and on day 5)""]	[""- glycemic control (every 3 hours) and daily insulin requirement\n- rate of nosocomial infection (microbiolgical diagnostic of tracheal secretion, urin and blood, C-reactive protein, leukocyte count and procalcitonin on study admission and on day 5)""]	[""Rate of nosocomial infection (microbiological diagnosis of tracheal secretion, urin and blood culture, clinical and radiological criteria of nosocomial infection)""]	NA
DRKS00000125	Implementation of shared decision-making by physician training to optimise hypertension treatment in Southern Baden.	Shared decision-making in antihypertensive therapy: a cluster randomised controlled trial	10.1186/1471-2296-14-135	https://www.ncbi.nlm.nih.gov/pubmed/24024587	7	2009-06-02	Recruiting planned	Recruiting complete, follow-up complete	2009-06-05	2011-09-27	2013-09-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\nBlood pressure values (RR, systolic : diastolic):\nRR 24-h mean < 130:80;\nRR daytime mean < 135:85;\nRR nighttime mean < 120:70.\n\nParticipation in the decision making regarding the treatment.""]	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\nBlood pressure values (RR, systolic : diastolic):\nRR 24-h mean < 130:80;\nRR daytime mean < 135:85;\nRR nighttime mean < 120:70.\n\nParticipation in the decision making regarding the treatment.""]	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\n(1) Change of systolic blood pressure (mean of 24-h-measurement) from baseline\n\n(2) Change of patients' perceived participation (SDM-Q-9) from baseline""]	[""Blood pressure optimization by patients with arterial hypertension by implementation of shared decision making.\n\n(1) Change of systolic blood pressure (mean of 24-h-measurement) from baseline\n\n(2) Change of patients' perceived participation (SDM-Q-9) from baseline""]	NA
DRKS00000304	Clinical effectiveness of the newer antipsychotic compounds olanzapine, quetiapine and aripiprazole in comparison with low dose conventional  antipsychotics (haloperidol and flupentixol) in patients with schizophrenia	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study	10.1016/s2215-0366(16)00085-7	https://pubmed.ncbi.nlm.nih.gov/27265548/	12	2009-12-21	Recruiting planned	Recruiting complete, follow-up complete	2010-04-16	2014-03-31	2016-06-02	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[""Primary efficacy endpoint:\nContentment with treatment in 1) patients and 2) psychiatrists;\nPatient: SF-36 (interviewer version with a time frame of one week); Psychiatrist: CGI-S.\nKey secondary endpoints:\nSubscores of SF-36, SWN-K, PSP, PANSS, matrics (selected centres).\nAssessment of safety:\nAdverse events, drop-out rates, SAS / AIMS / BARS and sexual dysfunction changes. Metabolic side effects: body mass index (BMI), waist circumference, HbA1c, fast blood glucose levels, lipid profile.""]	[""Primary efficacy endpoint:\nContentment with treatment in 1) patients and 2) psychiatrists;\nPatient: SF-36 (interviewer version with a time frame of one week); Psychiatrist: CGI-S.\nKey secondary endpoints:\nSubscores of SF-36, SWN-K, PSP, PANSS, matrics (selected centres).\nAssessment of safety:\nAdverse events, drop-out rates, SAS / AIMS / BARS and sexual dysfunction changes. Metabolic side effects: body mass index (BMI), waist circumference, HbA1c, fast blood glucose levels, lipid profile changes (total cholesterol / LDL cholesterol /HDL cholesterol, triglycerides) from baseline to week 24 (visit 6), serum concentration of the respective study drug (olanzapine, quetiapine, aripiprazole, haloperidol, flupentixol).""]	[""Two primary efficacy endpoints used in the study. 1) Quality of life from the patient's perspective with SF-36 (interviewer version with a time frame of one week) and 2) the change in clinical status from the perspective of the investigator with CGI. The change from baseline at week 24 is measured by AUC based on logarithmic transformed time scale.\n""]	[""Two primary efficacy endpoints used in the study. 1) Quality of life from the patient's perspective with SF-36 (interviewer version with a time frame of one week) and 2) the change in clinical status from the perspective of the investigator with CGI. The change from baseline at week 24 is measured by AUC based on logarithmic transformed time scale.\n""]	NA
DRKS00000486	prevention of depressive episodes on patients with Inflammatory Bowel Diesease	NA	NA	https://elibrary.klett-cotta.de/article/99.120110/aep-8-3-175	8	2011-08-26	Recruiting complete, follow-up continuing	Recruiting complete, follow-up complete	2010-08-30	2011-12-22	2013-08-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale)\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale)\n\n""]	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale)\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale)\n\n""]	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale).\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale).\n\nto compare both groups: IBDQ-D (Inflammatoy-bowel-disease-questionnaire - german version).\nlevel of diesase-specific quality of life.\n""]	[""pre: level of depression on questionnaires\nBDI (Beck- Depressions-Inventar) and ADS (general dpression scale).\n\npost :right after intervention, again level of depression on BDI (Beck- Depressions-Inventar) and ADS (general depression scale).\n\nto compare both groups: IBDQ-D (Inflammatoy-bowel-disease-questionnaire - german version).\nlevel of diesase-specific quality of life.\n""]	NA
DRKS00000542	Treatment of Binge eating disorder in adolescents	Cognitive-Behavioral Therapy for Adolescents with an Age-Adapted Diagnosis of Binge-Eating Disorder: A Randomized Clinical Trial	10.1159/000503116	https://www.karger.com/Article/Abstract/503116	17	2012-05-22	Recruiting ongoing	Recruiting complete, follow-up complete	2012-04-27	2016-12-07	2019-09-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[""Number of binge eating days during the last 28 days before end of treatment or rather waiting phase (4 months after randomization for CBT and WL) using EDE interview (eating disorder examination) and EDE-questionnaire""]	[""Number of binge eating episodes during the last 28 days before end of treatment (i. e. 4 months after randomization for CBT and WL) using EDE interview (eating disorder examination).""]	[""Number of binge eating episodes during the last 28 days before end of treatment (i. e. 4 months after randomization for CBT and WL) using EDE interview (eating disorder examination).""]	[""Number of binge eating episodes during the last 28 days before end of treatment (i. e. 4 months after randomization for CBT and WL) using EDE interview (eating disorder examination).""]	NA
DRKS00000713	Quality of sleep during conventional noninvasive ventilation and noninvasive ventilation with „intelligent volume assured pressure support (iVAPS)“	Impact of intelligent volume-assured pressure support on sleep quality in stable hypercapnic chronic obstructive pulmonary disease patients: a randomized, crossover study	10.1159/000364946	NA	5	2011-02-24	Recruiting ongoing	Recruiting complete, follow-up complete	2011-01-05	2011-11-15	2014-08-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""sleep efficiency (percentage of sleep time compared to \""total in bed time\"")""]	[""sleep efficiency (percentage of sleep time compared to \""total in bed time\"")""]	[""Stadium 3/4 sleep (assessed by polysomnography)""]	[""Stadium 3/4 sleep (assessed by polysomnography)""]	NA
DRKS00000715	Evaluation of endotracheal intubation performed with a semirigid endoscope (Bonfils-Fibrescope) in toddlers and infants.	A randomized controlled comparison of the Bonfils fiberscope and the GlideScope Cobalt AVL video laryngoscope for visualization of the larynx and intubation of the trachea in infants and small children with normal airways	10.1111/pan.12137	http://onlinelibrary.wiley.com/doi/10.1111/pan.12137/abstract	10	2011-02-07	Recruiting ongoing	Recruiting complete, follow-up complete	2011-03-01	2013-03-15	2013-03-18	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[""time needed for intubation, measured with a stop-watch""]	[""time needed for intubation, from touching the instruments until firts Ventilation with measured exhaled CO2, measured with a stop-watch during intubation""]	NA	[""time needed for intubation, from touching the instruments until firts Ventilation with measured exhaled CO2, measured with a stop-watch during intubation""]	NA
DRKS00003132	GREAT - a randomised aneurysm trial	GREAT-a randomized controlled trial comparing HydroSoft/HydroFrame and bare platinum coils for endovascular aneurysm treatment: procedural safety and core-lab-assessedangiographic results	10.1007/s00234-016-1693-y	https://link.springer.com/article/10.1007/s00234-016-1693-y	4	2011-07-06	Recruiting ongoing	Recruiting complete, follow-up complete	2009-10-01	2016-05-02	2016-04-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[""Recanalisationrate at angiographic follow-up 18 months after initial treatment""]	[""Recanalisationrate at angiographic follow-up 18 months after initial treatment""]	NA	[""Composite outcome of major aneurysm recurrence on follow-up angiography and clinical outcome within 18 months\n(Formulation of endpoint amended for clarification; primary endpoint combining angiographic outcomes [major recurrence], re-treatment, and clinical outcomes in the absence of angiographic follow-up was specified before the trial started)\n""]	NA
DRKS00003691	Eletrical cardioversion versus defibrillation of atrial fibrilation - a clinical trial	NA	10.4126/frl01-006416711	https://repository.publisso.de/resource/frl%3A6416711	4	2012-03-29	Recruiting ongoing	Recruiting complete, follow-up complete	2008-02-19	2015-10-15	2019-07-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""Induction of ventricular fibbrilation or ventricular tachycardia""]	[""Induction of ventricular fibbrilation or ventricular tachycardia""]	[""Induction of ventricular fibbrilation or ventricular tachycardia during treatment""]	[""Induction of ventricular fibbrilation or ventricular tachycardia during treatment""]	NA
DRKS00004235	Prospective, controlled study of deep brain stimulation (DBS) in the region of the posterior subthalamic area (PSA) with a randomized, double-blinded, cross-over comparison between PSA- and nucleus ventralis intermedius (VIM)-DBS for the treatment of essential tremor (ET).	DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial	10.1212/wnl.0000000000005956	https://pubmed.ncbi.nlm.nih.gov/29970404/	8	2013-07-09	Recruiting ongoing	Recruiting complete, follow-up complete	2013-01-07	2017-01-11	2018-07-03	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[""Reduction of tremor 12 months after implantation in the PSA measured on tremor rating scale. Tremor rating scale Baseline versus Tremor rating scale 12 months follow up""]	[""Reduction of the Fahn Tremor Rating Scale (FTRS) at 3, 5 and 7 months after implantation and stimulation by PSA-DBS com-pared to baseline\n\nPlease note: Amendment from 04.11.2014 regarding the timepoint of Assesment of primary Endpoint. Approved by the Ethics Commitee.""]	[""Reduction of the Fahn Tremor Rating Scale (FTRS) at 3, 5 and 7 months after implantation and stimulation by PSA-DBS com-pared to baseline\n\nPlease note: Amendment from 04.11.2014 regarding the timepoint of Assesment of primary Endpoint. Approved by the Ethics Commitee.""]	NA	NA
DRKS00004239	Intervention Study on the Development and Implementation of a Practice Guideline for the Appropriate Pain Management of Older Persons in Nursing Homes	Nonpharmacologic Pain Management Interventions in German Nursing Homes: A Cluster Randomized Trial	10.1016/j.pmn.2014.09.002	https://www.linkedin.com/pulse/nonpharmacologic-pain-management-interventions-german-velandy-manohar	8	2012-07-25	Recruiting ongoing	Recruiting complete, follow-up complete	2012-02-13	2012-12-31	2015-08-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[""changes in perceived pain, Numeric Rating Scale (NRS) within the Brief Pain Inventory (BPI) © Radbruch et al. 1999; Loick et al. 2004\nData collection will start before the intervention and will be continued 3 and 6 months afterwards.\n\n\n\n\n""]	[""changes in perceived pain, Numeric Rating Scale (NRS) within the Brief Pain Inventory (BPI) © Radbruch et al. 1999; Loick et al. 2004\nData collection will start before the intervention and will be continued 3 and 6 months afterwards.\n\n\n\n\n""]	[""changes in perceived pain, Numeric Rating Scale (NRS) within the Brief Pain Inventory (BPI) © Radbruch et al. 1999; Loick et al. 2004\nData collection will start before the intervention and will be continued 3 and 6 months afterwards.""]	no maximum age	NA
DRKS00004537	Ultrasound-guided peripheral nerve blocks in combination with general anesthesia on an outpatient basis, in terms of processing time, hemodynamic stability, complications, postoperative pain, and sympathetic activity compared to general anesthesia	Combination of general anesthesia and peripheral nerve block with low-dose ropivacaine reduces postoperative pain for several days after outpatient arthroscopy: A randomized controlled clinical trial	10.1097/md.0000000000006046	https://pubmed.ncbi.nlm.nih.gov/28178149/	3	2013-03-25	Recruiting ongoing	Recruiting complete, follow-up complete	2012-06-15	2015-07-31	2017-02-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""operational process times - perioperative documentation OP changing times / PACU (post-anesthesia care unit) discharge home\n\nPostoperative pain 3 days - telephone interview on 2 postoperative day""]	[""operational process times - perioperative documentation OP changing times / PACU (post-anesthesia care unit) discharge home\n\nPostoperative pain 3 days - telephone interview on 2 postoperative day""]	[""incidence and severity of postoperative pain, and time spent in recovery room - telephone interview on PACU and 2 postoperative days""]	NA	NA
DRKS00004595	The value of intraglandular application of botulinum toxin for prevention of radiation-induced sialadenitis in head and neck cancer: a scintigraphic analysis.	Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial	10.1371/journal.pone.0151316	https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+Efficacy+of+Botulinum+Toxin+to+Preserve+Gland+Function+after+Radiotherapy+in+Patients+with+Head+and+Neck+Cancer%3A+A+Prospective%2C+Randomized%2C+Placebo-Controlled%2C+Double-Blinded+Phase+I+Clinical+Trial	6	2012-12-14	Recruiting complete, follow-up complete	Recruiting complete, follow-up complete	2010-07-12	2012-11-01	2016-03-18	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[""Difference of the\nproportional uptake of radionuklide after treatment with BoNT or placebo. The primary endpoint will be determined via szinitgraphiy before and after study treatment.""]	NA	[""Difference of the\nproportional uptake of radionuklide after treatment with BoNT or placebo. The primary endpoint will be determined via szinitgraphiy before and after study treatment.""]	[""Difference of the proportional uptake of radionuklide after treatment with BoNT or placebo. The primary endpoint will be determined via szinitgraphiy before and after study treatment.""]	NA
DRKS00005159	Improvement of endogenous regeneration in female healthy volunteers through physical exercise “REBIRTH aktiv women”	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women	10.1177/2047487319849505	https://journals.sagepub.com/doi/10.1177/2047487319849505	5	2013-09-25	Recruiting planned	Recruiting complete, follow-up complete	2013-11-20	2015-03-26	2019-05-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[""Differences in telomere length in mononuclear cells (cells will be drwan from venous blood) between baseline and after 6 months intervention. Peak oxygen consumption (VO2peak) at baseline and after 6 months.""]	[""Differences in telomere length in mononuclear cells (cells will be drwan from venous blood) between baseline and after 6 months intervention. Peak oxygen consumption (VO2peak) at baseline and after 6 months.""]	[""Differences in telomere length in mononuclear cells (cells will be drwan from venous blood) between baseline and after 6 months intervention. Peak oxygen consumption (VO2peak) at baseline and after 6 months.""]	NA	NA
DRKS00006098	Saarland against colorectal cancer - Join in!	Screening for Bowel Cancer: Increasing Participation via Personal Invitation	10.3238/arztebl.2017.0087	https://www.aerzteblatt.de/int/archive/article/186297	4	2014-04-23	Recruiting ongoing	Recruiting complete, follow-up complete	2012-05-02	2014-04-30	2017-02-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""Primary aims of the pilot project are the detection and quantification of the increase in participation rate in colorectal cancer early detection through a logistic uncomplex personal invitation procedure. The issues include in particular:\n• To what extent can the use of the test for occult blood in the stool be increased through a personal invitation letter with an information booklet?\n• To what extend can the sending of a stool test kit together with the personal invitation letter further increase participation?\n• To what extend is a colonoscopy performed in case of a positive test result?\n• To what extend can the use of screening colonoscopy be increased through a personal invitation letter with an information booklet?\n• What effects can be achieved in terms of participation at initial cover letter and follow-up letter in one year distance?\n• For all questions: Are there differences between women and men?""]	[""Primary aims of the pilot project are the detection and quantification of the increase in participation rate in colorectal cancer early detection through a logistic uncomplex personal invitation procedure. The issues include in particular:\n• To what extent can the use of the test for occult blood in the stool be increased through a personal invitation letter with an information booklet?\n• To what extend can the sending of a stool test kit together with the personal invitation letter further increase participation?\n• To what extend is a colonoscopy performed in case of a positive test result?\n• To what extend can the use of screening colonoscopy be increased through a personal invitation letter with an information booklet?\n• What effects can be achieved in terms of participation at initial cover letter and follow-up letter in one year distance?\n• For all questions: Are there differences between women and men?""]	[""Primary aims of the pilot project are the detection and quantification of the increase in participation rate in colorectal cancer early detection through a logistic uncomplex personal invitation procedure. The issues include in particular:\n- To what extent can the use of the test for occult blood in the stool be increased through a personal invitation letter with an information booklet?\n- To what extend can the sending of a stool test kit together with the personal invitation letter further increase participation?\n- To what extend is a colonoscopy performed in case of a positive test result?\n- To what extend can the use of screening colonoscopy be increased through a personal invitation letter with an information booklet?\n- What effects can be achieved in terms of participation at initial cover letter and follow-up letter in one year distance?\n- For all questions: Are there differences between women and men?""]	NA	NA
DRKS00006866	European Comparative Effectiveness Research on Internet-based Depression Treatment	Barriers and facilitators for the implementation of blended psychotherapy for depression: A qualitative pilot study of therapists' perspective	10.1016/j.invent.2018.01.002	https://pubmed.ncbi.nlm.nih.gov/30135779/	6	2014-12-02	Recruiting planned	Recruiting complete, follow-up complete	2015-03-11	2017-06-30	2018-01-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	[""The project E-Compared ends on June, the 30st in 2017. The study E-Compared Germany ends with the last interview of the last participant - at the latest in September 2017. The last assessment for all study participants is the M.I.N.I. 5.0. After the last assessment the TAU group gets access to the bCBT.\n\nProcess:\n0. Pre-Screening (PHQ-9)\n1. First Online-Questionnaire + Baseline Interview\n- Treatment -\n2. Second Online-Questionnaire (3 months after baseline)\n3. Third Online-Questionnaire (6 months after baseline)\n4. Fourth Online-Questionnaire + Follow-Up Interview (12 months after baseline)\n\nAll questionnaires will be assessed via online-testplatform (www.unipark.de). Baseline is the date of the randomisation on individual patient level.\n\nSymptomspecific Questionnaires - primary outcome:\nThe primary outcome is the Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001).\n\nPHQ-9 will be assessed to all 4 measurement points.""]	NA
DRKS00006887	The influence of a SOC-oriented coaching and physiotherapy on health and work ability in nurses with non-specific musculoskeletal complaints	The prevention of musculoskeletal complaints: a randomized controlled trial on additional effects of a work-related psychosocial coaching intervention compared to physiotherapy alone	10.1007/s00420-017-1202-6	https://link.springer.com/article/10.1007/s00420-017-1202-6#article-info	7	2014-11-07	Recruiting ongoing	Recruiting complete, follow-up complete	2014-04-14	2015-03-13	2017-03-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[""Musculoskeletal complaints will be measured by physical examination at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline and after 12 weeks], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12 and 22 weeks], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks].\n\nWork ability will be measured with the German version of the Work Ability Index (WAI, Hasselhorn & Freude 2007). Measuring times: Baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks.\n\n""]	[""Musculoskeletal complaints will be measured by physical examination at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline and after 12 weeks], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12 and 22 weeks], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks].\n\nWork ability will be measured with the German version of the Work Ability Index (WAI, Hasselhorn & Freude 2007). Measuring times: Baseline, after 2, 4, 6, 8, 10, 12 and 22 weeks.\n\n""]	[""Musculoskeletal complaints will be measured by physical examination at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline, after 12 weeks and 24 months], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12, 22 weeks and 24 months], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12, 22 weeks and 24 months].\n\nWork ability will be measured with the German version of the Work Ability Index (WAI, Hasselhorn & Freude 2007). Measuring times: Baseline, after 2, 4, 6, 8, 10, 12, 22 weeks and 24 months.\n\n""]	[""The effectiveness is measured primarily by musculoskeletal complaints. The physical examination is implemented at the beginning and end of the intervention according to Spallek et al., (2007) [measuring times: baseline, after 12 weeks and 24 months], by the Nordic Questionnaire (Kuorinka et al. 1987) [measuring times: baseline, after 12, 22 weeks and 24 months], and pain by the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) (Kerns et al. 1985) [measuring times: baseline, after 2, 4, 6, 8, 10, 12, 22 weeks and 24 months].\n""]	NA
DRKS00007634	Telemedically supported aftercare after living donor renal transplantation	Telemedically Supported Case Management of Living-Donor Renal Transplant Recipients to Optimize Routine Evidence-Based Aftercare: A Single-Center Randomized Controlled Trial	10.1111/ajt.14138	https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.14138	7	2015-01-28	Recruiting complete, follow-up continuing	Recruiting complete, follow-up complete	2011-10-28	2014-04-30	2016-11-15	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[""unplanned hospital re-admission""]	NA	[""Unplanned inpatient hospitalization (unplanned admission rate)""]	[""Unplanned inpatient hospitalization (unplanned admission rate) at 3,6, 12 months after transplantation""]	NA
DRKS00007689	Impulsivity-focused group intervention to reduce binge eating episodes in patients with binge eating disorder	IMPULS: Impulsivity-Focused Group Intervention to Reduce Binge Eating Episodes in Patients with Binge Eating Disorder - A Randomised Controlled Trial	10.1159/000499696	https://www.karger.com/Article/FullText/499696	10	2015-01-14	Recruiting ongoing	Recruiting complete, follow-up complete	2015-02-01	2017-09-30	2019-05-20	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""The frequency of binge eating episodes within the last 4 weeks at T0 (at the beginning) and T1 (after 8 weeks (at the end of the training period)), assessed by Item 10 of the Eating Disorder Examaniation Interview (Hilbert & Tuschen-Caffier, 2004)""]	[""The frequency of binge eating episodes within the last 4 weeks at T0 (at the beginning) and T1 (after 8 weeks (at the end of the training period)), assessed by Item 10 of the Eating Disorder Examaniation Interview (Hilbert & Tuschen-Caffier, 2004)""]	[""The frequency of binge eating episodes within the last 4 weeks at T0 (at the beginning) and T1 (after 8 weeks (at the end of the training period)), assessed by Item 10 of the Eating Disorder Examaniation Interview (Hilbert & Tuschen-Caffier, 2004)""]	no maximum age	NA
DRKS00007770	Effectiveness of work-related medical rehabilitation in cancer patients: a cluster randomized multicenter trial	[Work-Related Medical Rehabilitation in Cancer Rehabilitation - Short-Term Results from a Cluster-Randomized Multicenter-Trial]	10.1055/a-0604-0157	https://pubmed.ncbi.nlm.nih.gov/29801187/	11	2015-05-13	Recruiting planned	Recruiting complete, follow-up complete	2015-06-01	2017-11-08	2018-05-25	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""Primary outcome will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire: role functioning scale (T1, T3, T4, EORTC QLQ-C30, Aaronson et al. 1993).""]	[""Primary outcome will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire: role functioning scale (T1, T3, T4, EORTC QLQ-C30, Aaronson et al. 1993).""]	[""Primary outcome will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire: role functioning scale (T1, T3, T4, EORTC QLQ-C30, Aaronson et al. 1993).""]	[""Primary outcome is self-reported role functioning 12 months after Rehabilitation. The role functioning will be assessed at the beginning of cancer rehabilitation(T1), as well as 3 months (T3) and 12 months (T4) after the end of cancer rehabilitation with a questionnaire (EORTC QLQ-C30, Aaronson et al. 1993).""]	NA
DRKS00008548	Post stationary telemedical care of patients with severe psychiatric disorders	Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla)	10.1186/s12888-018-1737-4	https://pubmed.ncbi.nlm.nih.gov/29843676/	4	2015-05-21	Recruiting ongoing	Recruiting complete, follow-up complete	2015-01-30	2017-07-21	2018-05-29	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[""The primary endpoint is the evaluation medication adherence. The assesssment instrument is the MARS-D (German version of the Medication Adherence Report Scale). Times of measurement are baseline, 3- and 6-months-follow ups. The hypothesis is that after 6 months, the medication adherence in the intervention group is better than the control group.""]	[""The primary endpoint is the evaluation medication adherence. The assesssment instrument is the MARS-D (German version of the Medication Adherence Report Scale). Times of measurement are baseline, 3- and 6-months-follow ups. The hypothesis is that after 6 months, the medication adherence in the intervention group is better than the control group.""]	NA	no maximum age	NA
DRKS00008927	Development and evaluation of a virtual exposure therapy in a driving simulator for patients with driving phobia - A pilot study	Treating patients with driving phobia by virtual reality exposure therapy - a pilot study	10.1371/journal.pone.0226937	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226937	10	2015-11-02	Recruiting planned	Recruiting complete, follow-up complete	2016-04-08	2017-06-02	2020-01-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[""Avoidance behavior during the driving test in real traffic. The most important criterion is if the patients are able to manage at least one task/situation/individualized part of the course in the driving training with the driving instructor, which the patients rated before the treatment as not being manageable (or only with very strong anxiety).\nThe decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form) and subjectively by the patient himself with anxiety ratings (Subjective-Unit-of –Distress-Scale).\n""]	[""Avoidance behavior during the driving test in real traffic. The most important criterion is if the patients are able to manage at least one task/situation/individualized part of the course in the driving training with the driving instructor, which the patients rated before the treatment as not being manageable (or only with very strong anxiety).\nThe decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form) and subjectively by the patient himself with anxiety ratings (Subjective-Unit-of –Distress-Scale).\n""]	[""Avoidance behavior during the driving test in real traffic. The primary criterion is if the patients are able to master at least one driving task/situation in the driving test with a driving instructor, which they had rated before as not being manageable (or only with very strong anxiety). The decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form).""]	[""Avoidance behavior during the driving test in real traffic. The primary criterion is if the patients are able to master at least one driving task/situation in the driving test with a driving instructor, which they had rated before as not being manageable (or only with very strong anxiety). The decision for the success of the therapy is made by means of the rating of the driving instructor and of a traffic psychologist regarding the avoidance behavior (half-structured observation form).""]	NA
DRKS00010089	""Healthy Eating, Active Play - Promoting a healthy lifestyle in Young CHILDren (HEALTH SURVEY)"" – Study for the investigation of efficacy and cost effectiveness of the prevention program ""Join the healthy boat - kindergarten""	Intervention effects of a kindergarten-based health promotion programme on obesity related behavioural outcomes and BMI percentiles	10.1016/j.pmedr.2019.100931	https://www.sciencedirect.com/science/article/pii/S2211335519301056	6	2016-02-24	Recruiting planned	Recruiting complete, follow-up complete	2016-09-12	2017-11-30	2019-06-28	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""Primary outcomes are the changes (difference of follow-up measurements and baseline\nmeasurements) in\n- nutrition (e.g. consumption of sugar-sweetened beverages, fruit, vegetables, high-calorie food)\n- child’s time spent with screen media\n- child’s physical activity/energy expenditure\n- Health knowledge and attitude in parents and child care workers\n\nThe questionnaires are self-constructed.\nBaseline measurements: September/October 2016\nFollow-Up measurements: June/July 2017""]	[""Primary outcomes are the changes (difference of follow-up measurements and baseline\nmeasurements) in\n- nutrition (e.g. consumption of sugar-sweetened beverages, fruit, vegetables, high-calorie food)\n- child’s time spent with screen media\n- child’s physical activity/energy expenditure\n- Health knowledge and attitude in parents and child care workers\n\nThe questionnaires are self-constructed.\nBaseline measurements: September/October 2016\nFollow-Up measurements: June/July 2017""]	[""Primary outcomes are the changes (difference of follow-up measurements and baseline\nmeasurements) in\n- nutrition (e.g. consumption of sugar-sweetened beverages, fruit, vegetables, high-calorie food)\n- child’s time spent with screen media\n- child’s physical activity/energy expenditure\n- Health knowledge and attitude in parents and child care workers\n\nThe questionnaires are self-constructed.\nBaseline measurements: September/October 2016\nFollow-Up measurements: September/October 2017""]	NA	NA
DRKS00010190	Brief behavioral therapeutic intervention for reducing depersonalization during exams in test anxiety	Evaluation of a brief cognitive behavioral group intervention to reduce depersonalization in students with high levels of trait test anxiety: a randomized controlled trial	10.1080/10615806.2020.1736936	https://www.tandfonline.com/doi/abs/10.1080/10615806.2020.1736936	8	2016-03-22	Recruiting planned	Recruiting complete, follow-up complete	2016-04-10	2017-09-30	2020-03-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[""Significant difference between the intervention and of the waitlist control group in the reported severity of experienced depersonalization during the Trier Social Stress Test for groups (TSST-G; von Dawans, Kirschbaum, & Heinrichs, 2011), measured with the adapted version of the German Cambridge Depersonalization Scale (original: Sierra, 2000; German version: adapted version: Michal et al, 2004; Hoyer, Braeuer, Crawcour, Klumbies, & Kirschbaum 2013) directly after the TSST-G.""]	[""Significant difference between the intervention and of the waitlist control group in the reported severity of experienced depersonalization during the Trier Social Stress Test for groups (TSST-G; von Dawans, Kirschbaum, & Heinrichs, 2011), measured with the adapted version of the German Cambridge Depersonalization Scale (original: Sierra, 2000; German version: adapted version: Michal et al, 2004; Hoyer, Braeuer, Crawcour, Klumbies, & Kirschbaum 2013) directly after the TSST-G.""]	[""Significant difference between the intervention and of the waitlist control group in the reported severity of experienced depersonalization during the Trier Social Stress Test for groups (TSST-G; von Dawans, Kirschbaum, & Heinrichs, 2011), measured with the adapted version of the German Cambridge Depersonalization Scale (original: Sierra, 2000; German version: adapted version: Michal et al, 2004; Hoyer, Braeuer, Crawcour, Klumbies, & Kirschbaum 2013) directly after the TSST-G.""]	70 Years	NA
DRKS00010530	Early diagnosis and Treatment of acute kidney injury	The Effects of Intensive Versus Routine Treatment in Patients with Acute Kidney Injury	10.3238/arztebl.2020.0289	https://www.aerzteblatt.de/archiv/213628/Effekte-einer-intensivierten-Versorgung-im-Vergleich-zur-ueblichen-Versorgung-bei-akuter-Nierenschaedigung	6	2016-05-18	Recruiting ongoing	Recruiting complete, follow-up complete	2016-06-01	2016-10-26	2020-04-24	TRUE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	FALSE	NA	post_completion	[""Renal recovery (Proportions of patients, mL/min) according to recommendations by the KDIGO Initiative (serum creatinine, proteinuria) at hospital discharge""]	NA	[""Renal recovery (Proportions of patients, mL/min) according to recommendations by the KDIGO Initiative (serum creatinine, proteinuria) at hospital discharge""]	[""Renal recovery (Proportions of patients, mL/min) according to recommendations by the KDIGO Initiative (serum creatinine, proteinuria) at hospital discharge""]	NA
DRKS00010623	Investigation of the autonomic regulation of delayed onset muscle soreness	The pain threshold of high-threshold mechanosensitive receptors subsequent to maximal eccentric exercise is a potential marker in the prediction of DOMS associated impairment	10.1371/journal.pone.0185463	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630131/	5	2016-06-08	Recruiting ongoing	Recruiting complete, follow-up complete	2016-04-29	2016-07-15	2016-10-06	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[""Pressure pain threshold (over time) when comparing\na) Group 1 (preventive) to control\nOR\nb) Group 2 (rehabilitative) to control""]	[""Pressure pain threshold (over time) when comparing\na) Group 1 (preventive) to control\nOR\nb) Group 2 (rehabilitative) to control""]	NA	99 Years	NA
DRKS00011013	Effect of hyperthermic baths (HTB) on depression	NA	10.1101/409276	https://www.biorxiv.org/content/10.1101/409276v1.abstract	6	2016-09-19	Recruiting ongoing	Recruiting complete, follow-up complete	2016-09-30	2017-03-20	2018-09-12	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[""Hamilton Depression Rating Scale (HAMD-17 score) after 2 weeks of intervention (4 treatments) in comparison of hot bath group with control group (physical exercise).""]	[""Hamilton Depression Rating Scale (HAMD-17 score) after 2 weeks of intervention (4 treatments) in comparison of hot bath group with control group (physical exercise).""]	[""Hamilton Depression Rating Scale (HAMD-17 score) after 2 weeks of intervention (4 treatments) in comparison of HTB group with control group (physical exercise).""]	NA	NA
DRKS00012409	Acute effects of moderate walking on postprandial events after consuming different high-energy meals in elderly men and women with a risk phenotype for cardiovascular disease	Acute Impact of Dietary Pattern and Walking on Postprandial Attention, Mood, and Satiety in Older Adults: A Randomized Crossover Trial	10.3390/nu11102294	https://www.mdpi.com/2072-6643/11/10/2294	11	2017-05-03	Recruiting planned	Recruiting complete, follow-up complete	2017-06-06	2017-07-30	2019-09-26	TRUE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[""Parameter of endothelial function, inflammation, oxidation and lipid and glucose metabolism; at fasting state and 1.5, 3.0 and 4.5 hours postprandially""]	NA	[""serum triglycerides, measured at fasting state and 1.5, 3.0 and 4.5 hours postprandially\n""]	80 Years	NA
NCT00047099	Combination Chemotherapy in Treating Women With Breast Cancer	Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study	10.1038/bjc.2016.82	https://www.ncbi.nlm.nih.gov/pubmed/27031854	26	2005-06-23	Recruiting	Completed	NA	NA	2016-03-31	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of time to progression""}]
NCT00052468	Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer	CXCL12 expression by healthy and malignant ovarian epithelial cells	10.1186/1471-2407-11-97	https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-97	14	2005-06-23	Recruiting	Completed	NA	NA	2011-03-16	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: Whole Study Period ]\n\nSurvival time is calculated from the date of enrollment into the study until the date of death from any cause""}]	[]
NCT00055874	Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV	10.1182/blood-2009-08-237115	https://pubmed.ncbi.nlm.nih.gov/19965667/	45	2005-06-23	Recruiting	Completed	NA	2012-03-31	2009-11-18	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Risk group-dependent survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Progression-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Hematologic, cytogenetic, and molecular response rates""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Risk group-dependent survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Progression-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Hematologic, cytogenetic, and molecular response rates""}]
NCT00056056	Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)	10.1111/j.1365-2133.2012.11156.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2012.11156.x/abstract	35	2005-06-23	Recruiting	Terminated	NA	NA	2012-09-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate (complete clinical response [CCR) and partial response [PR])\n[ Time Frame: 35 months after first patient in ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate (complete clinical response [CCR) and partial response [PR])\n[ Time Frame: 35 months after first patient in ]""}]
NCT00061984	Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial	10.1016/s1470-2045(14)70063-4	https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(14)70063-4	38	2005-06-23	Recruiting	Completed	NA	NA	2014-03-05	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]
NCT00079105	A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years	Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study	10.1182/blood-2011-12-396556	https://www.ncbi.nlm.nih.gov/pubmed/22577177	52	2005-06-23	Recruiting	Completed	NA	2010-12-01	2012-05-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging\n[ Time Frame: 6 month intervals ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease-free survival by routine imaging at 6 month intervals""}]
NCT00086580	Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients	Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial	10.1016/s1470-2045(11)70242-x	https://www.ncbi.nlm.nih.gov/pubmed/21992852?dopt=Abstract	18	2005-06-23	Recruiting	Completed	NA	NA	2011-10-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00088530	BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial	10.1016/s1470-2045(12)70212-7	https://www.ncbi.nlm.nih.gov/pubmed/22652183?dopt=Abstract	16	2005-06-23	Recruiting	Completed	2004-07-01	2008-08-01	2012-05-30	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response\n[ Time Frame: 84 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response\n[ Time Frame: 84 days ]""}]	[See Results Section.]	NA
NCT00094497	Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)	Combination chemotherapy in advanced adrenocortical carcinoma	10.1056/nejmoa1200966	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00094497	21	2005-06-23	Recruiting	Completed	2004-06-01	2010-10-01	2012-05-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: At the final analysis ]""}]	[See Results Section.]	NA
NCT00094653	MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma	Improved survival with ipilimumab in patients with metastatic melanoma	10.1056/nejmoa1003466	https://www.ncbi.nlm.nih.gov/pubmed/20525992?dopt=Abstract	50	2005-06-26	Recruiting	Completed	2004-09-01	2009-01-01	2010-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best Objective Response Rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best Objective Response Rate (BORR)\n[ Time Frame: BORR will be measure at 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of overall survival of patients administered MDX-010 in combination with gp 100 melanoma peptide vaccine versus those administered gp 100 melanoma peptide vaccine alone\n[ Time Frame: The study will end when 481 deaths are observed ]""}]	[See Results Section.]	NA
NCT00095875	Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)	Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial	10.1016/s1470-2045(13)70011-1	http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970011-1/abstract	49	2005-06-23	Recruiting	Completed	NA	2012-04-01	2013-02-13	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[]	NA	NA	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival at 3 years""}]
NCT00098137	Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation	Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial	10.1161/circep.111.965178	https://www.ncbi.nlm.nih.gov/pubmed/22157519	9	2005-06-23	Recruiting	Completed	2005-01-01	2008-05-01	2011-12-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)\n[ Time Frame: 12 months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of days with documented episodes of paroxysmal atrial fibrillation (number of days with paroxysmal atrial fibrillation/number of days with at least one readable Tele-ECG recording)\n[ Time Frame: 12 months follow-up ]""}]	NA
NCT00111345	Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004	10.1182/blood-2013-02-484097	https://pubmed.ncbi.nlm.nih.gov/23704089/	9	2005-06-23	Recruiting	Unknown status	2004-03-01	NA	2013-05-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free and absolute survival from the date of diagnosis concerning objective 1 and from the date of randomisation concerning objective 2\n[ Time Frame: 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Concerning objective 3: Disease-free survival from the date of randomisation\n[ Time Frame: 5 years ]""}]
NCT00114348	ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia	Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group	10.1200/jco.2012.48.5680	https://www.ncbi.nlm.nih.gov/pubmed/23775972?dopt=Abstract	4	2005-06-23	Recruiting	Completed	2003-08-01	2012-07-01	2013-06-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of MRD""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""event-free and overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""the toxicity associated with each treatment strategy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of MRD""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""event-free and overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""the toxicity associated with each treatment strategy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of MRD\n[ Time Frame: a ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""event-free and overall survival\n[ Time Frame: a ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""the toxicity associated with each treatment strategy\n[ Time Frame: a ]""}]	NA	NA
NCT00118573	Comparison of Surveillance Versus Aortic Endografting for Small Aneurysm Repair	Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR): results from a randomised trial	10.1016/j.ejvs.2010.08.026	https://linkinghub.elsevier.com/retrieve/pii/S1078-5884(10)00527-7	7	2005-06-30	Recruiting	Terminated	2004-09-01	2010-05-01	2010-09-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality at 3 years\n[ Time Frame: 3 years ]""}]	NA
NCT00119717	Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)	Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial	10.1161/strokeaha.110.609933	NA	32	2005-07-07	Recruiting	Completed	2005-06-01	2010-04-01	2011-05-12	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The safety of the NeuroFlo device and procedure will be compared to medical management alone""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""All adverse events out to 90 days will be reported""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Efficacy will be assessed at 90 days using a global outcome score.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The safety of the NeuroFlo device and procedure will be compared to medical management alone\n[ Time Frame: 90 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy will be assessed using a global outcome score\n[ Time Frame: 90 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The safety of the NeuroFlo device and procedure will be compared to medical management alone\n[ Time Frame: 90 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy will be assessed using a global outcome score\n[ Time Frame: 90 days ]""}]	NA
NCT00120406	Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery	Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results	10.1161/circinterventions.111.962324	https://www.ncbi.nlm.nih.gov/pubmed/21953370?dopt=Abstract	23	2005-07-11	Recruiting	Completed	2005-03-01	2011-01-01	2011-09-27	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary patency of the superfemoropopliteal artery evaluated at 12 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary patency of the superfemoropopliteal artery evaluated at 12 months\n[ Time Frame: 12 months. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary patency of the superfemoropopliteal artery evaluated at 12 months\n[ Time Frame: 12 months. ]""}]	[See Results Section.]	NA
NCT00124813	Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma	Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma	10.1007/s12288-011-0103-1	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332274/	9	2005-07-27	Recruiting	Unknown status	2002-08-01	NA	2012-06-01	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Induction therapy:""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""- Response Rate""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""- Overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""- Death rate""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Maintenance therapy:""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""- Progression-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""- Number of patients discontinuing therapy due to toxicity""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Induction therapy: response rate, overall survival, death rate""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Maintenance therapy: progression-free survival, overall survival, number of patients discontinuing therapy due to toxicity""}]
NCT00133978	Trial of Glutamine and Antioxidant Supplementation in Critically Ill Patients	A randomized trial of glutamine and antioxidants in critically ill patients	10.1056/nejmoa1212722	https://www.ncbi.nlm.nih.gov/pubmed/23594003?dopt=Abstract	16	2005-08-22	Recruiting	Completed	2005-04-01	2011-12-01	2013-04-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome for this study is 28-day mortality.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome for this study is 28-day mortality.\n[ Time Frame: 28 day mortality ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome for this study is 28-day mortality.\n[ Time Frame: 28 day mortality ]\n\n28-day mortality/status: at 28 days after randomization; 14 day mortality/status: at 14 days after randomization; Hospital mortality, % died in hospital, % discharged from hospital, % alive and still in hospital; Kaplan-Meier survival curves to 6 months; Subgroup analyses: two vs more than two organ failures on presentation, severity of illness, sepsis vs other admission diagnosis, age, comorbidity""}]	[See Results Section.]	NA
NCT00150878	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission	Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial	10.1016/s1470-2045(12)70349-2	https://www.ncbi.nlm.nih.gov/pubmed/22959335?dopt=Abstract	6	2005-09-06	Recruiting	Terminated	2003-12-01	2009-12-01	2012-09-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation\n[ Time Frame: 12 months ]\n\nProportion of patients dying without prior relapse""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Treatment-related mortality at 12 months after transplantation\n[ Time Frame: 12 months ]\n\nProportion of patients dying without prior relapse""}]	NA
NCT00151242	Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B	10.3324/haematol.13378	https://www.ncbi.nlm.nih.gov/pubmed/19059939?dopt=Abstract	13	2005-09-06	Recruiting	Completed	2004-07-01	2011-08-01	2008-12-04	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""CR-rate after induction therapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete remission (CR)-rate after induction therapy\n[ Time Frame: after the second induction cycle ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse-free survival, one year after consolidation therapy with high-dose cytarabine considering different temporal sequences (1-3-5 versus 1-2-3) of the consolidation therapy\n[ Time Frame: One year after consolidation therapy ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Event-free survival\n[ Time Frame: two years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete remission (CR)-rate after induction therapy\n[ Time Frame: after the second induction cycle ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse-free survival, one year after consolidation therapy with high-dose cytarabine considering different temporal sequences (1-3-5 versus 1-2-3) of the consolidation therapy\n[ Time Frame: One year after consolidation therapy ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Event-free survival\n[ Time Frame: two years ]""}]	NA
NCT00163267	Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel	Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease	10.1583/13-4275mr.1	https://www.ncbi.nlm.nih.gov/pubmed/24093324	6	2005-09-12	Not yet recruiting	Completed	2005-09-01	2009-12-01	2013-10-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet activation during and after the intervention""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet activation during and after the intervention""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Platelet activation during and after the intervention\n[ Time Frame: 6-12 hours ]\n\nmeasured in a chandler loop model""}]	NA	NA
NCT00167583	NA	NA	NA	NA	8	2005-09-09	Recruiting	Completed	NA	2014-12-01	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of disease activity and preservation of visual acuity (monthly, at one and 2 yearss)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to improvement and remission""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of disease activity and preservation of visual acuity (monthly, at one and 2 years)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to improvement and remission\n[ Time Frame: 2 years ]""}]
NCT00170326	Progressive Ventricular Dysfunction Prevention in Pacemaker Patients	Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF)	10.1093/eurjhf/hfr041	https://www.ncbi.nlm.nih.gov/pubmed/21613427	6	2005-09-13	Recruiting	Completed	2002-01-01	2009-03-01	2011-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evolution of the ejection fraction (EF) of the left ventricle (LV) and the ventricular volumes.\n[ Time Frame: 12 months ]""}]	NA
NCT00170690	Preference Study With Elderly Patients Recurrent Ovarian Cancer	Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial	10.1186/s40661-017-0040-2	https://gynoncrp.biomedcentral.com/articles/10.1186/s40661-017-0040-2	7	2005-09-12	Recruiting	Completed	NA	2011-12-01	2017-03-07	FALSE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of patient´s compliance in both arms defined as therapy break-offs\n[ Time Frame: during study treatment ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of patient´s compliance in both arms defined as therapy break-offs\n[ Time Frame: during study treatment ]""}]
NCT00180102	AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years	High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial	10.1200/jco.2012.46.4743	https://www.ncbi.nlm.nih.gov/pubmed/23630210	7	2005-09-12	Recruiting	Completed	2003-12-01	2009-11-01	2013-04-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""- overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""- relapse-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""relapse-free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""relapse-free survival""}]	NA	NA
NCT00182819	Radiation Therapy or Temozolomide in Treating Patients With Gliomas	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study	10.1016/s1470-2045(16)30313-8	https://www.ncbi.nlm.nih.gov/pubmed/27686946?dopt=Abstract	57	2005-09-15	Not yet recruiting	Completed	NA	2013-01-01	2016-09-27	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	FALSE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: 5 years ]""}]
NCT00185159	Olmesartan Medoxomil in Diabetes Mellitus	Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study	10.1007/s00125-009-1577-3	https://www.ncbi.nlm.nih.gov/pubmed/19876613?dopt=Abstract	6	2005-09-12	Recruiting	Completed	2004-10-01	NA	2009-10-30	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to the first occurrence of microalbuminuria""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine\n[ Time Frame: Time to the first occurrence ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urine\n[ Time Frame: Time to the first occurrence ]""}]
NCT00204529	Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB	Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial	10.1093/annonc/mdw225	https://www.sciencedirect.com/science/article/pii/S0923753419347532?via%3Dihub	10	2005-09-12	Recruiting	Completed	NA	NA	2020-01-06	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to distant metastasis""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to distant metastasis\n[ Time Frame: From date of randomization until the date of first documented distant metastases or date of death from any cause, whichever came first, assessed up to 60 months ]""}]
NCT00204542	Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head	Open label randomized study comparing 3 months vs. 6 months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group	10.1111/j.1468-3083.2011.04005.x	https://www.ncbi.nlm.nih.gov/pubmed/21414035	10	2005-09-13	Recruiting	Completed	2005-06-01	2009-03-01	2011-03-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis\n[ Time Frame: 6 weeks after end of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis\n[ Time Frame: 6 weeks after end of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Histologically controlled complete clearance of the actinic keratosis\n[ Time Frame: 6 weeks after end of treatment ]""}]	NA
NCT00211237	CAFE Study - Cancer Patient Fracture Evaluation	Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial	10.1016/s1470-2045(11)70008-0	https://www.ncbi.nlm.nih.gov/pubmed/21333599	25	2005-09-13	Recruiting	Completed	2005-05-01	2008-04-01	2011-02-16	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint of the study is the improvement in functional status, as measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 month.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The improvement in functional status, as measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 month""}]	[See Results Section.]	[See Results Section.]	NA
NCT00224770	Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation	Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial	10.1016/s1474-4422(16)30234-4	NA	11	2005-09-21	Recruiting	Completed	2005-08-01	2011-08-01	2016-10-11	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Procedure related mortality""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of cerebritis, meningitis""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Rate of rebleeding""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mortality\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Procedure related mortality\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of cerebritis, meningitis\n[ Time Frame: 30 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Rate of rebleeding\n[ Time Frame: 30 days ]""}]	[See Results Section.]	NA	NA
NCT00232830	The Study to Assess AMI Treated With Balloon Angioplasty.	Sirolimus-eluting versus uncoated stents in acute myocardial infarction	10.1056/nejmoa062006	http://www.nejm.org/doi/full/10.1056/NEJMoa062006	17	2005-10-04	Active, not recruiting	Completed	2003-10-01	NA	2006-09-14	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 1 year post-procedure.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vesselpost-procedure.\n[ Time Frame: 1 and 6 months and at 1, 3, 4, and 5 years post-procedure. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel at 1 year post-procedure.""}]
NCT00251251	Resynchronization/Defibrillation for Ambulatory Heart Failure Trial	Cardiac-resynchronization therapy for mild-to-moderate heart failure	10.1056/nejmoa1009540	http://www.nejm.org/doi/full/10.1056/NEJMoa1009540	10	2005-11-08	Recruiting	Completed	2003-04-01	2010-09-01	2010-11-14	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome is a composite of all cause total mortality and hospitalization for CHF""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome is a composite of all cause total mortality and hospitalization for CHF""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary outcome is a composite of all cause total mortality and hospitalization for CHF\n[ Time Frame: Study end ]""}]	NA
NCT00256152	Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial	Subclinical atrial fibrillation and the risk of stroke	10.1056/nejmoa1105575	http://www.nejm.org/doi/full/10.1056/NEJMoa1105575	7	2005-11-17	Recruiting	Completed	2004-09-01	2010-06-01	2012-01-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary study outcome will be a composite of:""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Ischemic stroke, Non-CNS systemic embolism""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary study outcome will be a composite of:""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Ischemic stroke, Non-CNS systemic embolism""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of ischemic stroke & Non-CNS systemic embolism\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Symptomatic or Asymptomatic AT documented by ECG\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of ischemic stroke & Non-CNS systemic embolism\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Symptomatic or Asymptomatic AT documented by ECG\n[ Time Frame: 3 years ]""}]	NA
NCT00262119	MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure	Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial	10.1093/eurheartj/ehu165	https://www.ncbi.nlm.nih.gov/pubmed/24771721?dopt=Abstract	17	2005-12-04	Not yet recruiting	Completed	2006-02-01	2012-02-01	2014-04-25	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death for all causes at 2 years""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of permanent atrial fibrillation at 2 years""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of cardiovascular hospitalization at 2 years""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death for all causes at 2 years\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of permanent atrial fibrillation at 2 years\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Death for all causes at 2 years\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of permanent atrial fibrillation at 2 years\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Incidence of Cardiovascular hospitalizations at 2 years\n[ Time Frame: 2 years ]""}]	[See Results Section.]	NA
NCT00263419	Stress-relief Management for Treatment of Late Complications in Type 2 Diabetes	Sustained effects of a mindfulness-based stress-reduction intervention in type 2 diabetic patients: design and first results of a randomized controlled trial (the Heidelberger Diabetes and Stress-study)	10.2337/dc11-1343	http://care.diabetesjournals.org/content/35/5/945	5	2005-12-07	Recruiting	Unknown status	2005-01-01	NA	2012-02-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression of albuminuria""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression of albuminuria\n[ Time Frame: 1,2,3,4 and 5 year ]""}]
NCT00268853	A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin	Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma	10.1093/annonc/mdt289	NA	10	2005-12-21	Recruiting	Completed	2005-11-01	2010-11-01	2013-08-14	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to compare the standard CHOP-R and to show that the response rate for CPOP-R is not inferior to that of CHOP-R""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.\n[ Time Frame: Subjects followed for 5 years post treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.\n[ Time Frame: Subjects followed for 5 years post treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to show that the response rate for CPOP-R is not inferior to that of CHOP-R.\n[ Time Frame: Subjects followed for 5 years post treatment ]""}]	NA
NCT00272948	Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial	10.1016/s0140-6736(11)61938-7	http://www.sciencedirect.com/science/article/pii/S0140673611619387?via%3Dihub	8	2006-01-04	Recruiting	Completed	2005-12-01	2009-12-01	2012-02-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The aim of this trial is to evaluate prophylactic Defibrotide (DF) in a pediatric patient population at high risk for Veno-occlusive Disease (VOD).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary objective is to evaluate if prophylactic DF has an impact on the:""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""- incidence of VOD,""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""- the severity of VOD and""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""- the mortality due to VOD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD\n[ Time Frame: Day + 30 post HSCT ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate if prophylactic DF has an impact on the incidence of VOD\n[ Time Frame: Day + 30 post HSCT ]""}]	NA	NA
NCT00275054	Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in ""Real-Life"" Outside of Clinical Trials	10.21873/anticanres.13382	https://pubmed.ncbi.nlm.nih.gov/31092457/	51	2006-01-10	Recruiting	Completed	NA	2007-07-01	2019-05-01	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	FALSE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Development of a new prognostic staging system""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Development of a new prognostic staging system""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Development of a new prognostic staging system""}]
NCT00281515	Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer	Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV	10.1016/j.ygyno.2012.04.050	https://www.ncbi.nlm.nih.gov/pubmed/22564713?dopt=Abstract	6	2006-01-24	Recruiting	Completed	2006-01-01	NA	2012-05-04	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: every 3 months until PD ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival""}]
NCT00282646	Safety and Feasibility Study of Autologous Bone Marrow Cell Transplantation in Patients With Peripheral Arterial Occlusive Disease (PAOD)	Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA)	10.1161/circinterventions.110.958348	http://circinterventions.ahajournals.org/content/4/1/26	7	2006-01-25	Recruiting	Completed	2005-10-01	2010-10-01	2011-01-04	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ankle brachial index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ankle brachial index\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ankle brachial index\n[ Time Frame: 6 months ]""}]	NA
NCT00284713	Progenitor Cell Therapy in Dilative Cardiomyopathy	Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease	10.1016/j.jacc.2012.02.033	http://www.sciencedirect.com/science/article/pii/S156919931000144X?via%3Dihub	7	2006-01-31	Recruiting	Completed	2004-05-01	2009-01-01	2012-06-05	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LV function (Ejection fraction within 3 months) Simpson""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LV function (Ejection fraction within 3 months) Simpson\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LV function (Ejection fraction within 3 months) Simpson\n[ Time Frame: 4 months ]""}]	NA	NA
NCT00298363	Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease	10.1002/hep.23952	https://www.ncbi.nlm.nih.gov/pubmed/21254162?dopt=Abstract	17	2006-02-28	Not yet recruiting	Completed	2006-03-01	2010-12-01	2010-10-27	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety (adverse events and laboratory tests, discontinuations due to adverse events)\n[ Time Frame: Week 48 ]""}]	NA	[See Results Section.]	NA
NCT00303459	Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension	10.1183/13993003.02044-2014	http://erj.ersjournals.com/content/46/2/405.long	31	2006-03-16	Not yet recruiting	Completed	2006-04-01	2013-09-01	2015-06-25	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from baseline to first adjudicated morbidity/mortality event""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline to Week 16 in 6 Minute Walk Test""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time from baseline to first adjudicated morbidity/mortality event\n[ Time Frame: From baseline to first adjudicated morbidity/mortality event ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00307450	Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease	Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial	10.1007/s00702-010-0472-x	https://www.ncbi.nlm.nih.gov/pubmed/20803300	4	2006-03-27	Recruiting	Completed	2006-03-01	2009-03-01	2010-08-29	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified AIMS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified AIMS""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Modified AIMS\n[ Time Frame: 11 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""UPDRS items 32 & 33\n[ Time Frame: 11 weeks ]""}]	NA	NA
NCT00312845	Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial	10.1016/s1470-2045(11)70150-4	NA	20	2006-04-07	Recruiting	Completed	NA	2010-03-01	2011-07-01	FALSE	FALSE	TRUE	TRUE	TRUE	NA	TRUE	FALSE	TRUE	unknown	[]	NA	[See Results Section.]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: 40 months to the end of the study ]""}]
NCT00317642	A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)	Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial	10.1200/jco.2011.37.9743	http://ascopubs.org/doi/abs/10.1200/JCO.2011.37.9743?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed	38	2006-04-24	Not yet recruiting	Completed	NA	2012-09-01	2012-05-14	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival""}]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00322101	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation	10.1111/bjh.13476	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526353/	50	2006-05-02	Recruiting	Completed	NA	2013-02-01	2016-08-01	FALSE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	TRUE	unknown	[]	NA	[See Results Section.]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: At 2 years ]""}]
NCT00323297	Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial	10.1186/s12872-017-0674-3	https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-017-0674-3	81	2006-05-05	Not yet recruiting	Completed	2006-09-01	2012-08-01	2017-09-06	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the effect on exercise capacity (as measured by the 6 Minute Walk Test) after 12 weeks of treatment of sildenafil (20mg TID) or placebo, when added to subjects with PAH who are stabilized on bosentan therapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the effect on exercise capacity (as measured by the 6 Minute Walk Test) after 12 weeks\n[ Time Frame: Week 12 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00324311	Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care	A novel rapid and selective enzymatic debridement agent for burn wound management: a multi-center RCT	10.1016/j.burns.2013.08.013	https://www.ncbi.nlm.nih.gov/pubmed/24074719	6	2006-05-10	Recruiting	Completed	2005-12-01	2009-10-01	2013-09-26	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point is % treated wound excised (tangential and/or minor excision), in first surgery.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds\n[ Time Frame: Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Co-primary: % treated wound autografted of deep partial wounds\n[ Time Frame: Post-debridement autografts ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds\n[ Time Frame: Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Co-primary: % treated wound autografted of deep partial wounds\n[ Time Frame: Post-debridement autografts ]""}]	NA	NA
NCT00326066	A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients.	Fluorophotometric study of the effect of the glaukos trabecular microbypass stent on aqueous humor dynamics	10.1167/iovs.09-3972	https://www.ncbi.nlm.nih.gov/pubmed/20207977?dopt=Abstract	8	2006-05-12	Recruiting	Completed	2005-02-01	NA	2010-03-05	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary effectiveness measure will be intraocular pressure measurement from preoperative baseline.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Incidence of adverse events during the surgical procedure and postoperative period.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]
NCT00326079	A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2	Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study	10.1136/bjophthalmol-2011-300218	http://bjo.bmj.com/content/96/5/645.short	8	2006-05-12	Recruiting	Unknown status	2004-08-01	NA	2012-01-23	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary effectiveness measure will be intraocular pressure measurement from preoperative baseline.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Incidence of adverse events during the surgical procedure and postoperative period.""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy\n[ Time Frame: 24 months ]""}]
NCT00326989	Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium	Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial	10.1001/jama.2013.3527	http://jamanetwork.com/journals/jama/fullarticle/1679402	8	2006-05-16	Recruiting	Completed	2006-05-01	2011-09-01	2013-04-17	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement in global ejection fraction on LV angiography\n[ Time Frame: 4 months ]""}]	NA
NCT00330369	DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial	10.1016/s0140-6736(09)61500-2	https://www.sciencedirect.com/science/article/pii/S0140673609615002	14	2006-05-24	Not yet recruiting	Completed	2006-06-01	2009-04-01	2009-09-11	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy measure is change from baseline in trough sitting systolic blood pressure measured by sphygmomanometry""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The co-primary efficacy measures are change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The co-primary efficacy measures are change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Baseline to Week 14 ]""}]	NA
NCT00331890	ICTUS Study: International Citicoline Trial on Acute Stroke	Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)	10.1016/s0140-6736(12)60813-7	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60813-7/abstract	28	2006-05-30	Not yet recruiting	Terminated	2006-10-01	2012-02-01	2012-06-11	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a GEE analysis including NIHSS, mRS and Barthel Index""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total recovery at three months of onset, based on a global test analysis including NIHSS, mRS and Barthel Index\n[ Time Frame: 3 months ]""}]	NA
NCT00334594	Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial	10.1016/s1470-2045(15)00208-9	http://www.sciencedirect.com/science/article/pii/S1470204515002089?via%3Dihub	29	2006-06-07	Recruiting	Completed	NA	2013-12-01	2015-11-02	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	FALSE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete macroscopic resection (part 1)\n[ Time Frame: After surgery (15 weeks after trial registration) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Loco-regional relapse-free survival (part 2)\n[ Time Frame: From surgery until the first occurrence of loco-regional relapse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete macroscopic resection (part 1)\n[ Time Frame: After surgery (15 weeks after trial registration) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Loco-regional relapse-free survival (part 2)\n[ Time Frame: From surgery until the first occurrence of loco-regional relapse ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete macroscopic resection (part 1)\n[ Time Frame: After surgery (15 weeks after trial registration) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Loco-regional relapse-free survival (part 2)\n[ Time Frame: From surgery until the first occurrence of loco-regional relapse ]""}]
NCT00335543	Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery	Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial	10.1007/s00066-014-0737-7	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289008/	24	2006-06-08	Recruiting	Completed	NA	2009-06-01	2014-09-25	FALSE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median survival""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median survival""}]
NCT00338689	European Childhood Obesity Project: Early Programming by Infant Nutrition?	Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical trial	10.3945/ajcn.2008.27091	NA	7	2006-06-19	Active, not recruiting	Active, not recruiting	2002-10-01	NA	2009-04-22	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""anthropometry at birth and at 3, 6, 12, 24, 30, 36, 42, 48, 54, 60, 66 and 72 months of age""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Body mass index BMI: derived from measured body height (m) and body weight (kg) as body weight / height²\n[ Time Frame: At age 11 years ]\n\nBody height (cm) will be determined with calibrated clinical equipment Body weight (kg) will be determined with calibrated clinical equipment BMI calculated""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""anthropometry\n[ Time Frame: at birth and at 3, 6, 12, 24, 30, 36, 42, 48, 54, 60, 66 and 72, 84, 96 months of age ]""}]
NCT00344253	Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis	Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial	10.1016/j.ajo.2013.05.002	https://www.ncbi.nlm.nih.gov/pubmed/23786783	4	2006-06-22	Recruiting	Completed	2006-03-01	2011-03-01	2013-06-17	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12\n[ Time Frame: at month 1,3,6 and 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in visual acuity (3 lines ETDRS)at month 1,3,6 and 12\n[ Time Frame: at month 1,3,6 and 12 ]""}]	NA	NA
NCT00349076	Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial	10.1016/s1470-2045(15)00159-x	https://pubmed.ncbi.nlm.nih.gov/26189067/	13	2006-07-05	Not yet recruiting	Completed	2006-07-01	2010-12-01	2015-07-15	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease free survival at 3 years defined as the interval from randomization to locoregional or metastatic recurrence or the appearance or a secondary colorectal cancer or death, whichever occurs first.\n[ Time Frame: 3 years ]""}]	NA
NCT00349089	Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy	Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study	10.1093/annonc/mds578	https://pubmed.ncbi.nlm.nih.gov/23161898/	9	2006-07-04	Not yet recruiting	Completed	2006-10-01	2013-12-01	2012-11-15	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin\n[ Time Frame: 4 month ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the clinical feasibility rate of 4 cycles of adjuvant chemotherapy with Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin\n[ Time Frame: 4 month ]""}]	NA
NCT00353496	Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours	Lanreotide in metastatic enteropancreatic neuroendocrine tumors	10.1056/nejmoa1316158	https://www.ncbi.nlm.nih.gov/pubmed/25014687?dopt=Abstract	26	2006-07-17	Recruiting	Completed	2006-06-01	2013-06-01	2014-07-17	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to either disease progression or death within 96 weeks after the first study drug administration.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to either disease progression or death\n[ Time Frame: Within 96 weeks after the first study drug administration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to either disease progression or death\n[ Time Frame: Within 96 weeks after the first study drug administration ]""}]	[See Results Section.]	NA
NCT00354133	Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease	Neurostimulation for Parkinson's disease with early motor complications	10.1056/nejmoa1205158	https://www.ncbi.nlm.nih.gov/pubmed/23406026?dopt=Abstract	9	2006-07-19	Not yet recruiting	Active, not recruiting	2006-07-01	2011-12-01	2013-02-14	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PDQ-39\n[ Time Frame: 24 months ]\n\nDifference in the PDQ-39 summary index at 24 months compared to the baseline assessment.""}]	NA
NCT00355095	Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis	A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis	10.1002/ana.23573	http://onlinelibrary.wiley.com/doi/10.1002/ana.23573/abstract	9	2006-07-20	Not yet recruiting	Completed	2006-08-01	2011-02-01	2012-08-27	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline. Measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.\n[ Time Frame: 4 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""nerve fiber loss in the optical nerve head determined by optical coherence tomography at weeks 4,8 and 16 compared to baseline. Measurements at baseline and week 16 are used to calculate estimates for changes and differences between the groups.\n[ Time Frame: 4 months ]""}]	NA
NCT00355862	Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial	10.1097/tp.0000000000000965	https://pubmed.ncbi.nlm.nih.gov/26555945/	10	2006-07-24	Recruiting	Completed	2006-01-01	2009-03-01	2016-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival\n[ Time Frame: 5 year follow up after last patient in ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival\n[ Time Frame: 5 year follow up after last patient in ]""}]	NA	NA
NCT00359424	Interventional Management of Stroke (IMS) III Trial	Endovascular therapy after intravenous t-PA versus t-PA alone for stroke	10.1056/nejmoa1214300	https://www.ncbi.nlm.nih.gov/pubmed/23390923?dopt=Abstract	23	2006-07-31	Not yet recruiting	Terminated	2006-08-01	2014-05-01	2013-02-07	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy: modified Rankin Scale score, dichotomized to 0-2 verses greater than 2 at 3 months from randomization.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety:(1) death due to any cause within 3 months""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""(2) presence of symptomatic ICH (intracranial hemorrhage) within the first 24 (+ 6 hours) hours.""}]	[See Results Section.]	NA	NA	NA
NCT00359918	Randomized Multicenter Trial of Prehospital Initiated Facilitated Percutaneous Coronary Intervention (PCI) Versus Primary PCI in ST-segment-Elevation MI (STEMI)	Randomized comparison of pre-hospital-initiated facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention in acute myocardial infarction very early after symptom onset: the LIPSIA-STEMI trial (Leipzig immediate prehospital facilitated angioplasty in ST-segment myocardial infarction)	10.1016/j.jcin.2011.01.013	https://www.ncbi.nlm.nih.gov/pubmed/21700245?dopt=Abstract	5	2006-08-01	Recruiting	Completed	2006-08-01	2009-08-01	2011-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI\n[ Time Frame: 1-6 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size and microvascular obstruction assessed by MRI\n[ Time Frame: 1-6 days ]""}]	NA
NCT00366158	EVITA: Evaluation of VIP Feature in Pacemaker Patients	Minimizing right ventricular pacing in pacemaker patients with intact and compromised atrioventricular conduction : Results from the EVITA Trial	10.1007/s00399-015-0394-2	https://link.springer.com/article/10.1007%2Fs00399-015-0394-2	7	2006-08-18	Not yet recruiting	Completed	2006-08-01	2009-02-01	2015-08-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of ventricular pacing\n[ Time Frame: 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of ventricular pacing\n[ Time Frame: 6 and 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of ventricular pacing\n[ Time Frame: 6 and 12 months ]""}]	NA
NCT00368953	YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus	Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial	10.1016/j.jcin.2010.11.016	https://www.ncbi.nlm.nih.gov/pubmed/21511226?dopt=Abstract	7	2006-08-28	Not yet recruiting	Completed	2006-09-01	2009-12-01	2011-04-01	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""In-stent late lumen loss\"" at follow-up-angiography (9 months)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""In-stent late lumen loss\"" at follow-up-angiography (9 months)\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""\""In-stent late lumen loss\"" at follow-up-angiography (9 months)\n[ Time Frame: 9 months ]""}]	NA	NA
NCT00369018	A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.	Photodynamic therapy of cervical intraepithelial neoplasia 1-3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate--a double-blind, dose-finding study	10.1002/lsm.22041	https://www.ncbi.nlm.nih.gov/pubmed/22693121	4	2006-08-28	Recruiting	Completed	2006-08-01	2009-07-01	2012-06-12	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 months ]""}]	NA	NA
NCT00372216	CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction	Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial	10.1007/s00392-011-0393-1	NA	10	2006-09-04	Not yet recruiting	Completed	2006-10-01	2009-10-01	2011-12-21	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TIMI 2/3 patency of the infarct-related artery immediately prior to PCI""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TIMI 2/3 patency of the infarct-related artery immediately prior to PCI\n[ Time Frame: Assessment at primary PCI, asap after inclusion of the subject ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TIMI 2/3 patency of the infarct-related artery immediately prior to PCI\n[ Time Frame: Assessment at primary PCI, asap after inclusion of the subject ]""}]	NA	NA
NCT00373425	A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial	10.1200/jco.2015.61.8918	https://www.ncbi.nlm.nih.gov/pubmed/26324372?dopt=Abstract	63	2006-09-07	Recruiting	Completed	NA	2013-06-01	2015-08-31	FALSE	FALSE	TRUE	TRUE	TRUE	NA	TRUE	FALSE	TRUE	unknown	[]	NA	[See Results Section.]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Disease Free Survival (DFS)\n[ Time Frame: Every 3 months during active phase and every 6 months during long term follow-up (up to 6 years) ]\n\nDFS is the time from the date of randomization until the first day NSCLC relapse is documented by radiological exam and/or biopsy, or until death in the absence of relapse.""}]
NCT00373451	Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome	Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction	10.1056/nejmoa1109596	NA	15	2006-09-07	Recruiting	Completed	2006-07-01	2011-05-01	2011-11-13	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite end point of death, large recurrent MI, urgent TVR or major bleeding within 30 days from randomization""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding\n[ Time Frame: 30 days ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of death, large recurrent myocardial infarction (MI), urgent target vessel revascularization (TVR) or major bleeding\n[ Time Frame: 30 days ]""}]	NA
NCT00379470	Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)	NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality	10.1016/j.ejca.2012.04.011	http://www.sciencedirect.com/science/article/pii/S0959804912003528?via%3Dihub	28	2006-09-20	Recruiting	Completed	2006-09-01	2009-11-01	2012-05-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 2 years from initiation of accrual ]""}]	NA	NA
NCT00382967	A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms	Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study	10.1136/jnnp-2011-301695	https://www.ncbi.nlm.nih.gov/pubmed/22492213?dopt=Abstract	10	2006-09-29	Not yet recruiting	Completed	NA	2010-07-01	2012-04-06	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	TRUE	TRUE	unknown	[]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical management from Visit 1 to Visit 3.\n[ Time Frame: Visit 1 (baseline) and Visit 3 (3 months) ]""}]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical management from Visit 1 to Visit 3.\n[ Time Frame: Visit 1 (baseline) and Visit 3 (3 months) ]""}]
NCT00385697	The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus	Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial	10.1016/s0140-6736(11)60931-8	https://www.sciencedirect.com/science/article/pii/S0140673611609318	63	2006-10-10	Recruiting	Completed	2006-10-01	2010-03-01	2011-06-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Successful versus unsuccessful clinical responses at 12 months. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Successful versus unsuccessful clinical responses. A successful response requires that both components of a composite endpoint are met. The composite endpoint includes both the subject's total daily insulin usage and his/her HbA1c levels.\n[ Time Frame: at 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first primary endpoint is a composite endpoint at 52 weeks: the proportion of subjects with both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%.\n[ Time Frame: at 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The second primary endpoint is the mean HbA1c change from baseline at 52 weeks after randomization.\n[ Time Frame: at 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The first primary endpoint is a composite endpoint at 52 weeks: the proportion of subjects with both a total daily insulin dose of less than 0.5 U/kg/day and HbA1c level of less than 6.5%.\n[ Time Frame: at 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The second primary endpoint is the mean HbA1c change from baseline at 52 weeks after randomization.\n[ Time Frame: at 12 months ]""}]	NA
NCT00388505	Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis	Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial	10.1016/j.jcf.2010.10.003	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086197/	8	2006-10-16	Recruiting	Completed	2006-02-01	2009-03-01	2010-11-12	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results\n[ Time Frame: AEs - weeks 1, 2, 3, 5, 7, 9, 13, 17, 21 and 25. Safety labs - weeks -4, 1, 5, 9, 13, 17, 21 and 25. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety assessed by incidence of treatment-emergent adverse events and clinical laboratory results\n[ Time Frame: AEs - weeks 1, 2, 3, 5, 7, 9, 13, 17, 21 and 25. Safety labs - weeks -4, 1, 5, 9, 13, 17, 21 and 25. ]""}]	[See Results Section.]	NA
NCT00389181	A Randomized Trial of Unruptured Brain AVMs	Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial	10.1016/s0140-6736(13)62302-8	https://www.ncbi.nlm.nih.gov/pubmed/24268105?dopt=Abstract	20	2006-10-16	Not yet recruiting	Completed	2006-10-01	2013-12-01	2013-11-20	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite event of death from any cause or symptomatic stroke (hemorrhage or infarction confirmed by imaging)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite event of death from any cause or symptomatic stroke (hemorrhage or infarction confirmed by imaging)\n[ Time Frame: from enrollment to study end for primary outcomes of death or symptomatic stroke including hemorrhage ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference of 5-year event rates between two arms\n[ Time Frame: 5 years ]\n\nThe hypothesis to be tested is that there is no difference between medical management and interventional therapy in the time to stroke or death from any cause.""}]	NA
NCT00389779	DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension	Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial	10.1161/hypertensionaha.110.156976	https://www.ncbi.nlm.nih.gov/pubmed/20921430	12	2006-10-18	Not yet recruiting	Completed	2006-12-01	2009-08-01	2010-10-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary efficacy measures: changes from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in trough sitting systolic and diastolic blood pressure measured by sphygmomanometry\n[ Time Frame: Baseline to Week 14 ]""}]	NA
NCT00391443	BUILD 3: Bosentan Use in Interstitial Lung Disease	BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis	10.1164/rccm.201011-1874oc	http://www.atsjournals.org/doi/abs/10.1164/rccm.201011-1874OC	40	2006-10-20	Not yet recruiting	Completed	2006-11-01	2009-06-01	2011-04-07	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to occurrence of disease worsening or death up to End of Study.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to occurrence of disease worsening or death up to End of Study.\n[ Time Frame: 18-32 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to occurrence of disease worsening or death up to End of Study.\n[ Time Frame: 18-32 months ]""}]	[See Results Section.]	NA
NCT00391612	EASE Trial: Exhale Airway Stents for Emphysema	Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial	10.1016/s0140-6736(11)61050-7	http://www.sciencedirect.com/science/article/pii/S0140673611610507	56	2006-10-20	Recruiting	Unknown status	2006-05-01	2009-10-01	2011-09-10	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FVC""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""mMRC.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced Vital Capacity (FVC)\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""modified Medical Research Council (mMRC) score (breathlessness)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced Vital Capacity (FVC)\n[ Time Frame: 6 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""modified Medical Research Council (mMRC) score (breathlessness)\n[ Time Frame: 6 months ]""}]	NA	NA
NCT00392054	First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)	Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial	10.1001/jama.2014.467	https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2014.467	4	2006-10-23	Recruiting	Completed	2006-08-01	2012-01-01	2014-02-19	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy: Time to first recurrence of electrocardiographically documented symptomatic atrial fibrillation lasting >30 seconds during Follow-up Period.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety: Ablation Arm: Severe (>70%) PV stenosis at 3 and 12 month follow-up. Thromboembolic event with residual sequelae, TIA, pericarditis, myocardial infarction, diaphragmatic paralysis, procedural complication requiring intervention and death.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Primary Safety: AAD Arm: Torsade de Pointes, syncope, bradycardia requiring pacemaker, other pro-arrhythmic events, any other significant adverse events leading to drug discontinuation. Bleeding complications associated with OAC therapy.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first episode of symptomatic atrial fibrillation\n[ Time Frame: Assessed during 21 month follow-up period ]\n\nTime to first recurrence of electrocardiographically documented symptomatic atrial fibrillation lasting >30 seconds during Follow-up Period. The follow-up period begins 90 days after randomization.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Comparison of proportion of patients with an occurrence of any of a cluster of serious complications in either arm\n[ Time Frame: Assessed during entire 24 month study period ]\n\n\n\nAblation arm cluster: death, cardiac tamponade, severe PV stenosis>70%, atrioesophageal fistula, thromboembolism, vascular complications (i.e. arterial pseudoaneurysm, arteriovenous fistula and hematoma leading to transfusion), phrenic nerve injury or complete AV block requiring permanent pacemaker implantation.\n\nAntiarrhythmic drug arm cluster: Death, torsade de pointes, bradycardia leading to pacemaker insertion, syncope, QRS duration prolongation > 50% of baseline, 1:1 atrial flutter or any other significant adverse events that leads to drug discontinuation.""}]	NA	[See Results Section.]	NA
NCT00393679	Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children	A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial	10.1371/journal.pmed.1001119	http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001119	10	2006-10-27	Not yet recruiting	Completed	2007-07-01	2009-07-01	2011-11-08	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.\n[ Time Frame: Day 28 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.\n[ Time Frame: Day 28 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.\n[ Time Frame: Day 28 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.\n[ Time Frame: Day 28 ]""}]	NA
NCT00396981	MAPS Trial: Matrix And Platinum Science	Stent-assisted coiling versus coiling alone in unruptured intracranial aneurysms in the matrix and platinum science trial: safety, efficacy, and mid-term outcomes	10.3174/ajnr.a3755	NA	20	2006-11-06	Not yet recruiting	Completed	2007-03-01	2011-03-01	2013-11-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Target Aneurysm Recurrence (TAR) defined as clinically relevant recurrence resulting in target aneurysm reintervention, rupture/re-rupture and/or patient death at 12 months ±3 months post procedure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Target Aneurysm Recurrence (TAR) defined as clinically relevant recurrence resulting in target aneurysm reintervention, rupture/re-rupture and/or neurologic patient death.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Target Aneurysm Recurrence (TAR) defined as clinically relevant recurrence resulting in target aneurysm reintervention, rupture/re-rupture and/or death from an unknown cause.\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00397345	TroVax Renal Immunotherapy Survival Trial	Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study	10.1158/1078-0432.ccr-10-2082	https://www.ncbi.nlm.nih.gov/pubmed/20881001	14	2006-11-08	Recruiting	Completed	2006-09-01	2009-07-01	2010-09-29	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""overall survival\n[ Time Frame: 18 months ]""}]	NA
NCT00400387	Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss	Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme	10.7326/m14-2062	https://www.annals.org/article.aspx?doi=10.7326/M14-2062	7	2006-11-15	Recruiting	Completed	2006-11-01	2012-12-01	2015-05-05	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ongoing intact pregnancy at 24 weeks of gestation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ongoing intact pregnancy at 24 weeks of gestation\n[ Time Frame: at 24 weeks of gestation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ongoing intact pregnancy at 24 weeks of gestation\n[ Time Frame: at 24 weeks of gestation ]""}]	NA	NA
NCT00401453	OatMeal and Insulin Resistance: OMA-IR	NA	10.1055/s-0029-1222046	https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0029-1222046	7	2006-11-17	Not yet recruiting	Completed	2007-01-01	2010-02-01	2009-04-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""daily insulin requirements and glycemic control""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""daily insulin requirements and glycemic control\n[ Time Frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""daily insulin requirements and glycemic control\n[ Time Frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention ]""}]	NA
NCT00402168	A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids	Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study	10.2215/cjn.05840710	https://www.ncbi.nlm.nih.gov/pubmed/21051752	92	2006-11-21	Not yet recruiting	Completed	2006-12-01	2009-06-01	2010-11-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in calculated glomerular filtration rate (GFR) from baseline to 12 months post randomization""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in calculated glomerular filtration rate (GFR)\n[ Time Frame: from baseline to 12 months post randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in calculated glomerular filtration rate (GFR)\n[ Time Frame: from baseline to 12 months post randomization ]""}]	[See Results Section.]	NA
NCT00402428	Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients	Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1	10.1053/j.gastro.2010.06.066	http://www.sciencedirect.com/science/article/pii/S0016508510010097?via%3Dihub	18	2006-11-20	Not yet recruiting	Completed	2006-12-01	NA	2010-06-27	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR) at Week 72""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR)\n[ Time Frame: Week 72 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response (SVR)\n[ Time Frame: Week 72 ]""}]
NCT00402532	Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation	Everolimus Versus Mycophenolate Mofetil De Novo After Lung Transplantation: A Prospective, Randomized, Open-Label Trial	10.1111/ajt.13835	https://www.ncbi.nlm.nih.gov/pubmed/27104933	6	2006-11-20	Recruiting	Completed	2005-03-01	2011-11-01	2016-06-15	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and Severity of Bronchiolitis obliterans syndrome within 2 years from Transplantation""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mortality within 2 years of Transplantation""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Need for Change of Immunosuppressive Medication within 2 years of Transplantation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of bronchiolitis obliterans syndrome and mortality and need for change of immunosuppressive medication within 2 years from transplantation\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence and severity of bronchiolitis obliterans syndrome and mortality and need for change of immunosuppressive medication within 2 years from transplantation\n[ Time Frame: 2 years ]""}]	NA	NA
NCT00402675	Randomized Trial of Immediate Versus Early and Selective Invasive Percutaneous Coronary Intervention in NSTEMI	Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial)	10.1093/eurheartj/ehr418	NA	2	2006-11-21	Recruiting	Completed	2006-07-01	2009-12-01	2012-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite: death, re-myocardial infarction, recurrent unstable angina within 6 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite: death, re-myocardial infarction, recurrent unstable angina within 6 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""peak creatine kinase- MB level\n[ Time Frame: 5 days ]""}]	NA	NA
NCT00405756	A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.	Continuous lenalidomide treatment for newly diagnosed multiple myeloma	10.1056/nejmoa1112704	https://www.ncbi.nlm.nih.gov/pubmed/22571200?dopt=Abstract	24	2006-11-29	Not yet recruiting	Completed	2007-01-01	NA	2012-05-10	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00410384	A Study of Belimumab in Subjects With Systemic Lupus Erythematosus	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus	10.1002/art.30613	https://www.ncbi.nlm.nih.gov/pubmed/22127708?dopt=Abstract	37	2006-12-08	Not yet recruiting	Completed	2006-12-01	2009-06-01	2011-12-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is response rate at Week 52.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""At Wk 52 the % of subjects with great than or equal to 4 point reduction from baseline in SELENA SLEDAI score & no worsening in PGA & no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline at the time of assessment.\n[ Time Frame: 52 Weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00412893	Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial	10.1016/s0140-6736(15)01159-9	https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(15)01159-9	35	2006-12-18	Recruiting	Completed	2006-12-01	NA	2015-12-10	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall outcome (clinical, mycological and radiological response)""}]	NA	NA	[See Results Section.]	[See Results Section.]
NCT00418574	Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients	Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study	10.1200/jco.2012.46.4057	https://www.ncbi.nlm.nih.gov/pubmed/23478059?dopt=Abstract	56	2007-01-04	Recruiting	Terminated	2006-12-01	2010-12-01	2013-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival to be documented in double blind condition by CT scan every 12 weeks up to recurrence or up to 3 months after last administered dose""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free survival to be documented in double blind condition by CT scan\n[ Time Frame: Every 12 weeks up to recurrence or up to 3 months after last administered dose ]""}]	[See Results Section.]	NA	NA
NCT00419250	A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia	10.3109/10428194.2011.618232	https://www.ncbi.nlm.nih.gov/pubmed/21879809?dopt=Abstract	40	2007-01-05	Recruiting	Completed	2006-12-01	2009-12-01	2011-11-15	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: June 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: February 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: February 2010 ]""}]	NA
NCT00419601	Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants	Remifentanil/midazolam versus fentanyl/midazolam for analgesia and sedation of mechanically ventilated neonates and young infants: a randomized controlled trial	10.1007/s00134-012-2532-1	https://dx.doi.org/10.1007/s00134-012-2532-1	4	2007-01-05	Recruiting	Completed	2006-11-01	2010-04-01	2012-03-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of the artificial ventilation after discontinuation of the opioid infusion""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of the artificial ventilation after discontinuation of the opioid infusion\n[ Time Frame: End of study medication and time of extubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Duration of the artificial ventilation after discontinuation of the opioid infusion\n[ Time Frame: at time of extubation (expected to be within 48 hours following discontinuation of the opioid infusion) ]\n\nExtubation time point after discontinuation of the opioid infusion. Start of opioid infusion at the latest 12 h after intubation. Maximum duration of the opioid infusion 96 h.""}]	NA	NA
NCT00422916	Treatment of Overweight Children and Adolescents	An effective lifestyle intervention in overweight children: findings from a randomized controlled trial on ""Obeldicks light""	10.1016/j.clnu.2009.12.010	http://www.sciencedirect.com/science/article/pii/S0261561410000038?via%3Dihub	5	2007-01-16	Recruiting	Completed	2007-01-01	NA	2010-01-27	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight status""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight status\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight status""}]
NCT00425698	Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation	High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation	10.1038/ki.2011.349	https://www.ncbi.nlm.nih.gov/pubmed/22012130	10	2007-01-22	Not yet recruiting	Completed	2007-02-01	2009-05-01	2011-10-19	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Kidney graft function 6 weeks after transplantation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Kidney graft function\n[ Time Frame: 6 weeks after transplantation ]""}]	[See Results Section.]	NA	NA
NCT00428948	Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Tolvaptan in patients with autosomal dominant polycystic kidney disease	10.1056/nejmoa1205511	http://www.nejm.org/doi/full/10.1056/NEJMoa1205511	18	2007-01-29	Not yet recruiting	Completed	2007-01-01	2011-01-01	2012-11-03	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate long-term efficacy of tolvaptan in ADPKD through rate of renal volume change (%) for tolvaptan-treated compared to placebo-treated subjects.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate long-term efficacy of tolvaptan in ADPKD through rate of renal volume change (%) for tolvaptan-treated compared to placebo-treated subjects.\n[ Time Frame: 36 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of total kidney volume change(%)\n[ Time Frame: 36 months ]""}]	[See Results Section.]	NA
NCT00430118	Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia	Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome	10.3324/haematol.2011.045229	http://www.haematologica.org/content/97/3/402	36	2007-01-30	Recruiting	Completed	2000-07-01	2012-01-01	2012-03-01	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of dexamethasone vs prednisone during the induction phase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk (HR) patients""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety and efficacy of treatment reduction during reintensification in standard-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EFS after second delayed reintensification in medium-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Outcome after extended reintensification therapy in HR patients""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of dexamethasone vs prednisone during the induction phase""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety and efficacy of treatment reduction during reintensification in standard-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EFS after second delayed reintensification in intermediate-risk patients""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Outcome after extended reintensification therapy in high-risk patients""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of dexamethasone vs prednisone during the induction phase\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patients\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety and efficacy of treatment reduction during reintensification in standard-risk patients\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EFS after second delayed reintensification in intermediate-risk patients\n[ Time Frame: End of Trial ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Outcome after extended reintensification therapy in high-risk patients\n[ Time Frame: End of Trial ]""}]	NA
NCT00433927	5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial	10.1016/s1470-2045(14)70330-4	NA	7	2007-02-09	Recruiting	Unknown status	2007-01-01	2013-12-01	2014-07-31	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate\n[ Time Frame: approximate 6 months after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response rate\n[ Time Frame: approximate 6 months after randomisation ]""}]	NA	NA
NCT00434161	A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma	In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden	10.1038/bmt.2012.257	https://www.ncbi.nlm.nih.gov/pubmed/23241739	29	2007-02-08	Recruiting	Completed	2006-12-01	2009-02-01	2012-12-17	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum severity of oral mucositis (WHO grades 0/1, 2, 3, or 4)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum severity of oral mucositis (WHO grades 0/1, 2, 3, or 4)\n[ Time Frame: at Day 32 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of cataract development or progression (change of ≥0.3 in LOCS III score)\n[ Time Frame: at month 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Maximum severity of oral mucositis (WHO grades 0/1, 2, 3, or 4)\n[ Time Frame: at Day 32 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Incidence of cataract development or progression (change of ≥0.3 in LOCS III score)\n[ Time Frame: at month 12 ]""}]	[See Results Section.]	NA
NCT00437307	Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse	Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)	10.1093/annonc/mdw418	https://pubmed.ncbi.nlm.nih.gov/27789470/	9	2007-02-20	Not yet recruiting	Completed	2007-03-01	2010-07-01	2015-10-26	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival after 1 year-follow-up""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival\n[ Time Frame: after 1 year-follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival\n[ Time Frame: after 1 year-follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""progression-free survival\n[ Time Frame: after 1 year-follow-up ]""}]	NA
NCT00437385	Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients	Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial	10.1016/j.biopsych.2013.11.030	https://www.ncbi.nlm.nih.gov/pubmed/24462229?dopt=Abstract	2	2007-02-20	Recruiting	Completed	2005-03-01	2010-03-01	2013-12-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Score on HAMD after 6 and 12 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Score on HAMD after 6 and 12 months""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Score on HAMD after 6 and 12 months\n[ Time Frame: 6 and 12 months after enetering continuation phase ]""}]	NA	NA
NCT00438451	Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs	A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy	10.1111/epi.12926	NA	6	2007-02-21	Recruiting	Completed	2007-01-01	2011-12-01	2015-02-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""58-week retention rate measured by the number of drop outs due to adverse events or seizures from day 1 of treatment""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""58-week retention rate measured by the number of drop outs due to adverse events or seizures from day 1 of treatment""}]	[See Results Section.]	NA	NA
NCT00440167	Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine	Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)	10.1136/gutjnl-2012-302759	NA	4	2007-02-22	Recruiting	Unknown status	2006-06-01	NA	2012-07-07	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""TTF2\n[ Time Frame: approximate 6 months after first line treatment ]\n\nTime to treatment failure, after 2nd line (crossover) therapy""}]
NCT00447187	Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk	High-dose subconjunctival cyclosporine a implants do not affect corneal neovascularization after high-risk keratoplasty	10.1016/j.ophtha.2014.03.016	http://www.sciencedirect.com/science/article/pii/S0161642014002401	12	2007-03-12	Not yet recruiting	Terminated	2007-03-01	2009-09-01	2014-04-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""immunological rejection""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""graft loss""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""immunological rejection""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""graft loss""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""graft rejection or graft failure\n[ Time Frame: 52 weeks ]""}]	NA	NA
NCT00449969	Out-of-hospital Cardiopulmonary Resuscitation and AED Feedback	The addition of voice prompts to audiovisual feedback and debriefing does not modify CPR quality or outcomes in out of hospital cardiac arrest--a prospective, randomized trial	10.1016/j.resuscitation.2010.11.006	http://www.sciencedirect.com/science/article/pii/S0300957210010713?via%3Dihub	9	2007-03-20	Not yet recruiting	Completed	2007-04-01	2009-12-01	2012-10-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ratio of patients with spontaneous circulation until admission to the hospital""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ratio of patients with spontaneous circulation\n[ Time Frame: admission to the hospital ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ratio of patients with spontaneous circulation\n[ Time Frame: admission to the hospital ]""}]	NA	NA
NCT00450684	Cardiac Resynchronization Therapy in Congenital Heart Defects	NA	NA	http://scidok.sulb.uni-saarland.de/volltexte/2017/6827/pdf/Dissertation_ohne_Lebenslauf.pdf	26	2007-03-21	Not yet recruiting	Completed	2007-05-01	2013-09-01	2016-01-01	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ejection fraction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""VO2max""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""QRS-interval""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ejection fraction\n[ Time Frame: 7 visits ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""QRS-interval\n[ Time Frame: 7 visits ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ejection fraction\n[ Time Frame: 7 visits ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""QRS-interval\n[ Time Frame: 7 visits ]""}]	NA	NA
NCT00451958	A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy	Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer	10.1111/j.1742-1241.2011.02637.x	https://www.ncbi.nlm.nih.gov/pubmed/21342376	15	2007-03-23	Recruiting	Completed	2007-03-01	NA	2011-02-22	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical safety parameters (adverse events including death from any causse, physical examination, vtal signs, ECGs, and body weight)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical significant changes in laboratory safety parameters (clinical chemistry, haematology, and urinalysis)""}]	NA	NA	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in clinical safety parameters (adverse events including death from any cause, physical examination, vital signs, ECGs and body weight)\n[ Time Frame: 6 months, until all patients have been treated for at least 5 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical significant changes in laboratory safety parameters (clinical chemistry, haematology and urinalysis)\n[ Time Frame: 3 months, until all patients have been treated for at least 5 years ]""}]
NCT00454389	A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration	Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET)	10.1016/j.ophtha.2012.07.068	https://www.ncbi.nlm.nih.gov/pubmed/23174399	10	2007-03-29	Not yet recruiting	Unknown status	2007-04-01	2010-09-01	2012-11-20	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects losing fewer than 15 letters of best corrected visual acuity score at 12 months compared to baseline. Gain of 15 more letters of best correct visual acuity score compared to baseline\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00456092	Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis	Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study	10.1002/art.34627	http://onlinelibrary.wiley.com/doi/10.1002/art.34627/abstract	12	2007-04-02	Recruiting	Completed	2007-01-01	2009-05-01	2012-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline\n[ Time Frame: Monthly ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve ACR criteria for 20% improvement at Day 85/Early termination visit compared with baseline\n[ Time Frame: Monthly ]""}]	[See Results Section.]	NA
NCT00461656	Povidone-iodine Antisepsis for Strabismus Surgery	NA	NA	http://iovs.arvojournals.org/article.aspx?articleid=2351700	6	2007-04-17	Not yet recruiting	Completed	2009-09-01	2012-12-01	2012-03-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI.\n[ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI.\n[ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the mean numbers of bacterial colony forming units from pre-irrigation to post-irrigation with PI.\n[ Time Frame: Cultures taken during surgery, evaluated within 2 days postoperatively ]""}]	NA
NCT00464204	Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis	Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study	10.1186/cc11358	https://www.ncbi.nlm.nih.gov/pubmed/22624531?dopt=Abstract	21	2007-04-20	Not yet recruiting	Completed	2007-07-01	2010-02-01	2012-05-24	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of study drug required to achieve initial hemodynamic stabilization""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Amount of enteral calories during 7 days after hemodynamic stabilization""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of study drug required to achieve initial hemodynamic stabilization\n[ Time Frame: until hemodynamic stabilization (max. 48 hours) ]""}]	[See Results Section.]	NA	NA
NCT00466102	Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases	Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study	10.1007/s00432-013-1518-x	http://onlinelibrary.wiley.com/doi/10.1002/ejp.843/full	12	2007-04-25	Recruiting	Unknown status	2006-12-01	2010-12-01	2013-09-27	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo\n[ Time Frame: 40 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the time to progression (TTP) in patients with no change in bone metastases after an 8 week run in treatment with RAD001 compared to placebo\n[ Time Frame: 40 weeks ]""}]	NA	NA
NCT00467857	Study of the Combination of a Cyanoacrylate and Surgical Solutions in Reducing Skin Flora Contamination	A randomized trial of a skin sealant to reduce the risk of incision contamination in cardiac surgery	10.1016/j.athoracsur.2011.03.132	https://www.ncbi.nlm.nih.gov/pubmed/21704290?dopt=Abstract	8	2007-04-30	Recruiting	Completed	2007-04-01	2009-03-01	2011-06-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Qualitative reduction in skin flora at the end of surgery compared to the intact skin flora at the start of the surgery between two treatment groups.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Qualitative reduction in skin flora at the end of surgery compared to the intact skin flora at the start of the surgery between two treatment groups.\n[ Time Frame: 6 months ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00479557	Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease	Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease	10.3233/jad-150376	https://www.ncbi.nlm.nih.gov/pubmed/26967206?dopt=Abstract	18	2007-05-24	Recruiting	Completed	2007-05-01	2012-02-01	2016-04-12	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adverse events and other safety assessment, tolerability, and immunogenicity.\n[ Time Frame: 2 years participation per patient ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the safety and tolerability of multiple doses of ACC-001 in subjects with mild to moderate AD.\n[ Time Frame: 2 years participation per patient ]""}]	[See Results Section.]	NA	NA
NCT00480077	Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)	Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure	10.1161/circulationaha.111.043042	http://circ.ahajournals.org/content/124/16/1719.long	7	2007-05-29	Recruiting	Terminated	2007-03-01	2012-01-01	2011-09-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective is to investigate if a reduction in combined endpoint of HF hospitalizations and all-cause mortality, in HF subjects managed with standard clinical assessment and using OptiVol® Fluid Status Monitoring with Cardiac Compass Report\n[ Time Frame: study duration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective is to investigate if a reduction in combined endpoint of HF hospitalizations and all-cause mortality, in HF subjects managed with standard clinical assessment and using OptiVol® Fluid Status Monitoring with Cardiac Compass Report\n[ Time Frame: study duration ]""}]	NA	[See Results Section.]	NA
NCT00491036	Intraaortic Balloon Pump in Cardiogenic Shock II	Intraaortic balloon support for myocardial infarction with cardiogenic shock	10.1056/nejmoa1208410	https://pubmed.ncbi.nlm.nih.gov/22920912/	8	2007-06-22	Not yet recruiting	Completed	2009-06-01	2012-06-01	2012-08-26	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality\n[ Time Frame: 30 day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality\n[ Time Frame: 30 day ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality\n[ Time Frame: 30 day ]""}]	NA
NCT00499265	Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery	Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer	10.1038/bjc.2013.62	https://www.ncbi.nlm.nih.gov/pubmed/23412098	18	2007-07-10	Not yet recruiting	Completed	2007-04-01	NA	2013-02-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Antitumor activity""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Efficacy, in terms of response rate, progression-free survival, time to first metastasis, overall survival, and tumor and uPA system-related markers""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy, in terms of response rate, progression-free survival, time to first metastasis, overall survival, and tumor and uPA system-related markers\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety, in terms of vital signs, ECG, biochemistry, hematology (including coagulation), and adverse events\n[ Time Frame: 3 years ]""}]
NCT00502554	Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation	Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients	10.1111/ajt.12155	https://www.ncbi.nlm.nih.gov/pubmed/23406373	4	2007-07-16	Not yet recruiting	Terminated	2007-08-01	2010-04-01	2013-02-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 stabilisation\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 stabilisation\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 stabilisation\n[ Time Frame: 6 month ]""}]	NA	NA
NCT00505570	PRIMA PFO Migraine Trial	Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial	10.1093/eurheartj/ehw027	NA	13	2007-07-20	Recruiting	Terminated	2006-05-01	2013-01-01	2016-02-22	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Migraine headache frequency\n[ Time Frame: 12 months ]""}]	NA
NCT00508664	Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)	Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II	10.1093/annonc/mdy332	https://pubmed.ncbi.nlm.nih.gov/30412221/	11	2007-07-27	Recruiting	Completed	2007-07-01	2009-12-01	2018-08-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation\n[ Time Frame: LFS-rate 2 years after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation\n[ Time Frame: LFS-rate 2 years after randomisation ]""}]	NA	NA
NCT00518895	Trial of Dacarbazine With or Without Genasense in Advanced Melanoma	Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'	10.1097/cmr.0000000000000056	https://insights.ovid.com/pubmed?pmid=24667300	15	2007-08-17	Recruiting	Completed	2007-08-01	2011-03-01	2014-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primary: progression-free survival; overall survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and overall survival\n[ Time Frame: Every 42 days from date of randomization during protocol therapy ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and overall survival\n[ Time Frame: Every 42 days from date of randomization during protocol therapy ]""}]	NA	NA
NCT00521664	A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups	Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study	10.1016/s0140-6736(12)60689-8	https://www.ncbi.nlm.nih.gov/pubmed/22877506	4	2007-08-27	Recruiting	Completed	2004-09-01	2010-09-01	2012-10-13	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)\n[ Time Frame: 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy)\n[ Time Frame: 2010 ]""}]	NA	NA
NCT00522834	Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma	Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma	10.1200/jco.2012.44.5585	http://ascopubs.org/doi/10.1200/JCO.2012.44.5585	30	2007-08-29	Recruiting	Terminated	2007-08-01	2009-06-01	2013-02-11	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: June 2009 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free survival\n[ Time Frame: June 2009 ]""}]	NA
NCT00529503	A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial	10.3109/10428194.2015.1007504	http://www.tandfonline.com/doi/full/10.3109/10428194.2015.1007504	19	2007-09-12	Recruiting	Terminated	2007-09-01	2010-02-01	2015-02-26	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.\n[ Time Frame: 9 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete response as assessed by CT and PET scans and revised response criteria for malignant lymphoma.\n[ Time Frame: 9 weeks ]""}]	NA	NA
NCT00530348	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial	10.1016/s0140-6736(12)61769-3	https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(12)61769-3	47	2007-09-13	Recruiting	Completed	2007-09-01	2011-03-01	2012-11-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[See Results Section.]	NA
NCT00530764	A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.	Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial	10.1016/j.jpain.2012.01.003	http://www.sciencedirect.com/science/article/pii/S1526590012000193?via%3Dihub	26	2007-09-13	Not yet recruiting	Completed	2007-11-01	2009-10-01	2012-04-05	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain) during the last three days of week 5.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure is the IVRS 11-point Numeric Rating Scale pain score (average pain).""}]	[See Results Section.]	[See Results Section.]	NA
NCT00533221	Pilot Study of Growth Hormon to Treat SMA Typ II and III	Somatropin treatment of spinal muscular atrophy: a placebo-controlled, double-blind crossover pilot study	10.1016/j.nmd.2013.10.011	https://www.ncbi.nlm.nih.gov/pubmed/24300782?dopt=Abstract	4	2007-09-20	Not yet recruiting	Completed	2007-10-01	2009-05-01	2013-11-13	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary: sum of strength (hand held myometry)\n[ Time Frame: 20 weeks ]""}]	NA
NCT00538590	Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery	Capsule excision and Ologen implantation for revision after glaucoma drainage device surgery	10.1007/s00417-010-1385-y	https://link.springer.com/article/10.1007/s00417-010-1385-y	5	2007-10-01	Recruiting	Completed	2007-07-01	2010-08-01	2010-04-20	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""IOP<18mmHg at 180 days after surgery without anti-glaucoma medication""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""IOP<18mmHg at 180 days after surgery without anti-glaucoma medication\n[ Time Frame: 180 days ]""}]	NA	[See Results Section.]	NA
NCT00543881	Telemedical Interventional Monitoring in Heart Failure	The 6-min walk test in heart failure: is it a max or sub-maximum exercise test?	10.1007/s00421-009-1128-0	https://www.ncbi.nlm.nih.gov/pubmed/19618202?dopt=Abstract	11	2007-10-12	Not yet recruiting	Completed	2007-10-01	2009-04-01	2009-07-18	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Mortality\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Mortality\n[ Time Frame: 1 year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""all cause mortality""}]	NA
NCT00545077	Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women	Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study	10.1200/jco.2014.57.2388	http://ascopubs.org/doi/full/10.1200/JCO.2014.57.2388	12	2007-10-16	Not yet recruiting	Completed	2007-11-01	2011-12-01	2015-02-17	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""·To compare the progression-free survival (PFS) between both treatment arms.\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""·To compare the progression-free survival (PFS) between both treatment arms.\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""·To compare the progression-free survival (PFS) between both treatment arms.\n[ Time Frame: 2 years ]""}]	[See Results Section.]	NA
NCT00545103	Prevention of Recurrence of Diverticulitis	Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials	10.1053/j.gastro.2014.07.004	https://www.ncbi.nlm.nih.gov/pubmed/25038431?dopt=Abstract	27	2007-10-16	Not yet recruiting	Completed	2007-11-01	2011-11-01	2014-07-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in predefined lab parameters\n[ Time Frame: 104 Weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time to presence of predefined symptoms of diverticulitis\n[ Time Frame: 104 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Abdominal pain\n[ Time Frame: 104 Weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""A 15% increase in white blood cell (WBC) count from baseline\n[ Time Frame: 104 Weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Bowel wall thickening (>5mm) and/or fat stranding as evidenced by spiral computerised axial tomography (CT) scan\n[ Time Frame: 104 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00545493	Efficacy of Tacrolimus and I.V.-Immunoglobulins in Rasmussen Encephalitis	Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins	10.1111/epi.12042	http://onlinelibrary.wiley.com/doi/10.1111/epi.12042/pdf	4	2007-10-16	Recruiting	Unknown status	2002-11-01	NA	2012-12-06	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to exit, criteria: Deterioration of motor function of the affected side by 15 % (>11 yrs of age: 8%) measured by the \""Motricity Index\"" (scale 0-100) or deterioration of the \""Hemispheric ratio\"" assessed by regular MRI scans by 15% (>11 yrs: 8%).""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to exit, criteria: Deterioration of motor function of the affected side by 15 % (>11 yrs of age: 8%) measured by the \""Motricity Index\"" (scale 0-100) or deterioration of the \""Hemispheric ratio\"" assessed by regular MRI scans by 15% (>11 yrs: 8%).\n[ Time Frame: until final included subject has been followed for one yer ]""}]
NCT00548405	Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial	10.1016/s0140-6736(12)61768-1	https://www.ncbi.nlm.nih.gov/pubmed/23122650?dopt=Abstract	63	2007-10-22	Recruiting	Completed	2007-10-01	2012-04-01	2012-11-01	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Sustained Accumulation of Disability (SAD)\n[ Time Frame: 2 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Relapse Rate\n[ Time Frame: 2 years ]""}]	NA	[See Results Section.]	NA
NCT00550004	Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine	RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients	10.1007/s00432-011-1005-1	https://link.springer.com/article/10.1007%2Fs00432-011-1005-1	11	2007-10-25	Recruiting	Terminated	2007-09-01	2009-08-01	2011-07-22	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: 18 months ]""}]	NA	NA
NCT00550862	Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid	10.1053/j.gastro.2014.12.005	http://www.sciencedirect.com/science/article/pii/S0016508514015303?via%3Dihub	8	2007-10-27	Recruiting	Completed	2007-10-01	2009-08-01	2014-12-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC) taking UDCA, to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC) taking UDCA, to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	NA	NA
NCT00554502	Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy	Intensive Supportive Care plus Immunosuppression in IgA Nephropathy	10.1056/nejmoa1415463	https://pubmed.ncbi.nlm.nih.gov/26630142/	13	2007-11-05	Not yet recruiting	Completed	2008-02-01	2013-12-01	2015-12-03	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""- Patients reaching full clinical remission of their disease. - GFR loss of 15 ml/min or higher from baseline GFR at the end of the 3 year study period.\n[ Time Frame: at the end of the 3 year study period. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patients reaching full clinical remission of their disease\n[ Time Frame: at the end of the 3 year study period. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GFR loss of 15 ml/min or higher from baseline GFR\n[ Time Frame: at the end of the 3 year study period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patients reaching full clinical remission of their disease\n[ Time Frame: at the end of the 3 year study period. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GFR loss of 15 ml/min or higher from baseline GFR\n[ Time Frame: at the end of the 3 year study period ]""}]	NA	NA
NCT00557921	Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)	Clopidogrel with or without omeprazole in coronary artery disease	10.1056/nejmoa1007964	https://www.ncbi.nlm.nih.gov/pubmed/20925534?dopt=Abstract	17	2007-11-12	Not yet recruiting	Terminated	2007-12-01	2009-11-01	2010-10-06	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforation\n[ Time Frame: Minimum of 48 weeks, up to 96 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of upper gastrointestinal clinical events, including gastroduodenal bleeding, symptomatic gastroduodenal ulcer, persistent pain with multiple gastric erosions, obstruction or perforation\n[ Time Frame: Anticipated minimum of 48 weeks, up to end of study ]""}]	NA	NA	NA
NCT00570765	Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)	NA	10.1016/s0168-8278(11)60030-5	http://www.journal-of-hepatology.eu/article/S0168-8278(11)60030-5/abstract	11	2007-12-07	Recruiting	Completed	2007-11-01	2010-04-01	2011-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC), to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC), to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In patients with primary biliary cirrhosis (PBC), to assess the effects of INT-747 on both 1) alkaline phosphatase (AP) levels and 2) safety\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	NA
NCT00574873	Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML	Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial	10.1200/jco.2011.38.7522	NA	98	2007-12-14	Not yet recruiting	Completed	2007-12-01	2010-07-01	2012-09-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cytogenetics response rate\n[ Time Frame: One year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cytogenetics response rate\n[ Time Frame: One year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cytogenetics response rate\n[ Time Frame: One year ]""}]	[See Results Section.]	NA
NCT00575588	52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period	Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia	10.1185/03007995.2014.880674	http://www.tandfonline.com/doi/abs/10.1185/03007995.2014.880674?journalCode=icmo20	12	2007-12-14	Recruiting	Completed	2007-12-01	NA	2014-01-30	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in glycosylated haemoglobin A1c (HbA1c)""}]	NA	NA	NA	[See Results Section.]
NCT00579657	Protein, Fiber, and Metabolic Syndrome - The PROFIMET Study	Effects of supplemented isoenergetic diets differing in cereal fiber and protein content on insulin sensitivity in overweight humans	10.3945/ajcn.110.004374	https://www.ncbi.nlm.nih.gov/pubmed/21633074	40	2007-12-21	Recruiting	Completed	2007-08-01	2008-09-01	2011-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""body composition and liver fat, peripheral and hepatic insulin sensitivity\n[ Time Frame: 3 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""body composition and liver fat, peripheral and hepatic insulin sensitivity\n[ Time Frame: 3 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in insulin sensitivity\n[ Time Frame: 6 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamp""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""change in insulin sensitivity\n[ Time Frame: 18 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamps""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in insulin sensitivity\n[ Time Frame: 6 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamps; relation with secondary outcome measures""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""change in insulin sensitivity\n[ Time Frame: 18 weeks ]\n\nwhole-body insulin sensitivity measured with euglycemic hyperinsulinemic clamp; hepatic insulin sensitivity measured with stable isotope techniques (DD-glucose) during the clamps; relation with secondary outcome measures""}]	NA
NCT00592553	Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)	Ataluren treatment of patients with nonsense mutation dystrophinopathy	10.1002/mus.24332	https://www.ncbi.nlm.nih.gov/pubmed/25042182	37	2008-01-01	Not yet recruiting	Completed	2008-02-01	2010-04-01	2014-10-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the effect of PTC124 on ambulation in subjects with nonsense-mutation-mediated DMD/BMD (as assessed by changes in the distance walked during a 6-minute walk test)\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00598637	Drug-eluting Stents to Treat Unprotected Coronary Left Main Disease	Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease	10.1016/j.jacc.2013.07.044	NA	7	2008-01-21	Recruiting	Completed	2007-12-01	2012-09-01	2013-08-21	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""incidence of MACE defined as a composite of death, MI and Target Lesion revascularization (TLR).\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of major adverse cardiac event (MACE) defined as a composite of death, myocardial infarction and target lesion revascularization.\n[ Time Frame: 1 year follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of major adverse cardiac event defined as a composite of death, myocardial infarction and target lesion revascularization.\n[ Time Frame: 1 year follow-up ]""}]	NA	NA
NCT00598676	3 Limus Agent Eluting Stents With Different Polymer Coating	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents	10.1002/ccd.22823	http://onlinelibrary.wiley.com/doi/10.1002/ccd.22823/full	4	2008-01-21	Recruiting	Completed	2007-09-01	2008-02-01	2011-03-11	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is a combined endpoint of cardiac death, myocardial infarction related to the target vessel or revascularization related to the target lesion.\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00598715	Efficacy Study of Two Different Strategies for Restenosis in Sirolimus-Eluting Stents	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial	10.1016/j.carrev.2014.02.001	http://www.sciencedirect.com/science/article/pii/S1553838914000475?via%3Dihub	5	2008-01-21	Recruiting	Completed	2007-10-01	2009-08-01	2014-02-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late luminal loss at follow-up angiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late luminal loss at follow-up angiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late luminal loss at follow-up angiography\n[ Time Frame: 6-8 months ]""}]	NA	NA
NCT00600444	PORTAS 2, Comparing Venae Sectio Versus Punction of Vena Subclavia for Insertion of a Totally Implantable Access Port	Insertion of totally implantable venous access devices: an expertise-based, randomized, controlled trial (NCT00600444)	10.1097/sla.0b013e318214ba21	http://journals.lww.com/annalsofsurgery/Abstract/2011/06000/Insertion_of_Totally_Implantable_Venous_Access.10.aspx	3	2008-01-24	Not yet recruiting	Completed	2008-02-01	2009-05-01	2011-06-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary success rate of the randomized intervention\n[ Time Frame: Operation day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary success rate of the randomized intervention\n[ Time Frame: Operation day ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary success rate of the randomized intervention\n[ Time Frame: Assessed on the day of surgery (day 0) ]""}]	NA	NA
NCT00605826	A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence	Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial	10.1016/s0140-6736(10)62297-0	http://www.sciencedirect.com/science/article/pii/S0140673610622970?via%3Dihub	10	2008-01-30	Recruiting	Completed	2006-08-01	2009-10-01	2011-03-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of fecal incontinence episodes\n[ Time Frame: 6 months after last blinded treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of fecal incontinence episodes\n[ Time Frame: 6 months after last blinded treatment ]""}]	NA	[See Results Section.]	NA
NCT00611910	Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial	10.1016/s0140-6736(11)61255-5	https://www.ncbi.nlm.nih.gov/pubmed/21872918	5	2008-01-29	Recruiting	Completed	2007-11-01	2011-02-01	2011-08-26	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation\n[ Time Frame: 12 months ]""}]	NA	NA
NCT00615264	Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients	Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial	10.2337/dc13-1391	http://care.diabetesjournals.org/content/37/5/1392.long	6	2008-02-13	Recruiting	Completed	2005-09-01	2011-09-01	2013-05-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stimulated C-peptide, as determined by change from baseline in C-peptide AUC measured in a 2-hour MMTT\n[ Time Frame: 0, 6, 12, 18, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Co-primaries: Stimulated C-peptide, as determined by change from baseline in C-peptide AUC measured in a 20 minutes glucagon-stimulated test (GST) or a 2-hour MMTT\n[ Time Frame: 0, 6, 12, 18, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Stimulated C-peptide, as determined by change from baseline in C-peptide AUC measured in a 20 minutes glucagon-stimulated test (GST)\n[ Time Frame: 0, to 24 months ]""}]	[See Results Section.]	NA
NCT00617175	Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III	Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial	10.1001/jama.2013.4598	NA	11	2008-02-14	Not yet recruiting	Completed	2008-03-01	2011-12-01	2013-05-08	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to demonstrate a 20% reduction of therapies (ATP and Shocks) delivered for treating spontaneous ventricular arrhythmia episodes with a fast cycle length (CL < 320 ms)\n[ Time Frame: end of study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is to demonstrate a 20% reduction of ventricular therapies (ATP and Shocks) delivered for treating spontaneous arrhythmia episodes with a fast cycle length (CL ≤ 320 ms)\n[ Time Frame: end of study ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00625898	BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab	NA	10.1158/1538-7445.am2016-3269	http://cancerres.aacrjournals.org/content/76/14_Supplement/3269.short	22	2008-02-28	Not yet recruiting	Terminated	2008-04-01	2012-08-01	2016-07-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: 10 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: up to 10 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: up to 10 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Invasive Disease-free Survival (IDFS)\n[ Time Frame: up to 10 years ]""}]	NA
NCT00626548	A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer	10.1016/j.juro.2012.03.008	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT00626548	28	2008-02-21	Recruiting	Terminated	2008-01-01	2011-03-01	2012-05-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and Overall survival\n[ Time Frame: Assessed at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival and Overall survival\n[ Time Frame: Assessed at study visits and assessments every 4 weeks for first 16 weeks then every 16 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00627094	Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers	Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness)	10.1161/circulationaha.109.931691	https://www.ncbi.nlm.nih.gov/pubmed/19128256	4	2008-02-20	Withheld	Completed	2008-03-01	2009-04-01	2008-09-01	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[]	[]	NA	[See Results Section.]	NA
NCT00627523	Genotropin Treatment In Very Young Children Born Small For Gestational Age	A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin®) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study	10.1111/cen.12968	http://onlinelibrary.wiley.com/doi/10.1111/cen.12968/abstract	79	2008-02-22	Not yet recruiting	Completed	2008-03-01	2013-12-01	2015-11-25	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the change from baseline in height SDS (Standard Deviation Score) and height velocity SDS, after 24 months of treatment.\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the change from baseline in height SDS (Standard Deviation Score) after 24 months of treatment.\n[ Time Frame: 24 months ]""}]	[See Results Section.]	NA	NA
NCT00630812	Long Term Administration of Inhaled Mannitol in Cystic Fibrosis	Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study	10.1164/rccm.201109-1666oc	https://www.ncbi.nlm.nih.gov/pubmed/22198974?dopt=Abstract	9	2008-02-27	Not yet recruiting	Completed	2008-05-01	2010-04-01	2011-12-28	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1\n[ Time Frame: 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""FEV1 Absolute Change from baseline (mL)\n[ Time Frame: 26 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in absolute FEV1\n[ Time Frame: 26 weeks ]""}]	[See Results Section.]	NA
NCT00631371	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects	Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial	10.1200/jco.2013.50.5305	NA	101	2008-02-28	Not yet recruiting	Completed	2008-03-01	2011-03-01	2013-12-02	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Tumor measurements and survival status\n[ Time Frame: On going ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Independently assessed progression free survival (PFS)\n[ Time Frame: every 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00636181	Positive Pressure Treatment of Obstructive Sleep Apnea	Positive airway pressure initiation: a randomized controlled trial to assess the impact of therapy mode and titration process on efficacy, adherence, and outcomes	10.5665/sleep.1166	https://www.ncbi.nlm.nih.gov/pubmed/21804670	4	2008-03-13	Recruiting	Completed	2008-01-01	2009-03-01	2011-08-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adequate reduction of apnea hypopnea index from baseline.\n[ Time Frame: 90 Days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adequate reduction of apnea hypopnea index from baseline.\n[ Time Frame: 180 Days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adequate reduction of apnea hypopnea index from baseline.\n[ Time Frame: 180 Days ]""}]	[See Results Section.]	NA
NCT00637169	Canadian Oxygen Trial (COT)	Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial	10.1001/jama.2013.5555	https://www.ncbi.nlm.nih.gov/pubmed/23644995?dopt=Abstract	11	2008-03-10	Recruiting	Completed	2006-12-01	2012-06-01	2013-05-22	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Survival without severe neurosensory disability to 18 to 21 months (corrected for prematurity)\n[ Time Frame: 18-21 months corrected for prematurity ]""}]	NA
NCT00639743	PEITHO Pulmonary Embolism Thrombolysis Study	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism	10.1016/j.jacc.2016.12.039	https://pubmed.ncbi.nlm.nih.gov/28335835/	11	2008-03-19	Recruiting	Completed	2007-11-01	2012-07-01	2017-03-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: select one ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: select one ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: Day 7 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: Day 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: Day 7 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: Day 7 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical composite endpoint of all-cause mortality or haemodynamic collapse within 7 days\n[ Time Frame: Day 7 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Haemodynamic collapse is defined as: need for cardiopulmonary resuscitation; or systolic blood pressure < 90 mm Hg for at least 15 min or drop of syst\n[ Time Frame: Day 7 ]""}]	NA
NCT00644059	Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines	Oil-in-water emulsion adjuvant with influenza vaccine in young children	10.1056/nejmoa1010331	https://www.ncbi.nlm.nih.gov/pubmed/21995388?dopt=Abstract	5	2008-03-25	Suspended	Completed	2007-11-01	2010-04-01	2011-10-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate safety and tolerability of one or two 0,25mL or 0,50mL IM injections of the study vaccine, compared to active control vaccine\n[ Time Frame: 181 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate safety and tolerability of one or two 0,25mL or 0,50mL IM injections of the study vaccine, compared to active control vaccine\n[ Time Frame: 181 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate safety and tolerability of one and two 0.25mL IM injections of the adjuvanted and non-adjuvanted influenza vaccines\n[ Time Frame: 7 days postvaccination ]\n\nSolicited local and systemic reactions were assessed and compared between adjuvanted and non-adjuvanted influenza vaccines in 6 to 36 month old subjects""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate efficacy of two 0.25mL IM injections of the adjuvanted influenza vaccine and non-influenza vaccines\n[ Time Frame: Each subject was assessed for one influenza season ]\n\nVirus-confirmed influenza illnesses were assessed and compared between the adjuvanted influenza vaccine and non-influenza vaccines in 6 to 36 month old subjects. This primary endpoint is only for homologous strains.""}]	[See Results Section.]	NA
NCT00650078	Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)	10.1136/annrheumdis-2011-201067	https://www.ncbi.nlm.nih.gov/pubmed/22562974	17	2008-03-31	Not yet recruiting	Completed	2008-03-01	2009-07-01	2012-05-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ACR 20 response rate\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ACR 20 response rate\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ACR 20 response rate\n[ Time Frame: Week 12 ]""}]	[See Results Section.]	NA
NCT00650143	Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction	Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: A double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial)	10.1016/j.ijcard.2015.11.180	https://www.ncbi.nlm.nih.gov/pubmed/26709136?dopt=Abstract	7	2008-03-31	Recruiting	Unknown status	2008-03-01	NA	2015-11-30	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of global myocardial function from baseline to 6 months of follow-up.\n[ Time Frame: Recruitment period: 1,5 years. Follow-up assessment: 1 year. Analyses and reporting: 6 months. Overall duration: 3 years. ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of global myocardial function from baseline to 6 months of follow-up.\n[ Time Frame: Recruitment period: 4,5 years. Follow-up assessment: 1 year. Analyses and reporting: 6 months. Overall duration: 6 years. ]""}]
NCT00656136	BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial	10.1016/s1470-2045(12)70087-6	https://www.ncbi.nlm.nih.gov/pubmed/22452896?dopt=Abstract	34	2008-04-09	Not yet recruiting	Completed	NA	2010-03-01	2012-03-26	FALSE	FALSE	TRUE	TRUE	TRUE	NA	FALSE	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival time (OS)\n[ Time Frame: 9 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival time (OS)\n[ Time Frame: 9 months ]""}]	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival time (OS)\n[ Time Frame: 9 months ]""}]
NCT00659789	Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial	10.1016/s1473-3099(13)70343-8	https://www.ncbi.nlm.nih.gov/pubmed/24525316?dopt=Abstract	14	2008-04-15	Not yet recruiting	Completed	2008-08-01	2010-07-01	2014-02-11	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the proportion of subjects who require resumption of ART between the interruption of ART at week 28 and end of study at week 52.\n[ Time Frame: Week 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the proportion of subjects who require resumption of ART between the interruption of ART at week 28 and end of study at week 52. To evaluate the % change in CD4 between week 28 and the last CD4 made prior to resumption of ART or week 52.\n[ Time Frame: Week 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the proportion of subjects who require resumption of ART between the interruption of ART at week 28 and end of study at week 52. To evaluate the % change in CD4 between week 28 and the last CD4 made prior to resumption of ART or week 52.\n[ Time Frame: Week 52 ]""}]	[See Results Section.]	NA
NCT00660179	Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension	Macitentan and morbidity and mortality in pulmonary arterial hypertension	10.1056/nejmoa1213917	NA	53	2008-04-16	Not yet recruiting	Completed	2008-04-01	2012-02-01	2013-08-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that either dose of ACT-064992 prolongs the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension.\n[ Time Frame: End of Study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that either dose of ACT-064992 prolongs the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension.\n[ Time Frame: End of Study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that either dose of ACT-064992 prolongs the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension.\n[ Time Frame: End of Study ]""}]	[See Results Section.]	NA
NCT00661830	Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO)	Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme	10.1016/j.ejca.2014.09.013	NA	12	2008-04-15	Not yet recruiting	Completed	2008-05-01	2010-06-01	2014-10-15	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: one year ]""}]	[See Results Section.]	NA	NA
NCT00665626	Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)	An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents	10.1002/art.30114	http://onlinelibrary.wiley.com/doi/10.1002/art.30114/abstract	11	2008-04-23	Not yet recruiting	Completed	2008-05-01	2009-08-01	2011-01-28	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to assess the efficacy of R788 100 mg PO bid compared with placebo, as determined by ACR20 responder rates at Month 3.\n[ Time Frame: Month 3 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to assess the efficacy of R788 100 mg PO bid compared with placebo, as determined by ACR20 responder rates at Month 3.\n[ Time Frame: Month 3 ]""}]	NA	[See Results Section.]	NA
NCT00666341	Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens	Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study	10.1111/j.1365-2222.2012.03971.x	https://www.ncbi.nlm.nih.gov/pubmed/22909165	8	2008-04-23	Recruiting	Completed	2007-11-01	NA	2012-06-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint of this study is the number of patients with at least one systemic reaction (according to Tryba Grade 1-4) with possible, probable or definite relationship to the study medication determined at the end of the up-titration phase\n[ Time Frame: November 2007 - July 2008 ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systemic reaction (according to Tryba)\n[ Time Frame: uptitration phase ]\n\nNumber of patients with at least one systemic reaction (according to Tryba Grade 1-4) with possible, probable or definite relationship to the study medication determined at the end of the uptitration phase.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety measured in terms of adverse events (AEs)""}]
NCT00667810	Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients	Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials	10.1186/s13195-016-0189-7	https://www.ncbi.nlm.nih.gov/pubmed/27176461?dopt=Abstract	43	2008-04-25	Not yet recruiting	Terminated	2008-05-01	2012-10-01	2016-05-12	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale; Disability Assessment for Dementia\n[ Time Frame: 78 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale total score\n[ Time Frame: 78 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Disability Assessment for Dementia total score\n[ Time Frame: 78 weeks ]""}]	[See Results Section.]	NA	NA
NCT00672334	Sodium Bicarbonate in Cardiac Surgery Study	Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial	10.1371/journal.pmed.1001426	https://www.ncbi.nlm.nih.gov/pubmed/23610561?dopt=Abstract	8	2008-05-01	Recruiting	Terminated	2008-04-01	2011-06-01	2013-04-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level\n[ Time Frame: within first two-five postoperative days. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level\n[ Time Frame: within first two-five postoperative days. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level after adjustment for relevant baseline characteristics\n[ Time Frame: within first two-five postoperative days. ]""}]	NA	NA
NCT00674700	Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis	Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy	10.1111/j.1365-2222.2012.04044.x	https://www.ncbi.nlm.nih.gov/pubmed/22994348/	4	2008-05-07	Active, not recruiting	Completed	2007-10-01	2009-01-01	2012-10-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the Average Rhinitis Total Symptom Score (ARTSS) at endpoint\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the Average Rhinitis Total Symptom Score (ARTSS) at endpoint\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the Average Rhinitis Total Symptom Score (ARTSS) at endpoint\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00676143	Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients	Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed	10.1016/j.jval.2015.03.1787	NA	37	2008-05-09	Not yet recruiting	Terminated	2008-05-01	2013-06-01	2015-04-10	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale; Disability Assessment for Dementia\n[ Time Frame: 78 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Alzheimer's Disease Assessment Scale-Cognitive Subscale Total Score\n[ Time Frame: 78 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Disability Assessment for Dementia Total Score\n[ Time Frame: 78 weeks ]""}]	NA	[See Results Section.]	NA
NCT00678392	Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial	10.1016/s0140-6736(11)61613-9	https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(11)61613-9	130	2008-05-12	Not yet recruiting	Completed	2008-06-01	2010-08-01	2011-11-04	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: 3 years ]""}]	[See Results Section.]	NA
NCT00678535	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial	10.1016/s1470-2045(13)70102-5	https://www.ncbi.nlm.nih.gov/pubmed/23594786	9	2008-05-14	Not yet recruiting	Completed	2008-06-01	2011-12-01	2013-04-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: Various Timepoints ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: Various Timepoints ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00681135	Mechanical Plaque Control and Gingivitis Reduction in Fixed Appliance Patients	A randomized clinical trial comparing the impact of different oral hygiene protocols and sealant applications on plaque, gingival, and caries index scores	10.1093/ejo/cjt043	https://www.ncbi.nlm.nih.gov/pubmed/23825160	6	2008-05-19	Recruiting	Completed	2008-04-01	2010-10-01	2013-07-03	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quigley-Hein-Index (QHI), Papillen-Blutungs-Index (PBI)\n[ Time Frame: every 4 weeks for 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque Indices\n[ Time Frame: every 4 weeks for 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Gingival Indices\n[ Time Frame: every 4 weeks for 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plaque Indices\n[ Time Frame: every 4 weeks for 3 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Gingival Indices\n[ Time Frame: every 4 weeks for 3 months ]""}]	NA	NA
NCT00683696	Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)	Cardiac-resynchronization therapy in heart failure with a narrow QRS complex	10.1056/nejmoa1306687	https://www.ncbi.nlm.nih.gov/pubmed/23998714	26	2008-05-21	Not yet recruiting	Terminated	2008-08-01	2013-12-01	2013-09-02	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.\n[ Time Frame: Full study duration (event driven trial). Minimum 1 year follow-up and expected median patient follow-up duration of 2 years. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.\n[ Time Frame: Full study duration (event driven trial). Minimum 1 year follow-up and expected median patient follow-up duration of 2 years. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.\n[ Time Frame: 6 months ]""}]	NA	[See Results Section.]	NA
NCT00687869	Participative Rehabilitation in Stroke Patients	Effect of a stroke support service in Germany: a randomized trial	10.1179/1074935714z.0000000047	https://www.ncbi.nlm.nih.gov/pubmed/25920942?dopt=Abstract	2	2008-05-28	Not yet recruiting	Completed	2008-06-01	2012-03-01	2015-04-28	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical scale of the Stroke Impact Scale 3.0\n[ Time Frame: before discharge from acute care, four weeks after discharge from the hospital or rehabilitation (in case of referral to a medical rehabilitation) immediately before randomization (baseline assessment), and 12 months after randomization ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""physical scale of the Stroke Impact Scale 3.0\n[ Time Frame: before discharge from acute care, four weeks after discharge from the hospital or rehabilitation (in case of referral to a medical rehabilitation) immediately before randomization (baseline assessment), and 12 months after randomization ]""}]	NA	NA
NCT00697333	Radiotherapy Planning Based on Positron Emission Tomography With Fluoro-deoxyglucose For Advanced NSCLC	Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial	10.1016/s1470-2045(20)30013-9	https://pubmed.ncbi.nlm.nih.gov/32171429/	8	2008-06-12	Not yet recruiting	Unknown status	2009-05-01	NA	2020-03-12	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""local progression free survival\n[ Time Frame: actuarial ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time to local progression\n[ Time Frame: actuarial ]\n\nTime from randomization to first evidence of local progression or last follow up""}]
NCT00701142	Haemocomplettan® P During Aortic Replacement	Fibrinogen concentrate reduces intraoperative bleeding when used as first-line hemostatic therapy during major aortic replacement surgery: results from a randomized, placebo-controlled trial	10.1016/j.jtcvs.2012.12.083	https://linkinghub.elsevier.com/retrieve/pii/S0022-5223(13)00002-0	7	2008-06-18	Recruiting	Completed	2008-06-01	2010-03-01	2013-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs)administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combined number of units of allogeneic blood products (platelets + FFP + RBCs) administered to subjects.\n[ Time Frame: From administration of Haemocomplettan® P until 24 hours later ]""}]	NA
NCT00705965	Effects of a Psychotherapy Intervention in Depressed Patients With Coronary Artery Disease	A Stepwise Psychotherapy Intervention for Reducing Risk in Coronary Artery Disease (SPIRR-CAD): Results of an Observer-Blinded, Multicenter, Randomized Trial in Depressed Patients With Coronary Artery Disease	10.1097/psy.0000000000000332	https://insights.ovid.com/pubmed?pmid=27187851	6	2008-06-26	Not yet recruiting	Completed	2008-11-01	2013-04-01	2016-07-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to year 1 in depressive symptoms (HADS-D)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to 18 months in depressive symptoms (HADS-D)\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to 18 months in depressive symptoms (HADS-D)\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline to 18 months in depressive symptoms (HADS-D)\n[ Time Frame: 18 months ]""}]	NA
NCT00708162	Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir	Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study	10.1016/s1473-3099(11)70249-3	https://www.ncbi.nlm.nih.gov/pubmed/22015077	17	2008-06-30	Not yet recruiting	Completed	2008-09-01	2010-10-01	2011-10-18	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48.\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48.\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects achieving and maintaining confirmed HIV-1 RNA < 50 copies/mL through Week 48.\n[ Time Frame: 48 weeks ]""}]	[See Results Section.]	NA
NCT00708942	Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1	Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia	10.1002/lsm.22255	https://www.ncbi.nlm.nih.gov/pubmed/24799181	7	2008-07-02	Not yet recruiting	Terminated	2009-01-01	2012-01-01	2014-05-06	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Lesion eradication\n[ Time Frame: 6 month ]""}]	[See Results Section.]	NA	NA
NCT00711230	NA	NA	NA	NA	9	2008-07-07	Recruiting	Completed	2008-04-01	2009-12-01	NA	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of DermaVir Patch\n[ Time Frame: Throughout the study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability of DermaVir Patch\n[ Time Frame: Throughout the study ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent of participants with primary safety endpoint\n[ Time Frame: 24 weeks ]\n\nPrimary safety endpoint: occurrence of at least two > Grade 3 adverse event including signs/symptoms, lab toxicities, and/or clinical events that is possibly or definitely related to study treatment (as judged by the GIEU006 team, including site clinicians on the team, blinded to treatment arm) any time from the first day of study treatment until 42 days after the last study vaccine administration.""}]
NCT00711295	Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups	Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients	10.1128/cvi.00065-14	https://www.ncbi.nlm.nih.gov/pubmed/24739978	8	2008-07-07	Not yet recruiting	Completed	2008-08-01	2009-03-01	2014-04-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency and severity of systemic reactions until 21 days after the first and second vaccinations\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by microneutralization (MN) assay >= 1:20.\n[ Time Frame: 42 days ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Antibody response 21 days after the second vaccination as measured by MN assay;\n[ Time Frame: 42 days ]""}]	NA
NCT00711503	Anti-Interleukin-1 in Diabetes Action	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials	10.1016/s0140-6736(13)60023-9	https://www.ncbi.nlm.nih.gov/pubmed/23562090?dopt=Abstract	9	2008-07-03	Not yet recruiting	Completed	2009-01-01	2012-01-01	2013-04-05	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Δ 2-h AUC C-peptide response\n[ Time Frame: 1 month, 3 months, 6 months, 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Δ 2-h AUC C-peptide response\n[ Time Frame: 1 month, 3 months, 6 months, 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Δ 2-h AUC C-peptide response\n[ Time Frame: 1 month, 3 months, 6 months, 9 months ]""}]	NA	NA
NCT00714311	Efficacy of Transference-Focused Psychotherapy for Borderline Personality Disorder	Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial	10.1192/bjp.bp.109.070177	https://pubmed.ncbi.nlm.nih.gov/20435966/	4	2008-07-09	Recruiting	Completed	2004-10-01	2009-02-01	2010-05-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission of borderline personality disorder according to the criteria of DSM-IV.\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drop-out\n[ Time Frame: 1 year ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Suicidality (suicide attempts)\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drop-out\n[ Time Frame: 1 year ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Suicidality (suicide attempts)\n[ Time Frame: 1 year ]""}]	[See Results Section.]	NA
NCT00715806	Claustrophobia and Magnetic Resonance Imaging	Reduction of claustrophobia with short-bore versus open magnetic resonance imaging: a randomized controlled trial	10.1371/journal.pone.0023494	https://www.ncbi.nlm.nih.gov/pubmed/21887259	5	2008-07-11	Recruiting	Completed	2008-07-01	2009-08-01	2011-08-22	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.\n[ Time Frame: During MRI ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.\n[ Time Frame: During MRI ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The ability of an open MRI scanner to reduce claustrophobic reactions that prevent MR examinations.\n[ Time Frame: Before or During MRI ]""}]	NA	NA
NCT00716079	The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial	Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage	10.1056/nejmoa1214609	https://www.ncbi.nlm.nih.gov/pubmed/23713578?dopt=Abstract	11	2008-07-14	Not yet recruiting	Completed	2008-09-01	2012-12-01	2013-05-29	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death or dependency, with dependency being defined by a score of 3 to 5 on the modified Rankin Scale (mRS)\n[ Time Frame: 90 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death or dependency, with dependency being defined by a score of 3 to 5 on the modified Rankin Scale (mRS)\n[ Time Frame: 90 days ]""}]	NA	[See Results Section.]	NA
NCT00718939	Rheos® Diastolic Heart Failure Trial	Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study	10.1016/j.jacc.2010.03.089	http://www.sciencedirect.com/science/article/pii/S0735109710027221	8	2008-07-17	Recruiting	Completed	2008-07-01	2010-12-01	2010-10-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assess left ventricular mass index (LVMI).\n[ Time Frame: at six months post- randomizatiom. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Assess safety by evaluating all adverse events.\n[ Time Frame: through six months post -implant ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assess left ventricular mass index (LVMI).\n[ Time Frame: at six months post- randomizatiom. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Assess safety by evaluating all adverse events.\n[ Time Frame: through six months post -implant ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assess left ventricular mass index (LVMI).\n[ Time Frame: at six months post- randomization. ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Assess safety by evaluating all adverse events.\n[ Time Frame: through six months post -implant ]""}]	NA
NCT00722566	A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study	10.1016/s1470-2045(11)70081-x	NA	14	2008-07-24	Recruiting	Completed	2008-06-01	2010-07-01	2011-04-18	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate\n[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate\n[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall response rate\n[ Time Frame: After 4 cycles (prior to the addition of dexamethasone) ]""}]	[See Results Section.]	NA
NCT00724022	Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation	Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial	10.1016/s0140-6736(16)32187-0	https://pubmed.ncbi.nlm.nih.gov/27871759/	9	2008-07-28	Active, not recruiting	Completed	2008-06-01	2010-09-01	2016-11-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The low dose tacrolimus study arm will be modified to further improve efficacy (prevention of BPAR, best possible renal function) and safety (adverse event profile) of immunosuppression.\n[ Time Frame: one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of immunosuppression measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.\n[ Time Frame: one year after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of immunosuppression measured in rejection rate confirmed by biopsy according to BANFF 97, modified 2005.\n[ Time Frame: one year after transplantation ]""}]	NA	NA
NCT00730548	Compare Remote Patient Management and Standard Care in CRT-D and ICD-patients to Assess the Effect on Heart Failure	A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices	10.1093/europace/euv039	https://www.ncbi.nlm.nih.gov/pubmed/25983310?dopt=Abstract	10	2008-08-04	Recruiting	Completed	2007-11-01	2011-04-01	2015-05-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hospital length of stay due to worsened heart failure\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hospital length of stay due to worsened heart failure\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first hospitalization due to worsened heart failure\n[ Time Frame: 15 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first hospitalization due to worsened heart failure\n[ Time Frame: 15 months ]""}]	NA
NCT00732953	Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries	Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease	10.1136/hrt.2011.226563	https://heart.bmj.com/content/97/16/1338.long	5	2008-08-08	Not yet recruiting	Completed	2009-01-01	2010-01-01	2011-07-20	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""late loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late loss\n[ Time Frame: 6 months ]""}]	NA
NCT00733343	Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure	Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure	10.1056/nejmoa1506459	https://pubmed.ncbi.nlm.nih.gov/26323938/	23	2008-08-11	Recruiting	Completed	2008-01-01	2015-05-01	2015-09-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""1) all cause mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""2) cardiovascular mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""3) all cause mortality or all cause hospitalization\n[ Time Frame: time to first event ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""1) all cause mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""2) cardiovascular mortality or unplanned hospitalization for worsening heart failure\n[ Time Frame: time to first event ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""3) all cause mortality or all cause hospitalization\n[ Time Frame: time to first event ]""}]	NA	[See Results Section.]	NA
NCT00740831	PGL4001 Versus GnRH-agonist in Uterine Myomas	Ulipristal acetate versus leuprolide acetate for uterine fibroids	10.1056/nejmoa1103180	https://www.ncbi.nlm.nih.gov/pubmed/22296076?dopt=Abstract	26	2008-08-22	Recruiting	Completed	2008-08-01	2010-01-01	2012-02-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary efficacy objective of this study is to compare efficacy of PGL4001 versus GnRH-agonist to reduce excessive uterine bleeding.\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary efficacy objective of this study is to compare efficacy of PGL4001 versus GnRH-agonist to reduce excessive uterine bleeding.\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary efficacy objective of this study is to compare efficacy of PGL4001 versus GnRH-agonist to reduce excessive uterine bleeding.\n[ Time Frame: 3 months ]""}]	[See Results Section.]	NA
NCT00742859	Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)	10.1093/eurheartj/eht039	https://academic.oup.com/eurheartj/article/34/20/1498/489785/Betrixaban-compared-with-warfarin-in-patients-with	8	2008-08-26	Not yet recruiting	Completed	2008-10-01	2009-08-01	2013-03-13	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.\n[ Time Frame: Up to one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.\n[ Time Frame: Up to one year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the occurrence of major or clinically relevant non-major bleeding.\n[ Time Frame: Up to one year ]""}]	[See Results Section.]	NA
NCT00747487	Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy	A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy	10.1093/brain/awr170	https://www.ncbi.nlm.nih.gov/pubmed/21788663?dopt=Abstract	9	2008-09-04	Recruiting	Completed	2007-11-01	NA	2011-07-25	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best recovery of logMAR visual acuity\n[ Time Frame: 24 weeks ]""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best recovery of logMAR visual acuity between baseline and Week 24 in either right or left eye\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Best recovery of logMAR visual acuity between baseline and Week 24 in either right or left eye\n[ Time Frame: 24 weeks ]""}]
NCT00748202	Berinert P Study of Subcutaneous Versus Intravenous Administration	Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study	10.1111/trf.12501	http://onlinelibrary.wiley.com/doi/10.1111/trf.12501/abstract	8	2008-09-04	Not yet recruiting	Completed	2008-09-01	2010-12-01	2013-11-24	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters\n[ Time Frame: i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120 and 168 hours. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters\n[ Time Frame: i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120, 168, 336 an 504 hours. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Individual courses of C1-inhibitor levels, from these will be derived pharmacokinetic parameters\n[ Time Frame: i.v. and s.c.samples: 0, 0.25, 0.5, 0.75 hours and 1, 2, 4, 6, 8, 12, 16, 20, 24, 36, 48, 60, 72, 120, 168, 336 an 504 hours. ]""}]	NA	NA
NCT00749996	Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease	Herniectomy versus herniectomy with the DIAM spinal stabilization system in patients with sciatica and concomitant low back pain: results of a prospective randomized controlled multicenter trial	10.1007/s00586-016-4796-6	NA	15	2008-09-09	Recruiting	Completed	2006-11-01	2011-03-01	2016-10-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate a statistically significant difference in the relief of back pain between both treatment groups. The endpoint will be the difference between baseline and 6-month of the patient's back-pain score on a Visual Analogue Scale (VAS).\n[ Time Frame: 6 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate a statistically significant difference in the relief of back pain between both treatment groups. The endpoint will be the difference between baseline and 6-month of the patient's back-pain score on a Visual Analogue Scale (VAS).\n[ Time Frame: 6 Months ]""}]	[See Results Section.]	NA	NA
NCT00751465	Dysfunctional Attention Processes in Fear of Blushing: Specificity and Changeability	Can a one-weekend group therapy reduce fear of blushing? Results of an open trial	10.1080/10615800903075132	https://www.ncbi.nlm.nih.gov/pubmed/19557558?dopt=Abstract	7	2008-09-11	Not yet recruiting	Completed	2008-11-01	2009-11-01	2010-05-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Liebowitz Social Anxiety Scale\n[ Time Frame: post, 6-months, and 12-months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brief Social Phobia Scale\n[ Time Frame: within, post, 6-months, and 12-months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brief Social Phobia Scale\n[ Time Frame: within, post, 6-months, and 12-months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Brief Social Phobia Scale\n[ Time Frame: pre, within, post, 6-months, and 12-months follow-up ]\n\nBrief Social Phobia Scale BSPS is an interview assessing fear and avoidance in seven social situations and severity of four bodily symptoms.""}]	NA
NCT00763971	Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17	European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder	10.1016/j.euroneuro.2012.11.012	https://www.ncbi.nlm.nih.gov/pubmed/23332456?dopt=Abstract	24	2008-09-30	Not yet recruiting	Completed	2008-10-01	2010-10-01	2013-01-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADHD Rating Scale\n[ Time Frame: Weekly for 7 weeks of treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ADHD Rating Scale\n[ Time Frame: Weekly for 7 weeks of treatment ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00764881	Effects of SH T00658ID on Libido	Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction	10.1111/jsm.12310	http://www.sciencedirect.com/science/article/pii/S1743609515302319?via%3Dihub	20	2008-10-01	Not yet recruiting	Completed	2009-01-01	2010-08-01	2012-09-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in the not weighted sum of Female Sexual Function Index (FSFI) sexual desire and the sexual arousal component scores, defined as the total of questions 1 to 6 of the FSFI.\n[ Time Frame: Baseline to cycle 6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The change in the not weighted sum of Female Sexual Function Index (FSFI) sexual desire and the sexual arousal component scores, defined as the total of questions 1 to 6 of the FSFI.\n[ Time Frame: Baseline to cycle 6 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00769457	OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network	Fluid status telemedicine alerts for heart failure: a randomized controlled trial	10.1093/eurheartj/ehw099	https://pubmed.ncbi.nlm.nih.gov/26984864/	12	2008-10-08	Recruiting	Completed	2008-09-01	2014-11-01	2016-03-16	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day 35 after implantation\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""All-cause of death or unplanned admission to hospital for cardiovascular reason from day of patient informed consent sign off\n[ Time Frame: 18 Months ]""}]	NA
NCT00769561	Biofeedback-Based Cognitive Behavioral Treatment for Temporomandibular Disorders	Biofeedback-based cognitive-behavioral treatment compared with occlusal splint for temporomandibular disorder: a randomized controlled trial	10.1097/ajp.0b013e3182850559	https://www.ncbi.nlm.nih.gov/pubmed/23446073?dopt=Abstract	3	2008-10-08	Recruiting	Completed	2008-06-01	2010-07-01	2013-12-01	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))\n[ Time Frame: Pre-Post-Design including 4 assessment points: pre-treatment, post-treatment, 3- and 6-month follow up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pain intensity (German Pain Questionnaire; Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD))\n[ Time Frame: Pre-Post-Design including 4 assessment points: pre-treatment, post-treatment, 3- and 6-month follow up ]""}]	NA	[See Results Section.]	NA
NCT00778648	Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms	NA	NA	https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/reduction-of-common-cold-symptoms-by-encapsulated-juice-powder-concentrate-of-fruits-and-vegetables-a-randomised-double-blind-placebo-controlled-trial/4E3A02A6D1E0EF0A17D0043394E843C4	3	2008-10-21	Active, not recruiting	Completed	2008-09-01	2009-05-01	2010-08-23	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to determine the effect of an encapsulated juice powder concentrate on the number of days with at least moderate common cold symptoms\n[ Time Frame: Common cold symptoms will be documented by participants with the common cold questionnaire during the study period. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to determine the effect of an encapsulated juice powder concentrate on the number of days with at least moderate common cold symptoms\n[ Time Frame: The number of days with at least moderate common cold symptoms will be assessed with a common cold questionnaire over a period of eight months. ]""}]	NA	[See Results Section.]	NA
NCT00784654	Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17	Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design	10.1016/j.jaac.2014.01.017	https://www.ncbi.nlm.nih.gov/pubmed/24839883?dopt=Abstract	22	2008-11-03	Not yet recruiting	Completed	2009-01-01	2011-08-01	2014-03-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Adverse Events and Vital Signs\n[ Time Frame: Weekly for the first 4 weeks of treatment; monthly for the final 48 weeks of treatment ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical Laboratory Results\n[ Time Frame: Week 20 amd Week 52 ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""ECGs\n[ Time Frame: Week 12, Week 24, Week 36 and Week 52 ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Discontinuations\n[ Time Frame: Throughout the 52-week study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite endpoint based on the ADHD Rating Scale-IV (ADHD-RS-IV)and Clinical Global Impressions - Severity of Illness (CGI-S)rating scale\n[ Time Frame: Weekly for the 6-week double-blind treatment period (final 6 weeks of study treatment) ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00786994	The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses	Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial	10.1111/bjd.13342	https://www.ncbi.nlm.nih.gov/pubmed/25124939?dopt=Abstract	7	2008-11-05	Recruiting	Completed	2008-10-01	2010-11-01	2015-02-25	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical clearance of all treated actinic keratoses\n[ Time Frame: 18 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance.\n[ Time Frame: 18 weeks ]\n\nObjective response of the marker actinic keratosis, defined as his-tologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective response of the marker actinic keratosis, defined as histologically complete or partial clearance.\n[ Time Frame: 18 weeks ]\n\nObjective response of the marker actinic keratosis, defined as his-tologically complete or partial clearance (partial clearance = down-grading in Cockerell-classification). The marker actinic keratosis is defined as an initially selected lesion within the target area that will be used for final biopsy.""}]	[See Results Section.]	NA
NCT00792220	""Mobile Stroke-Unit"" for Reduction of the Response Time in Ischemic Stroke	Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial	10.1016/s1474-4422(12)70057-1	http://www.sciencedirect.com/science/article/pii/S1474442212700571	8	2008-11-14	Not yet recruiting	Completed	2008-11-01	2011-07-01	2012-04-11	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time between emergency call and therapy decision\n[ Time Frame: 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time between emergency call and therapy decision""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time between emergency call and therapy decision""}]	NA
NCT00798317	Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.	Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes	10.1056/nejmoa1110823	NA	17	2008-11-25	Not yet recruiting	Completed	2008-12-01	2010-12-01	2012-08-16	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at day 28, as determined by masked Central Reading Centre (CRC) OCT evaluation.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at day 28, as determined by masked Central Reading Centre (CRC) OCT evaluation.\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with nonsurgical resolution of focal vitreomacular adhesion at day 28, as determined by masked Central Reading Centre (CRC) OCT evaluation.\n[ Time Frame: Day 28 ]""}]	[See Results Section.]	NA
NCT00798525	Argatroban Versus Lepirudin in Critically Ill Patients	Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial	10.1186/s13054-014-0588-8	https://www.ncbi.nlm.nih.gov/pubmed/25344113	7	2008-11-25	Not yet recruiting	Terminated	2009-01-01	2012-03-01	2014-10-25	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean running time of two consecutive haemodialysis circuits\n[ Time Frame: seven days starting at time of HIT suspicion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean running time of two consecutive haemodialysis circuits\n[ Time Frame: seven days starting at time of HIT suspicion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean running time of a maximum of two consecutive haemodialysis circuits\n[ Time Frame: seven days starting at time of HIT suspicion ]""}]	NA	NA
NCT00798967	Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects	Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure	10.1053/j.gastro.2012.09.007	https://www.ncbi.nlm.nih.gov/pubmed/22982184	15	2008-11-26	Recruiting	Completed	2008-11-01	2010-12-01	2012-09-11	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage who demonstrate a response at Week 20 and maintain that response through Week 24. A response is at least a 20% reduction from baseline in weekly PN volume.\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage who demonstrate a response at Week 20 and maintain that response through Week 24. A response is at least a 20% reduction from baseline in weekly PN volume.\n[ Time Frame: 24 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00800384	Shockless Implant Evaluation	Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)	10.1016/s0140-6736(14)61903-6	NA	15	2008-12-01	Not yet recruiting	Completed	2009-01-01	2012-04-01	2015-02-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First occurrence of the composite of failed first appropriate clinical shock from the ICD or arrhythmic death\n[ Time Frame: Mean follow-up of 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First occurrence of the composite of failed first appropriate clinical shock from the ICD or arrhythmic death\n[ Time Frame: Mean follow-up of 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""First occurrence of the composite of failed first appropriate clinical shock from the ICD or arrhythmic death\n[ Time Frame: Mean follow-up of 3 years ]""}]	[See Results Section.]	NA
NCT00802425	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss	Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study	10.1097/mao.0000000000000466	https://www.ncbi.nlm.nih.gov/pubmed/24979398	13	2008-12-03	Recruiting	Completed	2008-12-01	2012-07-01	2014-09-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hearing loss\n[ Time Frame: 7 days ]\n\nAverage change in hearing loss in dB between the baseline and D7 for the three contiguous frequencies with the worst hearing loss, identified at study entry""}]	NA	NA
NCT00803205	Study of Ataluren (PTC124™) in Cystic Fibrosis	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial	10.1016/s2213-2600(14)70100-6	https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(14)70100-6	36	2008-12-04	Not yet recruiting	Completed	2009-07-01	2012-03-01	2014-05-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1 second (FEV1)\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1 second (FEV1)\n[ Time Frame: 48 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1 second (FEV1)\n[ Time Frame: 48 weeks ]""}]	[See Results Section.]	NA
NCT00803634	Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)	Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO)	10.1016/j.ahj.2013.12.023	https://www.ncbi.nlm.nih.gov/pubmed/?term=Clevidipine+in+acute+heart+failure%3A+Results+of+the+A+Study+of+Blood+Pressure+Control+in+Acute+Heart+Failure%E2%80%94A+Pilot+Study+(PRONTO)	19	2008-12-04	Not yet recruiting	Completed	2008-12-01	2010-12-01	2014-01-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time and percent of patients that attain the initial prespecified SBP target range (minimum of 20 mm Hg and a maximum of 40 mm Hg apart) and a 15% reduction in SBP from baseline within the first 30 minutes\n[ Time Frame: Within initial 30-minute treatment period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time and percent of patients that attain the initial prespecified SBP target range (minimum of 20 mm Hg and a maximum of 40 mm Hg apart) and a 15% reduction in SBP from baseline within the first 30 minutes\n[ Time Frame: Within initial 30-minute treatment period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Median time and percent of patients that attain the initial prespecified SBP target range (minimum of 20 mm Hg and a maximum of 40 mm Hg apart) and a 15% reduction in SBP from baseline within the first 30 minutes\n[ Time Frame: Within initial 30-minute treatment period ]""}]	[See Results Section.]	NA
NCT00804102	Transcorneal Electrical Stimulation Therapy for Retinal Disease	Phosphene thresholds elicited by transcorneal electrical stimulation in healthy subjects and patients with retinal diseases	10.1167/iovs.12-9612	https://www.ncbi.nlm.nih.gov/pubmed/23049087?dopt=Abstract	5	2008-12-05	Enrolling by invitation	Completed	2008-01-01	2010-07-01	2012-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""enhanced field of vision, lower threshold for electrical evoked phosphenes\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""enhanced field of vision, lower threshold for electrical evoked phosphenes\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""enhanced field of vision, enhanced visual acuity, lower threshold for electrical evoked phosphenes\n[ Time Frame: 3 years ]""}]	NA	NA
NCT00807300	Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma	Radioablation by Image-Guided (HDR) Brachytherapy and Transarterial Chemoembolization in Hepatocellular Carcinoma: A Randomized Phase II Trial	10.1007/s00270-018-2127-5	https://pubmed.ncbi.nlm.nih.gov/30488303/	5	2008-12-10	Recruiting	Completed	2006-10-01	2015-12-01	2018-11-28	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to progression\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to untreatable progression\n[ Time Frame: the follow up period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to untreatable progression\n[ Time Frame: the follow up period ]""}]	NA	NA
NCT00808236	Pre-ROSC Intra-Nasal Cooling Effectiveness	Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness)	10.1161/circulationaha.109.931691	https://www.ncbi.nlm.nih.gov/pubmed/20679548?dopt=Abstract	6	2008-12-11	Recruiting	Completed	2008-11-01	2009-06-01	2010-08-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ROSC rate\n[ Time Frame: within 1 hour of arrest ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ROSC rate\n[ Time Frame: within 1 hour of arrest ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00810043	Medtronic SCORE Study - Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty	A randomized trial comparing 2 techniques of balloon kyphoplasty and curette use for obtaining vertebral body height restoration and angular-deformity correction in vertebral compression fractures due to osteoporosis	10.3174/ajnr.a3363	https://www.ncbi.nlm.nih.gov/pubmed/23179647	10	2008-12-15	Not yet recruiting	Completed	2009-02-01	2010-10-01	2012-11-22	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Compare vertebral body anatomy height restoration obtained after balloon kyphoplasty when 1) curette is used first followed by an inflatable bone tamp (IBT) and 2) the IBT is used first, followed by the curette, and then an IBT\n[ Time Frame: 48 hours post procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Compare vertebral body anatomy height restoration obtained after balloon kyphoplasty when 1) curette is used first followed by an inflatable bone tamp (IBT) and 2) the IBT is used first, followed by the curette, and then an IBT\n[ Time Frame: 48-hr post procedure; 30-day ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00816660	Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial	10.1182/blood-2013-01-479527	http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=23777763	16	2009-01-02	Recruiting	Completed	2008-12-01	2010-10-01	2013-06-18	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after various doses of rVWF:rFVIII.\n[ Time Frame: approximately up to 9 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses\n[ Time Frame: Up to 30 days after the last investigational product infusion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses\n[ Time Frame: Up to 30 days after the last investigational product infusion ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate the immediate tolerability and safety after single-dose injections of rVWF:rFVIII at various doses\n[ Time Frame: Up to 30 days after the last investigational product infusion ]""}]	NA
NCT00819286	Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain	Sternal closure with rigid plate fixation versus wire closure: a randomized controlled multicenter trial	10.1016/j.athoracsur.2012.07.085	https://www.ncbi.nlm.nih.gov/pubmed/23103010	12	2009-01-07	Recruiting	Completed	2008-12-01	2011-01-01	2012-10-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in anterior chest wall pain\n[ Time Frame: 3-6 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in anterior chest wall pain\n[ Time Frame: 3-6 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00822393	Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial	10.1016/s2352-3026(19)30157-7	https://pubmed.ncbi.nlm.nih.gov/31606445/	21	2009-01-13	Recruiting	Completed	2008-11-01	2012-03-01	2019-10-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 1 year after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 1 year after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 2 years after transplantation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event-free survival (EFS)\n[ Time Frame: within 2 years after transplantation ]""}]	NA
NCT00823212	The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions	A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial	10.1016/j.jacc.2011.02.016	https://www.ncbi.nlm.nih.gov/pubmed/21470815	23	2009-01-13	Withheld	Completed	2009-01-01	2010-10-01	2011-04-04	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Twelve-month target lesion failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.\n[ Time Frame: 12-month post index procedure ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Twelve-month target lesion failure (TLF) rate, defined as any ischemia-driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.\n[ Time Frame: 12-month post index procedure ]""}]	[See Results Section.]	NA
NCT00827983	Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)	Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study	10.1016/j.fertnstert.2013.09.010	https://www.ncbi.nlm.nih.gov/pubmed/24140033?dopt=Abstract	6	2009-01-22	Recruiting	Completed	2009-01-01	2010-11-01	2013-10-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ongoing pregnancy rate at the end of the study\n[ Time Frame: 10 weeks after treatment start ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ongoing pregnancy rate at the end of the study\n[ Time Frame: 10 weeks after treatment start ]""}]	[See Results Section.]	NA	NA
NCT00831233	Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer	Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233)	10.1159/000345423	https://www.ncbi.nlm.nih.gov/pubmed/23258223	9	2009-01-27	Not yet recruiting	Terminated	2009-04-01	2010-07-01	2012-12-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LUTS relief based on reduction in IPSS (questionnaire)\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""LUTS relief based on reduction in IPSS (questionnaire)\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00833248	Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer	Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide	10.1016/j.clon.2012.09.010	https://www.ncbi.nlm.nih.gov/pubmed/23257248?dopt=Abstract	13	2009-01-30	Not yet recruiting	Completed	2009-04-01	2011-06-01	2012-12-17	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean percentage reduction in prostate volume\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean percentage reduction in prostate volume\n[ Time Frame: After 12 weeks treatment compared to Baseline ]""}]	[See Results Section.]	NA	NA
NCT00835978	Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial	10.1016/s1470-2045(13)70464-9	http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70464-9/fulltext	84	2009-02-02	Not yet recruiting	Completed	2009-03-01	2012-10-01	2013-10-18	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Response Rate\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Response Rate\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Response Rate\n[ Time Frame: 3 years ]""}]	[See Results Section.]	NA
NCT00841256	Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children	High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study	10.1016/j.jaci.2012.06.047	https://pubmed.ncbi.nlm.nih.gov/22939758/	11	2009-02-10	Recruiting	Completed	NA	2013-08-01	2012-08-29	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of Symptom-Medication-Score""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of Symptom-Medication-Score\n[ Time Frame: After 1 year of treatment ]\n\nThe change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of Symptom-Medication-Score\n[ Time Frame: After 1 year of treatment ]\n\nThe change of the area under the curve of the symptom and medication score (SMS) from the baseline season to the season after 1 year of treatment.""}]
NCT00844649	Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine	10.1056/nejmoa1304369	https://www.ncbi.nlm.nih.gov/pubmed/24131140?dopt=Abstract	62	2009-02-13	Not yet recruiting	Completed	2009-03-01	2012-12-01	2013-10-16	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""the primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and gemcitabine versus gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.\n[ Time Frame: EOS and Follow-Up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and Gemcitabine versus Gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.\n[ Time Frame: EOS and Follow-Up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and Gemcitabine versus Gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.\n[ Time Frame: EOS and Follow-Up ]""}]	[See Results Section.]	NA
NCT00850629	Hormonal Regulation of Body Weight Maintenance	Hormonal regulatory mechanisms in obese children and adolescents after previous weight reduction with a lifestyle intervention: maintain - paediatric part - a RCT from 2009-15	10.1186/s40608-016-0110-8	https://pubmed.ncbi.nlm.nih.gov/27298729/	4	2009-02-24	Not yet recruiting	Completed	2009-10-01	2012-07-01	2016-06-10	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight regain during lifestyle intervention in children, adolescents and adults vs. placebo\n[ Time Frame: 18 month ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Weight regain during lifestyle intervention in children, adolescents and adults vs. placebo\n[ Time Frame: 18 month ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""BMI will be assessed during lifestyle intervention in (1) children and adolescents and (2) adults vs. placebo\n[ Time Frame: 21 months ]\n\nBMI (kg/m2) will be analyzed after intentional weight loss in two comparable parts of a randomized controlled trial including (1) children and adolescents and (2) adults. Therefore effects of a multimodal lifestyle intervention will be compared to placebo.""}]	NA
NCT00864253	A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma	10.1093/annonc/mdv324	https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv324	38	2009-03-17	Not yet recruiting	Completed	2009-04-01	2011-06-01	2015-09-26	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is progression-free survival (PFS) based on a blinded radiology assessment of response using RECIST response guidelines.\n[ Time Frame: Every 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is progression-free survival (PFS) based on a blinded radiology assessment of response using RECIST response guidelines.\n[ Time Frame: Every 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00867672	Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial	10.1200/jco.19.01053	https://pubmed.ncbi.nlm.nih.gov/31794324/	8	2009-03-23	Not yet recruiting	Completed	2011-11-01	2015-02-01	2019-12-03	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective best response rate (complete remission (CR) and partial remission (PR))\n[ Time Frame: 12 months after randomization of the last patient ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective best response rate (complete remission (CR) and partial remission (PR))\n[ Time Frame: 12 months after randomization of the last patient ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Objective best response rate (complete remission (CR) and partial remission (PR))\n[ Time Frame: 12 months after randomization of the last patient ]""}]	NA	NA
NCT00868166	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS	A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis	10.1111/ene.12344	http://onlinelibrary.wiley.com/doi/10.1111/ene.12344/full	8	2009-03-23	Not yet recruiting	Completed	2009-04-01	2011-04-01	2014-01-21	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be the overall 18-month survival rate.\n[ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be the overall 18-month survival rate.\n[ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure will be the overall 18-month survival rate.\n[ Time Frame: Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days). ]""}]	[See Results Section.]	NA
NCT00873119	Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial	10.1002/cncr.29229	http://onlinelibrary.wiley.com/doi/10.1002/cncr.29229/full	13	2009-03-31	Recruiting	Completed	2009-02-01	2012-02-01	2015-01-21	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival measured by RECIST criteria\n[ Time Frame: May 2010 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival measured by RECIST criteria\n[ Time Frame: May 2010 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00874848	Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer	A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer	10.1007/s10637-017-0450-3	NA	18	2009-04-02	Not yet recruiting	Completed	2009-08-01	2012-07-01	2017-03-16	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To determine the objective response rate (ORR) in each study arm\n[ Time Frame: Approximately 1.5 years ]""}]	[See Results Section.]	NA	NA
NCT00879229	ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis	Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: An algorithm application model	10.1016/j.rmed.2014.12.011	http://www.resmedjournal.com/article/S0954-6111(14)00449-1/fulltext	12	2009-04-08	Not yet recruiting	Terminated	2009-07-01	2011-05-01	2015-01-03	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in six-minute walk distance (6MWD).\n[ Time Frame: 16 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in six-minute walk distance (6MWD).\n[ Time Frame: 16 weeks ]""}]	[See Results Section.]	NA	NA
NCT00886704	Omega-3 Fatty Acids, the Omega-3 Index, and Atherosclerosis	Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index	10.1017/s0007114510001054	https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effects-of-a-convenience-drink-fortified-with-n3-fatty-acids-on-the-n3-index/A283F41DD8F75D19ED12B14619561443	4	2009-04-22	Recruiting	Completed	2009-04-01	2009-08-01	2010-04-27	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Omega-3 Index\n[ Time Frame: day one and at 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Omega-3 Index\n[ Time Frame: day one and at 8 weeks ]""}]	NA	[See Results Section.]	NA
NCT00887978	Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension	Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial	10.1378/chest.12-2875	https://www.ncbi.nlm.nih.gov/pubmed/23669822?dopt=Abstract	9	2009-04-23	Not yet recruiting	Completed	2009-06-01	2011-07-01	2013-09-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in 6-minute walk distance from Baseline to Week 16""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in 6-minute walk distance from Baseline to Week 16""}]	[See Results Section.]	NA	NA
NCT00888433	Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?	10.1097/hjh.0b013e328344db3a	NA	8	2009-04-24	Withheld	Completed	2009-06-01	2010-09-01	2011-05-01	TRUE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood Pressure Reduction\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood Pressure Reduction\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00888940	Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery	A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial)	10.1016/j.jtcvs.2011.06.001	https://linkinghub.elsevier.com/retrieve/pii/S0022-5223(11)00600-3	7	2009-04-26	Not yet recruiting	Completed	2009-06-01	2010-01-01	2011-07-02	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate the relative efficacy of ecallantide and Cyklokapron(R) in the reduction of blood loss in subjects undergoing cardiac surgery including the use of CPB, associated with a high risk of bleeding.\n[ Time Frame: Over the duration of the study. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective is to evaluate the relative efficacy of ecallantide and Cyklokapron(R) in the reduction of blood loss in subjects undergoing cardiac surgery including the use of CPB, associated with a high risk of bleeding.\n[ Time Frame: Over the duration of the study. ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00895830	Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV)	Intravenous buspirone for the prevention of postoperative nausea and vomiting	10.1007/s00228-012-1284-8	https://link.springer.com/article/10.1007%2Fs00228-012-1284-8	6	2009-05-07	Not yet recruiting	Completed	2009-05-01	2009-11-01	2012-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[See Results Section.]	NA	NA
NCT00900146	Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients	Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial	10.1161/circulationaha.112.122556	NA	7	2009-05-11	Recruiting	Terminated	2009-04-01	2012-05-01	2012-11-05	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess safety and tolerability of four doses of ACZ885 vs. placebo over 4 months in patients with T2DM To assess the effect on HbA1c of four doses of ACZ885 vs. placebo as an add-on regimen over 4 months in patients with T2DM\n[ Time Frame: 4 months ]""}]	[See Results Section.]	NA	NA	NA
NCT00903331	Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study	Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial	10.1183/09031936.00104612	NA	27	2009-05-15	Not yet recruiting	Completed	2009-05-01	2011-06-01	2013-05-16	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that macitentan positively affects FVC compared with placebo in patients with IPF.\n[ Time Frame: Baseline - 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that macitentan positively affects FVC compared with placebo in patients with IPF.\n[ Time Frame: Baseline - 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To demonstrate that macitentan positively affects FVC compared with placebo in patients with IPF.\n[ Time Frame: Baseline - 12 months ]""}]	[See Results Section.]	NA
NCT00905268	A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients	The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms	10.1161/circulationaha.111.059477	https://www.ncbi.nlm.nih.gov/pubmed/?term=MICONOS	4	2009-05-19	Active, not recruiting	Completed	2006-04-01	2009-12-01	2012-02-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52\n[ Time Frame: 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52\n[ Time Frame: 1 year ]\n\n(Where the patient populations are not normally distributed for ICARS the responder analysis will be used as the primary endpoint and a clinically relevant margin of 2.5 ICARS points will be applied)""}]	[See Results Section.]	NA
NCT00905840	A Study to Treat Patients With Edentulous Mandibles With Two Straumann 3.3mm Diameter Bone Level Implants	A double-blind randomized controlled trial (RCT) of Titanium-13Zirconium versus Titanium Grade IV small-diameter bone level implants in edentulous mandibles--results from a 1-year observation period	10.1111/j.1708-8208.2010.00324.x	https://www.ncbi.nlm.nih.gov/pubmed/21414131	7	2009-05-20	Active, not recruiting	Completed	2007-11-01	2009-10-01	2011-03-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Crestal Bone Level between surgery and 12 months\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Crestal Bone Level between surgery and 12 months\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Crestal Bone Level between surgery and 12 months\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT00909532	Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation	10.1056/nejmoa1105185	NA	14	2009-05-26	Recruiting	Completed	2009-05-01	2010-07-01	2011-11-03	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[See Results Section.]	NA
NCT00909727	Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation	Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation	10.1164/rccm.201301-0153oc	http://www.atsjournals.org/doi/abs/10.1164/rccm.201301-0153OC?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&	16	2009-05-26	Not yet recruiting	Completed	2009-06-01	2010-02-01	2013-06-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change from baseline in percent predicted forced expiratory volume in 1 second (% predicted FEV1) through Week 24\n[ Time Frame: 24 weeks ]""}]	[See Results Section.]	NA	NA
NCT00913744	Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion	Safety of intravitreal ocriplasmin for focal vitreomacular adhesion in patients with exudative age-related macular degeneration	10.1016/j.ophtha.2014.10.006	NA	13	2009-06-03	Not yet recruiting	Completed	2009-12-01	2012-12-01	2014-11-27	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with release of focal vitreomacular adhesion by day 28 as determined by masked Central Reading Center\n[ Time Frame: Day 28 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with release of focal vitreomacular adhesion by day 28 as determined by masked Central Reading Center\n[ Time Frame: Day 28 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00916409	Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial	10.1001/jama.2017.18718	https://pubmed.ncbi.nlm.nih.gov/29260225/	123	2009-06-08	Not yet recruiting	Completed	2009-06-01	2015-01-01	2017-12-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS) time\n[ Time Frame: 3 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS) time\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival (PFS) time\n[ Time Frame: 5 years ]""}]	NA	NA
NCT00917046	The SMARTEX Heart Failure Study	High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction	10.1161/circulationaha.116.022924	https://www.ncbi.nlm.nih.gov/pubmed/28082387?dopt=Abstract	16	2009-06-09	Recruiting	Completed	2009-01-01	2013-06-01	2017-01-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac volumes and functions (reverse remodeling and improved left ventricular function)\n[ Time Frame: Baseline-12 weeks- 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cardiac volumes and functions (reverse remodeling and improved left ventricular function)\n[ Time Frame: Baseline-12 weeks- 1 year ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison between groups in change of left ventricular end diastolic diameter from baseline to 12 weeks\n[ Time Frame: Baseline-12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""comparison between groups in change of left ventricular end diastolic diameter from baseline to 12 weeks\n[ Time Frame: Baseline-12 weeks ]""}]	NA
NCT00919295	Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome	Efficacy and safety of mirtazapine in fibromyalgia syndrome patients: a randomized placebo-controlled pilot study	10.1345/aph.1r725	http://journals.sagepub.com/doi/pdf/10.1345/aph.1R725	6	2009-06-11	Recruiting	Completed	2008-12-01	2011-10-01	2013-06-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure for part II of this study will be \""change from baseline in the severity of the pain visual analog scale (PVAS) score\"".\n[ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure for part II of this study will be \""change from baseline in the severity of the pain visual analog scale (PVAS) score\"".\n[ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure for part II of this study will be \""change from baseline in the severity of the pain visual analog scale (PVAS) score\"" and pain responders (>= 30% PVAS reduction).\n[ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ]""}]	NA	NA
NCT00924638	Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke	Cryptogenic stroke and underlying atrial fibrillation	10.1056/nejmoa1313600	https://www.ncbi.nlm.nih.gov/pubmed/24963567	8	2009-06-18	Recruiting	Completed	2009-06-01	2013-05-01	2014-06-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first documented episode of AF\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first documented episode of AF\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first documented episode of AF\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00924989	A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study	10.1016/s1470-2045(15)70081-1	https://www.ncbi.nlm.nih.gov/pubmed/25795408?dopt=Abstract	34	2009-06-18	Not yet recruiting	Completed	2009-08-01	2013-11-01	2015-03-18	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival of single agent OSI-906 vs placebo\n[ Time Frame: 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival of single agent OSI-906 versus placebo\n[ Time Frame: 33 months ]\n\nTime from date of randomization until time of documented death""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival of single agent OSI-906 versus placebo\n[ Time Frame: 33 months ]\n\nTime from date of randomization until time of documented death""}]	NA
NCT00925301	Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease	Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat	10.1056/nejmoa1510198	https://doi.org/10.1056/NEJMoa1510198	56	2009-06-19	Not yet recruiting	Completed	2009-08-01	2012-07-01	2016-08-11	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""kidney GL-3 (assessed histologically in kidney biopsy samples)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""kidney GL-3 (assessed histologically in kidney biopsy samples)\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""kidney GL-3 (assessed histologically in kidney biopsy samples)\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00927173	Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder	Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial	10.1002/wps.20199	https://www.ncbi.nlm.nih.gov/pubmed/25655160	25	2009-06-23	Not yet recruiting	Completed	2009-09-01	2011-12-01	2015-02-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 5 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HDRS-21\n[ Time Frame: 5 weeks ]""}]	NA
NCT00930813	LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis	The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty	10.1016/j.jcin.2013.05.022	http://www.sciencedirect.com/science/article/pii/S1936879813015306?via%3Dihub	9	2009-06-30	Recruiting	Completed	2009-06-01	2010-06-01	2014-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic late lumen loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic late lumen loss\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Angiographic late lumen loss\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00931463	A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen	Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study	10.1016/s0140-6736(13)61164-2	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61164-2/abstract	9	2009-07-01	Not yet recruiting	Completed	2009-09-01	2012-09-01	2013-06-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization.\n[ Time Frame: 48 weeks following randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization.\n[ Time Frame: 48 weeks following randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary outcome measure of this study is a comparison of the virological efficacy of the two strategies as measured by the proportion of participants with HIV RNA < 200 copies/mL 48 weeks after randomization.\n[ Time Frame: 48 weeks following randomization ]""}]	[See Results Section.]	NA
NCT00932893	An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene	Crizotinib versus chemotherapy in advanced ALK-positive lung cancer	10.1056/nejmoa1214886	https://www.ncbi.nlm.nih.gov/pubmed/23724913?dopt=Abstract	86	2009-07-02	Not yet recruiting	Completed	2009-09-01	2012-06-01	2013-06-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS) of PF-02341066 vs Pemetrexed or Docetaxel\n[ Time Frame: 30 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS) of PF-02341066 vs Pemetrexed or Docetaxel\n[ Time Frame: 30 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS) of PF-02341066 vs Pemetrexed or Docetaxel\n[ Time Frame: 30 months ]""}]	[See Results Section.]	NA
NCT00941733	Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia	Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial	10.1016/j.jacc.2014.06.1198	https://pubmed.ncbi.nlm.nih.gov/25301459/	14	2009-07-17	Not yet recruiting	Completed	2009-09-01	2013-08-01	2014-10-14	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA)\n[ Time Frame: 12 months or at TLR time ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinically driven TLR of the target lesion in the amputation free surviving patients\n[ Time Frame: 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Composite of all cause death, major amputation and clinically driven TLR\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA)\n[ Time Frame: 12 months or at TLR time ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinically driven TLR of the target lesion in the amputation free surviving patients\n[ Time Frame: 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Composite of all cause death, major amputation and clinically driven TLR\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Late lumen loss (LLL) of the target lesion by quantitative vascular angiography (QVA)\n[ Time Frame: 12 months or at TLR time ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinically driven TLR of the target lesion in the amputation free surviving patients\n[ Time Frame: 12 months ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Composite of all cause death, major amputation and clinically driven TLR\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT00943111	A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)	Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial	10.1016/s0140-6736(14)61841-9	https://www.ncbi.nlm.nih.gov/pubmed/25819691	24	2009-07-21	Not yet recruiting	Completed	2009-08-01	2012-09-01	2015-03-26	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary objective of this study in patients with Gaucher disease type 1 who have been stabilized with Cerezyme is to demonstrate that, the majority of patients who receive Genz-112638 remain stable.\n[ Time Frame: 39 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The percentage of patients who remain stable for 52 weeks (the primary analysis period)\n[ Time Frame: 52 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT00949975	A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium	A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium	10.3109/15412555.2011.641803	https://www.ncbi.nlm.nih.gov/pubmed/22458939?dopt=Abstract	9	2009-07-30	Not yet recruiting	Completed	2009-07-01	2010-08-01	2012-04-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dose response and efficacy of AZD9668 through the recording and evaluation of FEV 1 pre-dose at clinic visit\n[ Time Frame: Every 4 weeks except in run in period (from V1b to V2 ) in which it will be 2 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dose response and efficacy of AZD9668 through the recording and evaluation of FEV 1 pre-dose at clinic visit\n[ Time Frame: Every 4 weeks except in run in period (from V1b to V2 ) in which it will be 2 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Dose response and efficacy of AZD9668 through the recording and evaluation of FEV 1 pre-dose at clinic visit\n[ Time Frame: Every 4 weeks except in run in period (from V1b to V2 ) in which it will be 2 weeks ]""}]	[See Results Section.]	NA
NCT00950300	A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial	10.1016/s1470-2045(12)70329-7	https://www.ncbi.nlm.nih.gov/pubmed/22884505?dopt=Abstract	131	2009-07-30	Not yet recruiting	Completed	NA	NA	2012-08-09	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""trastuzumab serum concentrations, comparing sc versus iv administration\n[ Time Frame: throughout cycles 1 to 8 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""pathologic complete response\n[ Time Frame: after surgery between cycles 8 and 9 ]""}]	NA	NA	[See Results Section.]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""trastuzumab serum concentrations, comparing sc versus iv administration\n[ Time Frame: throughout cycles 1 to 8 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""pathologic complete response\n[ Time Frame: after surgery between cycles 8 and 9 ]""}]
NCT00958776	A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza	Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients	10.1093/cid/ciu632	https://www.ncbi.nlm.nih.gov/pubmed/25115871?dopt=Abstract	85	2009-08-12	Not yet recruiting	Terminated	2009-11-01	2012-11-01	2014-08-12	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the effect of treatment with peramivir plus standard of care (SOC) compared to placebo plus SOC on time to clinical resolution in adults and adolescents who are hospitalized with acute influenza.\n[ Time Frame: Day 5 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measurement of vital signs and oxygen saturation will be summarized by visit, changes from baseline.\n[ Time Frame: Thru Day 10 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measurement of vital signs and oxygen saturation will be summarized by visit, changes from baseline.\n[ Time Frame: Thru Day 10 ]""}]	[See Results Section.]	NA
NCT00974155	The Early Medication Change (EMC) Trial	Early improvement of executive test performance during antidepressant treatment predicts treatment outcome in patients with Major Depressive Disorder	10.1371/journal.pone.0194574	https://pubmed.ncbi.nlm.nih.gov/29668746/	7	2009-09-09	Not yet recruiting	Completed	2009-09-01	2014-05-01	2018-04-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission from MDD on day 56, defined as a HAMD17 sum score ≤ 7, in non-improvers on day 14 (n=192)\n[ Time Frame: 8 weeks ]""}]	NA	NA
NCT00976521	The INFUSE - Anterior Myocardial Infarction (AMI) Study	Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial	10.1001/jama.2012.421	https://www.ncbi.nlm.nih.gov/pubmed/22447888?dopt=Abstract	17	2009-09-11	Recruiting	Completed	2009-09-01	2012-01-01	2012-03-25	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size (percentage of total LV mass) measured by cardiac MRI\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Infarct size (percentage of total LV mass) measured by cardiac MRI\n[ Time Frame: 30 days ]""}]	NA	[See Results Section.]	NA
NCT00976859	Efficacy of Cognitive Restructuring and Imagery Modification to Reduce the Feeling of Being Contaminated After Childhood Sexual Abuse	A randomized controlled trial on cognitive restructuring and imagery modification to reduce the feeling of being contaminated in adult survivors of childhood sexual abuse suffering from posttraumatic stress disorder	10.1159/000348450	NA	5	2009-09-14	Not yet recruiting	Completed	2009-09-01	2011-10-01	2013-05-22	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Emotional held negative self-belief of being polluted(How much you feel this is true, regardless of how you think rationally)on 0-100 Likert scales anchored at \""I do not belief at all that I am polluted\"" and \""I am completely convinced that I am polluted\""\n[ Time Frame: at the beginning and at the end of the intervention session, after a week at the beginning of the third session ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Vividness of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Distress related to the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intensity of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Vividness of the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Distress associated to the feeling of being contaminated (0-100: \""not at all\"" till \""extremely\"")\n[ Time Frame: pre treatment, post treatment, follow up ]""}]	NA	NA
NCT00979745	Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)	Afamelanotide for Erythropoietic Protoporphyria	10.1056/nejmoa1411481	https://www.ncbi.nlm.nih.gov/pubmed/26132941	6	2009-09-17	Not yet recruiting	Completed	2009-09-01	2011-05-01	2015-07-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of phototoxic reaction measured by visual analogue scale\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of phototoxic reaction measured by visual analogue scale\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Severity of phototoxic reaction measured by visual analogue scale\n[ Time Frame: 9 months ]""}]	[See Results Section.]	NA
NCT00988208	Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial	10.1016/s1470-2045(15)70025-2	http://www.sciencedirect.com/science/article/pii/S1470204515700252?via%3Dihub	51	2009-10-01	Not yet recruiting	Completed	2009-11-01	2013-11-01	2015-03-03	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: Cycle 1 Day 1 until subject death ]""}]	[See Results Section.]	[See Results Section.]	[See Results Section.]	NA
NCT00988754	School Based Health Promotion Program in Secondary Schools	Retinal vessel diameter, obesity and metabolic risk factors in school children (JuvenTUM 3)	10.1016/j.atherosclerosis.2011.12.029	https://www.ncbi.nlm.nih.gov/pubmed/22244041?dopt=Abstract	3	2009-10-01	Recruiting	Completed	2008-07-01	2012-07-01	2011-12-27	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily physical activity > 60 minutes\n[ Time Frame: 4 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily physical activity > 60 minutes\n[ Time Frame: 4 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily physical activity > 60 minutes\n[ Time Frame: 4 years ]\n\nnumber of days with physical activity > 60 minutes""}]	NA
NCT00996463	Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients	A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan	10.1186/s12879-014-0619-8	https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-014-0619-8	4	2009-10-15	Not yet recruiting	Completed	2010-01-01	2010-09-01	2014-11-25	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound closure time\n[ Time Frame: 75 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound closure time\n[ Time Frame: 75 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound closure time\n[ Time Frame: 75 days ]""}]	NA	NA
NCT00996554	Randomized Study Comparing Two Established Gastrointestinal Suture Techniques - One-layer-continuous Versus Double-layer-continuous Suture	Single-Layer Continuous Versus Double-Layer Continuous Suture in Colonic Anastomoses-a Randomized Multicentre Trial (ANATECH Trial)	10.1007/s11605-015-3003-0	https://www.ncbi.nlm.nih.gov/pubmed/26525206?dopt=Abstract	3	2009-10-15	Recruiting	Terminated	2004-01-01	2012-01-01	2015-11-02	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Frequency of clinical anastomostic leaks\n[ Time Frame: 3 months ]""}]	NA
NCT00998556	Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study	10.1093/eurheartj/ehx355	https://pubmed.ncbi.nlm.nih.gov/28934837/	8	2009-10-19	Not yet recruiting	Completed	2010-06-01	2016-03-01	2017-07-27	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular ejection fraction (LVEF) from baseline to six months follow-up\n[ Time Frame: 6 months ]\n\nChange in left ventricular ejection fraction (LVEF) from baseline to six months follow-up as assessed by cardiac Magnetic Resonance Imaging (MRI) & Echocardiography""}]	NA
NCT01009138	Evaluation of a Diabetes-specific Cognitive Behavioural Treatment for Subthreshold Depression	The effect of a Diabetes-Specific Cognitive Behavioral Treatment Program (DIAMOS) for patients with diabetes and subclinical depression: results of a randomized controlled trial	10.2337/dc14-1416	https://www.ncbi.nlm.nih.gov/pubmed/25605812	10	2009-11-05	Not yet recruiting	Completed	2009-11-01	2011-09-01	2015-01-20	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptoms (CES-D)\n[ Time Frame: baseline, 2 weeks after treatment, 6 months-FU, 12 months-FU ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptoms (CES-D-Score)\n[ Time Frame: Baseline, 12 months-FU ]\n\nThe Center for Epidemiologic Studies Depression Scale (CES-D) is used for the assessment of depressive symptoms. The decicive measurement of this primary outcome variable is conducted 12 month after termination of the treatment (12 month follow up). The difference of the CES-D scores between baseline and 12 months follow up is calculated.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Symptoms (CES-D-Score)\n[ Time Frame: Baseline, 12 months-FU ]\n\nThe Center for Epidemiologic Studies Depression Scale (CES-D) is used for the assessment of depressive symptoms. The decicive measurement of this primary outcome variable is conducted 12 month after termination of the treatment (12 month follow up). The difference of the CES-D scores between baseline and 12 months follow up is calculated.""}]	[See Results Section.]	NA
NCT01014767	Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors	NA	10.1093/neuonc/nov229.01	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639153/#__ffn_sectitle	14	2009-11-16	Recruiting	Terminated	2009-11-01	2012-11-01	2015-11-09	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Disease Progression\n[ Time Frame: Baseline to disease progression or death (up to 6 cycles of 28-day treatment) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Toxicity during first 4 months of therapy\n[ Time Frame: Baseline to 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Disease Progression\n[ Time Frame: Till disease progression or death (up to 6 cycles of 28-day treatment) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Toxicity during first 4 months of therapy\n[ Time Frame: 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Disease Progression\n[ Time Frame: Till disease progression or death (up to 6 cycles of 28-day treatment) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Toxicity during first 4 months of therapy\n[ Time Frame: 4 Months ]""}]	[See Results Section.]	NA
NCT01016873	INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study	10.1016/j.ophtha.2013.02.016	http://www.sciencedirect.com/science/article/pii/S0161642013001504	13	2009-11-19	Not yet recruiting	Completed	2009-11-01	2012-05-01	2013-09-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Lucentis® injections.\n[ Time Frame: During the first 52 weeks. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Lucentis® injections.\n[ Time Frame: During the first 52 weeks. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of Lucentis® injections.\n[ Time Frame: During the first 52 weeks. ]""}]	[See Results Section.]	NA
NCT01019434	Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma	A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma	10.1158/1078-0432.ccr-14-0951-t	https://pubmed.ncbi.nlm.nih.gov/25338498/	9	2009-11-24	Recruiting	Completed	2009-10-01	2013-10-01	2014-10-22	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival at 1 year""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival at 1 year\n[ Time Frame: 1 year ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival at 1 year\n[ Time Frame: 1 year ]""}]	NA
NCT01020630	Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program	10.1186/s12885-016-2736-9	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01020630	10	2009-11-23	Recruiting	Completed	2009-11-01	2012-11-01	2016-08-31	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.\n[ Time Frame: After first and second cycle, then after every second cycles or if clinically indicated until progress of disease ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.\n[ Time Frame: Average time period: up to one year (participants are followed until progression or death) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.\n[ Time Frame: Average time period: up to one year (participants are followed until progression or death) ]""}]	NA	NA
NCT01021423	A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).	Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation	10.1111/bjh.12449	https://www.ncbi.nlm.nih.gov/pubmed/23834234?dopt=Abstract	14	2009-11-25	Not yet recruiting	Terminated	2009-11-01	2013-05-01	2013-07-09	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival (PFS)\n[ Time Frame: Until 80% of subjects have died or 5 years after last subject randomized ]""}]	[See Results Section.]	NA	[See Results Section.]	NA
NCT01022242	Study of PXL01 Versus Placebo to Inhibit Adhesion Formation After Flexor Tendon Surgery	PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trial	10.1371/journal.pone.0110735	http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110735	6	2009-11-30	Not yet recruiting	Completed	2009-12-01	2012-05-01	2014-10-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary variable is Total Active Motion (TAM) at the proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints (i.e. TAM2) of the affected digit at actively made fist at 12 weeks after surgery.\n[ Time Frame: from administration until 12 months after. ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary variable is Total Active Motion (TAM) at the proximal interphalangeal (PIP), and distal interphalangeal (DIP) joints (i.e. TAM2) of the affected digit at actively made fist at 12 weeks after surgery.\n[ Time Frame: from administration until 12 months after. ]""}]	[See Results Section.]	NA	NA
NCT01027884	Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)	Characterization of pulmonary function in 10-18 year old patients with Duchenne muscular dystrophy	10.1016/j.nmd.2016.12.014	https://pubmed.ncbi.nlm.nih.gov/28189481/	21	2009-12-08	Recruiting	Completed	2009-07-01	2013-12-01	2017-01-06	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Objective: to assess the efficacy of idebenone, compared to placebo, in improving or delaying the loss of respiratory function in patients with DMD. Primary endpoint: percent predicted peak expiratory flow (PEF)\n[ Time Frame: Efficacy assessments: Baseline, Week 13, 26 , 39, 52 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Objective: to assess the efficacy of idebenone, compared to placebo, in improving or delaying the loss of respiratory function in patients with DMD. Primary endpoint: percent predicted peak expiratory flow (PEF)\n[ Time Frame: Efficacy assessments: Baseline, Week 13, 26 , 39, 52 ]""}]	[See Results Section.]	NA	NA
NCT01030666	Effect of Postsurgical Systemic Doxycycline After Regenerative Periodontal Therapy	Regenerative therapy of infrabony defects with or without systemic doxycycline. A randomized placebo-controlled trial	10.1111/j.1600-051x.2012.01861.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1600-051X.2012.01861.x/abstract	9	2009-12-10	Active, not recruiting	Terminated	2007-04-01	2011-01-01	2012-03-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""vertical clinical attachment gain 6 months after surgery\n[ Time Frame: baseline, 6, 12, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""vertical clinical attachment gain 6 months after surgery\n[ Time Frame: baseline, 6, 12, 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""vertical clinical attachment gain 6 months after surgery\n[ Time Frame: baseline, 6, 12, 24 months ]""}]	[See Results Section.]	NA
NCT01041950	A Randomised Controlled Trial of Lumbar Drainage to Treat Communicating Hydrocephalus After Severe Intraventricular Hemorrhage	Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: A randomized trial and individual patient data meta-analysis	10.1002/ana.24834	https://pubmed.ncbi.nlm.nih.gov/27888608/	7	2010-01-04	Recruiting	Completed	2009-11-01	2014-07-01	2017-01-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""modified Rankin scale and Barthel index\n[ Time Frame: 3 and 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirement of permanent VP-shunt\n[ Time Frame: 14 days ]\n\nif three attempts to clamp the EVD (control group) or LD (treatment group) fail, or overall extra-corporal drainage time exceeds 14 days, a VP-shunt is placed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirement of permanent VP-shunt\n[ Time Frame: 14 days ]\n\nif three attempts to clamp the EVD (control group) or LD (treatment group) fail, or overall extra-corporal drainage time exceeds 14 days, a VP-shunt is placed.""}]	NA	NA
NCT01045746	Effects of Whole-Body Vibration on Balance in the Elderly Population	Feasibility and effects of applying stochastic resonance whole-body vibration on untrained elderly: a randomized crossover pilot study	10.1186/s12877-015-0021-4	https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-015-0021-4	5	2010-01-08	Active, not recruiting	Completed	2010-01-01	2010-08-01	2015-03-12	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""static and dynamic Balance\n[ Time Frame: after on session, four and eight weeks, Follow up 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""static and dynamic Balance\n[ Time Frame: after on session, four and eight weeks, Follow up 4 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""static balance\n[ Time Frame: after one session, four and eight weeks ]""}]	NA	NA
NCT01047891	Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer	Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial	10.1016/s1470-2045(18)30372-3	https://pubmed.ncbi.nlm.nih.gov/30100379/	3	2010-01-12	Not yet recruiting	Completed	2010-01-01	2015-02-01	2018-08-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective: Determination of the progression-free survival (PFS) of patients treated with topotecan and sorafenib versus topotecan and placebo\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective: Determination of the progression-free survival (PFS) of patients treated with topotecan and sorafenib versus topotecan and placebo\n[ Time Frame: 18 months ]\n\nThe primary target value of this study is the comparison of the median progression-free survival time between the two study arms. Progression-free survival time (PFS) of a patient is defined as the time in months from start of the first therapy cycle until PD or death is observed""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary objective: Determination of the progression-free survival (PFS) of patients treated with topotecan and sorafenib versus topotecan and placebo\n[ Time Frame: 18 months ]\n\nThe primary target value of this study is the comparison of the median progression-free survival time between the two study arms. Progression-free survival time (PFS) of a patient is defined as the time in months from start of the first therapy cycle until PD or death is observed""}]	NA	NA
NCT01049971	REDWIL: Reduction of Wound Infections in Laparoscopic Colon Resections by Wound Protectors	Reduction of wound infections in laparoscopic-assisted colorectal resections by plastic wound ring drapes (REDWIL)?--A randomized controlled trial	10.1007/s00423-012-0954-4	https://link.springer.com/article/10.1007/s00423-012-0954-4	2	2010-01-14	Active, not recruiting	Completed	2007-12-01	2010-06-01	2012-04-21	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of wound infections\n[ Time Frame: 10 days, 3 months, 6 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of wound infections\n[ Time Frame: 10 days, 3 months, 6 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""percentage of wound infections\n[ Time Frame: 6 months postoperatively ]\n\nthe total percentage of wound infections within 6 months postoperatively will be analyzed""}]	NA	NA
NCT01050686	Need for Subcutaneous Wound Drains in Ileostomy Reversal	Necessity of subcutaneous suction drains in ileostomy reversal (DRASTAR)-a randomized, controlled bi-centered trial	10.1007/s00423-016-1436-x	https://pubmed.ncbi.nlm.nih.gov/27138020/	4	2010-01-14	Not yet recruiting	Completed	2010-03-01	2014-11-01	2016-05-01	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""length of hospital stay (days)\n[ Time Frame: 3 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""length of hospital stay (days)\n[ Time Frame: 3 months postoperatively ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""length of hospital stay (days)\n[ Time Frame: 3 months postoperatively ]""}]	NA	NA
NCT01056341	Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy	A randomized, controlled trial of oral propranolol in infantile hemangioma	10.1056/nejmoa1404710	http://www.nejm.org/doi/full/10.1056/NEJMoa1404710	28	2010-01-24	Not yet recruiting	Completed	2010-01-01	2011-11-01	2015-02-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete/nearly complete resolution of the target IH at W24 compared to baseline based on the intra-patient blinded centralised independent qualitative assessments of W24 photographs.\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete/nearly complete resolution of the target IH at W24 compared to baseline based on the intra-patient blinded centralised independent qualitative assessments of W24 photographs.\n[ Time Frame: 6 months ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01058980	ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial	Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial	10.1016/s0140-6736(15)60026-5	NA	9	2010-01-28	Recruiting	Completed	2009-12-01	2013-09-01	2015-07-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first recurrence of electrocardiographically documented, symptomatic AF or atrial flutter/tachycardia between 3 and 12 months post ablation in the absence of antiarrhythmic drug therapy.\n[ Time Frame: Between 3 and 12 months post ablation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first recurrence of electrocardiographically documented, symptomatic AF or atrial flutter/tachycardia between 3 and 12 months post ablation in the absence of antiarrhythmic drug therapy.\n[ Time Frame: Between 3 and 12 months post ablation ]\n\nThe primary outcome is time to first recurrence of symptomatic ECG-documented AF or atrial flutter/tachycardia between days 91 & 365 after ablation, or repeat ablation procedure during the first 90 days. AF or atrial flutter/tachycardia will qualify as an arrhythmia recurrence after ablation if it lasts 30 seconds or longer and is documented by 12-lead ECG, surface ECG rhythm strips, or TTM recordings. Documented episodes will be adjudicated by a blinded committee. Time 0 is defined as day 91 post ablation with FUp's extending 365 days post ablation.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first recurrence of electrocardiographically documented, symptomatic AF or atrial flutter/tachycardia between 3 and 12 months post ablation in the absence of antiarrhythmic drug therapy.\n[ Time Frame: Between 3 and 12 months post ablation ]\n\nThe primary outcome is time to first recurrence of symptomatic ECG-documented AF or atrial flutter/tachycardia between days 91 & 365 after ablation, or repeat ablation procedure during the first 90 days. AF or atrial flutter/tachycardia will qualify as an arrhythmia recurrence after ablation if it lasts 30 seconds or longer and is documented by 12-lead ECG, surface ECG rhythm strips, or TTM recordings. Documented episodes will be adjudicated by a blinded committee. Time 0 is defined as day 91 post ablation with FUp's extending 365 days post ablation.""}]	NA	NA
NCT01063829	Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients	Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation	10.1056/nejmoa1309533	http://www.nejm.org/doi/full/10.1056/NEJMoa1309533	16	2010-02-04	Not yet recruiting	Completed	2010-02-01	2011-10-01	2014-05-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HCMV reactivation or HCMV End-Organ Disease\n[ Time Frame: 92 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HCMV reactivation or HCMV End-Organ Disease\n[ Time Frame: 92 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""HCMV reactivation or HCMV End-Organ Disease\n[ Time Frame: 92 days ]""}]	[See Results Section.]	NA
NCT01065311	Mindfulness-based Cognitive Therapy for Chronic Depression	A randomized controlled trial on the efficacy of mindfulness-based cognitive therapy and a group version of cognitive behavioral analysis system of psychotherapy for chronically depressed patients	10.1037/ccp0000042	https://www.ncbi.nlm.nih.gov/pubmed/26371617	4	2010-02-08	Not yet recruiting	Completed	2010-10-01	2013-03-01	2015-08-10	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Depression\n[ Time Frame: Post intervention and 6 months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Depression\n[ Time Frame: Post intervention and 6 months follow-up ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Depression\n[ Time Frame: Change from Baseline in HAM-D at 8 weeks ]""}]	NA	NA
NCT01067703	Remote Ischaemic Preconditioning for Heart Surgery (RIPHeart-Study)	A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery	10.1056/nejmoa1413579	https://pubmed.ncbi.nlm.nih.gov/26436208/	5	2010-02-10	Not yet recruiting	Terminated	2010-12-01	2014-05-01	2015-10-05	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]\n\nTime frame until hospital discharge""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]\n\nTime frame until hospital discharge""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite of all-cause mortality, non-fatal myocardial infarction, any new stroke, and/or acute renal failure\n[ Time Frame: In-hospital ]\n\nTime frame until hospital discharge""}]	NA
NCT01078168	Alzheimer's Disease Acitretin Medication	Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin	10.1212/wnl.0000000000001017	https://www.ncbi.nlm.nih.gov/pubmed/25344383	3	2010-03-01	Not yet recruiting	Completed	2010-03-01	2013-01-01	2014-10-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in CSF APPSα concentration at Visit 3 compared to Baseline\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in CSF APPSα concentration at Visit 3 compared to Baseline\n[ Time Frame: 4 weeks ]""}]	NA	[See Results Section.]	NA
NCT01078298	Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression	Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial	10.7326/0003-4819-159-6-201309170-00005	https://www.ncbi.nlm.nih.gov/pubmed/24042367?dopt=Abstract	30	2010-02-26	Not yet recruiting	Completed	2010-03-01	2011-09-01	2013-09-17	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the 4-week Continuous Quit Rate (CQR) for Weeks 9 through 12\n[ Time Frame: wk 9-12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint is the 4-week Continuous Quit Rate (CQR) for Weeks 9 through 12\n[ Time Frame: wk 9-12 ]""}]	[See Results Section.]	NA	NA
NCT01079104	Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units	First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis	10.1186/s12876-017-0569-x	https://www.ncbi.nlm.nih.gov/pubmed/28209134	6	2010-03-01	Not yet recruiting	Terminated	2010-09-01	2013-08-01	2017-02-16	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""30-day mortality rate\n[ Time Frame: 30 days ]\n\nMortality 30 days after the first intervention""}]	NA
NCT01079442	Coffee Trial - Does Coffee Intake Reduce Postoperative Ileus After Elective Colectomy?	Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy	10.1002/bjs.8885	http://onlinelibrary.wiley.com/doi/10.1002/bjs.8885/epdf	2	2010-03-02	Enrolling by invitation	Completed	2010-03-01	2011-03-01	2012-09-14	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first bowel movement\n[ Time Frame: patients postoperative in hospital stay (mean 6 days) ]\n\nTime from end of surgery until patient's first bowel movement (i.e. passage of solid stool).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first bowel movement\n[ Time Frame: patients postoperative in hospital stay (mean 6 days) ]\n\nTime from end of surgery until patient's first bowel movement (i.e. passage of solid stool).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first bowel movement\n[ Time Frame: patients postoperative in hospital stay (mean 6 days) ]\n\nTime from end of surgery until patient's first bowel movement (i.e. passage of stool).""}]	NA	NA
NCT01081145	Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)	Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study	10.1111/jcpp.12492	https://www.ncbi.nlm.nih.gov/pubmed/26871297?dopt=Abstract	50	2010-03-04	Not yet recruiting	Completed	2010-04-01	2013-06-01	2016-02-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV)\n[ Time Frame: weekly ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical Global Impressions- Severity of Illness Scale (CGI-S)\n[ Time Frame: weekly ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention deficit/Hyperactivity Disorder Rating Scale-IV (ADHD-RS-IV)\n[ Time Frame: weekly ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Clinical Global Impressions- Severity of Illness Scale (CGI-S)\n[ Time Frame: weekly ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01086839	Sino-nasal Inhalation of Sodium Chloride 6,0% in Patients With Cystic Fibrosis and Chronic Rhinosinusitis	Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial	10.1016/j.jcf.2016.05.003	https://www.ncbi.nlm.nih.gov/pubmed/27267518	5	2010-03-12	Not yet recruiting	Completed	2010-03-01	2013-04-01	2016-06-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Variations in the Sino-nasal-outcome test SNOT-20 adapt CF\n[ Time Frame: days 1, 29, 57 and 85 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Variations in the Sino-nasal-outcome test SNOT-20 adapt CF\n[ Time Frame: days 1, 29, 57 and 85 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in the Sino-nasal-outcome test SNOT-20 adapt CF\n[ Time Frame: days 1, 29, 57 and 85 ]""}]	NA	NA
NCT01087723	European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial	Bivalirudin started during emergency transport for primary PCI	10.1056/nejmoa1311096	https://www.ncbi.nlm.nih.gov/pubmed/24171490?dopt=Abstract	6	2010-03-15	Recruiting	Completed	2010-02-01	2013-08-01	2013-10-30	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death , re-infarction (MI) or non-CABG-related protocol major bleeding\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death and non-CABG-related protocol major bleeding\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of death and non-CABG-related protocol major bleeding\n[ Time Frame: 30 days ]""}]	[See Results Section.]	NA
NCT01089231	Effects of Omega-3 Fatty Acids on the Human Gene Expression	Transcriptome-based identification of antioxidative gene expression after fish oil supplementation in normo- and dyslipidemic men	10.1186/1743-7075-9-45	https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-9-45	5	2010-03-17	Not yet recruiting	Completed	2010-03-01	2010-07-01	2012-03-05	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gene expression\n[ Time Frame: before, after four hours, after seven days and after three months ]\n\n\n\nto asses changes in gene expression patterns of male subjects (healthy vs. hyperlipidemic) after consumption of 3 g omega-3 fatty acids (2.5 g EPA/DHA) per day at different time points (four hours, seven days and three months)\n\nto detect differences in gene expression patterns between healthy subjects and subjects with hyperlipidemia""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gene expression\n[ Time Frame: before, after four hours, after seven days and after three months ]\n\n\n\nto asses changes in gene expression patterns of male subjects (healthy vs. hyperlipidemic) after consumption of 3 g omega-3 fatty acids (2.5 g EPA/DHA) per day at different time points (four hours, seven days and three months)\n\nto detect differences in gene expression patterns between healthy subjects and subjects with hyperlipidemia""}]	[See Results Section.]	NA	NA
NCT01094080	Formula With Modified Content of Protein and Improved Fatty Acids and Their Impact on Infant Growth and Health	Infant formula composition affects energetic efficiency for growth: the BeMIM study, a randomized controlled trial	10.1016/j.clnu.2013.12.007	NA	10	2010-03-25	Recruiting	Completed	2010-02-01	2011-08-01	2013-12-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: postnatal age 30 and 120 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""average weight gain\n[ Time Frame: postnatal age 30 and 120 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight from day 30 to day 120\n[ Time Frame: postnatal age 30 to 120 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change of weight from day 30 to day 120\n[ Time Frame: postnatal age 30 to 120 days ]""}]	NA
NCT01097434	Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence Tomography	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography	10.1007/s10554-014-0376-1	https://www.ncbi.nlm.nih.gov/pubmed/24452729	4	2010-03-31	Not yet recruiting	Completed	2010-04-01	2011-05-01	2014-01-23	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of uncovered stent strut segments assessed by OCT for each evaluable strut segment\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of uncovered stent strut segments assessed by OCT for each evaluable strut segment\n[ Time Frame: 6-8 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of uncovered stent strut segments assessed by OCT\n[ Time Frame: 6-8 months ]""}]	NA	NA
NCT01097967	Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy	Longitudinal polysomnographic assessment from acute to subacute phase in infratentorial versus supratentorial stroke	10.1159/000356323	https://pubmed.ncbi.nlm.nih.gov/24435018/	7	2010-04-01	Not yet recruiting	Unknown status	2010-07-01	NA	2014-01-16	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	TRUE	FALSE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Occurence of new vascular events or death in stroke survivors (myocardial infarction, stroke, death) assessed by telephone or reported\n[ Time Frame: 24 monts after stroke ]\n\nNew vascular events will be assessed by regular telephone interviews at 6,12 and 24 months after stroke""}]	[]
NCT01101139	Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery	Postoperative impairment of motor function at train-of-four ratio ≥0.9 cannot be improved by sugammadex (1 mg kg-1)	10.1093/bja/aeu453	https://www.ncbi.nlm.nih.gov/pubmed/25586724?dopt=Abstract	2	2010-04-08	Recruiting	Completed	2010-04-01	2011-05-01	2015-01-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[]	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Muscle functionMuscle function following the investigational drug""}]	NA	NA
NCT01103284	Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-015929-37/results	13	2010-04-13	Not yet recruiting	Completed	2010-04-01	2013-10-01	2016-07-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""beta-cell function, measured as change from baseline in stimulated C-peptide secretion (AUC) during a mixed-meal tolerance test\n[ Time Frame: 25 months after 1st administration ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""beta-cell function, measured as change from baseline in stimulated C-peptide secretion (AUC) during a mixed-meal tolerance test\n[ Time Frame: 25 months after 1st administration ]""}]	[See Results Section.]	NA	NA
NCT01105143	Effects of Negative Energy Balance on Muscle Mass Regulation	Association between Subcutaneous Adipose Tissue Inflammation, Insulin Resistance, and Calorie Restriction in Obese Females	10.4049/jimmunol.2000108	https://pubmed.ncbi.nlm.nih.gov/32482712/	2	2010-04-15	Not yet recruiting	Completed	2012-03-01	2015-05-01	2020-07-01	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of myocellular insulin sensitivity (hyperinsulinemic clamp) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of myocellular insulin sensitivity by hyperinsulinemic clamp in mg•kg-1•min-1/(mU•L-1)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes of skeletal muscle mass (air displacement plethysmography) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of muscle mass (in % of body weight)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes of myocellular insulin sensitivity (hyperinsulinemic clamp) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of myocellular insulin sensitivity by hyperinsulinemic clamp in mg•kg-1•min-1/(mU•L-1)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Changes of skeletal muscle mass (air displacement plethysmography) during negative energy balance and during stabilized modification of body composition after weight loss.\n[ Time Frame: 4 months ]\n\nAnalysis of muscle mass (in % of body weight)""}]	NA	NA
NCT01106365	Repetitive Deep Transcranial Magnetic Stimulation in Multiple Sclerosis	Effects of deep repetitive transcranial magnetic stimulation on brain-derived neurotrophic factor serum concentration in healthy volunteers	10.1159/000358088	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01106365	18	2010-04-16	Recruiting	Completed	2010-02-01	2013-02-01	2014-03-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[]	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: 3x/week during treatment phase ]\n\nexamination by physician, assessement of adverse events""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: 3x/week during treatment phase ]\n\nexamination by physician, assessement of adverse events""}]	NA
NCT01106430	Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate	Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study	10.1007/s40263-013-0104-8	NA	39	2010-04-16	Not yet recruiting	Completed	2010-06-01	2014-01-01	2013-12-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical Global Impression-Improvement (CGI-I) Score\n[ Time Frame: 9 weeks ]\n\nClinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.""}]	[See Results Section.]	NA	[See Results Section.]	NA
NCT01106586	Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults	Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial	10.1016/s0140-6736(12)60918-0	https://www.ncbi.nlm.nih.gov/pubmed/22748590?dopt=Abstract	15	2010-04-19	Not yet recruiting	Completed	2010-04-01	2011-11-01	2012-06-30	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[See Results Section.]	NA
NCT01108510	Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results	10.1093/infdis/jit122	https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jit122	11	2010-04-20	Not yet recruiting	Completed	2010-04-01	2012-01-01	2013-03-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects that achieve HIV-1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]""}]	[See Results Section.]	NA
NCT01110915	Advisa MRI Clinical Study	Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla	10.1016/j.hrthm.2013.01.022	https://www.ncbi.nlm.nih.gov/pubmed/23333721?dopt=Abstract	9	2010-04-23	Not yet recruiting	Completed	2010-06-01	2012-03-01	2013-01-17	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication-free rate\n[ Time Frame: 1 Month post MRI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.75V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.75V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI /waiting period to 1-month post-MRI/waiting period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication-free rate\n[ Time Frame: 1 Month post MRI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI /waiting period to 1-month post-MRI/waiting period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication-free rate\n[ Time Frame: 1 Month post MRI ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI /waiting period to 1-month post-MRI/waiting period ]""}]	[See Results Section.]	NA
NCT01112579	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure: The DEFEAT-HF Study	10.1016/j.jchf.2015.10.006	https://pubmed.ncbi.nlm.nih.gov/26682789/	8	2010-04-27	Recruiting	Completed	2010-04-01	2014-09-01	2016-12-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in left ventricular volumes as measured by cardiac echo\n[ Time Frame: Baseline and 6 months ]""}]	[See Results Section.]	NA	NA
NCT01112865	Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects	Results from an international multicenter trial evaluating the ease-of-use of and preference for a newly developed disposable injection pen for the treatment of growth hormone deficiency in treatment-naïve children and adults	10.2147/mder.s59821	https://www.dovepress.com/results-from-an-international-multicenter-trial-evaluating-the-ease-of-peer-reviewed-article-MDER	27	2010-04-27	Not yet recruiting	Completed	2010-07-01	2011-11-01	2014-04-11	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of dyads and adult subjects that reported the Genotropin Mark VII pen as no different or easier to use compared the current Genotropin Pen\n[ Time Frame: 4 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of dyads and adult subjects that reported the Genotropin Mark VII pen as no different or easier to use compared the current Genotropin Pen\n[ Time Frame: 4 months ]""}]	[See Results Section.]	NA	NA
NCT01115101	Superiority Study for Pain Treatment After Cesarean	Pain management after cesarean: a randomized controlled trial of oxycodone versus intravenous piritramide	10.1007/s00404-012-2384-5	https://www.ncbi.nlm.nih.gov/pubmed/22622852	4	2010-05-03	Completed	Completed	2009-07-01	2009-11-01	2012-05-24	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference of Pain Scores on the Visual Analog Scale\n[ Time Frame: 6 month ]\n\n\n\nThe primary outcome measure was the change in patients assessment of pain after cesarean (CS) from baseline.\n\nFor pain assessment a visual analog scale (VAS) was used. Women were asked to quantify pain using an eleven point numerical rating score from 0 to 10, with 0 indicating no pain, and 10 the worst pain. Pain level was evaluated before therapy (2h after CS), 12h, 24h, 32h, 40h, 48 and 72h after CS.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference of Pain Scores on the Visual Analog Scale\n[ Time Frame: 6 month ]\n\n\n\nThe primary outcome measure was the change in patients assessment of pain after cesarean (CS) from baseline.\n\nFor pain assessment a visual analog scale (VAS) was used. Women were asked to quantify pain using an eleven point numerical rating score from 0 to 10, with 0 indicating no pain, and 10 the worst pain. Pain level was evaluated before therapy (2h after CS), 12h, 24h, 32h, 40h, 48 and 72h after CS.""}]	[See Results Section.]	NA
NCT01117519	Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery	Influence of goal-directed therapy with balanced crystalloid-colloid or unbalanced crystalloid solution on base excess	10.1177/0300060513509548	https://www.ncbi.nlm.nih.gov/pubmed/24514432	9	2010-05-04	Not yet recruiting	Completed	2010-05-01	2011-06-01	2014-02-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standard Base Excess\n[ Time Frame: 2 days ]\n\nAfter administration of 2 litres of study medication. In recovery room. On general ward.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standard Base Excess\n[ Time Frame: 2 days ]\n\nAfter administration of 2 litres of study medication. In recovery room. On general ward.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Standard Base Excess\n[ Time Frame: up to 2 days ]\n\nAfter administration of 2 litres of study medication. In recovery room. On general ward.""}]	NA	NA
NCT01117818	Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease	Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite Scales	10.14283/jpad.2015.67	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746013/	8	2010-05-04	Not yet recruiting	Completed	2010-09-01	2013-12-01	2016-02-08	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)\n[ Time Frame: 18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cognitive(ADAS-cog modified) and functional(ADCS-ADL modified)\n[ Time Frame: 18 months ]""}]	NA	NA
NCT01119469	Comparing Cognitive Therapy and Exposure Therapy in Individuals With Hypochondriasis	Cognitive therapy versus exposure therapy for hypochondriasis (health anxiety): A randomized controlled trial	10.1037/ccp0000013	https://pubmed.ncbi.nlm.nih.gov/25495359/	11	2010-05-06	Not yet recruiting	Completed	2010-06-01	2013-06-01	2014-12-15	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)\n[ Time Frame: 3 months ]\n\nclinician-rated measure that assesses hypochondriacal obsessions, compulsions and avoidance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Illness Attitude Scales (IAS)\n[ Time Frame: 3 months ]\n\nself-report measure that assesses attitudes, fears, and beliefs associated with the psychopathology of hypochondriasis and that of abnormal illness behavior""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)\n[ Time Frame: 3 months ]\n\nclinician-rated measure that assesses hypochondriacal obsessions, compulsions and avoidance""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hypochondriasis Yale-Brown Obsessive-Compulsive Scale (H-YBOCS)\n[ Time Frame: 3 months ]\n\nclinician-rated measure that assesses hypochondriacal obsessions, compulsions and avoidance""}]	NA	NA
NCT01121666	Multi-centre Study to Compare Efficacy and Safety of AFOLIA and Gonal-f in Women for Assisted Reproductive Treatment	NA	NA	https://insights.ovid.com/human-reproduction/hurep/2013/06/001/108-phase-iii-assessor-blinded-randomised-multi/137/00004683	8	2010-05-11	Not yet recruiting	Completed	2010-06-01	2011-12-01	2013-01-01	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of oocytes retrieved\n[ Time Frame: At the day of hCG administration but not longer than 16 days after start of treatment with r-hFSH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of oocytes retrieved\n[ Time Frame: At the day of hCG administration but not longer than 16 days after start of treatment with r-hFSH ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of oocytes retrieved\n[ Time Frame: At the day of hCG administration but not longer than 16 days after start of treatment with r-hFSH ]""}]	[See Results Section.]	NA
NCT01123512	The Kiva® System as a Vertebral Augmentation Treatment	KAST Study: The Kiva System As a Vertebral Augmentation Treatment-A Safety and Effectiveness Trial: A Randomized, Noninferiority Trial Comparing the Kiva System With Balloon Kyphoplasty in Treatment of Osteoporotic Vertebral Compression Fractures	10.1097/brs.0000000000000906	https://www.ncbi.nlm.nih.gov/pubmed/25822543	16	2010-05-12	Withheld	Completed	2010-07-01	2012-08-01	2015-06-15	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm Visual Analog Scale (VAS)\n[ Time Frame: 12 Month Post-op ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI)\n[ Time Frame: 12 Month Post-op ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Absence of device-related serious adverse events, defined as device-related adverse events requiring surgical reintervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation\n[ Time Frame: 12 Month Post-op ]""}]	[See Results Section.]	NA	NA
NCT01124214	Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study)	In vivo endomicroscopy improves detection of Barrett's esophagus-related neoplasia: a multicenter international randomized controlled trial (with video)	10.1016/j.gie.2013.09.020	https://www.ncbi.nlm.nih.gov/pubmed/24219822?dopt=Abstract	22	2010-05-14	Recruiting	Completed	2010-04-01	2012-12-01	2013-11-09	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year, 6 months for early outcome analysis ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with HGD or CA divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with HGD or CA divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with HGD or CA divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""compare diagnostic yield\n[ Time Frame: 1 year ]\n\n\n\nCompare the diagnostic yield (defined as the proportion of mucosal biopsy samples with neoplasia) of HRE plus EM with directed biopsy (HRE-EM-DB) over HRE with directed biopsy of all mucosal lesions followed by random biopsy (HRE-DB-RB) to diagnose BE in flat mucosa and mucosal lesions\n\nThe mean diagnostic yield for IEN will be calculated (number of mucosal biopsies and EMR specimens with High Grade Dysplasia (HGD) or Carcinoma (CA) divided by total number of mucosal biopsies obtained) by group and compared, using a chi square or Fisher's exact test for independent groups, depending on the distribution of the data.""}]	NA
NCT01124786	A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity	10.1200/jco.2013.51.0826	http://ascopubs.org/doi/full/10.1200/jco.2013.51.0826	35	2010-05-14	Recruiting	Completed	2010-05-01	2012-10-01	2013-11-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival in patients with low hENT1 expression\n[ Time Frame: Monthly follow up after treatment discontinuation until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival in patients with low hENT1 expression\n[ Time Frame: Monthly follow up after treatment discontinuation until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival in patients with low hENT1 expression\n[ Time Frame: Monthly follow up after treatment discontinuation until death ]""}]	[See Results Section.]	NA
NCT01130493	A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066	Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients	10.1016/j.parkreldis.2014.08.004	https://www.ncbi.nlm.nih.gov/pubmed/25306200	20	2010-05-24	Recruiting	Completed	2010-05-01	2011-03-01	2014-08-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Parkinson's Disease Patient Diary\n[ Time Frame: Weeks 1-11 ]\n\nA subject-completed diary of Parkinson's Disease(PD) symptoms.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Parkinson's Disease Patient Diary\n[ Time Frame: Weeks 1-11 ]\n\nA subject-completed diary of Parkinson's Disease(PD) symptoms.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Parkinson's Disease Patient Diary\n[ Time Frame: Weeks 1-11 ]\n\nA subject-completed diary of Parkinson's Disease(PD) symptoms.""}]	[See Results Section.]	NA
NCT01137968	Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)	A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer	10.1093/annonc/mdu550	https://www.ncbi.nlm.nih.gov/pubmed/25467017	23	2010-06-04	Recruiting	Completed	2010-05-01	2012-05-01	2014-12-02	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression, as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-free survival\n[ Time Frame: From randomization to documented disease progression or death, whichever occurs earlier, through the end of the study period (8 mos. after the last participant is randomized) ]\n\nDefined as the time from randomization to documented disease progression or death, whichever occurs earlier,as determined by the Investigator's assessment according to RECIST, or death from any cause, whichever occurs earlier.""}]	NA
NCT01143272	Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea	Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial	10.1093/ofid/ofw011	https://www.ncbi.nlm.nih.gov/pubmed/26973849?dopt=Abstract	9	2010-06-11	Not yet recruiting	Terminated	2010-06-01	2012-11-01	2016-01-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative incidence of any antibiotic-associated diarrhoea\n[ Time Frame: 2 years ]\n\nCumulative incidence of any antibiotic-associated diarrhoea""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cumulative incidence of any antibiotic-associated diarrhoea\n[ Time Frame: 2 years ]\n\nCumulative incidence of any antibiotic-associated diarrhoea""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hazard of any antibiotic-associated diarrhoea\n[ Time Frame: 29 months ]\n\nhazard of any antibiotic-associated diarrhoea""}]	[See Results Section.]	NA
NCT01147874	Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics	10.1016/j.jaad.2013.07.023	NA	10	2010-06-17	Not yet recruiting	Completed	2010-08-01	2011-09-01	2013-08-24	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The prevalence of PsA in subjects with psoriasis based on a clinical rheumatology assessment.\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The prevalence of PsA in subjects with psoriasis as determined by clinical assessment by a rheumatologist including physical exam, medical history and results from laboratory analysis.\n[ Time Frame: 8 weeks ]""}]	[See Results Section.]	NA	NA
NCT01147939	Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)	International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia	10.1200/jco.2013.52.8562	https://www.ncbi.nlm.nih.gov/pubmed/24841975?dopt=Abstract	31	2010-06-21	Not yet recruiting	Completed	2010-06-01	2013-06-01	2014-05-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: Until death or until 6 months follow-up is completed for all patients ]\n\nTime from date of randomisation until the date of death""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: Until 300 events occur ]\n\nTime from date of randomisation until the date of death""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall survival\n[ Time Frame: Until 300 events occur ]\n\nTime from date of randomisation until the date of death""}]	NA	NA
NCT01153139	Long-term Bilateral Theta Burst Stimulation for the Treatment of Major Depression	Treatment of major depression with bilateral theta burst stimulation: a randomized controlled pilot trial	10.1016/j.jad.2013.12.025	https://www.ncbi.nlm.nih.gov/pubmed/24411682	4	2010-06-28	Recruiting	Completed	2010-04-01	2012-08-01	2013-12-28	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the Montgomery-Åsberg Depression Rating Scale (MADRS) after 6 weeks of treatment\n[ Time Frame: baseline, after the end of treatment (week 6) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of responders (response = decrease of the Montgomery-Åsberg Depression Rating Scale for at least 50%)\n[ Time Frame: after the end of treatment (week 6) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of responders (response = decrease of the Montgomery-Åsberg Depression Rating Scale for at least 50%)\n[ Time Frame: after the end of treatment (week 6) ]""}]	NA	NA
NCT01154140	A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung	First-line crizotinib versus chemotherapy in ALK-positive lung cancer	10.1056/nejmoa1408440	https://www.ncbi.nlm.nih.gov/pubmed/25470694	82	2010-06-29	Not yet recruiting	Completed	2011-01-01	2013-11-01	2014-12-04	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival [PFS] based on Response Evaluation Criterion in Solid Tumors [RECIST] version 1.1 (documented by independent radiology laboratory)\n[ Time Frame: 35 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS)\n[ Time Frame: 35 months ]\n\nThe period from study entry until disease progression, death or date of last contact. Progression Free Survival [PFS] based on Response Evaluation Criterion in Solid Tumors [RECIST] version 1.1 (documented by independent radiology laboratory)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival (PFS)\n[ Time Frame: 35 months ]\n\nThe period from study entry until disease progression, death or date of last contact. Progression Free Survival [PFS] based on Response Evaluation Criterion in Solid Tumors [RECIST] version 1.1 (documented by independent radiology laboratory)""}]	[See Results Section.]	NA
NCT01163032	Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder	Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials	10.1016/s0140-6736(15)60031-9	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60031-9/fulltext	28	2010-07-13	Not yet recruiting	Completed	2010-08-01	2012-11-01	2015-08-04	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjective average total night time sleep\n[ Time Frame: Weeks 3-6 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To assess the efficacy of tasimelteon in subjects with N24HSWD as measured by the proportion of entrainment.\n[ Time Frame: 4 weeks ]\n\nTo determine the efficacy of tasimelteon in entraining the endogenous circadian melatonin rhythm to the 24 hour period in patients with N24HSWD.""}]	[See Results Section.]	NA	NA
NCT01166997	ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism	Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism	10.1161/circulationaha.113.005544	https://www.ncbi.nlm.nih.gov/pubmed/24226805?dopt=Abstract	10	2010-07-20	Recruiting	Completed	2010-07-01	2013-04-01	2013-11-13	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of RV/LV ratio\n[ Time Frame: 24 hours ]\n\nRV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of RV/LV ratio\n[ Time Frame: 24 hours ]\n\nRV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of RV/LV ratio\n[ Time Frame: 24 hours ]\n\nRV/LV ratio will be measured by echocardiography at baseline. RV/LV ratio will be measured again by echocardiography at 24 hours.""}]	[See Results Section.]	NA
NCT01168791	Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma	10.1200/jco.2016.67.6684	https://www.ncbi.nlm.nih.gov/pubmed/27621408	34	2010-07-21	Recruiting	Completed	2010-07-01	2012-07-01	2016-11-10	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall Survival\n[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months, then every 12 weeks until death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival followed by Overall Survival\n[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months/until progression, then every 12 weeks until then death ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival followed by Overall Survival\n[ Time Frame: assessed every 6 weeks for 22 weeks, then 8 weeks for 6 months/until progression, then every 12 weeks until then death ]""}]	NA	NA
NCT01171274	Effects of Hatha Yoga on Chronic Neck Pain	Randomized-controlled trial comparing yoga and home-based exercise for chronic neck pain	10.1097/ajp.0b013e318251026c	https://www.ncbi.nlm.nih.gov/pubmed/?term=Randomized-controlled+Trial+Comparing+Yoga+and+Home-based+Exercise+for+Chronic+Neck+Pain	7	2010-07-27	Not yet recruiting	Completed	2010-08-01	2010-12-01	2013-03-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Week 11 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Week 11 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Neck pain intensity (100mm visual analog scale)\n[ Time Frame: Week 10 ]\n\n100mm visual analog scale""}]	NA	NA
NCT01171820	SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions (Diabetic Sub-Study)	The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions	10.1016/j.ahj.2012.02.006	https://www.ncbi.nlm.nih.gov/pubmed/22607866	3	2010-07-27	Active, not recruiting	Completed	2006-11-01	2009-07-01	2012-04-11	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""In-stent Late Loss(LL)\n[ Time Frame: 270 days ]""}]	NA	[See Results Section.]	[See Results Section.]	NA
NCT01172938	Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor	10.1136/annrheumdis-2013-205056	http://ard.bmj.com/content/73/6/1020.long	23	2010-07-28	Recruiting	Completed	2010-06-01	2012-04-01	2014-03-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve the American College of Rheumatology criteria for a 20% improvement (ACR 20), compared with baseline\n[ Time Frame: Weeks 0-24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each treatment group who achieve the American College of Rheumatology criteria for a 20% improvement (ACR 20), compared with baseline\n[ Time Frame: Weeks 0-24 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""American College of Rheumatology 20 (ACR 20)\n[ Time Frame: 16 weeks ]\n\nProportion of subjects in each treatment group who achieve the American College of Rheumatology criteria for a 20% improvement (ACR 20), compared with baseline after 16 weeks of treatment""}]	[See Results Section.]	NA
NCT01176968	Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study	10.1093/eurheartj/ehu164	https://www.ncbi.nlm.nih.gov/pubmed/24780614	27	2010-08-04	Not yet recruiting	Completed	2010-09-01	2012-10-01	2014-04-29	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation.\n[ Time Frame: 0-18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first event of cardiovascular mortality, re-hospitalization or extended initial hospital stay due to diagnosis of heart failure, sustained ventricular tachycardia or fibrillation.\n[ Time Frame: 0-18 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first event of cardiovascular mortality,re-hospitalization or extended initial hospital stay due to diagnosis of heart failure,sustained ventricular tachycardia or fibrillation,ejection fraction ≤40% or BNP above age adjusted cut off\n[ Time Frame: 0-23 months ]""}]	[See Results Section.]	NA
NCT01178255	Efficacy and Safety of Homeopathy for Moderate Depression (Acute Phase)	Homeopathy for depression: a randomized, partially double-blind, placebo-controlled, four-armed study (DEP-HOM)	10.1371/journal.pone.0074537	https://www.ncbi.nlm.nih.gov/pubmed/24086352	4	2010-08-09	Not yet recruiting	Terminated	2010-08-01	2011-11-01	2013-09-23	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""primary endpoint is the total score on the 17-item Hamilton Depression Rating Scale - (HAM-D)\n[ Time Frame: six weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""primary endpoint is the mean total depression score post treatment\n[ Time Frame: six weeks ]\n\ntotal score on the 17-item Hamilton Depression Rating Scale - (HAM-D)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""primary endpoint is the mean total depression score post treatment\n[ Time Frame: six weeks ]\n\ntotal score on the 17-item Hamilton Depression Rating Scale - (HAM-D)""}]	NA	NA
NCT01180400	A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder	Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant	10.1016/j.euroneuro.2013.12.008	https://www.sciencedirect.com/science/article/pii/S0924977X13003532	13	2010-08-11	Not yet recruiting	Completed	2010-08-01	2011-08-01	2013-12-21	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 8 (baseline) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 9 ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 10 ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16).\n[ Time Frame: Will be scored at Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 8 (baseline) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 9 ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 10 ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""Change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from randomization to end of treatment.\n[ Time Frame: Will be scored at Week 16 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01186510	Lung Perfusion With Oxygenated Blood During Aortic Clamping	The influence of selective pulmonary perfusion on the inflammatory response and clinical outcome of patients with chronic obstructive pulmonary disease undergoing cardiopulmonary bypass	10.1093/icvts/ivu062	https://academic.oup.com/icvts/article-lookup/doi/10.1093/icvts/ivu062	4	2010-08-20	Recruiting	Completed	2010-08-01	2012-11-01	2014-03-14	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker\n[ Time Frame: 5 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Inflammatory marker\n[ Time Frame: 5 days ]""}]	NA	NA
NCT01186861	Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer	10.1038/bjc.2017.226	https://www.ncbi.nlm.nih.gov/pubmed/28772281	33	2010-08-19	Not yet recruiting	Completed	2010-11-01	2013-06-01	2017-08-03	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib (Arm A), or erlotinib and placebo (Arm B) in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC\n[ Time Frame: 22 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population\n[ Time Frame: 22 months ]\n\nPFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population\n[ Time Frame: 22 months ]\n\nPFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The Progression Free Survival (PFS) of maintenance OSI-906 plus erlotinib, or placebo plus erlotinib in patients with nonprogression following four cycles of first-line platinum-based chemotherapy for advanced NSCLC in the overall population\n[ Time Frame: 22 months ]\n\nPFS is defined as the time from randomization to disease progression based on RECIST v1.1 or death due to any cause whichever comes first""}]	NA
NCT01187888	Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy	PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy	10.1007/s00415-016-8169-1	https://www.ncbi.nlm.nih.gov/pubmed/27230855	4	2010-08-23	Recruiting	Terminated	2010-01-01	2012-06-01	2016-05-26	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial\n[ Time Frame: 1 year ]\n\nSince there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exerct a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduction of the reported deterioration using the PSP rating scale\n[ Time Frame: 1 year ]\n\nTo assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial\n[ Time Frame: 1 year ]\n\nSince there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exerct a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduction of the reported deterioration using the PSP rating scale\n[ Time Frame: 1 year ]\n\nTo assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial\n[ Time Frame: 1 year ]\n\nSince there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exert a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Reduction of the reported deterioration using the PSP rating scale\n[ Time Frame: 1 year ]\n\nTo assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.""}]	NA	NA
NCT01191359	Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch	Immunologic response and safety in birch pollen sublingual versus oral vestibule immunotherapy: a pilot study	10.1016/j.jaci.2014.03.026	https://www.ncbi.nlm.nih.gov/pubmed/24794686	3	2010-08-27	Active, not recruiting	Completed	2010-01-01	2010-12-01	2014-05-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch\n[ Time Frame: after 4, 8, 12, 24, 36 weeks of treatment ]\n\nspecific antibody determination""}]	NA	NA
NCT01194219	Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)	10.1016/j.jaad.2015.03.049	https://www.ncbi.nlm.nih.gov/pubmed/26089047	30	2010-09-01	Recruiting	Completed	2010-08-01	2012-02-01	2015-07-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving at least a 75% improvement in Psoriasis Area Severity Index (PASI) score.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects achieving at least a 75% improvement in Psoriasis Area Severity Index (PASI) score.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01196195	KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)	Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children	10.1097/qad.0000000000000862	NA	6	2010-09-07	Recruiting	Completed	2010-08-01	2012-07-01	2015-11-28	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 48 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: Week 36 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 24 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 12 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 8 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 4 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological supression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""To compare the pharmokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children\n[ Time Frame: week 4 ]\n\nAUC, Cmin and Cmax values of lopinavir after once-daily and twice-daily dosing (in the same children)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 48 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 Ribonucleic acid (RNA) ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: Week 36 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 24 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 12 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 8 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 4 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""To compare the pharmacokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children\n[ Time Frame: week 4 ]\n\nArea under the curve (AUC), minimum observed plasma concentration (Cmin) and maximum observed plasma concentration (Cmax) values of lopinavir after once-daily and twice-daily dosing (in the same children)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 48 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 Ribonucleic acid (RNA) ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: Week 36 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 24 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 12 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 8 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""To evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).\n[ Time Frame: week 4 ]\n\nTo evaluate whether once-daily dosing of lopinavir/ritonavir is comparable to twice-daily dosing in terms of virological suppression. This is measured by HIV-1 RNA ≥50 copies/ml (confirmed).""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""To compare the pharmacokinetics of twice-daily lopinavir/ritonavir tablets with once-daily dosing in the same children\n[ Time Frame: week 4 ]\n\nArea under the curve (AUC), minimum observed plasma concentration (Cmin) and maximum observed plasma concentration (Cmax) values of lopinavir after once-daily and twice-daily dosing (in the same children)""}]	NA	NA
NCT01197508	A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy	10.3109/15622975.2014.989261	https://www.ncbi.nlm.nih.gov/pubmed/25602163?dopt=Abstract	10	2010-09-08	Not yet recruiting	Completed	2010-09-01	2012-02-01	2015-01-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery_Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16)\n[ Time Frame: Will be scored at Weeks 8 (baseline), 9, 10, 12, 14 and 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Montgomery_Asberg Depression Rating Scale (MADRS) total score from randomization (Week 8) to end of treatment (Week 16)\n[ Time Frame: Will be scored at Weeks 8 (baseline), 9, 10, 12, 14 and 16 ]""}]	[See Results Section.]	NA	NA
NCT01208233	Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke	Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial	10.1016/j.jstrokecerebrovasdis.2015.11.026	https://www.ncbi.nlm.nih.gov/pubmed/26738812?dopt=Abstract	37	2010-09-22	Not yet recruiting	Terminated	2010-12-01	2014-03-01	2015-12-28	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability assessed by an Independent Data and Safety Monitoring Board (DSMB) using data, including AEs , vital signs, brain MRI, ECG, physical (including neurological) examination, NIHSS scores, laboratory tests.\n[ Time Frame: Day 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects with Modified Rankin Scale (mRS) less than or equal to 2\n[ Time Frame: Day 90 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety and tolerability assessed by an Independent Data and Safety Monitoring Board (DSMB) using data, including SAEs, AEs , vital signs, brain MRI, ECG, physical (including neurological) examination, NIHSS scores, laboratory tests.\n[ Time Frame: Day 14 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects with Modified Rankin Scale (mRS) less than or equal to 2\n[ Time Frame: Day 90 ]""}]	NA	[See Results Section.]	NA
NCT01214278	Bioavailability of Different n-3 Fatty Acid Formulations	Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil	10.1186/1476-511x-10-145	https://www.ncbi.nlm.nih.gov/pubmed/21854650	4	2010-10-04	Not yet recruiting	Completed	2010-10-01	2010-11-01	2011-08-22	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""EPA- and DHA levels\n[ Time Frame: baseline ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""EPA- and DHA levels\n[ Time Frame: two hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""EPA- and DHA levels\n[ Time Frame: four hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EPA- and DHA level\n[ Time Frame: six hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""EPA- and DHA levels\n[ Time Frame: eight hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""EPA- and DHA levels\n[ Time Frame: 24 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""EPA- and DHA levels\n[ Time Frame: 48 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""EPA- and DHA levels\n[ Time Frame: 72 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""EPA- and DHA levels\n[ Time Frame: baseline ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""EPA- and DHA levels\n[ Time Frame: two hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""EPA- and DHA levels\n[ Time Frame: four hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""EPA- and DHA level\n[ Time Frame: six hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""EPA- and DHA levels\n[ Time Frame: eight hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""EPA- and DHA levels\n[ Time Frame: 24 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""EPA- and DHA levels\n[ Time Frame: 48 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""EPA- and DHA levels\n[ Time Frame: 72 hours after the supplementation ]\n\nto assess levels of EPA and DHA in plasma phospholipids to determine the AUC0-24, tmax and cmax and detect differences of the bioavailability between the four n-3 FA formulations""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under concentration time curve (AUC)\n[ Time Frame: about 24 hours ]\n\nConcentration of eicosapentanoiec acid (EPA) and docosahexanoiec acid (DHA) was measured at baseline and after 2, 4, 6, 8 and 24 hours.""}]	NA
NCT01215071	Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA	Relationship of the number of removed lymph nodes to bladder cancer and competing mortality after radical cystectomy	10.1016/j.eururo.2014.07.046	http://www.sciencedirect.com/science/article/pii/S0302283814007362	4	2010-10-05	Active, not recruiting	Completed	2006-03-01	2013-03-01	2014-08-19	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free Survival\n[ Time Frame: 5 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression free Survival\n[ Time Frame: 5 years ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Recurrence free Survival (RFS)\n[ Time Frame: 5 years ]\n\nDefinition Recurrence-free survival: Time from radical cystectomy to tumor reccurence or death from any cause up to 5 years""}]	NA
NCT01217528	Reduction of Inappropriate Implantable Cardioverter Defibrillator (ICD) Therapies in Primary Prevention Patients	Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study	10.1007/s00392-015-0870-z	https://link.springer.com/article/10.1007%2Fs00392-015-0870-z	6	2010-10-07	Recruiting	Completed	2009-08-01	2012-07-01	2015-05-23	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEventfree survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEventfree survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEvent free survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Endpoint\n[ Time Frame: 12 months ]\n\n\n\nEvent free survival of:\n\ninappropriate ICD therapies (only stored tachycardias with proper stored EGM documentation are taken into account) AND\nspontaneous, documented, sustained (>30s) ventricular tachycardia, that was not treated by the ICD""}]	NA
NCT01220856	NA	NA	NA	NA	6	2010-10-13	Recruiting	Completed	2010-07-01	2012-11-01	NA	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of insulin-independent patients following a single donor-single islet cell transplantation\n[ Time Frame: day 75 +/- 5 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The proportion of insulin-independent patients after a single donor-single islet cell transplantation\n[ Time Frame: up to one year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Time to achieve insulin-independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Total time of insulin independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""13."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""14."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""15."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""16."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""17."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: monh 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""18."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""19."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""20."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""21."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""22."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""23."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""24."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""25."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""26."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""27."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""28."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 12 post-transplant ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of insulin-independent patients following a single donor-single islet cell transplantation\n[ Time Frame: day 75 +/- 5 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""The proportion of insulin-independent patients after a single donor-single islet cell transplantation\n[ Time Frame: up to one year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Time to achieve insulin-independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""Total time of insulin independence after the transplant\n[ Time Frame: up to 1 year after the transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""7."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""8."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""9."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""10."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 1 post- transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""11."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""12."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""13."",""content"":""Change in average daily insulin requirements (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""14."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""15."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""16."",""content"":""HbA1c (absolute and % decrease from pre-transplant levels)\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""17."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: monh 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""18."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""19."",""content"":""The proportion of patients free of severe hypoglycaemic events\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""20."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""21."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""22."",""content"":""The proportion of patients free of hypoglycaemic events with reduced awareness\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""23."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""24."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""25."",""content"":""Beta-cell function as assessed by beta-score and Transplant Estimated Function\n[ Time Frame: month 12 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""26."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 3 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""27."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 6 post-transplant ]""},{""section"":""Primary Outcome Measures:"",""label"":""28."",""content"":""Basal (fasting) and -10 to 120 min time course of glucose, C-peptide and insulin derived from the mixed meal tolerance test\n[ Time Frame: month 12 post-transplant ]""}]	NA	NA	[See Results Section.]
NCT01221610	BIOLUX P-I First in Man Study	Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial	10.1177/1526602814564383	http://journals.sagepub.com/doi/abs/10.1177/1526602814564383	6	2010-10-14	Recruiting	Completed	2010-10-01	NA	2015-02-01	FALSE	FALSE	FALSE	TRUE	TRUE	NA	NA	FALSE	TRUE	unknown	[]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).\n[ Time Frame: 6 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Assessment of the 6 months late lumen loss in the target lesion measured by quantitative vascular angiography (QVA).\n[ Time Frame: 6 months ]""}]
NCT01223352	Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension	A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3	10.1111/bcp.13267	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510076/	25	2010-10-15	Not yet recruiting	Completed	2011-01-01	2013-08-01	2017-03-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily exposure to bosentan (AUC over 24 hours)\n[ Time Frame: 24 hours ]\n\nDaily exposure to bosentan, i.e., AUC over a period of 24 h (AUC0-24h), and calculated as a multiple of the exposure over a dosing interval (AUCτ), 3 × AUCτ and 2 × AUCτ for three times and two times daily dosing, respectively.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily exposure to bosentan (AUC over 24 hours)\n[ Time Frame: 24 hours ]\n\nDaily exposure to bosentan, i.e., AUC over a period of 24 h (AUC0-24h), and calculated as a multiple of the exposure over a dosing interval (AUCτ), 3 × AUCτ and 2 × AUCτ for three times and two times daily dosing, respectively.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Daily exposure [AUC(0-24c)] to bosentan\n[ Time Frame: At Week 4, after at least 2 weeks of stable study drug treatment ]\n\n\n\nDaily exposure was measured by the area under the plasma concentration-time curve over a period of 24 hours [AUC(0-24)].\n\nConcentrations of bosentan were measured directly in blood samples collected prior to study drug administration and up to 12 hours or up to 8 hours post-dose for the b.i.d and t.i.d. dosing regimen, respectively. AUC(0-24) was calculated as a multiple of AUCtau (i.e., the AUC over a dosing interval): AUCtau x 2 for the b.i.d. dosing regimen and AUCtau x 3 for the t.i.d. regimen. As the smallest dose unit was 8 mg (1/4 tablet), it was not possible to achieve the exact target dose of 2 mg/kg. Therefore, AUC(0-24) was corrected to 2 mg/kg (target dose) [AUC(0-24c)].""}]	[See Results Section.]	NA
NCT01228149	COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy	Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma	10.1371/journal.pone.0171636	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310886/	7	2010-10-25	Recruiting	Completed	2010-08-01	2014-04-01	2017-02-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP\n[ Time Frame: 12 weeks ]\n\nmeasurement of eye pressure in mmHg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP\n[ Time Frame: 12 weeks ]\n\nmeasurement of eye pressure in mmHg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean IOP reduction (ΔIOP) three months after trabeculectomy in comparison to the mean preoperative IOP\n[ Time Frame: 12 weeks ]\n\nmeasurement of eye pressure in mmHg""}]	[See Results Section.]	NA
NCT01229774	Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty	Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac	10.1007/s00264-015-3077-z	https://www.springermedizin.de/comparative-clinical-study-of-the-prophylaxis-of-heterotopic-oss/8241318	3	2010-10-27	Not yet recruiting	Completed	2011-02-01	2014-08-01	2016-04-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[]	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Perioperative blood loss after implantation of a hip joint endoprosthesis\n[ Time Frame: Three days ]\n\nThe primary objective of the study is the designation of the perioperative blood loss after implantation of a hip joint endoprosthesis under the influence of Etoricoxib or of Diclofenac. The expectations hypothesis is that under Etoricoxib patients will loose a smaller quantity of blood than under Diclofenac.""}]	NA	NA
NCT01230086	Trop-Shock DFT-testing Versus None	ICD Shock, Not Ventricular Fibrillation, Causes Elevation of High Sensitive Troponin T after Defibrillation Threshold Testing--The Prospective, Randomized, Multicentre TropShock-Trial	10.1371/journal.pone.0131570	https://www.ncbi.nlm.nih.gov/pubmed/26208329?dopt=Abstract	5	2010-10-27	Recruiting	Completed	2010-08-01	2013-03-01	2015-07-24	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of hs Troponin\n[ Time Frame: 6 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of high sensitivity Troponin\n[ Time Frame: 6 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of high sensitivity Troponin\n[ Time Frame: 6 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Influence of different ICD-implantation strategies on release of high sensitivity Troponin\n[ Time Frame: 6 hours ]""}]	NA
NCT01232283	Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.	Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)	10.1111/bjd.14164	https://www.ncbi.nlm.nih.gov/pubmed/26357944	25	2010-11-01	Not yet recruiting	Completed	2010-11-01	2012-03-01	2015-11-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects who achieve at least a 75% reduction in Psoriasis Area Severity Index (PASI-75) at Week 16 from baseline.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects who achieve at least a 75% reduction in Psoriasis Area Severity Index (PASI-75) at Week 16 from baseline.\n[ Time Frame: From Baseline (pre-dose) to Week 16 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01241591	A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial	10.1016/s0140-6736(14)62113-9	http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962113-9/supplemental	26	2010-11-12	Not yet recruiting	Completed	2010-11-01	2013-01-01	2015-06-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA) response ie, the proportion of subjects achieving a PGA of \""clear\"" or \""almost clear\"", at Week 12\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response ie, the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline, at Week 12.\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA) response ie, the proportion of subjects achieving a PGA of \""clear\"" or \""almost clear\"", at Week 12\n[ Time Frame: 12 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response ie, the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline, at Week 12.\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01244048	Intervention With n3 LC-PUFA-supplemented Yogurt	Randomized placebo-controlled intervention with n-3 LC-PUFA-supplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors	10.1016/j.clnu.2012.12.010	http://www.sciencedirect.com/science/article/pii/S026156141200283X	2	2010-11-18	Completed	Completed	2008-10-01	2008-11-01	2012-12-28	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)\n[ Time Frame: change from baseline after 5 weeks or 10 weeks ]\n\n\n\nchange from baseline after 5 weeks (first period) 10 weeks wash-out change from baseline after 10 weeks (second period)\n\nGroup 1: placebo (first and second period) Group 2: 0.8 g n3 LC-PUFA/125 g yoghurt per day (first and second period) Group 3: 3 g n3 LC-PUFA/200 g yoghurt per day (first and second period)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)\n[ Time Frame: change from baseline after 10 weeks ]\n\n\n\nchange from baseline after 10 weeks\n\nGroup 1: placebo Group 2: 0.8 g n3 LC-PUFA/125 g yoghurt per day Group 3: 3 g n3 LC-PUFA/200 g yoghurt per day""}]	NA	NA
NCT01244061	A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider	Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial	10.1038/clpt.2014.124	https://www.ncbi.nlm.nih.gov/pubmed/24911368	30	2010-11-18	Not yet recruiting	Completed	2010-12-01	2012-11-01	2014-06-09	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Continuous Abstinence Rate for Weeks 9-12 (CAR 9-12)\n[ Time Frame: Weeks 9-12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Continuous Abstinence Rate for Weeks 9-12 (CAR 9-12)\n[ Time Frame: Weeks 9-12 ]""}]	[See Results Section.]	NA	NA
NCT01244490	Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)	Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial	10.1016/j.euroneuro.2014.09.014	https://www.ncbi.nlm.nih.gov/pubmed/25453486?dopt=Abstract	25	2010-11-18	Not yet recruiting	Completed	2010-12-01	2013-08-01	2014-10-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score\n[ Time Frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score\n[ Time Frame: Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01247051	Comparison of Two Different Heart-lung Machine Filling Methods: Precoating Versus Colloidal Fluids	Pre-filling of the extracorporeal circuit with autologous blood is safe, but not effective in optimizing biocompatibility in high-risk patients	10.1177/0267659112447654	NA	2	2010-11-23	Recruiting	Completed	NA	2011-08-01	2012-05-25	FALSE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	FALSE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood loss""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood loss\n[ Time Frame: 24 hours ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood loss""}]
NCT01251328	Near INfrared Spectroscopy in Aortic valvE ReplacemenT	Comparison of sedation and general anaesthesia for transcatheter aortic valve implantation on cerebral oxygen saturation and neurocognitive outcome†	10.1093/bja/aev294	https://www.ncbi.nlm.nih.gov/pubmed/26424178?dopt=Abstract	4	2010-11-30	Not yet recruiting	Completed	2010-12-01	2012-04-01	2015-09-29	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral oxygen desaturation during the \""rapid pacing\"" period\n[ Time Frame: up to 48 hours ]\n\nBiomarkers for cerebral ischemia will be measured up to 48 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral oxygen desaturation during the \""rapid pacing\"" period\n[ Time Frame: up to 48 hours ]\n\nBiomarkers for cerebral ischemia will be measured up to 48 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cerebral oxygen desaturation during the \""rapid pacing\"" period and periprocedural\n[ Time Frame: up to 48 hours ]\n\nBiomarkers for cerebral ischemia will be measured up to 48 hours""}]	NA	NA
NCT01252940	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF	Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants	10.1097/qad.0000000000000087	http://journals.lww.com/aidsonline/Abstract/2014/01280/Simplification_to.6.aspx	12	2010-12-02	Recruiting	Completed	2010-11-01	2012-02-01	2014-01-28	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 24\n[ Time Frame: 24 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 24\n[ Time Frame: 24 Weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01255722	Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography	Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial	10.1007/s00330-016-4437-9	https://www.ncbi.nlm.nih.gov/pubmed/27271922	5	2010-12-06	Recruiting	Completed	2010-11-01	2012-09-01	2016-06-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluability of CT scans based upon segments assessment using a 5-point evaluation scale grading the quality and the interpretability of images.\n[ Time Frame: < 24h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluability of CT scans based upon segments assessment using a 5-point evaluation scale grading the quality and the interpretability of images.\n[ Time Frame: < 24h ]""}]	[See Results Section.]	NA	NA
NCT01255813	Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache	Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study	10.1177/0333102412473667	https://www.ncbi.nlm.nih.gov/pubmed/23314784	7	2010-12-06	Recruiting	Completed	2010-12-01	2012-06-01	2013-01-11	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of device related serious Adverse Events (AEs)\n[ Time Frame: 15 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Acute pain relief response (as defined by patient)\n[ Time Frame: 15 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of device related Serious Adverse Events (SAEs)\n[ Time Frame: Implant through the Experimental Period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Acute Pain Relief response (as defined by patient)\n[ Time Frame: 15 minutes ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of device related Serious Adverse Events (SAEs)\n[ Time Frame: Implant through the Experimental Period ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Acute Pain Relief response (as defined by patient)\n[ Time Frame: 15 minutes ]""}]	NA
NCT01256424	Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia	A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2	10.1016/j.ajog.2014.10.1107	https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(14)02199-1	12	2010-12-07	Not yet recruiting	Completed	2011-04-01	2012-07-01	2014-10-31	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare lesion response rates of three different doses of HAL PDT and placebo (no illumination) at 3 months after treatment.\n[ Time Frame: 3 months after last treatment ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To compare lesion response rates of three different doses of HAL PDT and placebo (no illumination) at 3 months after treatment.\n[ Time Frame: 3 months after last treatment ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01258153	Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic	NA	10.1016/s0016-5085(15)31431-1	https://www.gastrojournal.org/article/S0016-5085(15)31431-1/pdf	13	2010-12-09	Recruiting	Completed	2010-11-01	2013-12-01	2015-04-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline.\n[ Time Frame: One week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline.\n[ Time Frame: One week ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absolute change of the mean daily crying and fussing time for three consecutive days while on treatment versus baseline.\n[ Time Frame: One week ]""}]	[See Results Section.]	NA
NCT01258738	Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes	Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial	10.1002/art.38721	http://onlinelibrary.wiley.com/doi/10.1002/art.38721/abstract	22	2010-12-09	Not yet recruiting	Completed	2011-02-01	2012-12-01	2014-08-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who achieve Assessments in Ankylosing Spondylitis (ASAS) 40 at week 12.\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who achieve Assessments in Ankylosing Spondylitis (ASAS) 40 at week 12.\n[ Time Frame: 12 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who achieve Assessments in Ankylosing Spondylitis (ASAS) 40 at week 12.\n[ Time Frame: 12 weeks ]""}]	[See Results Section.]	NA
NCT01262677	Once-A-Day Pregabalin For Partial Seizures	Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial	10.1111/epi.12690	http://onlinelibrary.wiley.com/doi/10.1111/epi.12690/full	28	2010-12-16	Not yet recruiting	Completed	2011-02-01	2012-08-01	2014-06-24	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind maintenance treatment phase.\n[ Time Frame: Week 2 to week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind treatment phase.\n[ Time Frame: Week 0 to week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint will be the log transformed (loge) 28 day seizure rate for all partial onset seizures collected during the double blind treatment phase.\n[ Time Frame: Week 0 to week 14 ]""}]	[See Results Section.]	NA
NCT01263522	Optimization of Preventive Effects of Physical Training	Irisin and exercise training in humans - results from a randomized controlled training trial	10.1186/1741-7015-11-235	https://bmcmedicine.biomedcentral.com/articles/10.1186/1741-7015-11-235	2	2010-12-17	Recruiting	Completed	2010-12-01	2013-12-01	2013-11-05	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VO2max\n[ Time Frame: 6 months ]\n\ndetermined during treadmill testing""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VO2max\n[ Time Frame: 6 months ]\n\ndetermined during treadmill testing""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""VO2 max\n[ Time Frame: 6 months ]\n\ndetermined during treadmill testing""}]	NA
NCT01270126	Trial of Alternating Current Stimulation in Optic Neuropathy	Non-invasive alternating current stimulation improves vision in optic neuropathy	10.3233/rnn-2011-0624	http://content.iospress.com/download/restorative-neurology-and-neuroscience/rnn624?id=restorative-neurology-and-neuroscience%2Frnn624	4	2011-01-04	Completed	Completed	2006-11-01	2010-12-01	2011-01-01	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Nov 2006 - Dec 2010 ]\n\nCentral visual fields were assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field were characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors was defined as the primary outcome criterion.""}]	NA	NA	[See Results Section.]	NA
NCT01271790	A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C	All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection	10.1002/hep.27053	http://onlinelibrary.wiley.com/doi/10.1002/hep.27053/full	11	2011-01-06	Recruiting	Completed	2010-12-01	2012-11-01	2014-05-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response\n[ Time Frame: 24 weeks of off-treatment follow-up ]\n\nSustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response\n[ Time Frame: 24 weeks of off-treatment follow-up ]\n\nSustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sustained virologic response\n[ Time Frame: 24 weeks of off-treatment follow-up ]\n\nSustained virologic response (SVR) defined as undetectable hepatitis C virus (HCV) RNA 24 weeks after treatment cessation""}]	NA	NA
NCT01276639	A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials	10.1111/bjd.14018	http://onlinelibrary.wiley.com/doi/10.1111/bjd.14018/abstract	26	2011-01-12	Not yet recruiting	Completed	2011-03-01	2013-04-01	2015-10-29	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA) response, ie, the proportion of subjects achieving a PGA of \""clear\"" or \""almost clear\"", at Week 16.\n[ Time Frame: Week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to baseline at Week 16.\n[ Time Frame: Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician Global Assessment (PGA) response, ie, the proportion of participants achieving a PGA of \""clear\"" or \""almost clear\"" at week 16\n[ Time Frame: Week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of participants achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline at Week 16\n[ Time Frame: Week 16 ]""}]	[See Results Section.]	NA	NA
NCT01280877	Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)	Alternating Current Stimulation for Vision Restoration after Optic Nerve Damage: A Randomized Clinical Trial	10.1371/journal.pone.0156134	https://www.ncbi.nlm.nih.gov/pubmed/27355577?dopt=Abstract	6	2011-01-19	Recruiting	Completed	2010-12-01	2012-02-01	2016-06-29	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field sectors\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Detection accuracy (DA) change in percent over baseline within defective visual field\n[ Time Frame: Baseline - 8 weeks after stimulation; First follow-up 2 days after treatment course; Second follow-up 8 weeks after treatment course ]\n\nCentral visual fields assessed with computer-based high-resolution perimetry (HRP). Based on such plots, areas of the visual field are characterized as intact, partially damaged or absolutely impaired (blind). Detection accuracy (DA) change in percent above baseline within defective visual field sectors is defined as the primary outcome criterion.""}]	NA
NCT01281189	Phase 3 Study of Dexpramipexole in ALS	Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial	10.1016/s1474-4422(13)70221-7	https://linkinghub.elsevier.com/retrieve/pii/S1474-4422(13)70221-7	27	2011-01-20	Not yet recruiting	Completed	2011-03-01	2013-01-01	2013-09-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A joint rank of functional outcomes adjusted for mortality.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A joint rank of functional outcomes adjusted for mortality.\n[ Time Frame: 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A joint rank of functional outcomes adjusted for mortality.\n[ Time Frame: 12 months ]""}]	[See Results Section.]	NA
NCT01282918	NORDIC ICD (Cardioverter Defibrillator Implantation) Trial	Intra-operative defibrillation testing and clinical shock efficacy in patients with implantable cardioverter-defibrillators: the NORDIC ICD randomized clinical trial	10.1093/eurheartj/ehv292	https://academic.oup.com/eurheartj/article/36/37/2500/2466025	5	2011-01-24	Not yet recruiting	Completed	2011-01-01	2014-07-01	2015-06-25	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average efficacy of the first ICD shock for all true ventricular tachyarrhythmias\n[ Time Frame: 24 months ]\n\nThe primary endpoint is the average efficacy of the first ICD shock for all true ventricular tachyarrhythmias of a patient in the observational period. More precisely, the primary endpoint will be determined as the number of true ventricular tachyarrhythmias of a patient (that were efficiently terminated by the first shock delivered by the ICD) divided by the number of true ventricular tachyarrhythmias (treated with at least one ICD shock) of the same patient.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average efficacy of the first ICD shock for all true ventricular tachyarrhythmias\n[ Time Frame: 12 months ]\n\nThe primary endpoint is the average efficacy of the first ICD shock for all true ventricular tachyarrhythmias of a patient in the observational period. More precisely, the primary endpoint will be determined as the number of true ventricular tachyarrhythmias of a patient (that were efficiently terminated by the first shock delivered by the ICD) divided by the number of true ventricular tachyarrhythmias (treated with at least one ICD shock) of the same patient.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Average efficacy of the first ICD shock for all true ventricular tachyarrhythmias\n[ Time Frame: 12 months ]\n\nThe primary endpoint is the average efficacy of the first ICD shock for all true ventricular tachyarrhythmias of a patient in the observational period. More precisely, the primary endpoint will be determined as the number of true ventricular tachyarrhythmias of a patient (that were efficiently terminated by the first shock delivered by the ICD) divided by the number of true ventricular tachyarrhythmias (treated with at least one ICD shock) of the same patient.""}]	NA	NA
NCT01284062	Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients	Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study	10.1136/gutjnl-2014-308337	http://gut.bmj.com/content/64/6/894	29	2011-01-25	Not yet recruiting	Completed	2011-03-01	2013-04-01	2015-01-07	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fold change from baseline in fecal calprotectin at Week 14.\n[ Time Frame: Week 14 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fold change from baseline in fecal calprotectin at Week 14.\n[ Time Frame: Week 14 ]""}]	[See Results Section.]	NA	NA
NCT01285271	A Pre- and Post- Coronary Artery Bypass Graft Implantation Disposed Application of Xenon	Feasibility and safety of xenon compared with sevoflurane anaesthesia in coronary surgical patients: a randomized controlled pilot study	10.1093/bja/aet072	https://academic.oup.com/bja/article-lookup/doi/10.1093/bja/aet072	4	2011-01-26	Not yet recruiting	Completed	2011-05-01	2011-09-01	2013-04-11	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation\n[ Time Frame: an average of 4 to 6 hours ]\n\n\n\nThe feasibility of xenon application compared to sevoflurane application will be assessed by:\n\nThe depth of anaesthesia level\nThe peri-anaesthetic respiratory profile\nThe peri-anaesthetic haemodynamic profile\n\nThe following safety parameters will be assessed:\n\nDoses and concentration of study treatments\nTrans-esophageal echocardiography\nMeasures of renal function\nIntra-operative blood loss and amount of transfused blood/products\nNeed for hemodynamic and inotropic support\nThe patient's regional cerebral tissue oxygenation rSO2\nThe incidence of AE and SAE""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation\n[ Time Frame: an average of 4 to 6 hours ]\n\n\n\nThe feasibility of xenon application compared to sevoflurane application will be assessed by:\n\nThe depth of anaesthesia level\nThe peri-anaesthetic respiratory profile\nThe peri-anaesthetic haemodynamic profile\n\nThe following safety parameters will be assessed:\n\nDoses and concentration of study treatments\nTrans-esophageal echocardiography\nMeasures of renal function\nIntra-operative blood loss and amount of transfused blood/products\nNeed for hemodynamic and inotropic support\nThe patient's regional cerebral tissue oxygenation rSO2\nThe incidence of AE and SAE""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluation of the safety and feasibility of xenon application for general anesthesia before and after CABG implantation\n[ Time Frame: an average of 4 to 6 hours ]\n\n\n\nThe feasibility of xenon application compared to sevoflurane application will be assessed by:\n\nThe depth of anaesthesia level\nThe peri-anaesthetic respiratory profile\nThe peri-anaesthetic haemodynamic profile\n\nThe following safety parameters will be assessed:\n\nDoses and concentration of study treatments\nTrans-esophageal echocardiography\nMeasures of renal function\nIntra-operative blood loss and amount of transfused blood/products\nNeed for hemodynamic and inotropic support\nThe patient's regional cerebral tissue oxygenation rSO2\nThe incidence of AE and SAE""}]	NA	NA
NCT01291693	Testing Delivery Channels of Brief Motivational Alcohol Intervention	In-person alcohol counseling versus computer-generated feedback: Results from a randomized controlled trial	10.1037/hea0000556	https://pubmed.ncbi.nlm.nih.gov/28967769/	6	2011-02-07	Not yet recruiting	Completed	2011-02-01	2013-03-01	2017-10-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, highest blood alcohol concentration, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, highest blood alcohol concentration, the Alcohol Use Disorder Identification Test-Consumtion (AUDIT-C) score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Risky drinking\n[ Time Frame: 6, 12, 18, 24 months ]\n\nDetermined by using average alcohol consumption per day, heavy occasional drinking, highest blood alcohol concentration, the Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) score""}]	NA	NA
NCT01299480	A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years	Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents	10.1093/jpids/piv039	https://www.ncbi.nlm.nih.gov/pubmed/26407272	12	2011-02-16	Not yet recruiting	Completed	2011-03-01	2012-05-01	2015-08-04	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint for the co-primary objectives are the proportion of subjects achieving an rLP2086-specific SBA titer >=1:4 , for each of the 4 primary strains, measured 1 month after the third vaccination with rLP2086 vaccine (in groups 1 and 2).\n[ Time Frame: 1 month after the third vaccination ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoint for the co-primary objectives are the proportion of subjects achieving an rLP2086-specific SBA titer >=1:4 , for each of the 4 primary strains, measured 1 month after the third vaccination with rLP2086 vaccine (in groups 1\n[ Time Frame: 1 month after the third vaccination ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""and 2).\n[ Time Frame: 1 month after the third vaccination ]""}]	[See Results Section.]	NA	NA
NCT01302600	Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.	Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial	10.1016/s1474-4422(17)30085-6	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01302600	5	2011-02-18	Recruiting	Completed	2010-11-01	2013-09-01	2017-04-28	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Function Measure\n[ Time Frame: every 6 months ]\n\nMotor fonction Measure (MFM) D1+D2 score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Function Measure\n[ Time Frame: every 6 months ]\n\nMotor fonction Measure (MFM) D1+D2 score""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor Function Measure\n[ Time Frame: every 6 months ]\n\nMotor function Measure (MFM) D1+D2 score""}]	NA	NA
NCT01303224	Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)	The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS	10.1136/gutjnl-2015-310683	http://gut.bmj.com/content/66/8/1403.long	13	2011-02-23	Recruiting	Completed	2010-10-01	2012-05-01	2016-04-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response for satisfactory relief of overall IBS symptoms and of abdominal pain/discomfort satisfactory relief during 8 weeks of treatment-(75% rule)\n[ Time Frame: Eight weeks ]\n\n\n\nWeekly binary questions (yes/no): \""Did you have satisfactory relief of your overall IBS symptoms during the last week?\"" and \""Did you have satisfactory relief of your abdominal pain or discomfort during the last week?\""\n\nResponder: Report of satisfactory overall IBS symptom relief =\""Yes\"" and of satisfacory abdominal pain/discomfort relief = \""Yes\"" 6/8 weeks (75% rule)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Response for satisfactory relief of overall IBS symptoms and of abdominal pain/discomfort satisfactory relief during 8 weeks of treatment-(75% rule)\n[ Time Frame: Eight weeks ]\n\n\n\nWeekly binary questions (yes/no): \""Did you have satisfactory relief of your overall IBS symptoms during the last week?\"" and \""Did you have satisfactory relief of your abdominal pain or discomfort during the last week?\""\n\nResponder: Report of satisfactory overall IBS symptom relief =\""Yes\"" and of satisfacory abdominal pain/discomfort relief = \""Yes\"" 6/8 weeks (75% rule)""}]	[See Results Section.]	NA	NA
NCT01304992	Cholesterol-lowering Effects of Lupin Protein	Lupin protein positively affects plasma LDL cholesterol and LDL:HDL cholesterol ratio in hypercholesterolemic adults after four weeks of supplementation: a randomized, controlled crossover study	10.1186/1475-2891-12-107	https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-12-107	4	2011-02-25	Recruiting	Completed	2011-02-01	2011-08-01	2013-08-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cholesterol metabolism\n[ Time Frame: after 0,4,8,12,16 and 20 weeks ]\n\nBlood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cholesterol metabolism\n[ Time Frame: After 0, 4, 8, 12, 16 and 20 weeks ]\n\nBlood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cholesterol metabolism\n[ Time Frame: After 0, 4, 8, 12, 16 and 20 weeks ]\n\nBlood lipids (LDL cholesterol, total cholesterol, HDL cholesterol, triacylglyceroles)""}]	NA	NA
NCT01307020	Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain	Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain	10.1186/s10194-015-0541-5	https://thejournalofheadacheandpain.springeropen.com/articles/10.1186/s10194-015-0541-5	19	2011-03-01	Recruiting	Completed	2011-02-01	2011-10-01	2015-06-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients achieving at least 50 % of the theoretical maximum total pain relief score at 6 hours post-dosing.\n[ Time Frame: 6 hours ]\n\nPain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of patients achieving at least 50 % of the theoretical maximum total pain relief score at 6 hours post-dosing.\n[ Time Frame: 6 hours ]\n\nPain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is %""}]	[See Results Section.]	NA	NA
NCT01309243	Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults	Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110)	10.1097/qai.0000000000000017	NA	7	2011-03-03	Recruiting	Completed	2011-02-01	2012-11-01	2014-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who achieve HIV 1 RNA < 50 copies/mL at week 48\n[ Time Frame: 48 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy endpoint is the proportion of subjects who achieve HIV 1 RNA < 50 copies/mL at week 48\n[ Time Frame: 48 Weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01309737	A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials	10.1111/bjd.14018	http://onlinelibrary.wiley.com/doi/10.1111/bjd.14018/abstract	24	2011-03-04	Not yet recruiting	Completed	2011-03-01	2013-04-01	2015-10-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA)response, ie, the proportion of subjects achieving a PGA of\n[ Time Frame: Week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to baseline at Week 16.\n[ Time Frame: Week 16 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physician's Global Assessment (PGA)response, ie, the proportion of participants achieving a PGA of \""clear\"" or \""almost clear\"" at week 16\n[ Time Frame: week 16 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Psoriasis Area and Severity Index 75 (PASI75) response, ie, the proportion of participants achieving at least a 75% reduction in Psoriasis Area and Severity Index relative to baseline at Week 16\n[ Time Frame: week 16 ]""}]	[See Results Section.]	NA	NA
NCT01314716	Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis	Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials	10.1016/s2213-2600(14)70165-1	http://www.sciencedirect.com/science/article/pii/S2213260014701651?via%3Dihub	30	2011-03-11	Not yet recruiting	Completed	2011-04-01	2013-07-01	2014-08-18	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in QOL-B Respiratory Symptoms Score\n[ Time Frame: Baseline to end of treatment course 1 (Day 28) ]\n\nChange in the Respiratory Symptoms score on the Quality of Life Questionaire-Bronchiectasis(QOL-B) from baseline to the end of the placebo-controlled course 1 treatment with AZLI or placebo (Day 28)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in QOL-B Respiratory Symptoms Score\n[ Time Frame: Baseline to end of treatment course 1 (Day 28) ]\n\nChange in the Respiratory Symptoms score on the Quality of Life Questionaire-Bronchiectasis(QOL-B) from baseline to the end of the placebo-controlled course 1 treatment with AZLI or placebo (Day 28)""}]	[See Results Section.]	NA	NA
NCT01315002	Nicotine Effects on Endophenotypes of Schizophrenia	The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism	10.1007/s00213-013-3081-1	https://www.ncbi.nlm.nih.gov/pubmed/?term=The+effect+of+nicotine+on+sensorimotor+gating+is+modulated+by+a+CHRNA3+polymorphism	4	2011-03-14	Recruiting	Completed	2008-07-01	2012-03-01	2013-04-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cognitive functioning\n[ Time Frame: Three hours after patch application ]\n\nAbout three hours after the application of a nicotine/placebo patch, the change in cognitive functioning is assessed. The cognitive functions being assessed include prepulse inhibition, antisaccade eye movements, the continuous performance task, spatial working memory, and a verbal memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cognitive functioning\n[ Time Frame: Three hours after patch application ]\n\nAbout three hours after the application of a nicotine/placebo patch, the change in cognitive functioning is assessed. The cognitive functions being assessed include prepulse inhibition, antisaccade eye movements, the continuous performance task, spatial working memory, and a verbal memory task.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in cognitive functioning\n[ Time Frame: Three hours after patch application ]\n\nAbout three hours after the application of a nicotine/placebo patch, the change in cognitive functioning is assessed. The cognitive functions being assessed include prepulse inhibition, antisaccade eye movements, the continuous performance task, spatial working memory, and a verbal memory task.""}]	[See Results Section.]	NA
NCT01317290	Supplementation of Alpha-linolenic Acid (ALA)-Rich Oil in Humans	Cheek cell fatty acids reflect n-3 PUFA in blood fractions during linseed oil supplementation: a controlled human intervention study	10.1186/1476-511x-12-173	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842671/	4	2011-03-16	Not yet recruiting	Completed	NA	NA	2013-11-14	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""increase of n-3 LC-PUFA in human lipids\n[ Time Frame: 0,7,56 days ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""n-3 LC-PUFA in human lipids (EPA)\n[ Time Frame: 0,7,56 days ]\n\nEPA (% of total identified fatty acid methyl esters)""}]
NCT01323270	A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.	Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents	10.1093/jpids/piv064	https://www.ncbi.nlm.nih.gov/pubmed/26803328?dopt=Abstract	18	2011-03-24	Not yet recruiting	Completed	2011-03-01	2013-01-01	2016-01-23	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportions of subjects achieving prespecified criteria for the concomitant antigens 1 month after vaccination 1 (visit 2).\n[ Time Frame: 1 month after vaccination 1 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportions of subjects achieving prespecified criteria for the concomitant antigens 1 month after vaccination 1 (visit 2).\n[ Time Frame: 1 month after vaccination 1 ]""}]	[See Results Section.]	NA	NA
NCT01327534	Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI	Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction)	10.1016/j.jcin.2014.09.007	https://www.ncbi.nlm.nih.gov/pubmed/25616919?dopt=Abstract	6	2011-03-30	Not yet recruiting	Completed	2011-05-01	2013-03-01	2014-11-14	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylisation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylisation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""platelet reactivity index (PRI) measured by VASP phosphorylation\n[ Time Frame: 2 hours after initiation of therapy ]\n\nThe primary endpoint is the platelet reactivity index (PRI) measured by VASP phosphorylation 2 hours after the initiation of the therapy. The VASP assay was chosen because it is not influenced by the concomitant administration of GP IIb/IIIa inhibitors, which are expected to be given in 50-60% of STEMI patients.""}]	NA
NCT01327547	A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents	10.1179/1528433614z.0000000011	NA	45	2011-03-31	Not yet recruiting	Completed	2011-05-01	2013-04-01	2015-03-01	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities defined as >5x upper limit of normal (ULN) for subjects whose baseline ALT ≤ULN, or\n[ Time Frame: 48 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""or >3.5x baseline for subjects whose baseline ALT >ULN, at Week 48 in the maraviroc arm versus the placebo arm""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of subjects with Grade 3 and Grade 4 ALT abnormalities.\n[ Time Frame: 48 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01329731	Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients	Changes in white spot lesions following post-orthodontic weekly application of 1.25 per cent fluoride gel over 6 months-a randomized placebo-controlled clinical trial. Part I: photographic data evaluation	10.1093/ejo/cjw060	NA	4	2011-04-05	Recruiting	Completed	2011-03-01	2013-10-01	2017-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""WSL-size change\n[ Time Frame: 12 weeks ]\n\nChanges in size of white spot lesions (WSL) at 12 weeks (lesion size to total labial tooth area, %)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""WSL-size change\n[ Time Frame: 12 weeks ]\n\nChanges in size of white spot lesions (WSL) at 12 weeks""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""WSL-size change\n[ Time Frame: 12 weeks ]\n\nChanges in size of white spot lesions (WSL) at 12 weeks""}]	NA	NA
NCT01330394	Transcranial Direct Current Stimulation Over Dorsolateral Prefrontal Cortex in Alcoholism	A randomized controlled trial of targeted prefrontal cortex modulation with tDCS in patients with alcohol dependence	10.1017/s1461145714000984	NA	5	2011-04-06	Not yet recruiting	Completed	2011-06-01	2013-07-01	2014-07-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""use of alcohol\n[ Time Frame: one year and a half ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""use of alcohol\n[ Time Frame: one year and a half ]""}]	[See Results Section.]	NA	NA
NCT01330485	Deficits in Emotion Regulation Skills as a Maintaining Factor in Major Depressive Disorder	Affect regulation training reduces symptom severity in depression - A randomized controlled trial	10.1371/journal.pone.0220436	https://pubmed.ncbi.nlm.nih.gov/31465443/	8	2011-04-05	Recruiting	Completed	2010-11-01	2014-04-01	2019-08-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in depressive symptoms (BDI-II, HRSD)\n[ Time Frame: pre/post/follow-up design, including 10 points of measurement (before/during/after group based intervention and first 16 weeks of iCBT-D) ]\n\nInvestigating reciprocal associations between Depressive Symptom Severity (DSS) and General Emotion Regulation Skills (GEMS). Clarifying whether experimentally enhancing GEMS reduces DSS and whether fostering GEMS enhances outcome of subsequent individual CBT for depression (iCBT-D) on DSS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in depressive symptoms (Beck Depression Inventory, BDI-II; Hamilton Rating Scale for Depression, HRSD)\n[ Time Frame: pre/post/follow-up design, including 10 points of measurement (before/during/after group based intervention and first 16 weeks of iCBT-D) ]\n\nInvestigating reciprocal associations between Depressive Symptom Severity (DSS) and General Emotion Regulation Skills (GEMS). Clarifying whether experimentally enhancing GEMS reduces DSS and whether fostering GEMS enhances outcome of subsequent individual CBT for depression (iCBT-D) on DSS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depressive symptoms\n[ Time Frame: Pre to post ART, CFC or WLC; hence covering the ten week time period from the first assessment point (prior to randomization) to the assessment point 10 weeks later ]\n\nChange in depressive symptoms as assessed in Beck Depression Inventory (BDI-II) and Hamilton Rating Scale for Depression (HRSD) and aggregated to a composite score is possible""}]	NA	NA
NCT01331473	PROximal Protection VErsus NON-Protection in Carotid Artery Stenting	NA	NA	https://www.researchgate.net/publication/327302891_Neue_DWI-Lasionen_beim_Carotisstent_mit_und_ohne_proximales_Protektionssystem	3	2011-04-06	Not yet recruiting	Unknown status	2011-05-01	NA	2016-01-01	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Day 1-3 ]""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging\n[ Time Frame: Day 1-3 ]""}]
NCT01337297	Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction	Bilateral transcranial direct current stimulation over dorsolateral prefrontal cortex changes the drug-cued reactivity in the anterior cingulate cortex of crack-cocaine addicts	10.1016/j.brs.2013.09.007	https://www.ncbi.nlm.nih.gov/pubmed/24139147?dopt=Abstract	5	2011-04-15	Not yet recruiting	Completed	2011-06-01	2012-11-01	2013-10-12	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in the relapse frequencies to the use of crack-cocaine\n[ Time Frame: after two-weeks treatment with active-tDCS or sham-tDCS ]\n\nchanges in the number of relapses to the use of crack-cocaine after the completion of two-weeks of treatment sessions with active-tDCS or sham-tDCS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""changes in the relapse frequencies to the use of crack-cocaine\n[ Time Frame: after two-weeks treatment with active-tDCS or sham-tDCS ]\n\nchanges in the number of relapses to the use of crack-cocaine after the completion of two-weeks of treatment sessions with active-tDCS or sham-tDCS.""}]	[See Results Section.]	[See Results Section.]	NA
NCT01338922	Psychosocial Issues in Insulin Pump Therapy in Children With Type 1 Diabetes Mellitus (DM)	Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The pumpkin multicenter randomized controlled trial	10.1111/pedi.12777	https://pubmed.ncbi.nlm.nih.gov/30302877/	3	2011-04-19	Recruiting	Completed	2011-04-01	2015-07-01	2018-10-10	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life (patient)\n[ Time Frame: 6 months ]\n\nChild's HRQOL will be measured using the well-known standardized KINDL-R modular QOL questionnaire (Ravens-Sieberer, http://www.kindl.org. The widely used instrument provides a generic age-appropriate core-measure (24 items) and a diabetes-specific module (21 items).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Diabetes burden (main carer)\n[ Time Frame: 6 months ]\n\n\n\nThe main carer (parent) will report on the Overall Diabetes Burden using a one-dimensional 5-point intensity scale which was used in the pilot-study and showed sensitivity to change.\n\nComment: Two primary measures are used because independent information from the child (patient) and the main carer is requested""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life (patient)\n[ Time Frame: 6 months ]\n\nChild's HRQOL will be measured using the well-known standardized KINDL-R modular QOL questionnaire (Ravens-Sieberer, http://www.kindl.org. The widely used instrument provides a generic age-appropriate core-measure (24 items) and a diabetes-specific module (21 items).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Diabetes burden (main carer)\n[ Time Frame: 6 months ]\n\n\n\nThe main carer (parent) will report on the Overall Diabetes Burden using a one-dimensional 5-point intensity scale which was used in the pilot-study and showed sensitivity to change.\n\nComment: Two primary measures are used because independent information from the child (patient) and the main carer is requested""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life (HRQOL) (patient)\n[ Time Frame: 6 months ]\n\nChild's HRQOL will be measured using the well-known standardized KINDL-R (KINDL) modular questionnaire. The widely used instrument provides a generic age-appropriate core-measure (24 items) and a diabetes-specific module (21 items).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Diabetes burden (main carer)\n[ Time Frame: 6 months ]\n\n\n\nThe main carer (parent) will report on the Overall Diabetes Burden using a one-dimensional 5-point intensity scale which was used in the pilot-study and showed sensitivity to change.\n\nComment: Two primary measures are used because independent information from the child (patient) and the main carer is requested""}]	NA	NA
NCT01345630	Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1	Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment	10.1097/qad.0000000000001058	NA	40	2011-04-28	Not yet recruiting	Terminated	2011-09-01	2013-09-01	2016-05-15	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of patients with plasma HIV 1 RNA <50 copies/mL at Week 48.\n[ Time Frame: Week 48 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects with plasma HIV 1 RNA <50 copies/mL at Week 48.\n[ Time Frame: Week 48 ]\n\nNumber of subjects who meet the primary endpoint.""}]	[See Results Section.]	NA	NA
NCT01355835	Combined STN/SNr-DBS for the Treatment of Refractory Gait Disorders in Parkinson's Disease	Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson's disease	10.1007/s00415-011-5906-3	NA	4	2011-05-17	Recruiting	Completed	2011-02-01	2012-08-01	2011-02-02	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Gait score\n[ Time Frame: Three weeks after active treatment (STN vs. STN+SNr), respectively ]\n\nThe 'gait score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'gait score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""'Axial score'\n[ Time Frame: Three weeks after active treatment (STN vs. STN+SNr), respectively ]\n\n\n\nThe composite 'axial score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'axial score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.\n\nSafety: falls""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""'Axial score'\n[ Time Frame: Three weeks after active treatment (STN vs. STN+SNr), respectively ]\n\n\n\nThe composite 'axial score' is built by 8 items from the UPDRS II and III, all 5-point rated (0 to 4) representing increasing levels of pathology. The 'axial score' will be scored by the sum of the ratings across the 8 items (Range 0 to 32). As change in UPDRS scores is a common primary efficacy outcome measure in Parkinson's disease and only items of the original UPDRS are required for the definition of the primary endpoint, the statistical evaluation methods should be based on the psychometric validation of the UPDRS and no own validation studies are necessary.\n\nSafety: falls""}]	NA
NCT01357980	Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis	Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study	10.1002/nau.22954	http://onlinelibrary.wiley.com/doi/10.1002/nau.22954/full	16	2011-05-20	Not yet recruiting	Completed	2011-05-01	2013-03-01	2017-02-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean change from baseline in daily incontinence episode frequency\n[ Time Frame: Day 84 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean change from baseline in daily incontinence episode frequency\n[ Time Frame: Day 84 ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01360554	ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial	10.1016/s1470-2045(14)70452-8	NA	54	2011-05-24	Not yet recruiting	Completed	2011-06-01	2013-08-01	2014-10-15	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival per Independent Radiologic review in two co-primary populations.\n[ Time Frame: 10 months after anticipated LSLV ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival per Independent Radiologic review in two co-primary populations.\n[ Time Frame: 10 months after anticipated LSLV ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival per Independent Radiologic review in two co-primary populations.\n[ Time Frame: 10 months after anticipated LSLV ]""}]	[See Results Section.]	NA
NCT01360840	EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer	Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer	10.1158/1078-0432.ccr-15-2512	https://www.ncbi.nlm.nih.gov/pubmed/?term=NCT01360840	12	2011-05-25	Recruiting	Completed	2011-04-01	2014-09-01	2016-02-02	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: anticipated average time frame of 2 years ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical anti-tumor activity assessed as progression free survival (PFS)\n[ Time Frame: up to 3 months after last subject randomized ]""}]	[See Results Section.]	NA	NA
NCT01368471	Safety and Efficacy Study of MGuard Stent After a Heart Attack	Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial	10.1016/j.jacc.2012.09.004	NA	5	2011-06-07	Recruiting	Completed	2011-06-01	2012-06-01	2012-11-06	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST resolution) measured 60 to 90 minutes after the last angiogram.\n[ Time Frame: 60-90 minutes post-procedure ]\n\nWe will measure the incidence of complete ST segment resolution (defined as ≥70% ST resolution on an EKG) measured 60 to 90 minutes after the last angiogram.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution\n[ Time Frame: 60 to 90 minutes after the last angiogram ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution\n[ Time Frame: 60 to 90 minutes after the last angiogram ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The incidence of complete ST segment resolution (defined as ≥70% ST 1. The incidence of complete ST segment resolution\n[ Time Frame: 60 to 90 minutes after the last angiogram ]""}]	NA
NCT01370863	An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients	Randomized clinical trial: effect of the 5-HT4 receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment	10.1111/nmo.12484	http://onlinelibrary.wiley.com/doi/10.1111/nmo.12484/abstract	8	2011-06-09	Recruiting	Terminated	2010-12-01	2012-06-01	2014-12-21	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24-h pH/MII monitoring (pre- and post- treatment)\n[ Time Frame: 4 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""24-h pH/MII monitoring (pre- and post- treatment)\n[ Time Frame: 4 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01384058	Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes	Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus	10.1016/j.atherosclerosis.2011.10.043	http://www.sciencedirect.com/science/article/pii/S0021915011010677?via%3Dihub	3	2011-06-27	Completed	Completed	2007-11-01	2010-05-01	2011-11-09	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the Concentration of apoB in dLDL from baseline with ezetimibe, simvastatin or the combination of both drugs\n[ Time Frame: 12 weeks ]\n\nmulticentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the Concentration of Apolipoprotein B (ApoB) in dense Low Density Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs\n[ Time Frame: 12 weeks ]\n\nmulticentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of the concentration of apolipoprotein B (ApoB) in dense Low Densitiy Lipoprotein (dLDL) from baseline with ezetimibe, simvastatin or the combination of both drugs\n[ Time Frame: baseline and 6 weeks ]\n\nmulticentre, randomized, open-label study investigation in 6-week effect of ezetimibe (10mg/d), simvastatin (20mg/d) or combination of ezetimibe 10mg/simvastatin 20mg/d on concentrations of dLDL separated by preparative gradient ultracentrifugation in patients with type 2 diabetes.""}]	NA
NCT01387048	Study for Long-term Treatment of Acne Vulgaris With Skinoren Versus Differin	A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne	10.1111/jdv.12823	NA	3	2011-07-01	Not yet recruiting	Completed	2011-08-01	2012-08-01	2014-11-14	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Superiority of Skinoren 15% Gel\n[ Time Frame: 36 weeks ]\n\nSuperiority of Skinoren 15% Gel-group over the observational group in the maintanance phase. Change of Global Severity Grades (ISGA and Leeds)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel\n[ Time Frame: 36 weeks ]\n\nNon-inferiority of Skinoren 15% Gel over the current \""gold standard\"" Differin 0.1% gel in the long-term-treatment period: Change of Global severity grades""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Superiority of Skinoren 15% Gel\n[ Time Frame: 36 weeks ]\n\nSuperiority of Skinoren 15% Gel-group over the observational group in the maintanance phase. Change of Global Severity Grades (ISGA and Leeds)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel\n[ Time Frame: 36 weeks ]\n\nNon-inferiority of Skinoren 15% Gel over the current \""gold standard\"" Differin 0.1% gel in the long-term-treatment period: Change of Global severity grades""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Superiority of Skinoren 15% Gel\n[ Time Frame: 36 weeks ]\n\nSuperiority of Skinoren 15% Gel-group over the observational group in the maintanance phase. Change of Global Severity Grades (ISGA and Leeds)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Non-inferiority of Skinoren 15 % gel over the Differin 0.1% gel\n[ Time Frame: 36 weeks ]\n\nNon-inferiority of Skinoren 15% Gel over the current \""gold standard\"" Differin 0.1% gel in the long-term-treatment period: Change of Global severity grades""}]	NA	NA
NCT01389856	Persistent Pulmonary Hypertension of the Newborn	Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial	10.1016/j.jpeds.2016.06.078	https://www.ncbi.nlm.nih.gov/pubmed/27502103?dopt=Abstract	14	2011-07-07	Not yet recruiting	Terminated	2011-09-01	2013-12-01	2016-08-05	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with treatment failure\n[ Time Frame: From baseline to up to 14 days ]\n\n\n\nExploratory Endpoint:\n\nProportion of patients with treatment failure:\n\nNeed for extra corporeal membrane oxygenation (ECMO) or\nInitiation of alternative pulmonary vasodilator""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of patients with treatment failure\n[ Time Frame: From baseline to up to 14 days ]\n\n\n\nExploratory Endpoint:\n\nProportion of patients with treatment failure:\n\nNeed for extra corporeal membrane oxygenation (ECMO) or\nInitiation of alternative pulmonary vasodilator""}]	[See Results Section.]	NA	NA
NCT01394692	Comparative Study of Intraoperative MRI-guided vs. Conventional Glioma Surgery	Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial	10.1016/s1470-2045(11)70196-6	https://linkinghub.elsevier.com/retrieve/pii/S1470-2045(11)70196-6	2	2011-07-13	Completed	Completed	2007-10-01	2010-07-01	2011-08-23	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of Resection\n[ Time Frame: 72 hours ]\n\nThe extent of resection following surgery of a contrast-enhancing glioma according to postoperative high-field MRI within 72 hours""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Extent of Resection\n[ Time Frame: 72 hours ]\n\nThe extent of resection following surgery of a contrast-enhancing glioma according to postoperative high-field MRI within 72 hours""}]	[See Results Section.]	NA
NCT01401283	GDT by Cardiac Index Trending Via a Radial Arterial Line in General Surgery	Perioperative goal-directed hemodynamic therapy based on radial arterial pulse pressure variation and continuous cardiac index trending reduces postoperative complications after major abdominal surgery: a multi-center, prospective, randomized study	10.1186/cc12885	https://ccforum.biomedcentral.com/articles/10.1186/cc12885	5	2011-07-22	Not yet recruiting	Completed	2011-07-01	2012-06-01	2013-09-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hospital stay hospital stay\n[ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days ]\n\nlength of stay in the postoperative care unit length of hospital stay""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hospital stay hospital stay\n[ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days ]\n\nlength of stay in the postoperative care unit length of hospital stay""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""postoperative complications\n[ Time Frame: Participants will be followed from end of surgery for the duration of stay in the recovery room, for the duration of the complete hospital stay, an expected average of ten 10 days ]\n\nCategories of postoperative complications: Infection (respiratory, abdominal, UTI, wound), Respiratory (prolonged need for ventilation), Cardiovascular (edema, arrythmia, hypotension, AMI, stroke), Abdominal (constipation), Renal (urine output <500ml/d, ARF)""}]	[See Results Section.]	NA
NCT01405313	Modified Adaptive Servoventilation (ASV) Compared to Conventional ASV	Performance of conventional and enhanced adaptive servoventilation (ASV) in heart failure patients with central sleep apnea who have adapted to conventional ASV	10.1007/s11325-014-1083-9	https://www.ncbi.nlm.nih.gov/pubmed/25413958?dopt=Abstract	4	2011-07-28	Recruiting	Completed	2011-07-01	2011-09-01	2014-11-21	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""AHI\n[ Time Frame: Two nights ]\n\nPhysiological sleep signals including SpO2, respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apnea/hypopnea index (AHI)\n[ Time Frame: Two nights ]\n\nPhysiological sleep signals including pulse oximetry (SpO2), respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Apnea/hypopnea index (AHI)\n[ Time Frame: Two nights ]\n\nPhysiological sleep signals including pulse oximetry (SpO2), respiratory effort and nasal flow, will be recorded, analysed and reported in the form of an index per hour of sleep.""}]	[See Results Section.]	NA
NCT01409330	German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET)	Low-energy diets differing in fibre, red meat and coffee intake equally improve insulin sensitivity in type 2 diabetes: a randomised feasibility trial	10.1007/s00125-014-3457-8	NA	6	2011-08-03	Recruiting	Unknown status	2011-02-01	NA	2014-11-26	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""whole body insulin sensitivity\n[ Time Frame: 1 year ]\n\nmeasurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""whole body insulin sensitivity\n[ Time Frame: 8 weeks ]\n\nmeasurement of whole body insulin sensitivity with hyperinsulinamic euglicamic clamp""}]
NCT01412320	Cocoa Flavanols in Renal Disease	Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis	10.1371/journal.pone.0140215	https://www.ncbi.nlm.nih.gov/pubmed/26485680	4	2011-08-08	Recruiting	Completed	2011-08-01	2012-12-01	2015-10-20	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""An improvement of endothelial function as measured by flow-mediated dilation (FMD)\n[ Time Frame: 30 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The effect of flavanols on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.\n[ Time Frame: 30 days ]\n\nTo study the effect of flavanols on flow mediated dilation of the brachial artery after 5 minutes of forearm ischemia and reperfusion in patients with ESRD""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The effect of flavanols on endothelial function as measured by flow-mediated dilation (FMD) after forearm ischemia and reperfusion.\n[ Time Frame: 30 days ]\n\nTo study the effect of flavanols on flow mediated dilation of the brachial artery after 5 minutes of forearm ischemia and reperfusion in patients with ESRD""}]	NA	NA
NCT01417312	Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients	Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial	10.3945/ajcn.113.075309	https://www.ncbi.nlm.nih.gov/pubmed/25733633	12	2011-08-15	Recruiting	Completed	2011-07-01	2012-10-01	2015-01-14	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Systemic lipid oxidation\n[ Time Frame: Three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo\n[ Time Frame: Three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo\n[ Time Frame: Three months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Fasting and postprandial lipid oxidation in grams per hour, assessed by indirect calorimetry, after 3 months intake of green tea extract versus placebo\n[ Time Frame: Three months ]""}]	NA
NCT01418053	The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome	Efficacy of Caraway Oil Poultices in Treating Irritable Bowel Syndrome--A Randomized Controlled Cross-Over Trial	10.1159/000398790	https://www.ncbi.nlm.nih.gov/pubmed/26044145?dopt=Abstract	7	2011-08-15	Not yet recruiting	Completed	2011-08-01	2013-09-01	2015-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptome Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptom Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptom Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Irritable Bowel Syndrome - Symptom Severity Score\n[ Time Frame: at T2 (Day 21) ]\n\nIBS-SSS (Francis 1997)""}]	NA
NCT01420744	Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study)	10.1007/s00134-018-5143-7	https://pubmed.ncbi.nlm.nih.gov/29632995/	5	2011-08-19	Recruiting	Completed	2011-08-01	2015-02-01	2018-04-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator Free Days\n[ Time Frame: 28 days ]\n\nVFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator Free Days (VFDs)\n[ Time Frame: 28 days ]\n\nVFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Ventilator Free Days (VFDs)\n[ Time Frame: 28 days ]\n\nVFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.""}]	NA	NA
NCT01425359	Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina	Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)	10.1016/j.jacc.2013.02.011	https://www.ncbi.nlm.nih.gov/pubmed/23500237	10	2011-08-26	Not yet recruiting	Completed	2011-09-01	2013-03-01	2013-03-10	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The average weekly angina frequency over the last 6 weeks of treatment\n[ Time Frame: 6 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The average weekly angina frequency over the last 6 weeks of treatment\n[ Time Frame: 6 weeks ]""}]	NA	[See Results Section.]	NA
NCT01433523	House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma	Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial	10.1001/jama.2016.3964	https://jamanetwork.com/journals/jama/fullarticle/2516714	7	2011-09-13	Recruiting	Completed	2011-08-01	2013-04-01	2016-04-26	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of the risk of an asthma exacerbation.\n[ Time Frame: Measured during the last 4 months of the trial (months 14-18) ]\n\nNumber of asthma exacerbations reported in the IMP treated groups compared to number of asthma exacerbations reported in the placebo group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first moderate or severe asthma exacerbation after ICS reduction\n[ Time Frame: Measured during the last 6 months of the trial ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first moderate or severe asthma exacerbation after ICS reduction\n[ Time Frame: Measured during the last 6 months of the trial ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to first moderate or severe asthma exacerbation after ICS reduction\n[ Time Frame: Measured during the last 6 months of the trial ]""}]	NA
NCT01436162	Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder	Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies	10.1016/j.jad.2016.07.006	NA	48	2011-09-16	Not yet recruiting	Completed	2011-10-01	2013-12-01	2016-07-05	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks\n[ Time Frame: Baseline and up to 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks\n[ Time Frame: Baseline and up to 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01437930	Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients	Benefits of foods supplemented with vegetable oils rich in α-linolenic, stearidonic or docosahexaenoic acid in hypertriglyceridemic subjects: a double-blind, randomized, controlled trail	10.1007/s00394-014-0764-2	https://link.springer.com/article/10.1007%2Fs00394-014-0764-2	5	2011-09-20	Recruiting	Completed	2011-09-01	2012-04-01	2014-09-13	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Blood lipids (total cholesterol, HDL, LDL, TAG)\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG)\n[ Time Frame: 10 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""blood lipids (total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), TAG)\n[ Time Frame: 10 weeks ]""}]	NA	NA
NCT01442376	Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients	Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study	10.1016/s1470-2045(15)00520-3	http://www.sciencedirect.com/science/article/pii/S1470204515005203?via%3Dihub	20	2011-09-27	Recruiting	Completed	2011-09-01	2012-10-01	2016-01-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in proportion of patients with Complete Response (CR) defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 during first cycle\n[ Time Frame: 0 to 24 hours after T0 ]\n\nTime 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in proportion of patients with Complete Response (CR) defined as no vomiting, no retching, and no use of antiemetic rescue medication from 0 to 24 hours (acute phase) after T0 during first cycle\n[ Time Frame: 0 to 24 hours after T0 ]\n\nTime 0 (T0) is defined as the time when the patient starts the first cycle of chemotherapy""}]	[See Results Section.]	NA	NA
NCT01448213	Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)	NA	NA	https://iovs.arvojournals.org/article.aspx?articleid=2272397	8	2011-10-05	Active, not recruiting	Completed	2011-10-01	2014-10-01	2014-04-01	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Incidence of immunologic graft rejection episodes\n[ Time Frame: Within 1 year ]""}]	[See Results Section.]	NA	NA	NA
NCT01450865	Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo	Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial	10.1186/1479-5876-11-34	https://www.ncbi.nlm.nih.gov/pubmed/23394517?dopt=Abstract	3	2011-10-10	Completed	Completed	2009-10-01	2010-07-01	2013-02-08	FALSE	FALSE	TRUE	TRUE	FALSE	NA	TRUE	FALSE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Axonal Excitability as assessed with QTrac\n[ Time Frame: Before and two hours after intervention ]\n\nThe primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Axonal Excitability as assessed with QTrac\n[ Time Frame: Change of neuronal excitability from Baseline (before) to two hours after intervention ]\n\nThe primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Axonal Excitability as assessed with QTrac\n[ Time Frame: Change of neuronal excitability from Baseline (before) to two hours after intervention ]\n\nThe primary outcome parameter of axonal excitability was the relative refractory period (RRP) as assessed with threshold tracking techniques. Strength-duration time constant, rheobase current, refractoriness determined at 2 and 2.5 ms, superexcitability at 7 ms and threshold electrotonus over the 90 100 ms period were used as secondary outcome measures.""}]	NA
NCT01466387	A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: a randomized, open-label, multi-center study	10.1016/j.tmaid.2014.04.011	NA	7	2011-11-07	Not yet recruiting	Completed	2011-11-01	2012-05-01	2014-05-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GMTs/GMCs of antibodies to typhoid Vi polysaccharide and yellow fever virus on Day 29.\n[ Time Frame: 28 Days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GMTs/GMCs of antibodies to Japanese encephalitis and rabies virus on Day 29.\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""GMTs/GMCs of antibodies to typhoid Vi polysaccharide and yellow fever virus on Day 29.\n[ Time Frame: 28 Days ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""GMTs/GMCs of antibodies to Japanese encephalitis and rabies virus on Day 29.\n[ Time Frame: 28 days ]""}]	[See Results Section.]	NA	NA
NCT01470677	Tachosil for the Prevention of Symptomatic Lymph Cysts	A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial	10.1186/1471-2407-14-635	https://pubmed.ncbi.nlm.nih.gov/25175029/	6	2011-11-09	Recruiting	Completed	2011-11-01	2016-01-01	2014-08-30	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""lymph cysts\n[ Time Frame: 4 weeks ]\n\n\n\nPrimary outcome variable:\n\n2.1. To evaluate the incidence of sonographically detected pelvic lymphoceles of at least 2cm in the largest diameter within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""symptomatic lymph cysts\n[ Time Frame: 4 weeks ]\n\n\n\nPrimary outcome variable:\n\n2.1. To evaluate the incidence of symptomatic pelvic lymphoceles defined by CTCAE 4.03 grade >2 within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""symptomatic lymph cysts\n[ Time Frame: 4 weeks ]\n\n\n\nPrimary outcome variable:\n\n2.1. To evaluate the incidence of symptomatic pelvic lymphoceles defined by CTCAE 4.03 grade >2 within 4 weeks after surgery in women undergoing open or laparoscopic pelvic lymphadenectomy for cervical and endometrial cancer with and without the application of Tachosil® during surgery.""}]	NA
NCT01472939	Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)	Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy	10.1111/apt.13115	http://onlinelibrary.wiley.com/doi/10.1111/apt.13115/abstract	12	2011-11-16	Not yet recruiting	Completed	2012-03-01	2013-05-01	2015-02-19	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of regurgitation-free days compared to placebo\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage of regurgitation-free days compared to placebo\n[ Time Frame: 8 weeks ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01474109	Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials	10.1001/jama.2016.5258	https://www.ncbi.nlm.nih.gov/pubmed/27163986?dopt=Abstract	25	2011-11-15	Not yet recruiting	Completed	2011-12-01	2014-04-01	2016-05-10	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cumulative number of digital ulcers up to week 16\n[ Time Frame: Period1: baseline (visit 2) to week 16. Period2: week 16 to end of study (which will occur when the last randomized patient, not prematurely withdrawn, has completed Period 1 and a 30 day safety follow-up period) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cumulative number of digital ulcers up to week 16\n[ Time Frame: Period1: baseline (visit 2) to week 16. Period2: week 16 to end of study (which will occur when the last randomized patient, not prematurely withdrawn, has completed Period 1 and a 30 day safety follow-up period) ]""}]	[See Results Section.]	NA	NA
NCT01475669	Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery	Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy	10.1093/bja/aew169	https://pubmed.ncbi.nlm.nih.gov/27317703/	34	2011-11-17	Not yet recruiting	Completed	2011-12-01	2014-07-01	2017-12-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total units of allogeneic blood products\n[ Time Frame: Up to 24 hours after investigational medicinal product (IMP) administration ]\n\nNumber of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total units of allogeneic blood products\n[ Time Frame: Up to 24 hours after investigational medicinal product (IMP) administration ]\n\nNumber of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Total units of allogeneic blood products\n[ Time Frame: Up to 24 hours after investigational medicinal product (IMP) administration ]\n\nNumber of units administered of all allogeneic blood products combined (fresh frozen plasma, platelets, and red blood cells)""}]	NA	NA
NCT01475838	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients	Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial	10.1016/s1473-3099(14)70782-0	NA	12	2011-11-18	Not yet recruiting	Completed	2011-11-01	2013-12-01	2014-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the FDA snapshot analysis\n[ Time Frame: Week 48 ]""}]	[See Results Section.]	NA
NCT01480362	Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds	Negative pressure wound therapy compared with standard moist wound care on diabetic foot ulcers in real-life clinical practice: results of the German DiaFu-RCT	10.1136/bmjopen-2018-026345	https://bmjopen.bmj.com/content/10/3/e026345	9	2011-11-25	Not yet recruiting	Completed	2011-11-01	2015-02-01	2020-03-24	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound Closure\n[ Time Frame: within a maximum treatment time of 16 weeks ]\n\n\n\nNumber of achieved and confirmed wound closures plus the time until complete wound closure (in days) The wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\n\nThe closure must remain at least for a period of 14 days.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Wound Closure\n[ Time Frame: within a maximum treatment time of 16 weeks ]\n\n\n\nNumber of achieved and confirmed wound closures plus the time until complete wound closure (in days) The wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material.\n\nThe closure must remain at least for a period of 14 days.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of achieved and confirmed wound closures within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time until wound closure within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of achieved and confirmed wound closures within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Time until wound closure within the maximum study treatment time\n[ Time Frame: 16 weeks ]\n\nComplete wound closure is defined as 100% epithelialization; no need for drainage, no need for supportive therapy or a means of assistance and absence of suture material. Wound closure must sustain at least for a period of 14 days and needs to be confirmed within a separate study visit 14 days after the first diagnosis of wound closure.""}]	NA
NCT01490268	Pain Therapy After Elective Cardiac Surgery	Analysis of total and unbound hydromorphone in human plasma by ultrafiltration and LC-MS/MS: application to clinical trial in patients undergoing open heart surgery	10.1016/j.jpba.2012.07.025	NA	3	2011-12-08	Recruiting	Completed	2011-11-01	2012-09-01	2012-07-31	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of sufentanil and hydromorphone\n[ Time Frame: 48 hours ]\n\n28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Numerical Rating Scale for Clinical Pain\n[ Time Frame: 8 hours ]\n\n11 assessements of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of sufentanil and hydromorphone\n[ Time Frame: 48 hours ]\n\n28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Numerical Rating Scale for Clinical Pain\n[ Time Frame: 8 hours ]\n\n11 assessements of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of sufentanil and hydromorphone\n[ Time Frame: 48 hours ]\n\n28 blood samples are taken during the study period of 48 hours postoperatively for characterizing the pharmacokinetics""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Numerical Rating Scale for Clinical Pain\n[ Time Frame: 8 hours ]\n\n11 assessments of patient's pain sensation using Numerical Rating Scale for Clinical Pain during patient-controlled analgesia with target-controlled infusion of hydromorphone 8 hours after extubation for characterizing the analgesic effect""}]	NA
NCT01495702	Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial	10.1016/s1473-3099(14)70796-0	http://www.sciencedirect.com/science/article/pii/S1473309914707960?via%3Dihub	11	2011-12-16	Recruiting	Completed	2011-11-01	2013-12-01	2014-06-05	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48\n[ Time Frame: 48 Weeks ]\n\nThe primary efficacy endpoint is the proportion of subjects who have HIV 1 RNA < 50 copies/mL at Week 48""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the FDA snapshot analysis\n[ Time Frame: Week 48 ]""}]	[See Results Section.]	NA
NCT01510704	Phase II Dose-ranging Study of APD421 in PONV	I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial	10.1093/bja/aet251	https://academic.oup.com/bja/article-lookup/doi/10.1093/bja/aet251	5	2012-01-12	Recruiting	Completed	2012-01-01	2012-04-01	2013-07-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Post-operative nausea or vomiting\n[ Time Frame: 24 hours ]""}]	[See Results Section.]	[See Results Section.]	NA
NCT01519466	Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study	Abstracts of the 50th EASD Annual Meeting, September 15-19, 2014, Vienna, Austria	10.1007/s00125-014-3355-0	https://link.springer.com/article/10.1007/s00125-014-3355-0	8	2012-01-24	Not yet recruiting	Completed	2012-01-01	2012-10-01	2014-08-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in time spent in euglycaemia\n[ Time Frame: Day 1-15 compared with Day 60-74 ]\n\nMasked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study. Analysis will assess the difference between the assessment and baseline phase for the intervention group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in time spent in euglycaemia\n[ Time Frame: Day 1-15 compared with Day 60-74 ]\n\nMasked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study. Analysis will assess the difference between the assessment and baseline phase for the intervention group.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in time spent in euglycaemia\n[ Time Frame: Day 1-15 compared with Day 60-74 ]\n\nMasked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study. Analysis will assess the difference between the assessment and baseline phase for the intervention group.""}]	[See Results Section.]	NA
NCT01523743	Quality of Life Intermittent Catheter Study	A prospective, randomized, crossover, multicenter study comparing quality of life using compact versus standard catheters for intermittent self-catheterization	10.1016/j.juro.2013.04.026	https://www.ncbi.nlm.nih.gov/pubmed/23587630	4	2012-01-30	Recruiting	Completed	2011-11-01	2012-04-01	2013-04-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 6 weeks ]\n\nDifference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 6 weeks ]\n\nDifference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Quality of life\n[ Time Frame: 6 weeks ]\n\nDifference in intermittent self-catheterisation quality of life measure, comparing compact versus standard urinary intermittent catheters""}]	[See Results Section.]	NA
NCT01525667	Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty	Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty	10.1002/jcsm.12316	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204595/	10	2012-02-02	Not yet recruiting	Completed	2012-11-01	2014-03-01	2018-09-19	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Safety\n[ Time Frame: 12 months ]\n\n\nAdverse events\nSafety laboratory values and ECG findings\nImmunological reaction""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Efficacy\n[ Time Frame: 12 months ]\n\n• Function of the GM assessing maximal contraction force""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary Efficacy End-Point\n[ Time Frame: 26 weeks ]\n\nFunction of the GM assessing maximal contraction force""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Primary Safety End-Point\n[ Time Frame: 104 weeks ]\n\nAdverse Event, Laboratory Values, ECG Findings and Immunological Reaction""}]	[See Results Section.]	NA	NA
NCT01530139	Strategies for Personalised Nutrition	Effects of a Web-Based Personalized Intervention on Physical Activity in European Adults: A Randomized Controlled Trial	10.2196/jmir.4660	NA	5	2012-02-08	Not yet recruiting	Completed	2012-08-01	2014-12-01	2015-10-14	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in Dietary Intake at 3 and 6 months\n[ Time Frame: Baseline, month 3 and 6. ]\n\nHabitual (usual) dietary intake will be measured using an on-line version of the EPIC Food Frequency Questionnaire (FFQ). Intakes of nutrients will be computed using a food composition data base which has been augmented with country-specific food composition data. Changes in dietary pattern will be compared between baseline and month 3 and 6 in all participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in Dietary Intake at 3 and 6 months\n[ Time Frame: Baseline, month 3 and 6. ]\n\nHabitual (usual) dietary intake will be measured using an on-line Food Frequency Questionnaire (FFQ). Intakes of nutrients will be computed using a food composition data base which has been augmented with country-specific food composition data. Changes in dietary pattern will be compared between baseline and month 3 and 6 in all participants.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in Dietary Intake at 3 and 6 months\n[ Time Frame: Baseline, month 3 and 6. ]\n\nHabitual (usual) dietary intake will be measured using an on-line Food Frequency Questionnaire (FFQ). Intakes of nutrients will be computed using a food composition data base which has been augmented with country-specific food composition data. Changes in dietary pattern will be compared between baseline and month 3 and 6 in all participants.""}]	NA
NCT01530399	Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery	NA	NA	http://www.themedicinescompany.com/investors/news/medicines-company-discontinues-phase-2b-trial-mdco-2010	6	2012-02-07	Not yet recruiting	Terminated	2012-03-01	2012-11-01	2012-10-04	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Chest tube drainage at 12 hours after surgery\n[ Time Frame: 12 hours post CABG ]\n\nChest tube drainage at 12 hours after surgery""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Chest tube drainage at 12 hours after surgery\n[ Time Frame: 12 hours post CABG ]\n\nChest tube drainage at 12 hours after surgery""}]	NA	[See Results Section.]	NA
NCT01534455	Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)	10.1097/cad.0000000000000722	https://pubmed.ncbi.nlm.nih.gov/30875348/	5	2012-02-13	Not yet recruiting	Terminated	2012-02-01	2015-02-01	2019-04-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Progression (TTP)\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety of the Therapy\n[ Time Frame: 3 years ]\n\nNumber and percent of patients who comply and tolerate the Therapy.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Toxicity of Therapy\n[ Time Frame: 3 years ]\n\nNumber and percent of patients with Adverse Events (any Grade and Grade 3/4).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Progression (TTP)\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety of the Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants who comply and tolerate the Therapy.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Toxicity of Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants with Adverse Events (any Grade and Grade 3/4).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Time to Progression (TTP)\n[ Time Frame: 3 years ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety of the Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants who comply and tolerate the Therapy.""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Toxicity of Therapy\n[ Time Frame: 3 years ]\n\nNumber and percentage of participants with Adverse Events (any Grade and Grade 3/4).""}]	NA	NA
NCT01534962	Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study	10.1016/j.hrthm.2015.01.021	https://www.ncbi.nlm.nih.gov/pubmed/25602175?dopt=Abstract	11	2012-02-16	Recruiting	Completed	2012-01-01	2013-09-01	2015-01-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the efficacy of 3 doses of Ranolazine (low, intermediate and high) versus placebo, given for up to 16 weeks, in maintaining sinus rhythm after successful DCC in patients with non-permanent atrial fibrillation (AFib).\n[ Time Frame: 16 weeks (112 days) ]\n\nTime (median; days) from randomisation (Day 1) to first documented AF recurrence.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of the efficacy of 3 doses of Ranolazine (low, intermediate and high) versus placebo, given for up to 16 weeks, in maintaining sinus rhythm after successful DCC in patients with non-permanent atrial fibrillation (AFib).\n[ Time Frame: 16 weeks (112 days) ]\n\nTime (median; days) from randomisation (Day 1) to first documented AF recurrence.""}]	[See Results Section.]	NA	NA
NCT01538355	A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis	Ketogenic diets attenuate cyclooxygenase and lipoxygenase gene expression in multiple sclerosis	10.1016/j.ebiom.2018.08.057	https://pubmed.ncbi.nlm.nih.gov/30292675/	7	2012-02-23	Recruiting	Completed	2011-12-01	2013-02-01	2018-10-03	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life and tolerability12 subscales with two summary scores physical health und mental health""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Health related quality of life and tolerability\n[ Time Frame: 5 Visits ]\n\n12 subscales with two summary scores physical health und mental health""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Multiple Sclerosis Quality of Life-54 questionnaire: Proof of feasibility at 6 months.\n[ Time Frame: Visit: Baseline, month 1, month 3 and month 6 ]\n\nTwo summary scores: physical health und mental health, 12 subscales and 2 single item scales.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Multiple Sclerosis Quality of Life-54 questionnaire: Proof of feasibility at 6 months.\n[ Time Frame: Visit: Baseline, month 1, month 3 and month 6 ]\n\nTwo summary scores: physical health und mental health, 12 subscales and 2 single item scales.""}]	NA
NCT01539512	A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)	Idelalisib and rituximab in relapsed chronic lymphocytic leukemia	10.1056/nejmoa1315226	https://www.ncbi.nlm.nih.gov/pubmed/24450857	26	2012-02-24	Not yet recruiting	Completed	2012-02-01	2014-02-01	2014-01-22	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression Free Survival\n[ Time Frame: 18 Months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Progression-Free Survival\n[ Time Frame: Baseline to Month 18 ]\n\nProgression-free survival (PFS) is defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause.""}]	NA	[See Results Section.]	NA
NCT01541579	Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial	10.1016/s0140-6736(16)31203-x	https://pubmed.ncbi.nlm.nih.gov/27477896/	11	2012-02-29	Not yet recruiting	Completed	2012-07-01	2016-01-01	2016-07-29	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Absence of collections > 2 cm of the treated perianal fistulas at 24 weeks confirmed by MRI\n[ Time Frame: 24 weeks ]\n\nRemission of perianal fistulising Crohn's disease at week 24 confirmed by MRI, defined as the clinical assessment of closure of all the external openings that were draining at baseline despite gentle finger compression at week 24, confirmed by MRI as absence of collections > 2 cm of the treated perianal fistulas at 24 weeks (central blind assessment).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Combine remission of perianal fistulising Crohn's\n[ Time Frame: 24 weeks ]\n\nCombined Remission of perianal fistulising Crohn's disease defined as the clinical assessment of closure of all treated external openings (EO) that were draining at baseline despite gentle finger compression at week 24, and absence of collections > 2 cm of the treated perianal fistulas confirmed by centrally blinded MRI assessment by week 24.""}]	NA
NCT01577134	Personal Resources of Elderly People With Multimorbidity	Revisiting self-regulatory techniques to promote physical activity in older adults: null-findings from a randomised controlled trial	10.1080/08870446.2016.1185523	http://www.tandfonline.com/doi/full/10.1080/08870446.2016.1185523?scroll=top&needAccess=true	3	2012-04-12	Recruiting	Completed	2012-04-01	2013-08-01	2016-05-24	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity (self-report)\n[ Time Frame: Baseline, 6 weeks, 10 weeks, 8.5 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity\n[ Time Frame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in physical activity\n[ Time Frame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months ]""}]	NA	NA
NCT01578525	Medication Safety of Elderly Patients in Hospital and Ambulatory Setting	Comprehensive pharmaceutical care to prevent drug-related readmissions of dependent-living elderly patients: a randomized controlled trial	10.1186/s12877-018-0814-3	https://pubmed.ncbi.nlm.nih.gov/29898670/	3	2012-04-13	Active, not recruiting	Completed	2012-04-01	2014-04-01	2018-06-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drug-related readmission""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drug-related readmission""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Drug-related readmission\n[ Time Frame: one year after discharge from the cooperating ward ]""}]	NA	NA
NCT01580592	Cold Urticaria Treatment With Xolair	Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial	10.1016/j.jaci.2017.01.043	https://pubmed.ncbi.nlm.nih.gov/28389393/	10	2012-04-18	Recruiting	Completed	2012-04-01	2015-05-01	2017-04-04	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in critical temperature thresholds (CTT) from baseline to day 70 after treatment with omalizumab compared to placebo\n[ Time Frame: day 70 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in critical temperature thresholds (CTT) from baseline to day 70 after treatment with omalizumab compared to placebo\n[ Time Frame: day 70 ]""}]	[See Results Section.]	NA	NA
NCT01586091	Safety Study of Levocetirizine and Fexofenadine	The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers	10.2340/00015555-1490	https://www.ncbi.nlm.nih.gov/pubmed/23147964?dopt=Abstract	2	2012-04-24	Completed	Completed	2011-02-01	2011-11-01	2013-05-01	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal- and flare and itch response\n[ Time Frame: 24 hours per treatment - two visits ]\n\nThe comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg twice daily against histamine induced wheal, flare and itch responses measured at 0 (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal- and flare and itch response\n[ Time Frame: 24 hours per treatment - two visits ]\n\nThe comparative efficacy of levocetirizine 5 mg once daily with that of fexofenadine 60 mg twice daily against histamine induced wheal, flare and itch responses measured at 0 (baseline), 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours.""}]	[See Results Section.]	NA
NCT01600014	Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp	Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study	10.1111/bjd.14222	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.14222	9	2012-05-15	Recruiting	Completed	2012-05-01	2013-12-01	2015-10-15	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of AKs\n[ Time Frame: 8 weeks after randomisation ]\n\nThe complete clearance rates 8 weeks after randomisation will be compared between ingenol mebutate gel, 0.015% and vehicle gel.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of AKs\n[ Time Frame: 8 weeks after randomisation ]\n\nThe complete clearance rates 8 weeks after randomisation will be compared between ingenol mebutate gel, 0.015% and vehicle gel.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete clearance of AKs\n[ Time Frame: 8 weeks after randomisation ]\n\nThe complete clearance rates 8 weeks after randomisation will be compared between ingenol mebutate gel, 0.015% and vehicle gel.""}]	[See Results Section.]	NA
NCT01607099	Sodium Picosulfate Plus Magnesium Citrate Versus Macrogol 4000 in the Bowel Cleansing Procedure: a Comparison of Efficiency and Compatibility	Single-day sodium picosulfate and magnesium citrate versus split-dose polyethylene glycol for bowel cleansing prior to colonoscopy: A prospective randomized endoscopist-blinded trial	10.1111/jgh.13010	NA	4	2012-05-25	Not yet recruiting	Completed	2012-09-01	2014-02-01	2015-05-13	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Valuation \""very distressing\""\n[ Time Frame: Just before colonoscopy up to 4 hours afterwards (0 to aprox 4 hours) ]\n\nPatients will fill in a report in which they rate the stress initated by the bowel cleansing procedure. The level ranges from 1 to 10 points. Valuations from 8 to 10 points will be considered as very distressing.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Valuation \""very distressing\""\n[ Time Frame: Just before colonoscopy up to 4 hours afterwards (0 to aprox 4 hours) ]\n\nPatients will fill in a report in which they rate the stress triggered by the bowel cleansing procedure. The level ranges from 1 to 10 points. Valuations from 8 to 10 points will be considered as very distressing.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Valuation \""very distressing\""\n[ Time Frame: Just before colonoscopy up to 4 hours afterwards (0 to aprox 4 hours) ]\n\nPatients will fill in a report in which they rate the stress triggered by the bowel cleansing procedure. The level ranges from 1 to 10 points. Valuations from 8 to 10 points will be considered as very distressing.""}]	NA	NA
NCT01627015	Safety, Acceptance and Metabolic Effects in Infants Receiving a Novel Low Glycaemic Index follow-on Formula	Effects of a Follow-On Formula Containing Isomaltulose (Palatinose™) on Metabolic Response, Acceptance, Tolerance and Safety in Infants: A Randomized-Controlled Trial	10.1371/journal.pone.0151614	NA	5	2012-06-21	Recruiting	Completed	2012-06-01	2014-04-01	2016-03-17	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""metabolic response\n[ Time Frame: After 4 week intervention period ]\n\nPrimary hypothesis to be tested is: After 4 week intervention period, metabolic response after feeding is significantly different between a follow-on formula containing low glycaemic carbohydrate and a conventional follow-on formula containing higher glycaemic carbohydrates.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""metabolic response\n[ Time Frame: After 4 week intervention period ]\n\nAfter 4 week intervention period, metabolic response after feeding is significantly different between a follow-on formula containing low glycaemic carbohydrate and a conventional follow-on formula containing higher glycaemic carbohydrates.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""metabolic response\n[ Time Frame: After 4 week intervention period ]\n\nAfter 4 week intervention period, metabolic response after feeding is significantly different between a follow-on formula containing low glycaemic carbohydrate and a conventional follow-on formula containing higher glycaemic carbohydrates.""}]	NA	NA
NCT01630434	International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation	Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study	10.1016/s2213-2600(18)30136-x	https://pubmed.ncbi.nlm.nih.gov/29650408/	13	2012-06-26	Withheld	Completed	2011-11-01	2014-08-01	2018-04-09	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	FALSE	NA	recruitment	[]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Primary study endpoint is a composite of patient and graft survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 at 72 hours post-transplantation.\n[ Time Frame: Day 30 after transplantation ]\n\nThis composite is a single outcome measure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of patient survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 within the first 72 hours post-transplantation.\n[ Time Frame: Day 30 after transplantation ]\n\nThis composite is a single outcome measure.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""A composite of patient survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 within the first 72 hours post-transplantation.\n[ Time Frame: Day 30 after transplantation ]\n\nThis composite is a single outcome measure.""}]	NA
NCT01636752	Effectiveness of Internet-based Depression Treatment	Effects of a Psychological Internet Intervention in the Treatment of Mild to Moderate Depressive Symptoms: Results of the EVIDENT Study, a Randomized Controlled Trial	10.1159/000445355	https://pubmed.ncbi.nlm.nih.gov/27230863/	5	2012-07-05	Recruiting	Completed	2012-07-01	2015-03-01	2016-05-27	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PHQ-9\n[ Time Frame: 12 wks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Personal Health Questionnaire (PHQ-9)\n[ Time Frame: 12 wks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Personal Health Questionnaire (PHQ-9)\n[ Time Frame: 12 wks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Personal Health Questionnaire (PHQ-9)\n[ Time Frame: 12 wks ]""}]	NA
NCT01650805	Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial	10.1016/s1470-2045(16)00080-2	http://www.sciencedirect.com/science/article/pii/S1470204516000802?via%3Dihub	33	2012-07-24	Recruiting	Terminated	2012-06-01	2021-06-01	2016-04-12	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Major Molecular response (MMR) rate\n[ Time Frame: 12 months after first dose ]\n\nTo compare the efficacy of ponatinib with imatinib as measured by major molecular response (MMR) rate at 12 months (1 month or cycle = 28 days)""}]	[See Results Section.]	NA	NA	NA
NCT01651780	Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial	10.1016/j.jacc.2015.10.003	https://pubmed.ncbi.nlm.nih.gov/26477635/	11	2012-07-26	Not yet recruiting	Completed	2012-10-01	2015-08-01	2015-10-15	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Major Bleeding\n[ Time Frame: 48h post or discharge ]\n\nMajor bleeding defined as Bleeding Academic Research Consortium (BARC) type ≥3 at 48 hours or hospital discharge whichever occurs first.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Major Bleeding\n[ Time Frame: 48 hours post-procedure or discharge ]\n\nThe primary end point will be major bleeding defined as Bleeding Academic Research Consortium (BARC) type ≥3b at 48 hours or hospital discharge whichever occurs first.""}]	NA	[See Results Section.]	NA
NCT01657305	Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)	Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program	10.1016/j.burns.2017.03.005	https://www.sciencedirect.com/science/article/pii/S0305417917301493	13	2012-08-03	Not yet recruiting	Completed	2012-08-01	2013-08-01	2017-04-08	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intra-individual difference in time to wound closure\n[ Time Frame: 2 to 4 weeks ]\n\nIntra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intra-individual difference in time to wound closure\n[ Time Frame: 2 to 4 weeks ]\n\nIntra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intra-individual difference in time to wound closure\n[ Time Frame: 2 to 4 weeks ]\n\nIntra-individual difference in time to wound closure between wound halves, either treated with Oleogel-S10 and non-adhesive wound dressing or treated with non-adhesive wound dressing alone""}]	[See Results Section.]	NA
NCT01660425	Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Support	Telephone-assisted self-help for parents of children with attention-deficit/hyperactivity disorder who have residual functional impairment despite methylphenidate treatment: a randomized controlled trial	10.1111/jcpp.12661	https://pubmed.ncbi.nlm.nih.gov/27878809/	5	2012-08-07	Recruiting	Unknown status	2012-05-01	NA	2016-11-23	FALSE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Weiss Functional Impairment Rating Scale (WFIRS-P), parent rating\n[ Time Frame: beginning, six months, 12 months; 16 months (control group) ]\n\nThe WFIRS-P is used for the assessment of psychosocial functioning of children diagnosed with ADHD.""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in Weiss Functional Impairment Rating Scale (WFIRS-P), parent rating\n[ Time Frame: baseline, six months, 12 months; 16 months (control group) ]\n\nThe WFIRS-P is used for the assessment of psychosocial functioning of children diagnosed with ADHD.""}]
NCT01663324	rTMS for the Treatment of Chronic Tinnitus: Optimization by Simulation of the Cortical Tinnitus Network	Triple-site rTMS for the treatment of chronic tinnitus: a randomized controlled trial	10.1038/srep22302	https://pubmed.ncbi.nlm.nih.gov/26927363/	6	2012-08-08	Recruiting	Completed	2012-07-01	2014-08-01	2016-03-01	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast Baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel&Hiller (contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel&Hiller (contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of treatment responders (TQ reduction ≥5, contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change of tinnitus severity as measured by the Tinnitus Questionnaire of Goebel&Hiller (contrast baseline versus day 12)\n[ Time Frame: Day 12 ]""}]	NA
NCT01668485	Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation	Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes	10.1007/s00125-013-3120-9	https://link.springer.com/article/10.1007%2Fs00125-013-3120-9	2	2012-08-15	Completed	Completed	2001-11-01	2010-11-01	2014-12-05	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Whole body glucose counterregulation\n[ Time Frame: 6-8 weeks ]\n\nWhole body glucose counterregulation is the difference in glucose infusion rates required to maintain the glycemic goal between the hypoglycemic and euglycemic clamp. Clamps were performed at two time points at least two weeks apart. Participants will be followed for the duration of 6-8 weeks to perform the euglycemic and hypoglycemic clamp tests.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Whole body glucose counterregulation\n[ Time Frame: 6-8 weeks ]\n\nWhole body glucose counterregulation is the difference in glucose infusion rates required to maintain the glycemic goal between the hypoglycemic and euglycemic clamp. Clamps were performed at two time points at least two weeks apart. Participants will be followed for the duration of 6-8 weeks to perform the hypoglycemic and euglycemic clamp tests.""}]	NA	NA
NCT01682720	Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection	Sofosbuvir and ribavirin in HCV genotypes 2 and 3	10.1056/nejmoa1316145	NA	8	2012-09-06	Not yet recruiting	Completed	2012-09-01	2013-10-01	2014-05-04	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy 12 weeks after discontinuation of therapy.\n[ Time Frame: 24 weeks ]\n\nTo determine the efficacy of treatment with GS-7977 + Ribavarin (RBV) compared to treatment with GS-7977 placebo + RBV placebo as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR 12).""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety and tolerability of GS-7977 + RBV.\n[ Time Frame: 12 weeks ]\n\nTo assess the safety and tolerability of GS-7977 + RBV compared to placebo control as measured by review of the accumulated safety data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy 12 weeks after discontinuation of therapy.\n[ Time Frame: 24 weeks ]\n\n•To determine the efficacy of treatment with GS 7977+ ribavirin (RBV) as measured by the proportion of subjects with sustained viral response 12 weeks after discontinuation of therapy (SVR12)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Safety and tolerability of GS-7977 + RBV.\n[ Time Frame: 12 weeks ]\n\n•To assess the safety and tolerability of GS-7977+RBV as measured by review of the accumulated safety data.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)\n[ Time Frame: Posttreatment Week 12 ]\n\nSVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Any adverse events leading to permanent discontinuation of study drug(s)\n[ Time Frame: Up to 24 weeks ]""}]	[See Results Section.]	NA
NCT01690117	German Adaptation of REACH II	Individualized support for informal caregivers of people with dementia - effectiveness of the German adaptation of REACH II	10.1186/s12877-017-0678-y	https://pubmed.ncbi.nlm.nih.gov/29233097/	3	2012-09-20	Not yet recruiting	Completed	2012-10-01	2015-01-01	2017-12-12	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Zarit Caregiver Burden Interview (ZBI)\n[ Time Frame: 9 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Zarit Caregiver Burden Interview (ZBI)\n[ Time Frame: 9 months ]""}]	[See Results Section.]	NA	NA
NCT01701479	Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)	NA	10.1200/jco.2016.34.15_suppl.10562	http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.10562	4	2012-10-03	Recruiting	Active, not recruiting	2010-11-01	2020-12-01	2016-05-01	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy endpoint\n[ Time Frame: day 15 of first cycle ]\n\n\n\nOn day 15 of the first cycle in ≥ 80% of patients:\n\nan increase of 500% and/or an absolute minimum increase to ≥100 cells/mcLof the CD16/CD56 positive activated NK cells, AND\na measurable ch14.18/CHO level of at least 1 µg/ml.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Pain-toxicity endpoint\n[ Time Frame: Day 5 of ch14.18/CHO infusion cycle 1 ]\n\ni.v. morphine free ch14.18/CHO infusion schedule after the first 5 days during the first cycle in >= 80% of patients""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: through study completion, an average of 1 year ]\n\n\n\nThe primary endpoint is event free survival calculated from the date of randomisation. The following will be considered as events:\n\ndisease progression or relapse\ndeath from any cause\nsecond neoplasm""}]	NA	NA	NA
NCT01703273	Low-level Intervention for Adolescents With Extreme Obesity	A Structured, Manual-Based Low-Level Intervention vs. Treatment as Usual Evaluated in a Randomized Controlled Trial for Adolescents with Extreme Obesity - the STEREO Trial	10.1159/000475717	https://pubmed.ncbi.nlm.nih.gov/28787738/	6	2012-10-09	Recruiting	Completed	2012-08-01	2014-12-01	2017-08-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint(tested hirarchically) of a) Compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint(tested hirarchically) of a) Compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint (tested hierarchically) of a) compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Composite primary endpoint (tested hierarchically) of a) compliance rate and b) changes in health related quality of life.\n[ Time Frame: baseline and 6 months ]\n\na) Number of regular participants at 6 months follow up will be divided by number of participants at baseline. b) Changes (randomization - 6 months follow up) in the 37 item DISABKIDS questionnaire will be assessed.""}]	NA
NCT01703819	Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects	Effects of Neurexan ® in an experimental acute stress setting--An explorative double-blind study in healthy volunteers	10.1016/j.lfs.2015.12.058	https://www.ncbi.nlm.nih.gov/pubmed/26772822	4	2012-10-10	Recruiting	Completed	2012-10-01	2013-04-01	2016-01-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[See Results Section.]	NA	NA
NCT01703832	Explorative Open Label Study of Efficacy Profile of Neurexan® in Experimental Acute Stress Setting in Healthy Subjects	Effects of Neurexan ® in an experimental acute stress setting--An explorative double-blind study in healthy volunteers	10.1016/j.lfs.2015.12.058	https://www.ncbi.nlm.nih.gov/pubmed/26772822	5	2012-10-10	Recruiting	Completed	2012-10-01	2013-04-01	2016-01-07	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area under the curve (AUC) of VAS tension values\n[ Time Frame: -210 minutes to +100 minutes ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Area under the curve (AUC) of VAS nervousness values\n[ Time Frame: -210 minutes to +100 minutes ]""}]	[See Results Section.]	NA	NA
NCT01713426	A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment	NA	NA	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738436/	6	2012-10-22	Recruiting	Completed	2012-07-01	2013-09-01	2015-11-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8, without change to background chronic pain medication\n[ Time Frame: Baseline and week 8 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8, without change to background chronic pain medication\n[ Time Frame: Baseline and week 8 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8\n[ Time Frame: Baseline and week 8 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects in each arm who achieve at least 30% decrease in the \""average pain for the past 24 hours\"" Numeric Pain Rating Scale (NPRS) score from baseline to week 8\n[ Time Frame: Baseline and week 8 ]""}]	NA
NCT01716286	Neural Correlates of an Olive Oil Essence	Olive oil aroma extract modulates cerebral blood flow in gustatory brain areas in humans	10.3945/ajcn.113.062679	https://www.ncbi.nlm.nih.gov/pubmed/24025630?dopt=Abstract	2	2012-10-24	Completed	Completed	2012-02-01	2012-03-01	2013-09-11	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in brain activity\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after yoghurt intake ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in brain activity\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after yoghurt intake ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in brain activity (cerebral blood flow change after yogurt intake)\n[ Time Frame: 30 minutes before as well as 30 minutes and 120 minutes after yoghurt intake ]""}]	NA
NCT01719263	Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study	Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial	10.1016/s2213-2600(16)00045-x	https://pubmed.ncbi.nlm.nih.gov/26899390/	10	2012-10-29	Recruiting	Completed	2012-06-01	2015-03-01	2016-02-16	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""change in pulmonary function\n[ Time Frame: Months 1, 3, 6, 12, 24, 36 ]\n\nChange in spirometry and/or lung volume measurements from baseline to months 1,3,6,12,24, and 36""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1-second (FEV1) compared to active comparator\n[ Time Frame: Year 1 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of Life (SGRQ)\n[ Time Frame: Year 1 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Forced expiratory volume in 1-second (FEV1) compared to active comparator\n[ Time Frame: Year 1 ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Quality of Life (SGRQ)\n[ Time Frame: Year 1 ]""}]	NA	NA
NCT01726387	Self-Management for Anxiety, Depression and Somatoform Disorders	Collaborative nurse-led self-management support for primary care patients with anxiety, depressive or somatic symptoms: Cluster-randomised controlled trial (findings of the SMADS study)	10.1016/j.ijnurstu.2016.08.007	https://pubmed.ncbi.nlm.nih.gov/27611093/	15	2012-11-13	Not yet recruiting	Completed	2013-03-01	2015-06-01	2016-08-21	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""General Self-Efficacy Scale (GSE)\n[ Time Frame: Baseline, 8 Weeks, 12 Months ]\n\n\n\nGSE assesses a general sense of perceived self-efficacy. It predicts coping with daily hassles as well as adaptation after experiencing all kinds of stressful life events.\n\nhttp://userpage.fu-berlin.de/%7Ehealth/engscal.htm \""The construct of Perceived Self-Efficacy reflects an optimistic self-belief (Schwarzer, 1992). This is the belief that one can perform a novel or difficult tasks, or cope with adversity -- in various domains of human functioning. Perceived self-efficacy facilitates goal-setting, effort investment, persistence in face of barriers and recovery from setbacks. It can be regarded as a positive resistance resource factor. Ten items are designed to tap this construct. Each item refers to successful coping and implies an internal-stable attribution of success. Perceived self-efficacy is an operative construct, i.e., it is related to subsequent behavior and, therefore, is relevant for clinical practice and behavior change.\""""}]	NA
NCT01728441	Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery	Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients With Femoropopliteal Arterial Disease	10.1016/j.jacc.2018.11.039	https://pubmed.ncbi.nlm.nih.gov/30765033/	6	2012-11-13	Recruiting	Completed	2012-10-01	2014-04-01	2019-02-19	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PSVR\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""TLR\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Peak Systolic Velocity Ratio (PSVR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""target lesion revascularization (TLR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Peak Systolic Velocity Ratio (PSVR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""target lesion revascularization (TLR)\n[ Time Frame: 12 months ]\n\nThe primary outcome will be the one-year primary patency rate (Kaplan-Meier estimate at 12 months).Primary patency is defined as absence of clinically-driven target lesion revascularization (TLR) or binary restenosis. Binary restenosis is defined as a peak systolic velocity ratio (PSVR) > 2.4 as evaluated by duplex ultrasound core laboratory analysis.""}]	NA	NA
NCT01731158	Sequential Therapy in Metastatic Renal Cell Carinoma	Circulating Tumor Cell Composition in Renal Cell Carcinoma	10.1371/journal.pone.0153018	https://pubmed.ncbi.nlm.nih.gov/27101285/	4	2012-11-16	Recruiting	Completed	2012-10-01	2016-05-01	2016-04-21	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PFS rate of 2nd line treatment at 6 months after randomisation\n[ Time Frame: 6 months after randomisation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PFS rate of 2nd line treatment at 6 months after randomisation\n[ Time Frame: 6 months after randomisation ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""PFS rate of 2nd line treatment at 6 months after randomisation\n[ Time Frame: 6 months after randomisation ]\n\nPFS rate""}]	NA
NCT01737034	A Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon	Carbohydrate quality and quantity affect glucose and lipid metabolism during weight regain in healthy men	10.3945/jn.113.179390	http://jn.nutrition.org/content/143/10/1593	2	2012-11-26	Completed	Completed	2011-01-01	2012-08-01	2013-08-14	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon\n[ Time Frame: Body composition measurement after 4 weeks ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon\n[ Time Frame: Body composition measurement after 6 weeks ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in body composition and energy metabolism after 3 weeks of underfeeding and 2 following weeks of refeeding\n[ Time Frame: Body composition measurement after 4 and 6 study weeks ]\n\nBody composition measurement including BODPOD, QMR, BIA Energy Metabolism measurement using indirect calorimetry""}]	NA	NA
NCT01741532	Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)	Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study	10.1016/s1474-4422(19)30142-5	NA	14	2012-12-03	Not yet recruiting	Completed	2012-12-01	2016-09-01	2019-07-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in severity of dystonia (using BAD scale) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: 18 months ]\n\nThe Barry-Albright Dystonia Scale (BAD) will be completed at baseline, months 6, 12 and 18 visits and will be assessed by central raters.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in patient's global impression of condition's improvement (using PGI-I) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: 18 months ]\n\nPatient Global Impression of Improvement (PGI-I) will be completed at months 6, 12 and 18 visits.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in severity of dystonia (using BAD scale) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: Baseline to 18 Months ]\n\nThe Barry-Albright Dystonia Scale (BAD) will be completed at baseline, months 6, 12 and 18 visits and will be assessed by central raters.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in patient's global impression of condition's improvement (using PGI-I) in patients with PKAN treated with deferiprone in comparison to placebo.\n[ Time Frame: Baseline to 18 months ]\n\nPatient Global Impression of Improvement (PGI-I) will be completed at months 6, 12 and 18 visits.""}]	[See Results Section.]	NA	NA
NCT01742468	Intervention With Long-chain n-3 Polyunsaturated Fatty Acids From Microalgae Oil in Patients With Rheumatoid Arthritis	Docosahexaenoic acid in the treatment of rheumatoid arthritis: A double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil	10.1016/j.clnu.2017.02.021	https://www.ncbi.nlm.nih.gov/pubmed/28302406	7	2012-12-04	Recruiting	Completed	2012-09-01	2012-12-01	2017-03-06	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""arachidonic acid/docosahexaenoic acid ratio in plasmal lipids and erythrocyte membranes\n[ Time Frame: 10 weeks ]\n\narachidonic acid is a precursor of eicosanoids (leukotriens 4 series, prostaglandins 2 series) docosahexaenoic acid is a precursor of (resolvins and protectins (pro-resolving)""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sum of tender and swollen joints (68/66), disease activity score DAS 28, ultrasound score US-7\n[ Time Frame: 10 weeks ]\n\nDisease activity parameters""}]	NA	NA
NCT01755143	Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment	MRI scanning in patients with new and existing CapSureFix Novus 5076 pacemaker leads: randomized trial results	10.1016/j.hrthm.2014.12.035	http://www.sciencedirect.com/science/article/pii/S1547527114015537	4	2012-12-18	Not yet recruiting	Completed	2012-12-01	2014-04-01	2014-12-30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication free rate\n[ Time Frame: MRI scan to one month later ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""MRI-related complication free rate\n[ Time Frame: MRI scan to one month later ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in atrial voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Proportion of subjects who experience an increase less than or equal to 0.5V in ventricular voltage thresholds\n[ Time Frame: Pre-MRI/waiting period (9-12 weeks post implant) to one month post-MRI/waiting period ]""}]	NA	[See Results Section.]	NA
NCT01766791	Resistance Exercise, Muscle Mass, Strength and Body Composition	Myocardial adaption to HI(R)T in previously untrained men with a randomized, longitudinal cardiac MR imaging study (Physical adaptions in Untrained on Strength and Heart trial, PUSH-trial)	10.1371/journal.pone.0189204	https://pubmed.ncbi.nlm.nih.gov/29216285/	4	2013-01-10	Recruiting	Completed	2013-01-01	2014-02-01	2017-12-07	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""fat free Cross Sectional Area (CSA) upper leg\n[ Time Frame: change from baseline in fat free Cross Sectional Area at 5 months ]\n\nfat free muscle cross sectional area of the upper leg at midfemur via Quantitative Computed Tomography (QCT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""fat free Cross Sectional Area (CSA) upper leg\n[ Time Frame: change from baseline in fat free Cross Sectional Area at 5 months ]\n\nfat free muscle cross sectional area of the upper leg at mid-femur via Quantitative Computed Tomography (QCT)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""fat free Cross Sectional Area (CSA) upper leg\n[ Time Frame: change from baseline in fat free Cross Sectional Area at 5 months ]\n\nfat free muscle cross sectional area of the upper leg at mid-femur via Quantitative Computed Tomography (QCT)""}]	NA	NA
NCT01769105	Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime	Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial	10.1016/j.jtos.2013.12.001	https://www.ncbi.nlm.nih.gov/pubmed/24725326	5	2013-01-15	Recruiting	Completed	2012-03-01	2013-07-01	2014-01-22	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of dry eye symptoms\n[ Time Frame: after 3 month ]\n\nThe symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of dry eye symptoms\n[ Time Frame: after 3 month ]\n\nThe symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Improvement of dry eye symptoms\n[ Time Frame: after 3 month ]\n\nThe symptoms of dry eyes are measured in our study with the OSDI and the SPEED questionaire. Primary outcome mearure (OSDI)""}]	[See Results Section.]	NA
NCT01785186	Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial	10.1016/s1473-3099(16)30274-2	NA	8	2013-02-04	Not yet recruiting	Completed	2013-04-01	2014-09-01	2016-10-26	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sputum culture conversion (2 negative cultures) using liquid media\n[ Time Frame: 0 - 12 weeks ]\n\nFrom enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sputum culture conversion (2 negative cultures) using liquid media\n[ Time Frame: 0 - 12 weeks ]\n\nFrom enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Sputum culture conversion (2 negative cultures) using liquid media\n[ Time Frame: 0 - 12 weeks ]\n\nFrom enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media.""}]	[See Results Section.]	NA
NCT01797458	European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth	Alternative Caries Management Options for Primary Molars: 2.5-Year Outcomes of a Randomised Clinical Trial	10.1159/000477855	https://pubmed.ncbi.nlm.nih.gov/29258064/	3	2013-02-21	Recruiting	Completed	2011-05-01	2013-12-01	2017-12-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Failure rate of the three treatment arms judged clinically\n[ Time Frame: up to 2 years ]\n\nFailure rate of the three treatment arms judged clinically after 1 and 2 years such as clear caries progression, secondary caries, loss of restoration, reversible pulpitis treated without requiring pulpotomy""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Failure rate of the three treatment arms judged clinically\n[ Time Frame: up to 2 years ]\n\nFailure rate of the three treatment arms judged clinically after 1 and 2 years such as clear caries progression, secondary caries, loss of restoration, reversible pulpitis treated without requiring pulpotomy""}]	[See Results Section.]	NA	NA
NCT01797484	Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia	Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial	10.1177/1074248418784290	https://journals.sagepub.com/doi/10.1177/1074248418784290	6	2013-02-20	Not yet recruiting	Completed	2013-07-01	2015-06-01	2018-06-24	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area of ischemic myocardium/cm² (longitudinal strain, radial/circumferential strain)\n[ Time Frame: 42 days after first dose of Ranolazine ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Area of ischemic myocardium/cm² (longitudinal strain, radial/circumferential strain)\n[ Time Frame: 42 days after first dose of Ranolazine ]""}]	[See Results Section.]	NA	NA
NCT01801280	Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study	10.1111/bcp.12664	https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.12664	3	2013-02-26	Recruiting	Completed	2012-01-01	2013-03-01	2015-04-24	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioavailability of mycophenolic acid (measured by AUC)\n[ Time Frame: Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours. ]\n\n\n\nEvaluation of the bioavailability (as measured by 12h AUC) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with Pantozol®; Myfortic® alone or in combination with Pantozol®.\n\nFor pharmacokinetic and pharmacodynamic parameters 12 samples (before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after oral drug administration) from venous blood will be collected.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Bioavailability of mycophenolic acid (measured by AUC)\n[ Time Frame: Study duration for each patient: 2 months. After 10-14 days of drug intake blood samples for full AUC will be collected and on the next day new treatment starts. Every patient has to visit the study centre four times for approximately 12 hours. ]\n\n\n\nEvaluation of the bioavailability (as measured by 12h AUC) of mycophenolic acid in stable renal transplant patients under immunosuppressive maintenance therapy after application of CellCept® alone or in combination with Pantozol®; Myfortic® alone or in combination with Pantozol®.\n\nFor pharmacokinetic and pharmacodynamic parameters 12 samples (before, 0.5h, 1h, 1.5h, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h after oral drug administration) from venous blood will be collected.""}]	NA	[See Results Section.]	NA
NCT01812291	Evaluation of a Stepped Care Approach to Manage Depression in Diabetes	Assessment of diabetes acceptance can help identify patients with ineffective diabetes self-care and poor diabetes control	10.1111/dme.12553	https://pubmed.ncbi.nlm.nih.gov/25047992/	5	2013-03-14	Recruiting	Completed	2012-02-01	2015-10-01	2014-08-02	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Mood (HAMD)\n[ Time Frame: Baseline, 12 month follow up ]\n\nThe Hamilton Rating Scale for Depression (HAMD) is used to assess levels of depressive mood. The decisive measurement of this primary outcome variable is conducted 12 months after the treatment (12 month follow up). The difference of the HAMD scores between baseline and 12 month follow up is calculated.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Mood - Hamilton Rating Scale for Depression (HAMD)\n[ Time Frame: 12 month ]\n\nMean difference between HAMD scores at baseline and at 12 month follow up""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depressive Mood - Hamilton Rating Scale for Depression (HAMD)\n[ Time Frame: 12 month ]\n\nMean difference between HAMD scores at baseline and at 12 month follow up""}]	NA
NCT01817738	Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer	NA	NA	https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-006314-14/results	7	2013-03-22	Recruiting	Terminated	2012-08-01	2016-09-01	2018-02-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I (Safety Lead-In): Occurence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period\n[ Time Frame: Up to 4 weeks ]\n\n\n\nSafety Lead in Portion:\n\nPatients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.\n[ Time Frame: Overall survival will be assessed during the lifetime of the study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I (Safety Lead-In): Occurrence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period\n[ Time Frame: Up to 4 weeks ]\n\n\n\nSafety Lead in Portion:\n\nPatients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.\n[ Time Frame: Overall survival will be assessed during the lifetime of the study ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I (Safety Lead-In): Occurrence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period\n[ Time Frame: Up to 4 weeks ]\n\n\n\nSafety Lead in Portion:\n\nPatients will receive CV9104 at a starting dose of 1920 µg in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.\n[ Time Frame: Overall survival will be assessed during the lifetime of the study ]""}]	NA	NA
NCT01818115	Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.	A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma	10.1016/j.ophtha.2015.03.031	https://pubmed.ncbi.nlm.nih.gov/25972254/	5	2013-03-25	Active, not recruiting	Completed	2011-01-01	2013-04-01	2015-05-09	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in mean diurnal Intraocular Pressure (IOP) at 12 months following the wash-out of all glaucoma medications.\n[ Time Frame: 12 months ]\n\nA 24 month visit will be conducted to confirm 12 month findings.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction in mean diurnal Intraocular Pressure (IOP) at 12 months following the wash-out of all glaucoma medications.\n[ Time Frame: 12 months ]\n\nA 24 month visit will be conducted to confirm 12 month findings.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in proportion of subjects with 20% reduction in mean diurnal Intraocular Pressure (IOP) at 24 months following the wash-out of all glaucoma medications.\n[ Time Frame: 24 months ]\n\nThe 24 month diurnal IOP will be compared to the baseline value and a % change will be determined for each subject. A 20% drop in diurnal IOP is a successful response to treatment.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Difference in proportion of subjects with 20% reduction in mean diurnal Intraocular Pressure (IOP) at 24 months following the wash-out of all glaucoma medications.\n[ Time Frame: 24 months ]\n\nThe 24 month diurnal IOP will be compared to the baseline value and a % change will be determined for each subject. A 20% drop in diurnal IOP is a successful response to treatment.""}]	NA
NCT01832389	Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage	Impact of Goal-Directed Therapy on Delayed Ischemia After Aneurysmal Subarachnoid Hemorrhage: Randomized Controlled Trial	10.1161/strokeaha.120.029279	NA	4	2013-04-11	Recruiting	Completed	2013-03-01	2015-11-01	2020-07-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of occurred delayed cerebral ischaemia (DCI) per patient\n[ Time Frame: 14 days ]\n\na 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of occurred delayed cerebral ischaemia (DCI) per patient\n[ Time Frame: 14 days ]\n\na 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""number of occurred delayed cerebral ischaemia (DCI) per patient\n[ Time Frame: 14 days ]\n\na 2 point increase in the score of the NIHSS-scale lasting for at least 8 hours or a ≥ 2-point decrease in the Glasgow Coma Scale (GCS) lasting for at least 8 hours (as signs of a new focal neurological deficit); and/or radiologic signs of cerebral infarction in presence of vasospasm. other causes of neurological aggravation (e.g. hydrocephalus, re-bleeding etc) had to be excluded.""}]	NA	NA
NCT01837901	Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa	Transcorneal Electrical Stimulation for Patients With Retinitis Pigmentosa: A Prospective, Randomized, Sham-Controlled Follow-up Study Over 1 Year	10.1167/iovs.16-19906	https://iovs.arvojournals.org/article.aspx?articleid=2599022	3	2013-04-22	Active, not recruiting	Completed	2011-07-01	2013-08-01	2017-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual Field\n[ Time Frame: one year ]\n\nChange in the area measured by kinetic visual field measurement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual Field\n[ Time Frame: one year ]\n\nChange in the area measured by kinetic visual field measurement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Visual Field\n[ Time Frame: one year ]\n\nChange in the area measured by kinetic visual field measurement""}]	[See Results Section.]	NA
NCT01853384	Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers	Baseline factors affecting closure of venous leg ulcers	10.1016/j.jvsv.2017.06.017	https://pubmed.ncbi.nlm.nih.gov/29037354/	10	2013-05-10	Not yet recruiting	Terminated	2013-11-01	2015-12-01	2017-11-01	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with complete wound closure over the treatment period.\n[ Time Frame: 12 Weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Proportion of subjects with complete wound closure over the treatment period.\n[ Time Frame: 12 Weeks ]""}]	[See Results Section.]	NA	NA
NCT01856244	Stability and Balance in Locomotion Through Exercise	Immediate effects of perturbation treadmill training on gait and postural control in patients with Parkinson's disease	10.1016/j.gaitpost.2016.08.020	https://pubmed.ncbi.nlm.nih.gov/27591395/	7	2013-05-16	Not yet recruiting	Completed	2013-06-01	2016-06-01	2016-08-26	TRUE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nBerg Balance Scale (BBS), Postural Sway in the Romberg Test with eyes open and eyes closed for 10 seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nMini - Balance Evaluation Systems Test (Mini - BESTest), Postural Sway in the Romberg Test with eyes open and eyes closed for 30 seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nMini - Balance Evaluation Systems Test (Mini - BESTest), Postural Sway in the Romberg Test with eyes open and eyes closed for 30 seconds""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline Gait Speed\n[ Time Frame: 8 weeks and 20 weeks ]\n\nSelf selected walking speed is assessed on a 10 meter walk distance""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from Baseline Balance\n[ Time Frame: 8 weeks and 20 weeks ]\n\nMini - Balance Evaluation Systems Test (Mini - BESTest), Postural Sway in the Romberg Test with eyes open and eyes closed for 30 seconds""}]	NA
NCT01879878	Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]	Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects-results from the POUDER pilot study	10.1007/s10637-019-00826-z	https://pubmed.ncbi.nlm.nih.gov/31250356/	5	2013-06-17	Not yet recruiting	Unknown status	2013-12-01	NA	2019-06-27	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""feasibility of a randomized controlled trial\n[ Time Frame: one year ]\n\nMain objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Feasibility of a randomized controlled trial\n[ Time Frame: One year ]\n\nMain objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy""}]
NCT01883765	Efficacy of Neurofeedback Training in Adults With ADHD	Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial	10.1016/s2215-0366(17)30291-2	https://www.sciencedirect.com/science/article/pii/S2215036617302912?via%3Dihub	2	2013-06-18	Recruiting	Completed	2013-02-01	2015-12-01	2017-08-09	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in ADHD symptomatology\n[ Time Frame: baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in ADHD symptomatology\n[ Time Frame: baseline, after 2 weeks (pre-treatment), after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes in ADHD symptomatology\n[ Time Frame: pre-treatment, after 8 weeks (mid-treatment), after 15 weeks (post-treatment) and after 6 months (follow-up) ]\n\nConners' Adult ADHD Rating Scale (CAARS) Scores""}]	NA	NA
NCT01885000	Patient-Reported Outcome Of Facial Erythema (PROOF)	Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study	10.1111/jdv.13305	http://onlinelibrary.wiley.com/doi/10.1111/jdv.13305/abstract	8	2013-06-21	Not yet recruiting	Completed	2013-07-01	2013-11-01	2015-09-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in Dermatology Life Quality Index score\n[ Time Frame: baseline and 8 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline in Dermatology Life Quality Index score\n[ Time Frame: baseline and 8 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""satisfaction with the overall study treatment\n[ Time Frame: Day 8 ]""}]	[See Results Section.]	NA
NCT01891864	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis	10.1111/bjd.15152	https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.15152	21	2013-06-28	Recruiting	Completed	2013-06-01	2015-04-01	2016-10-27	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1).\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1).\n[ Time Frame: Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary efficacy variable is the PASI 75 response rate (proportion of patients showing at least a 75% improvement in PASI) after the first 12 weeks of treatment (Treatment Period 1).\n[ Time Frame: Week 12 ]""}]	[See Results Section.]	NA
NCT01900067	Study to Evaluate Safety and Efficacy of Blanket Used to Prevent Anesthesia Induced Hypothermia	Active perioperative patient warming using a self-warming blanket (BARRIER EasyWarm) is superior to passive thermal insulation: a multinational, multicenter, randomized trial	10.1016/j.jclinane.2016.06.030	NA	2	2013-07-15	Completed	Completed	2012-11-01	2013-03-01	2016-06-17	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in the arithmetic mean of core body temperature measurements during the perioperative phase between the interventional treatment group and the control treatment group\n[ Time Frame: temperature measurments during pre,-intra and postoperative period, on average 1-5 hours, depending on the surgical intervention. ]\n\nThe subject's core body temperature at any time point is approximated by the arithmetic mean of three repeated tympanic temperature measurements every 15 minutes during the perioperative period""}]	NA	[See Results Section.]	NA	NA
NCT01923961	Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration	Haemodiafiltration at increased plasma ionic strength for improved protein-bound toxin removal	10.1111/apha.12730	NA	2	2013-08-14	Recruiting	Completed	2013-08-01	2015-03-30	2016-06-22	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of para-cresylsulfate and indoxylsulfate\n[ Time Frame: 4 hours ]\n\nDetermination of performance; calculation of removal ratios, clearances, and mass balances of protein-bound uremic toxins""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Plasma concentrations of para-cresylsulfate and indoxylsulfate\n[ Time Frame: 4 hours ]\n\nDetermination of performance; calculation of removal ratios, clearances, and mass balances of protein-bound uremic toxins""}]	NA	[See Results Section.]	NA
NCT01924962	Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries	A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial	10.1016/j.jcin.2018.05.041	https://www.sciencedirect.com/science/article/pii/S1936879818312111	3	2013-08-16	Recruiting	Completed	2011-08-01	2016-08-14	2018-10-08	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Regional left ventricular function\n[ Time Frame: 9 months ]\n\nimprovement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in regional left ventricular function at 9 months\n[ Time Frame: 9 months ]\n\nImprovement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure. For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Changes from baseline in regional left ventricular function at 9 months\n[ Time Frame: 9 months ]\n\nImprovement of the left ventricular function in the territory of the chronically occluded coronary artery assessed by magnetic resonance imaging before revascularisation and at 9 months post-procedure. For regional left ventricular analysis, wall thickening and systolic inward motion will be determined in 12 segments in all short axis slices by the modified centerline method.""}]	NA	NA
NCT01928433	Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis	Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections	10.1128/aac.02317-17	https://pubmed.ncbi.nlm.nih.gov/29339395/	4	2013-08-20	Recruiting	Completed	2012-12-01	2014-06-01	2018-03-27	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical and microbiological response of patients with cUTI or pyelonephritis.\n[ Time Frame: Day 17 ]\n\n\n\nThe primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).\n\nClinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as Elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group.\n\nThe micro-ITT population is composed of all randomized patients who have a baseline bacterial pathogen on culture of urine or blood that causes UTI against which the investigational drug has antibacterial activity.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Clinical and microbiological response of patients with cUTI or pyelonephritis.\n[ Time Frame: Day 17 ]\n\n\n\nThe primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).\n\nClinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as Elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group.\n\nThe micro-ITT population is composed of all randomized patients who have a baseline bacterial pathogen on culture of urine or blood that causes UTI against which the investigational drug has antibacterial activity.""}]	[See Results Section.]	NA	NA
NCT01928810	Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia	Running for extinction? Aerobic exercise as an augmentation of exposure therapy in panic disorder with agoraphobia	10.1016/j.jpsychires.2018.03.001	https://www.sciencedirect.com/science/article/abs/pii/S0022395617313560	4	2013-08-26	Active, not recruiting	Completed	2011-03-01	2013-10-01	2018-06-01	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Hamilton Rating Scale for Anxiety (CIPS 1995)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nGlobal interviewer rated measure for anxiety and severity indicator of an anxiety disorder""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Mobility Inventory (Chambless 1984)\n[ Time Frame: Change from Baseline to 31 weeks (follow-up) ]\n\nA 27-item inventory for the measurement of self-reported agoraphobic avoidance behavior""}]	NA	NA
NCT01956175	Electrical Pharyngeal Stimulation for Dysphagia Therapy in Tracheostomized Stroke Patients	Electrical pharyngeal stimulation for dysphagia treatment in tracheotomized stroke patients: a randomized controlled trial	10.1007/s00134-015-3897-8	https://pubmed.ncbi.nlm.nih.gov/26077087/	2	2013-10-01	Recruiting	Completed	2013-06-01	2014-08-01	2015-06-13	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Readiness for decannulation\n[ Time Frame: 5 days ]\n\nDifference in readiness for decannulation as assessed by a standardized fiberoptic endoscopic evaluation protocol post-treatment between real and sham treatment groups""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Readiness for decannulation\n[ Time Frame: 5 days ]\n\nDifference in readiness for decannulation as assessed by a standardized fiberoptic endoscopic evaluation protocol post-treatment between real and sham treatment groups""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Readiness for decannulation\n[ Time Frame: 3 days ]\n\nDifference in readiness for decannulation as assessed by a standardized fiberoptic endoscopic evaluation protocol after three days of treatment between real and sham treatment groups""}]	NA	NA
NCT01963793	Topical Aprepitant in Prurigo Patients	Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant	10.2340/00015555-2780	https://pubmed.ncbi.nlm.nih.gov/28853492/	6	2013-10-11	Not yet recruiting	Completed	2013-10-01	2014-07-01	2018-01-12	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""efficacy of topical aprepitant treatment\n[ Time Frame: 4 weeks ]\n\nTo investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""efficacy of topical aprepitant treatment\n[ Time Frame: 4 weeks ]\n\nTo investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""efficacy of topical aprepitant treatment\n[ Time Frame: 4 weeks ]\n\nTo investigate the efficacy of topical treatment with aprepitant on pruritus compared to placebo, after 4 weeks of treatment using VAS (Visual Analogue Score)""}]	[See Results Section.]	NA
NCT01994928	Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High-flow Nasal Cannula Oxygen.	High-Flow Nasal Cannula Versus Bag-Valve-Mask for Preoxygenation Before Intubation in Subjects With Hypoxemic Respiratory Failure	10.4187/respcare.04413	https://pubmed.ncbi.nlm.nih.gov/27274092/	4	2013-11-20	Recruiting	Completed	2013-11-01	2014-11-01	2016-06-07	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean decrease in the saturation of oxygen (SpO2) during intubation.\n[ Time Frame: during intubation ]\n\nMean decrease in the saturation of oxygen measured by pulse oximetry (SpO2 [%]) during intubation.""}]	NA
NCT02002871	Blue Light for Treating Eczema	Prospective, Randomized Study on the Efficacy and Safety of Local UV-Free Blue Light Treatment of Eczema	10.1159/000448000	https://www.karger.com/Article/FullText/448000	5	2013-12-02	Recruiting	Completed	2013-10-01	2014-03-01	2016-08-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the sum score of local Eczema rating of the target area as compared to the control area at end of treatment\n[ Time Frame: at week 4 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the sum score of local Eczema rating of the target area as compared to the control area at end of treatment\n[ Time Frame: at week 4 ]""}]	[See Results Section.]	NA	NA
NCT02004847	Blue Light for Treating Psoriasis Vulgaris	Prospective Randomized Long-Term Study on the Efficacy and Safety of UV-Free Blue Light for Treating Mild Psoriasis Vulgaris	10.1159/000430495	https://pubmed.ncbi.nlm.nih.gov/26044167/	6	2013-12-03	Recruiting	Completed	2013-09-01	2014-04-01	2015-06-02	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PASI of the target area (HI group) as compared to the control area at end of treatment\n[ Time Frame: at week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local Psoriasis area severity index (PASI) of the target area (High Intensity (HI) group) as compared to the control area at end of treatment\n[ Time Frame: at week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local Psoriasis area severity index (PASI) of the target area (High Intensity (HI) group) as compared to the control area at end of treatment\n[ Time Frame: at week 12 ]""}]	[See Results Section.]	NA
NCT02007772	Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients	Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD	10.2147/copd.s206111	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615713/	8	2013-12-06	Recruiting	Completed	2009-11-01	2017-07-01	2019-07-05	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""difference in capillary CO2 carbon dioxide\n[ Time Frame: Baseline, 6 weeks, 12 weeks ]\n\nThe primary endpoint is the difference of the relative decrease of capillary pC02 after the treatment with nasal high-flow compared with the baseline value and the relative decrease of the capillary pCO2 after treatment with BiPAP compared with the baseline value.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""difference in capillary CO2 carbon dioxide\n[ Time Frame: Baseline, 6 weeks, 12 weeks ]\n\nThe primary endpoint is the difference of the capillary pC02 between the treatment with nasal high-flow compared with the baseline value.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""difference in capillary CO2 carbon dioxide\n[ Time Frame: Baseline, 6 weeks, 12 weeks ]\n\nThe primary endpoint is the difference of the capillary pC02 between the treatment with nasal high-flow compared with the baseline value.""}]	NA	NA
NCT02025205	Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study	Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study	10.1164/rccm.201607-1383oc	https://pubmed.ncbi.nlm.nih.gov/27580428/	12	2013-12-27	Not yet recruiting	Completed	2014-08-01	2016-12-01	2016-11-01	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage change in Forced Expiratory Volume in 1 s (FEV1)\n[ Time Frame: At baseline and after 3 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percentage change in Forced Expiratory Volume in 1 s (FEV1)\n[ Time Frame: At baseline and after 3 months ]""}]	NA	[See Results Section.]	NA
NCT02034279	The INFECIR-2 Albumin Prevention Study	Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis	10.1016/j.cgh.2019.07.055	https://pubmed.ncbi.nlm.nih.gov/31394283/	4	2014-01-10	Not yet recruiting	Terminated	2014-05-01	2016-12-31	2019-08-05	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival\n[ Time Frame: 28-day survival ]\n\n28-day survival and in hospital survival (expected average 2 weeks) will be the primary outcome""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival\n[ Time Frame: hospitalization ]\n\nHospital survival will be the primary outcome""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""survival\n[ Time Frame: hospitalization ]\n\nHospital survival will be the primary outcome""}]	NA	NA
NCT02044913	Randomized-controlled Trial of Aftercare-Coordination by Phone for Depression and Anxiety	Effectiveness of telephone-based aftercare case management for adult patients with unipolar depression compared to usual care: A randomized controlled trial	10.1371/journal.pone.0186967	https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0186967	5	2014-01-22	Recruiting	Completed	2013-12-01	2015-06-01	2017-10-27	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure of the symptom severity - Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI)\n[ Time Frame: Change in the BDI and BAI from baseline (beginning of inpatient treatment) to follow up (6 months after termination of the intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure of the symptom severity - Beck Depression Inventory (BDI)\n[ Time Frame: Change in the BDI from the beginning of the intervention to follow up (6 months after termination of the intervention) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Measure of the symptom severity - Beck Depression Inventory (BDI)\n[ Time Frame: Change in the BDI from the beginning of the intervention to follow up (6 months after termination of the intervention) ]""}]	NA	NA
NCT02051660	German Evaluation of the Effectiveness of the Psychological Intervention Managing Cancer and Living Meaningfully (CALM)	Spiritual well-being mediates the association between attachment insecurity and psychological distress in advanced cancer patients	10.1007/s00520-019-04744-x	https://pubmed.ncbi.nlm.nih.gov/30887126/	6	2014-01-29	Recruiting	Completed	2013-03-01	2017-06-01	2019-03-18	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Patient Health Questionnaire-9 (PHQ-9)\n[ Time Frame: 6-months ]\n\nA reliable and valid 9-item measure of depression.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depression module of the Patient Health Questionnaire (PHQ-9)\n[ Time Frame: 6-months ]\n\nA reliable and valid 9-item measure of depression.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Beck Depression-Inventory II (BDI-II)\n[ Time Frame: 6-months ]\n\nA reliable and valid 21-item self-report instrument for evaluating the severity of depression.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Depression module of the Patient Health Questionnaire (PHQ-9)\n[ Time Frame: 6-months ]\n\nA reliable and valid 9-item measure of depression.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Beck Depression-Inventory II (BDI-II)\n[ Time Frame: 6-months ]\n\nA reliable and valid 21-item self-report instrument for evaluating the severity of depression.""}]	NA
NCT02052960	CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer	NA	10.1200/jco.2018.36.5_suppl.61	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.5_suppl.61	10	2014-01-31	Not yet recruiting	Completed	2014-01-01	2017-07-01	2018-02-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy of CetuGEX™ in terms of progression-free survival\n[ Time Frame: up to 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""To evaluate the efficacy of CetuGEX™ in terms of progression-free survival\n[ Time Frame: up to 24 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of CetuGEX™ (Tomuzotuximab) as compared to Cetuximab in terms of progression-free survival\n[ Time Frame: up to 24 months ]\n\nThe primary objective of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with platinum-based chemotherapy) in terms of PFS""}]	[See Results Section.]	NA
NCT02076646	A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma	NA	10.1007/s00262-019-02383-z	https://link.springer.com/article/10.1007/s00262-019-02383-z#citeas	4	2014-02-26	Recruiting	Unknown status	2013-10-01	2016-10-01	2019-09-03	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: Establish the maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2\n[ Time Frame: 21 days ]\n\nEstablish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: evaluation of the antitumor activity\n[ Time Frame: 36 months ]\n\nevaluation of the best objective response rate (BORR)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: Establish the maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2\n[ Time Frame: 21 days ]\n\nEstablish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: evaluation of the antitumor activity\n[ Time Frame: 36 months ]\n\nevaluation of the best objective response rate (BORR)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Phase I: maximum tolerated dose (MTD) and recommended dose (RD) of L19IL2\n[ Time Frame: From day 1 to day 21 of Cycle 1 (each cycle is 21-days) ]\n\nEstablish the MTD and the RD of L19IL2 (in combination with dacarbazine) to be used for phase II study""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Phase II: best objective response rate (BORR)\n[ Time Frame: Up to 1 year ]\n\nEvaluation of antitumor activity""}]	NA	NA
NCT02079311	Evaluation of Core Body Temperature When Using Forced Air Warming or an Active Blanket to Prevent Perioperative Hypothermia	Active perioperative patient warming using a self-warming blanket (BARRIER EasyWarm) is superior to passive thermal insulation: a multinational, multicenter, randomized trial	10.1016/j.jclinane.2016.06.030	https://www.sciencedirect.com/science/article/pii/S0952818016303051	3	2014-03-04	Recruiting	Completed	2014-01-01	2014-04-01	2016-07-17	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in core body temperature in the two treatment groups.\n[ Time Frame: Subjects will be followed for one day of hospital stay, data to be collected during the perioperative phase. Expected to be between 5-8 hours. ]\n\nTemperature assessments will be made using an oesophageal temperature probe when the subject is under general anaesthesia and by oral thermometer for all other temperature assessments performed in pre-, intra- and post-op.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The difference in core body temperature in the two treatment groups.\n[ Time Frame: Subjects will be followed for one day of hospital stay, data to be collected during the perioperative phase. Expected to be between 5-8 hours. ]\n\nTemperature assessments will be made using an oesophageal temperature probe when the subject is under general anaesthesia and by oral thermometer for all other temperature assessments performed in pre-, intra- and post-op.""}]	[See Results Section.]	NA	NA
NCT02096562	Knee Swelling Under Use of Compression Stockings After Outpatient Surgery	NA	10.1186/s12891-019-2540-1	https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-019-2540-1	4	2014-03-23	Recruiting	Completed	2013-07-01	2015-03-01	2019-04-09	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of Swelling (circumference and volume)\n[ Time Frame: 10 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of Swelling of lower Extremity (circumference in mm and volume in ml)\n[ Time Frame: 10 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Amount of Swelling of lower Extremity (circumference in mm and volume in ml)\n[ Time Frame: 10 days ]""}]	NA	NA
NCT02102919	Innovative Training Program for Elderly in Need of Care Individuals	Sensory-motor training targeting motor dysfunction and muscle weakness in long-term care elderly combined with motivational strategies: a single blind randomized controlled study	10.1186/s11556-016-0164-0	https://pubmed.ncbi.nlm.nih.gov/27239241/	6	2014-03-31	Recruiting	Completed	2013-01-01	2015-01-01	2016-05-28	FALSE	TRUE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical functional performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Physical performance\n[ Time Frame: after 8 weeks ]\n\nShort physical performance battery (SPBB): The SPBB examines 3 areas of lower extremity function: standing balance (semi-tandem stand, side-by-side stand, full tandem stand), usual walking speed and ability to stand from a chair. These areas represent essential tasks important for independent living.""}]	NA
NCT02126852	Comparison of AMG and EMG to Avoid Residual Paralysis After General Anesthesia	NA	NA	https://mediatum.ub.tum.de/1304544	3	2014-04-28	Recruiting	Completed	2014-04-01	2016-04-01	2017-09-04	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Comparison of TOF-ratios obtained with acceleromyography and electromyography\n[ Time Frame: during surgery (2 hours) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""This study evaluates the precision and agreement of TOF-ratios obtained with acceleromyography and electromyography during residual neuromuscular paralysis\n[ Time Frame: during surgery (2 hours) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""This study evaluates the precision and agreement of TOF-ratios obtained with acceleromyography and electromyography during residual neuromuscular paralysis\n[ Time Frame: during surgery (2 hours) ]""}]	NA	NA
NCT02148770	The Effect of Neurofeedback on Eating Behaviour	Volitional regulation of brain responses to food stimuli in overweight and obese subjects: A real-time fMRI feedback study	10.1016/j.appet.2017.01.032	https://www.sciencedirect.com/science/article/abs/pii/S0195666316305220?via%3Dihub	3	2014-05-27	Not yet recruiting	Unknown status	2014-11-01	NA	2017-01-25	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	NA	TRUE	unknown	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Functional Connectivity\n[ Time Frame: 3 weeks ]\n\nDifference in functional connectivity between the ventral medial prefrontal cortex and the dorsal lateral prefrontal cortex before and after the training sessions during food choice task inside the scanner""}]	NA	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Activity in the dlPFC during the training-session\n[ Time Frame: 1 day ]\n\nDifferences in dlPFC activity between baseline and after up-regulation during the neurofeedback training session, as well as the difference between the treatment and the sham groups (ANCOVA approach).""}]
NCT02148835	Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals	Bioavailability of Dietary Omega-3 Fatty Acids Added to a Variety of Sausages in Healthy Individuals	10.3390/nu9060629	NA	3	2014-05-23	Recruiting	Completed	2014-05-01	2014-12-01	2017-06-19	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in HS-Omega-3 Index\n[ Time Frame: 8 weeks ]\n\nThe HS-Omega-3 Index is the percentage of EPA+DHA in erythrocytes, as assessed with a highly standardized analytical procedure. Since the HS-Omega-3 Index correlates with tissue EPA+DHA, it represents an individual's status in EPA+DHA.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in HS-Omega-3 Index\n[ Time Frame: 8 weeks ]\n\nThe HS-Omega-3 Index is the percentage of EPA+DHA in erythrocytes, as assessed with a highly standardized analytical procedure. Since the HS-Omega-3 Index correlates with tissue EPA+DHA, it represents an individual's status in EPA+DHA.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in HS-Omega-3 Index\n[ Time Frame: 8 weeks ]\n\nThe HS-Omega-3 Index is the percentage of EPA+DHA in erythrocytes, as assessed with a highly standardized analytical procedure. Since the HS-Omega-3 Index correlates with tissue EPA+DHA, it represents an individual's status in EPA+DHA.""}]	[See Results Section.]	NA
NCT02169115	Urticaria Facticia Treatment With Omalizumab (UFO)	Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial	10.1016/j.jaci.2017.01.042	https://pubmed.ncbi.nlm.nih.gov/28389391/	5	2014-06-18	Recruiting	Completed	2012-12-01	2014-12-01	2017-04-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in provocation thresholds from baseline to day 70 in urticaria factitia patients after treatment with omalizumab compared to placebo\n[ Time Frame: 70 days ]\n\nPatients receive provocation test by FricTest (standardized stroking of the skin). The development of wheals within 30 minutes after provocation is monitored.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in provocation thresholds from baseline to day 70 in urticaria factitia patients after treatment with omalizumab compared to placebo\n[ Time Frame: 70 days ]\n\nPatients receive provocation test by FricTest (standardized stroking of the skin). The development of wheals within 30 minutes after provocation is monitored.""}]	[See Results Section.]	[See Results Section.]	NA
NCT02175953	Short-term Caregiver Psychotherapy	NA	10.1007/s00391-018-01501-3	https://link.springer.com/article/10.1007/s00391-018-01501-3	5	2014-06-25	Recruiting	Completed	2014-06-01	2015-11-01	2019-01-14	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in caregiver burden directly and 3 month after psychotherapeutical intervention\n[ Time Frame: before intervention, 0 and 3 month after end of intervention ]\n\nZarid Burden Interview will be used to measure caregiver burden""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in perceived self-efficacy directly and 3 month after psychotherapeutical intervention and reduction of symptoms of depression\n[ Time Frame: before intervention, 0 and 3 month after end of intervention ]\n\nSWE, a german self-efficacy self-rating scale, will be used for self-efficacy measurement AND ADS (German Version of the CES-D Scale) for measurement for symptoms of depression""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in perceived self-efficacy directly and 3 month after psychotherapeutical intervention and reduction of symptoms of depression\n[ Time Frame: before intervention, 0 and 3 month after end of intervention ]\n\nSWE, a german self-efficacy self-rating scale, will be used for self-efficacy measurement AND ADS (German Version of the CES-D Scale) for measurement for symptoms of depression""}]	NA	NA
NCT02189473	Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression	Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01)	10.1200/jco.2015.64.0862	https://pubmed.ncbi.nlm.nih.gov/26729431/	8	2014-07-10	Recruiting	Completed	2010-09-01	2015-07-01	2016-01-04	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor function\n[ Time Frame: at 1 month following radiotherapy ]\n\n\n\neffect of radiotherapy on motor function (improvement, no further progression, deterioration) 0 = Complete paraplegia\n\n= Palpable or visible muscle contractions\n= Active movement, without gravity\n= Active movement, against gravity\n= Active movement, against mild resistance\n= Active movement, against intermediate resistance\n= Active movement, against strong resistance\n= Normal strength""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor function\n[ Time Frame: at 1 month following radiotherapy ]\n\n\n\neffect of radiotherapy on motor function (improvement, no further progression, deterioration) 0 = Complete paraplegia\n\n= Palpable or visible muscle contractions\n= Active movement, without gravity\n= Active movement, against gravity\n= Active movement, against mild resistance\n= Active movement, against intermediate resistance\n= Active movement, against strong resistance\n= Normal strength""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Motor function\n[ Time Frame: at 1 month following radiotherapy ]\n\n\n\neffect of radiotherapy on motor function (improvement, no further progression, deterioration) 0 = Complete paraplegia\n\n= Palpable or visible muscle contractions\n= Active movement, without gravity\n= Active movement, against gravity\n= Active movement, against mild resistance\n= Active movement, against intermediate resistance\n= Active movement, against strong resistance\n= Normal strength""}]	[See Results Section.]	NA
NCT02196324	A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial	10.1016/j.jaad.2019.01.052	https://www.jaad.org/article/S0190-9622(19)30161-6/fulltext	5	2014-07-21	Recruiting	Completed	2014-07-01	2016-05-01	2019-03-17	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of VPD-737 5-mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of VPD-737 5-mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis\n[ Time Frame: 8 weeks ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""The primary endpoints are pairwise comparisons between treatments of Visual Analog Score (VAS) score over 24 hour period of serlopitant 5 mg tablets and placebo taken once daily for 8 weeks for prurigo nodularis\n[ Time Frame: 8 weeks ]""}]	[See Results Section.]	NA
NCT02196896	Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy	Online Self-Help as an Add-On to Inpatient Psychotherapy: Efficacy of a New Blended Treatment Approach	10.1159/000481177	https://www.karger.com/Article/Abstract/481177	8	2014-07-21	Recruiting	Completed	2014-06-01	2016-11-01	2017-11-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of depression measured with the \""Beck's Depression Inventory\"" (BDI-II)\n[ Time Frame: Six months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of depression measured with the \""Beck's Depression Inventory\"" (BDI-II)\n[ Time Frame: Three months after randomization ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Reduction of depression measured with the \""Beck's Depression Inventory\"" (BDI-II)\n[ Time Frame: Three months after randomization ]""}]	NA	NA
NCT02207582	Prefrontal Transcranial Random Noise Stimulation in Patients With Depression	Bifrontal high-frequency transcranial random noise stimulation is not effective as an add-on treatment in depression	10.1016/j.jpsychires.2020.10.011	https://www.sciencedirect.com/science/article/pii/S0022395620310141	5	2014-08-01	Recruiting	Terminated	2014-07-01	2017-01-01	2020-10-16	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))\n[ Time Frame: day 3; day 19 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))\n[ Time Frame: day 3; day 19 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))\n[ Time Frame: day 3; day 19 ]\n\nChange in depression severity measured by the 21-item Hamilton Depression Rating Scale (baseline (-day 3) versus end of treatment (day 19))""}]	NA	NA
NCT02216526	Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents	The effectiveness of standardized skin care regimens on skin dryness in nursing home residents: A randomized controlled parallel-group pragmatic trial	10.1016/j.ijnurstu.2017.02.006	https://pubmed.ncbi.nlm.nih.gov/28214613/	4	2014-08-13	Not yet recruiting	Completed	2014-09-01	2015-04-01	2017-02-07	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Overall Dry Skin Score (ODS)\n[ Time Frame: Day 56+/-4 ]\n\nClinical assessment of the presence or severity of skin dryness using a five point rating scale at right lower leg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Overall Dry Skin Score (ODS)\n[ Time Frame: Day 56+/-4 ]\n\nClinical assessment of the presence or severity of skin dryness using a five point rating scale at right lower leg""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from Baseline in Overall Dry Skin Score (ODS)\n[ Time Frame: Day 56+/-4 ]\n\nClinical assessment of the presence or severity of skin dryness using a five point rating scale at right lower leg""}]	[See Results Section.]	NA
NCT02223767	TMS Augmented Exposure Therapy	Medial prefrontal cortex stimulation accelerates therapy response of exposure therapy in acrophobia	10.1016/j.brs.2016.11.007	https://www.sciencedirect.com/science/article/abs/pii/S1935861X16303084	4	2014-08-21	Recruiting	Completed	2014-08-01	2015-04-01	2016-11-14	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Questionaires\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nanxiety questionaires""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Behavioral approach test\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nreal life anxiety measurement""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjective anxiety symptoms\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nanxiety questionaires""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Subjective anxiety in height situation\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nreal life anxiety measurement by an behavioral approach test""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Subjective anxiety symptoms\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nanxiety questionaires""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Subjective anxiety in height situation\n[ Time Frame: 4 weeks and at follow up 3 month later ]\n\nreal life anxiety measurement by an behavioral approach test""}]	NA	NA
NCT02273141	Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.	Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial	10.1055/a-0639-5070	https://www.thieme-connect.de/products/ejournals/html/10.1055/a-0639-5070	6	2014-10-22	Not yet recruiting	Completed	2014-10-01	2015-08-01	2018-07-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Use of Harefield Cleansing Scale to grade bowel cleansing efficacy\n[ Time Frame: Day of colonoscopy (Day 2) ]\n\nTo evaluate the overall bowel cleansing efficacy of NER1006 compared to SP+MS.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Use of Harefield Cleansing Scale to grade bowel cleansing efficacy\n[ Time Frame: Day of colonoscopy (Day 2) ]\n\nTo evaluate the overall bowel cleansing efficacy of NER1006 compared to SP+MS.""}]	[See Results Section.]	NA	NA
NCT02290613	Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)	10.1186/s13075-019-1981-0	https://pubmed.ncbi.nlm.nih.gov/31655622/	4	2014-11-10	Not yet recruiting	Completed	2014-12-01	2017-12-01	2019-10-26	TRUE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pulmonary arterial pressure change from baseline\n[ Time Frame: baseline, 6 months ]\n\nDetermine whether mean pulmonary arterial pressure of SSc patients with borderline - PAH (mPAP 21 24 mmHg, TPG >11 mmHg) can be reduced by 3 mm Hg (absolute change baseline vs. 6 months; equals 15%) following treatment with ambrisentan 10 mg/die (initiated with 5 mg/die and elevated up to 10 mg/die) over 6 months (primary endpoint) compared to baseline and placebo.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Mean pulmonary arterial pressure change from baseline\n[ Time Frame: baseline, 6 months ]\n\nDetermine whether mean pulmonary arterial pressure of SSc patients with borderline - PAH (mPAP 21 24 mmHg, TPG >11 mmHg) can be reduced by 3 mm Hg (absolute change baseline vs. 6 months; equals 15%) following treatment with ambrisentan 10 mg/die (initiated with 5 mg/die and elevated up to 10 mg/die) over 6 months (primary endpoint) compared to baseline and placebo.""}]	NA	[See Results Section.]	NA
NCT02299089	Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study	10.1007/s00280-018-3734-1	https://pubmed.ncbi.nlm.nih.gov/30535537/	9	2014-11-21	Not yet recruiting	Completed	2015-01-01	2016-02-01	2018-12-08	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacokinetic (PK) profile of octreotide after each injection of CAM2029 as compared with baseline PK for Sandostatin® Long-acting Release (LAR®)\n[ Time Frame: Baseline, Day 84 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Pharmacokinetic (PK) profile of octreotide after each injection of CAM2029 as compared with baseline PK for Sandostatin® Long-acting Release (LAR®)\n[ Time Frame: Baseline, Day 84 ]""}]	[See Results Section.]	NA	NA
NCT02334813	Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia	A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study	10.1159/000445420	https://pubmed.ncbi.nlm.nih.gov/27189086/	2	2015-01-07	Completed	Completed	2002-07-01	2015-01-01	2016-05-19	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission duration\n[ Time Frame: 6 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Remission duration\n[ Time Frame: 6 months ]""}]	[See Results Section.]	NA
NCT02337062	Phase IIIb Study of APD421 in Combination as PONV Prophylaxis	Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial	10.1097/aln.0000000000002133	https://pubs.asahq.org/anesthesiology/article/128/6/1099/19881/Amisulpride-Prevents-Postoperative-Nausea-and	6	2015-01-12	Not yet recruiting	Completed	2015-02-01	2015-09-01	2018-01-09	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete Response (protection from PONV)\n[ Time Frame: 24 hours ]\n\nProportion of patients with no PONV in the 24-hour period after end of surgery""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Complete Response (protection from PONV)\n[ Time Frame: 24 hours ]\n\nProportion of patients with no PONV in the 24-hour period after end of surgery""}]	[See Results Section.]	[See Results Section.]	NA
NCT02338388	Cesarean-scar Thickness and Closure Technique	Longitudinal transvaginal ultrasound evaluation of cesarean scar niche incidence and depth in the first two years after single- or double-layer uterotomy closure: a randomized controlled trial	10.1111/aogs.13213	https://pubmed.ncbi.nlm.nih.gov/28832909/	2	2015-01-12	Completed	Completed	2012-01-01	2014-04-01	2017-09-21	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cesarean scar-thickness\n[ Time Frame: 24 months ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""cesarean scar-thickness\n[ Time Frame: 24 months ]""}]	NA	NA
NCT02340299	Nasal HFOV Versus Nasal CPAP to Reduce Post-extubation pCO2	Hazards to avoid in future neonatal studies of nasal high-frequency oscillatory ventilation: lessons from an early terminated trial	10.1186/s13104-019-4268-2	https://pubmed.ncbi.nlm.nih.gov/31023363/	4	2015-01-13	Not yet recruiting	Terminated	2015-01-01	2017-12-31	2019-04-25	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paCO2 at 72 h after extubation\n[ Time Frame: 64 h to 80 h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paCO2 at 72 h after extubation\n[ Time Frame: 64 h to 80 h ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""paCO2 at 72 h after extubation\n[ Time Frame: 64 h to 80 h ]""}]	[See Results Section.]	NA
NCT02450578	DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria	DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection	10.1016/s1473-3099(17)30139-1	https://www.sciencedirect.com/science/article/pii/S1473309917301391?via%3Dihub	15	2015-05-18	Not yet recruiting	Completed	2015-10-01	2017-01-01	2017-03-28	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time from PfSPZ IV inoculation to the first positive thick blood smear\n[ Time Frame: Day 6 to Day 60 post-inoculum (daily) ]\n\nBlood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time from PfSPZ IV inoculation to the first positive thick blood smear\n[ Time Frame: Day 6 to Day 60 post-inoculum (daily) ]\n\nBlood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""time from PfSPZ IV inoculation to the first positive thick blood smear\n[ Time Frame: Day 6 to Day 60 post-inoculum (daily) ]\n\nBlood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination""}]	[See Results Section.]	NA
NCT02479412	A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma	Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial	10.1186/s12931-019-1000-7	https://pubmed.ncbi.nlm.nih.gov/30777086/	9	2015-06-19	Not yet recruiting	Completed	2015-06-01	2016-03-01	2019-02-18	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of AZD7594 by assessment of the change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15\n[ Time Frame: On Day 1 (pre-dose) and on Day 15 in each period ]\n\nComparison of the efficacy of AZD7594 in terms of change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15 (defined as the average of the values at 23:00 and 23:30 hours after last dose of investigational medicinal product [IMP] on Day 14) compared to placebo""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Efficacy of AZD7594 by assessment of the change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15\n[ Time Frame: On Day 1 (pre-dose) and on Day 15 in each period ]\n\nComparison of the efficacy of AZD7594 in terms of change from baseline in morning trough forced expiratory volume in 1 second (FEV1) on Day 15 (defined as the average of the values at 23:00 and 23:30 hours after last dose of investigational medicinal product [IMP] on Day 14) compared to placebo""}]	[See Results Section.]	NA	NA
NCT02534285	the Impact of Noise on Requirements of Anesthetics During General Anesthesia	NA	10.19224/ai2020.196	https://www.ai-online.info/archiv/2020/06-2020/laermabschirmung-senkt-nicht-den-desfluranbedarf-waehrend-allgemein-anaesthesien-fuehrt-aber-zu-einer-verminderung-von-bis-werten-60.html	4	2015-08-26	Recruiting	Completed	2015-08-01	2016-11-01	2020-06-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirements of the inhalational anesthetic desflurane, measured in expiratory volume percentage, to maintain a BIS-Index triggered depth of anesthesia\n[ Time Frame: one hour ]\n\nAimed BIS-index is 50, desflurane is measured in expiratory volume percentage""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirements of the inhalational anesthetic desflurane, measured in expiratory volume percentage, to maintain a BIS-Index triggered depth of anesthesia\n[ Time Frame: one hour ]\n\nAimed BIS-index is 50, desflurane is measured in expiratory volume percentage""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Requirements of the inhalational anesthetic desflurane, measured in expiratory volume percentage, to maintain a BIS-Index triggered depth of anesthesia\n[ Time Frame: one hour ]\n\nAimed BIS-index is 50, desflurane is measured in expiratory volume percentage""}]	[See Results Section.]	NA
NCT02548585	A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study	10.1016/s0140-6736(18)30726-8	https://pubmed.ncbi.nlm.nih.gov/29945727/	9	2015-09-10	Not yet recruiting	Completed	2015-10-01	2017-02-24	2018-06-23	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nPercent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in body weight in kg to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nChange from baseline in body weight in kg to end of treatment (Cohort 4 only)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nPercent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in body weight in kg to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nChange from baseline in body weight in kg to end of treatment (Cohort 4 only)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Percent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nPercent change from baseline in MMT glucose AUC (up to 240 minutes post MMT) to end of treatment (Cohort 4 only)""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change from baseline in body weight in kg to end of treatment (Cohort 4 only)\n[ Time Frame: 42 days post dosing ]\n\nChange from baseline in body weight in kg to end of treatment (Cohort 4 only)""}]	[See Results Section.]	NA
NCT02557698	Effectiveness of Using an Oil Bath Additive	The effectiveness of using a bath oil to reduce signs of dry skin: A randomized controlled pragmatic study	10.1016/j.ijnurstu.2016.10.010	https://pubmed.ncbi.nlm.nih.gov/27815985/	3	2015-09-22	Completed	Completed	2014-11-01	2015-04-01	2016-10-26	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Transepidermal water loss (TEWL) in g/m2/h at the left mid volar forearm\n[ Time Frame: Day 28 +/- 3 ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Transepidermal water loss (TEWL) in g/m2/h at the left mid volar forearm\n[ Time Frame: Day 28 +/- 3 ]""}]	[See Results Section.]	NA
NCT02566369	Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris	Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne	10.1016/j.jaad.2019.02.044	https://pubmed.ncbi.nlm.nih.gov/30802558/	15	2015-10-01	Not yet recruiting	Completed	2015-11-01	2018-01-01	2019-02-22	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Success rate, defined as the percentage of subjects who achieve an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement\n[ Time Frame: From Baseline to Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Success rate, defined as the percentage of subjects who achieve an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement\n[ Time Frame: From Baseline to Week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Success rate, defined as the percentage of subjects who achieve an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement\n[ Time Frame: From Baseline to Week 12 ]""}]	[See Results Section.]	NA
NCT02639520	Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs	Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial	10.1159/000493368	https://www.karger.com/Article/FullText/493368	6	2015-12-21	Not yet recruiting	Completed	2015-12-01	2017-06-01	2018-10-01	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4\n[ Time Frame: within 38 days after Visit 1 (=day 1) ]\n\nFor patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a \""treatment failure\"" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4\n[ Time Frame: within 38 days after Visit 1 (=day 1) ]\n\n\n\nFor patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a \""treatment failure\"" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.\n\nThe primary variable for the assessment of efficacy is the proportion of patients who received additional antibiotic treatment for acute lower uUTI between Visit 1 and Visit 4 (defined as AB-rate).""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Intake of any additional antibiotic medication for acute lower uUTIs between Visit 1 and Visit 4\n[ Time Frame: within 38 days after Visit 1 (=day 1) ]\n\n\n\nFor patients with consistent or worsening of acute lower uUTI symptoms during the trial the investigator may offer an additional antibiotic therapy at any post-baseline visit. In this case, the patient will be considered a \""treatment failure\"" due to lack of efficacy of the IMP. The alternative antibiotic therapy offered to the patient and the reason for the alternative therapy (i.e., persisting or recurrent symptoms) is to be documented.\n\nThe primary variable for the assessment of efficacy is the proportion of patients who received additional antibiotic treatment for acute lower uUTI between Visit 1 and Visit 4 (defined as AB-rate).""}]	NA	NA
NCT02647801	Self-control and Mindfulness Within Ambulatorily Assessed Network Systems Across Health Related Domains	A mind full of happiness: How mindfulness shapes affect dynamics in daily life	10.1037/emo0000562	https://pubmed.ncbi.nlm.nih.gov/30570315/	6	2016-01-04	Recruiting	Completed	2015-09-01	2016-12-01	2018-12-20	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Three items from the State Self-control Capacity Scale (SSCCS)\n[ Time Frame: From day 2 till day 41, six times a day between 10 am and 8 pm ]\n\nGerman version of the SSCCS. Self-report on current self-control capacity of participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Three items from the State Self-control Capacity Scale (SSCCS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nGerman version of the SSCCS. Self-report on current self-control capacity of participants.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Three items from the Mindfulness Attention Awareness Scale (MAAS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nItems from the German version of the MAAS. Self-report on current mindfulness of participants.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Three items from the State Self-control Capacity Scale (SSCCS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nGerman version of the SSCCS. Self-report on current self-control capacity of participants.""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Three items from the Mindfulness Attention Awareness Scale (MAAS)\n[ Time Frame: From day 1 till day 40, six times a day between 10 am and 8 pm ]\n\nItems from the German version of the MAAS. Self-report on current mindfulness of participants.""}]	NA	NA
NCT02672553	EDWARDS INTUITY Valve System CADENCE-MIS Study	A randomized multicenter trial of minimally invasive rapid deployment versus conventional full sternotomy aortic valve replacement	10.1016/j.athoracsur.2014.09.022	https://pubmed.ncbi.nlm.nih.gov/25441065/	2	2016-01-29	Completed	Completed	2012-05-01	2015-03-01	2014-11-20	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Cross-clamp time\n[ Time Frame: At time of surgery ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Cardiopulmonary bypass time\n[ Time Frame: At time of surgery ]""}]	NA	NA	[See Results Section.]	NA
NCT02677129	Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy	NA	10.1007/s00520-018-4478-5	https://link.springer.com/article/10.1007/s00520-018-4478-5#citeas	4	2016-02-04	Recruiting	Completed	2014-08-01	2016-09-01	2018-10-04	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Activities of daily living\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\nFunctional Independence Measurement (FIM) Questionnaire""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Activities of daily living\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\n- instrumental Activity of Daily Living (iADL)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short Physical Performance Battery\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\nShort battery of physical performance tests used to assess lower extremity function. Balance, gait, strength, and endurance are evaluated.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Short Physical Performance Battery\n[ Time Frame: Change between the first 12 weeks of chemotherapy ]\n\nShort battery of physical performance tests used to assess lower extremity function. Balance, gait, strength, and endurance are evaluated.""}]	NA	NA
NCT02724592	Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions	Self-assembling Peptide P11-4 and Fluoride for Regenerating Enamel	10.1177/0022034517730531	https://pubmed.ncbi.nlm.nih.gov/28892645/	2	2016-03-24	Completed	Completed	2013-02-01	2014-04-01	2017-09-11	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ICDAS (International Caries Detection and Assessment System) index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.\n[ Time Frame: 6 months ]\n\nEvaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using ICDAS caries index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""ICDAS (International Caries Detection and Assessment System) index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.\n[ Time Frame: 6 months ]\n\nEvaluation of the additional therapeutic benefit of Curodont™ compared to fluoride varnish (Duraphat®) alone on early occlusal carious lesions using ICDAS caries index, caries activity assessment according to Nyvad criteria and LASER fluorescence readings using Diagnodent® device.""}]	[See Results Section.]	NA
NCT02734901	Effects of Acute Red Raspberry Consumption on Vascular Function in Healthy Individuals	Plasma urolithin metabolites correlate with improvements in endothelial function after red raspberry consumption: A double-blind randomized controlled trial	10.1016/j.abb.2018.05.016	https://pubmed.ncbi.nlm.nih.gov/29802820/	3	2016-04-11	Recruiting	Completed	2016-03-01	2016-09-01	2018-05-24	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 2 h and 24 h in Endothelial function\n[ Time Frame: Baseline, 2 h and 24 h ]\n\nmeasured by flow mediated dilation (FMD) on baseline at 2 and 24 h postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 2 hour and 24 hour in Endothelial function\n[ Time Frame: Baseline, 2 hour and 24 hour ]\n\nmeasured by flow mediated dilation (FMD) on baseline at 2 and 24 hour postconsumption""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline to 2 hour and 24 hour in Endothelial function\n[ Time Frame: Baseline, 2 hour and 24 hour ]\n\nmeasured by flow mediated dilation (FMD) on baseline at 2 and 24 hour postconsumption""}]	NA	NA
NCT02735187	Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.	NA	NA	https://pdfs.semanticscholar.org/b3a6/c8239a9c030a1c7a3af8acbafc77c9a8ecc2.pdf?_ga=2.264204238.316868046.1597691860-1172082013.1597691860	4	2016-04-11	Recruiting	Completed	2016-03-01	2016-08-01	2019-01-01	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).\n[ Time Frame: week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).\n[ Time Frame: week 12 ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change from baseline (visit 2) of the local PSI of the blue light treated area (group 30) as compared to the VitaminD treated area (control) at end of treatment (Week 12).\n[ Time Frame: week 12 ]""}]	[See Results Section.]	NA
NCT02743260	Drug Transporter Interaction Study PHENTRA_2015_KPUK	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin	10.1002/cpt.1564	https://pubmed.ncbi.nlm.nih.gov/31247117/	3	2016-04-13	Recruiting	Completed	2016-04-01	2017-12-01	2019-08-12	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	NA	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavialability (CL/F) of pitavastatin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin\n[ Time Frame: 24 hours ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavailability (CL/F) of pitavastatin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir\n[ Time Frame: 24 hours ]""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin\n[ Time Frame: 24 hours ]""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavailability (CL/F) of pitavastatin\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""organic cation transporters 1 and 2 (OCT1/2), multidrug and toxic compound extrusion transporters 1 and 2,kidney splice variant (MATE1/2K): Renal clearance (CLr) of metformin\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""intestinal p-glycoprotein (P-gp): Peak Plasma Concentration (Cmax) of digoxin\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""4."",""content"":""renal p-glycoprotein (P-gp): Renal clearance (CLr) of digoxin:\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""5."",""content"":""organic anion transporter 1 (OAT1): Renal clearance (CLr) of adefovir\n[ Time Frame: 24 hours ]\n\nPK parameter""},{""section"":""Primary Outcome Measures:"",""label"":""6."",""content"":""organic anion transporter 3 (OAT3): Renal clearance (CLr) of sitagliptin\n[ Time Frame: 24 hours ]\n\nPK parameter""}]	NA
NCT02744638	Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis	Effect of a yoghurt drink containing Lactobacillus strains on bacterial vaginosis in women - a double-blind, randomised, controlled clinical pilot trial	10.3920/bm2017.0018	https://pubmed.ncbi.nlm.nih.gov/29065710/	3	2016-04-15	Recruiting	Completed	2015-02-01	2016-08-01	2017-10-25	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of BV-free woman\n[ Time Frame: 4 weeks ]\n\nThe rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Amsel criteria.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of BV-free woman\n[ Time Frame: 4 weeks ]\n\nThe rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Amsel criteria.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Rate of BV-free woman\n[ Time Frame: 4 weeks ]\n\nThe rate of BV-free women at the end of the yoghurt consumption period (day 28) as assessed by Nugent score""}]	NA	NA
NCT02752802	DyeVert System RCT	Impact of a novel contrast reduction system on contrast savings in coronary angiography - The DyeVert randomised controlled trial	10.1016/j.ijcard.2017.12.107	https://pubmed.ncbi.nlm.nih.gov/29373136/	4	2016-04-22	Recruiting	Completed	2016-04-01	2016-05-01	2018-01-02	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the total volume (percentage) of CM used comparing the DyeVert group to the control group.\n[ Time Frame: All data will be collected on the day of the procedure. ]\n\nDyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Evaluate the total volume (percentage) of CM used comparing the DyeVert group to the control group.\n[ Time Frame: All data will be collected on the day of the procedure. ]\n\nDyeVert is intended to reduce the total amount of contrast media (CM) administered during procedures requiring the injection of contrast media. Clinical evidence has demonstrated that CM can be toxic to the kidneys, leading to contrast induced nephropathy (CIN)""}]	[See Results Section.]	NA	NA
NCT02799069	Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy	Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo	10.1111/j.1365-2133.2011.10613.x	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2133.2011.10613.x/full	3	2016-06-09	Completed	Completed	2008-04-01	2009-08-01	2011-12-21	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Overall subject complete response\n[ Time Frame: 12 weeks after the last photodynamic therapy (PDT) ]\n\nAn overall complete responder was defined as a subject in whom all treated lesions were cleared 12 weeks after either the first PDT or re-treatment.""}]	NA	NA	[See Results Section.]	NA
NCT02851108	Methylene Blue Against Falciparum Malaria in Burkina Faso	Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial	10.1371/journal.pone.0222993	https://pubmed.ncbi.nlm.nih.gov/31600221/	4	2016-07-29	Not yet recruiting	Completed	2016-10-01	2016-12-01	2019-10-10	TRUE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin compared to the baseline\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin compared to the baseline\n[ Time Frame: 7 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in haemoglobin compared to the baseline\n[ Time Frame: 7 days ]""}]	[See Results Section.]	NA
NCT02861001	VivaSight-SL™ Versus Bronchoscopy for Percutaneous Tracheotomy	Bronchoscopy versus an endotracheal tube mounted camera for the peri-interventional visualization of percutaneous dilatational tracheostomy - a prospective, randomized trial (VivaPDT)	10.1186/s13054-017-1901-0	https://pubmed.ncbi.nlm.nih.gov/29284503/	3	2016-08-04	Recruiting	Completed	2016-04-01	2017-01-13	2017-12-29	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""visualization through the tube camera of endotracheal landmark structures for tracheotomy and visualization of the needle insertion (according to score)\n[ Time Frame: during tracheotomy ]\n\nfor score see detailed description""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""visualization through the tube camera of endotracheal landmark structures for tracheotomy and visualization of the needle insertion (according to score)\n[ Time Frame: during tracheotomy ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""visualization through the tube camera of endotracheal landmark structures for tracheotomy and visualization of the needle insertion (according to score)\n[ Time Frame: during tracheotomy ]""}]	NA	NA
NCT02870972	Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema	Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema	10.1056/nejmoa1716995	https://pubmed.ncbi.nlm.nih.gov/30044938/	9	2016-08-17	Recruiting	Completed	2016-08-01	2017-08-01	2018-07-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of confirmed HAE attacks\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of confirmed HAE attacks\n[ Time Frame: 28 days ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Number of confirmed HAE attacks\n[ Time Frame: 28 days ]""}]	[See Results Section.]	NA
NCT02896062	Development and Evaluation of a Sleep-coaching Program	Effects of a Workplace-Based Sleep Health Program on Sleep in Members of the German Armed Forces	10.5664/jcsm.7666	https://pubmed.ncbi.nlm.nih.gov/30853042/	2	2016-09-06	Recruiting	Completed	2014-10-01	2016-10-01	2019-03-19	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective sleep quality assessed by PSQI\n[ Time Frame: 5 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective sleep quality assessed by PSQI\n[ Time Frame: 5 months ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""subjective sleep quality assessed by PSQI\n[ Time Frame: 5 months ]\n\nPSQI total score""}]	NA	NA
NCT02930590	Effects of Different Support Surfaces on the Properties Skin After Loading	Comparing the effects of 3 different pressure ulcer prevention support surfaces on the structure and function of heel and sacral skin: An exploratory cross-over trial	10.1111/iwj.12883	https://onlinelibrary.wiley.com/doi/abs/10.1111/iwj.12883	3	2016-10-10	Recruiting	Completed	2016-09-01	2017-03-01	2017-12-26	FALSE	TRUE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Transepidermal Water Loss (TEWL) in g/m2/h on sacrum, heel and sternum (control area)\n[ Time Frame: at baseline, after two hours loading, 20 min after loading ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Transepidermal Water Loss (TEWL) in g/m2/h on sacrum, heel and sternum (control area)\n[ Time Frame: at baseline, after two hours loading, 20 min after loading ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change of Transepidermal Water Loss (TEWL) in g/m2/h on sacrum, heel and sternum (control area)\n[ Time Frame: at baseline, after two hours loading, 20 min after loading ]""}]	[See Results Section.]	NA
NCT02947542	Use of Different Diagnostic Coronary Catheters Over the Radial Access - the UDDC - Radial Trial	Performance of One- Compared With Two-Catheter Concepts in Transradial Coronary Angiography (from the Randomized Use of Different Diagnostic Catheters-Radial-Trial)	10.1016/j.amjcard.2018.07.039	https://www.sciencedirect.com/science/article/abs/pii/S0002914918316230	4	2016-10-26	Recruiting	Completed	2016-04-01	2016-11-01	2018-08-20	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Coronary angiography duration\n[ Time Frame: Day 0 (corresponding to time point of procedure) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Coronary angiography duration\n[ Time Frame: Day 0 (corresponding to time point of procedure) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Coronary angiography Duration (sec)\n[ Time Frame: Day 0 (corresponding to time point of procedure) ]\n\nassessed by Intention-to-treat analysis (IIT)""}]	NA	NA
NCT02975154	Microcurrent Therapy in the Treatment of Osteoarthritis of the Knee	NA	10.23736/s1973-9087.20.05921-3	NA	3	2016-11-23	Enrolling by invitation	Completed	2016-11-01	2017-09-04	2020-04-15	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	TRUE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Numerical Ratings scale (NRS) for pain (0-10)\n[ Time Frame: Change of NRS: Before treatment vs. end of treatment (in average 21 days later) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Numerical Ratings scale (NRS) for pain (0-10)\n[ Time Frame: Change of NRS: Before treatment vs. end of treatment (in average 21 days later) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Numerical Ratings scale (NRS) for pain (0-10)\n[ Time Frame: Change of NRS: Before treatment vs. end of treatment (in average 21 days later) ]\n\nnumerical Rating scale""}]	NA	NA
NCT02992236	Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers	Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers	10.1111/bcp.13870	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475696/	2	2016-12-09	Completed	Completed	2015-08-01	2016-05-01	2019-02-28	FALSE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Renal plasma flow\n[ Time Frame: 2 days ]\n\nRenal plasma flow measurement by PAH-Method""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Glomerular Filtration Rate\n[ Time Frame: 2 days ]\n\nby PAH-Method""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Renal plasma flow\n[ Time Frame: 2 days ]\n\nRenal plasma flow measurement by PAH-Method""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Glomerular Filtration Rate\n[ Time Frame: 2 days ]\n\nby PAH-Method""}]	[See Results Section.]	NA
NCT03042429	Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients	Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials	10.1002/pbc.22693	https://pubmed.ncbi.nlm.nih.gov/21298742/	2	2017-02-01	Completed	Completed	2007-01-01	2016-12-31	2010-12-09	FALSE	FALSE	FALSE	TRUE	FALSE	NA	NA	TRUE	NA	post_publication	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: up to 9 years ]\n\ntime from diagnosis to Event or last follow-up""}]	NA	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Event free survival\n[ Time Frame: up to 9 years ]\n\ndays from diagnosis to Event or last follow-up""}]	NA
NCT03105024	Self-efficacy Enhancement and Exposure Therapy	Low Perceived Self-Efficacy Impedes Discriminative Fear Learning	10.3389/fpsyg.2019.01191	https://pubmed.ncbi.nlm.nih.gov/31275188/	3	2017-04-03	Recruiting	Completed	2017-03-22	2017-11-29	2019-06-18	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Behavioral Approach Test (BAT)\n[ Time Frame: from pretreatment through follow-up (i.e. before treatment, approx. 2-3 days after treatment, 1 month after) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in subjective fear during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. before treatment, approx. 2-3 days after, 1 month after) ]\n\nSubjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in heart rate reactivity during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. before treatment, approx. 2-3 days after, 1 month after) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Behavioral Approach Test (BAT)\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after treatment, 1 month after) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in subjective fear during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]\n\nSubjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in heart rate reactivity during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Change in the Behavioral Approach Test (BAT)\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after treatment, 1 month after) ]""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Change in subjective fear during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]\n\nSubjective fear during the BATs will be measured using the Subjective Units of Distress Scale (SUDS)""},{""section"":""Primary Outcome Measures:"",""label"":""3."",""content"":""Change in heart rate reactivity during the BAT\n[ Time Frame: from pretreatment through follow-up (i.e. baseline, approx. 2-3 days after, 1 month after) ]""}]	NA	NA
NCT03134144	Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities	Influence of a passive lower-limb exoskeleton during simulated industrial work tasks on physical load, upper body posture, postural control and discomfort	10.1016/j.apergo.2019.05.018	https://www.sciencedirect.com/science/article/abs/pii/S0003687019300985?via%3Dihub	4	2017-04-25	Recruiting	Completed	2017-05-01	2017-10-15	2019-05-30	TRUE	FALSE	TRUE	TRUE	FALSE	NA	FALSE	TRUE	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Center of Pressure\n[ Time Frame: 2 hours ]\n\nIndicator for the balance of the study participants""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle activity\n[ Time Frame: 2 hours ]\n\nIndicator for the muscular load that may change when wearing the passive exoskeleton""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""Center of Pressure\n[ Time Frame: 2 hours ]\n\nIndicator for the balance of the study participants""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""Muscle activity\n[ Time Frame: 2 hours ]\n\nIndicator for the muscular load that may change when wearing the passive exoskeleton""}]	[See Results Section.]	NA
NCT03312816	Effect of Oxidized Plant Sterols on Serum Concentrations of Plant Sterol Oxidation Products (POP)	Serum Concentration of Plant Sterol Oxidation Products (POP) Compared to Cholesterol Oxidation Products (COP) after Intake of Oxidized Plant Sterols: A Randomised, Placebo-Controlled, Double-Blind Dose‒Response Pilot Study	10.3390/nu11102319	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835335/	3	2017-10-12	Recruiting	Completed	2017-10-01	2017-12-08	2019-09-30	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	NA	NA	recruitment	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""POP value\n[ Time Frame: 0 to 42 days ]\n\nTo estimate the change from baseline in serum POP concentration after intake of various POP doses.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""POP (plant sterol oxidation products) value\n[ Time Frame: 0 to 42 days ]\n\nTo estimate the change from baseline in serum POP concentration after intake of various POP doses.""}]	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""POP (plant sterol oxidation products) value\n[ Time Frame: 0 to 42 days ]\n\nTo estimate the change from baseline in serum POP concentration after intake of various POP doses.""}]	NA	NA
NCT03584451	Evaluation of the Effect of Rehabilitation Sport After Total Hip Arthroplasty (THA)	Sports Therapy Interventions Following Total Hip Replacement	10.3238/arztebl.2019.0001	https://www.aerzteblatt.de/archiv/204208/Sporttherapeutische-Massnahmen-nach-Huefttotalendoprothese	3	2018-07-11	Completed	Completed	2015-02-01	2017-07-01	2019-01-01	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	NA	NA	post_completion	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hip-related muscular strength\n[ Time Frame: change from baseline (6 weeks) at 6 months after THA ]\n\nhip-related muscular strength measured with isokinetic dynamometry""},{""section"":""Primary Outcome Measures:"",""label"":""2."",""content"":""hip-related muscular strength\n[ Time Frame: change from baseline (6 weeks) at 12 months after THA ]\n\nhip-related muscular strength measured with isokinetic dynamometry""}]	NA	[{""section"":""Primary Outcome Measures:"",""label"":""1."",""content"":""hip-related muscular strength\n[ Time Frame: change from baseline (6 weeks) at 6 months after THA ]\n\nhip-related muscular strength measured with isokinetic dynamometry""}]	NA	NA
